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1 Introduction 
 
1.1 B-cell lymphomas 
 
B-cell lymphomas are hematological malignancies developing from B-cells [1]. Traditionally, they are 
divided into Hodgkin and non-Hodgkin lymphoma (NHL) [1]. Another classification distinguishes low 
grade lymphomas, like follicular lymphoma (FL) from high grade lymphomas, like Burkitt lymphoma 
(BL) or diffuse large B-cell lymphoma (DLBCL) [1]. From a more clinical point of view, the high grade 
lymphomas are also referred to as aggressive lymphomas reflecting their noteworthy rapid growth 
but nevertheless good curability [1]. A further feature used for classification is the B-cell stage which 
they resemble, as for example B-lymphoblastic lymphoma is supposed to derive from immature B-
cells whereas BL, FL and DLBCL resemble mature B-cells [1]. The mature B-cell malignancies 
represent 4 % of new cancers each year and 90 % of malignant lymphomas worldwide [2],[3]. The 
most common mature B-cell lymphoma subtypes are FL and DLBCL [4]. The relative frequency of the 
subtypes varies in different parts of the world as for example FL is more common in the US and 
Western Europe than in Africa or Asia [5]. The median age of diagnosis for all mature B-cell 
lymphomas is between 60 and 70 years [1]. But DLBCL and especially BL are described to occur also 
at considerable frequencies in children [6]. As the focus of this thesis is on BL which is a mature 
aggressive B-cell lymphoma predominantly of childhood, features of pediatric B-cell lymphoma will 
be presented in the following. 
 
1.1.1 B-cell lymphomas in children 
 
In general, the cancer spectrum in children differs from that in adults. For example, the most 
frequent non-leukemic malignancies in children are embryonal tumors like neuroblastoma, Wilms 
tumor, rhabdomyosarcoma and retinoblastoma which are rare or do not exist at all in adults [7],[8]. 
Furthermore, the biological characteristics of a tumor may differ between children and adults as has 
been shown for acute lymphoblastic leukemia (ALL). In ALL the most common genetic alteration in 
children is the ETV6-RUNX1 fusion due to the translocation t(12;21) whereas in adult ALL, the most 
common translocation is the t(9;22) resulting in BCR-ABL1 fusion [8]. The reasons for the different 
spectra of malignancies might be that malignancies of the childhood arise predominantly within 
developing tissues that still undergo formation, growth or maturation, reflected by the high 
incidence of embryonic tumors as described above [9]. In adults, on the other hand, the most 
prevalent tumors are carcinomas derived from epithelia of the gastrointestinal tract, lung, breast or 
prostate [8].  
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Lymphoma is the third most frequent cancer in persons below the age of 18 years at diagnosis. It has 
accounted for 14 % of all childhood malignancies in the years 2009-2013 in Germany [10]. Refer to 
Table 1 for a comparison of the distribution of pediatric and adult lymphoma subtypes.  
Table 1: Distribution of lymphoma subtypes in children and adults. Adapted from [11]. 
  Children Adults 
 Lymphoma subtypes Distribution of lymphoma subtypes 
Hodgkin 
lymphoma 
Hodgkin lymphoma 46.0 % 13.0 % 
Non-Hodgkin 
lymphoma 
(NHL) 
Burkitt lymphoma 25.0 % 0.4 % 
T-lymphoblastic lymphoma 8.0 % 1.3 % 
Anaplastic large cell lymphoma 6.5 % 1.7 % 
Diffuse-large B-cell lymphoma 4.0 % 26.0 % 
B-lymphoblastic lymphoma 3.0 % 0.5 % 
Primary mediastinal B-cell lymphoma 1.0 % 0.4 % 
Follicular lymphoma 0.5 % 26.0 % 
Other 6.0 % 30.7 % 
 
About 5 % of the NHL in Western Europe are BL but the percentage differs between children and 
adults: 40 % of pediatric NHL are BL whereas only 1-2 % of adult NHL are BL [12].  
The following chapter will focus on the epidemiology and clinical features of BL, as it is the major 
subtype of lymphoma studied within this thesis. 
 
1.1.2 Burkitt lymphomas 
 
1.1.2.1 Epidemiology of Burkitt lymphomas 
 
Burkitt lymphomas belong to the mature aggressive B-cell lymphomas and as outlined above are the 
most common NHL of the childhood. In general, three clinical variants of BL are distinguished: 
endemic, sporadic and immunodeficiency-associated [1]. The epidemiologic features of each of them 
are shortly introduced in the following. 
Endemic BL (eBL) is the most common childhood malignancy in equatorial Africa, Papua New Guinea 
and Brazil accounting in these countries for 30-50 % of all childhood cancers [13]. The occurrence of 
eBL correlates with the geographical distribution of endemic malaria [14] in this so called malaria belt 
[15]. The incidence peak is between the ages of 4-7 years at diagnosis [1]. A hallmark of the endemic 
variant is the presence of the Epstein-Barr virus (EBV) genome in the majority of neoplastic cells [16]. 
Immunodeficiency-associated BL is frequently seen in association with HIV infection and occurs as 
initial manifestation of AIDS [17]. But also iatrogenic causes for immunodeficiency as for example 
immunosuppression upon transplantations have been described [18],[19]. 
Sporadic BL (sBL), which is the main BL variant studied within this thesis, occurs throughout the world 
but predominantly in North America and Western Europe [1]. The age distribution of BL according to 
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the surveillance, epidemiology and end results registry (SEER) of the Unites States in children is 
trimodal showing peaks between the ages of 5-9 years at diagnosis as well as in middle aged adults 
between 40-44 years at diagnosis and in the elderly between 80-84 years at diagnosis [20]. According 
to the Netherland Cancer Registry, a bimodal age distribution is observed with one age peak 
between 6-10 years at diagnosis and the other above 60 years at diagnosis [21]. To sum up, based on 
the above described studies, the main incidence peak in children is between the ages of 5-10 years, 
whereas in adults BL is diagnosed between the ages of 40-80 years. In Germany 49 % of the children 
with non-Hodgkin lymphoma younger than 15 years at diagnosis have BL [22]. Sporadic BL in children 
predominantly manifests in males whereas in females an increase in BL presentation has been 
associated with advanced age [20]. Thus, the male to female ratio in children (<20 years at diagnosis) 
is 3.13 whereas it declines to 2.31 in middle-aged adults (20-59 years at diagnosis) and to 1.53 in 
elderly (>60 years at diagnosis) [23]. In contrast to the eBL, EBV is only detected in 15-30 % of sBL 
[16].  
In high income countries pediatric sBL have a better outcome than their adult counterpart with an 
overall survival with current treatment of more than 90 % after 5 years [24] in contrast to 53-71 % in 
adults [25],[26].  
 
1.1.2.2 Clinical features and pathology of Burkitt lymphomas 
 
The focus of this thesis is on sporadic BL, which are referred to for the sake of convenience as BL. The 
following description of the features is confined to this variant. 
In about 90 % of children BL manifests in the ileo-caecal region [27]. In pediatric BL extranodal sites 
are most often affected whereas in adults a nodal presentation is more common [1]. Manifestations 
within the ovaries, kidneys and breast are also observed. The frequent abdominal involvement is 
associated with a respective clinical presentation including abdominal pain, nausea and vomiting. The 
majority of BL show a bulky disease and a high tumor burden. BL cells show a short doubling time of 
24-48 h [1], which in turn leads in pediatric BL to symptoms within a couple of weeks.  
About 30-38 % of patients with BL have been reported to have a bone marrow involvement [28],[27]. 
Of those, only few cases present as Burkitt leukemia or acute lymphoblastic leukemia-L3 with more 
than 25 % of bone marrow cells being lymphoma cells at diagnosis [27]. 
The single BL cells present as medium-sized cells harboring round nuclei with finely clumped 
chromatin and multiple nucleoli [1]. Furthermore, BL show a diffuse pattern of growth with many 
mitoses and a so called “starry sky pattern” which refers to numerous benign macrophages that 
ingest apoptotic BL cells [1].  
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BL express moderate levels of IgM and the B-cell associated antigens as CD19 and CD20. 
Furthermore, BL show a germinal center-like immunophenotype being CD10 and BCL6 positive. The 
majority of pediatric BL are negative or only weakly positive for BCL2, whereas positivity is most 
often observed in adults. Key feature of BL is the high positivity for the proliferation marker Ki67 
which reaches up to 100 % in the tumor cells [27]. 
A genetic hallmark of BL is the IG-MYC translocation which can be detected in almost 100 % of cases. 
This translocation juxtaposes the MYC gene to one of the immunoglobulin (IG) gene loci. The 
mechanism of the MYC translocation and its impact on Burkitt lymphomagenesis will be introduced 
in detail in 1.3.3. 
 
1.2 B-cell development and lymphomagenesis 
 
1.2.1 Stages of B-cell differentiation 
 
As B-cell lymphoma develop from B-cells at different maturation stages, the knowledge of the 
features of normal B-cell development is important for the understanding of B-cell 
lymphomagenesis. Figure 1 depicts the different stages of B-cell development with focus on the 
germinal center. 
B-cells derive from hematopoietic stem cells within the bone marrow which also give rise to T-cells 
and cells of the myeloid lineage. The B-cell lineage commitment is ensured upon expression of 
several transcription factors, like transcription factor 3 (TCF3), as well as by cytokine signaling via 
interleukin 7 [29],[30],[31]. Within the bone marrow the precursor cells differentiate via pro B-cell 
and pre B-cell stages to immature B-cells. During these steps, the V(D)J rearrangement of the 
immunoglobulin genes (1.2.2) takes place leading to the expression of a rearranged IgM on the 
surface of the immature B-cells. Subsequently, these B-cells are tested for successful rearrangement 
and autoreactivity. Self-reactive cells are negatively selected and undergo either (i) cell death by 
apoptosis or clonal deletion, (ii) produce a new receptor by receptor editing or (iii) enter a state of 
anergy or immunological tolerance [32]. The surviving, non-self-reactive B-cells leave the bone 
marrow and become mature, naïve B-cells. These cells circulate in the peripheral blood and are also 
found in primary lymphoid follicles [33]. Upon encounter of an antigen, the naïve B-cells might either 
mature directly into plasma cells which produce an early IgM antibody response or migrate to the 
center of the primary follicle and form the germinal center [33]. 
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Figure 1: B-cell differentiation in the germinal center. Naïve B-cells derive from precursor B-cells within the bone marrow 
where the immunoglobulin gene has undergone V(D)J rearrangement and a functional IgM surface protein is expressed. 
Upon encounter with an antigen, the naïve B-cells enter the germinal center where they undergo clonal expansion. During 
this time the immunoglobulin V genes of the now called centroblasts accumulate mutations induced by the somatic 
hypermutation machinery which contribute to the increase of the antigen-specificity. The cells now enter the light zone, 
where they are called centrocytes. At this stage, they become selected for a high affinity to the antigen. Only those cells 
with a high affinity do either reenter the dark zone for some additional rounds of clonal expansion or differentiate into 
antibody secreting plasma cells or memory B-cells. The BCR of centrocytes which have a low antigen-affinity undergo 
apoptosis. A further mechanism which increases the affinity of the immunoglobulin is the class switching which takes place 
in the light zone. Modified from [4]. 
 
Within the germinal center the immunoglobulins undergo affinity maturation. Initially, the B-cells 
enter the dark zone (DZ) where they proliferate extensively and are called centroblasts. During this 
stage, the immunoglobulin variant region genes accumulate mutations due to the activity of the 
somatic hypermutation machinery (1.2.2). After several rounds of cell division, the B-cells, now called 
centrocytes, enter the light zone (LZ). At this stage the class switch recombination (1.2.2) of the 
immunoglobulin gene takes place which is a further mechanism for affinity maturation [34]. In the LZ, 
the centrocytes are surrounded by follicular dendritic cells which present different antigens on their 
surface. The centrocytes compete with each other for the specific recognition of the antigen [33]. If a 
centrocyte recognizes the antigen it receives a signal to reenter the dark zone for some additional 
rounds of clonal expansion and further affinity maturation. A role for MYC in this so called cyclic 
reentry model for germinal center B-cells and, thus, for affinity maturation has been recently 
proposed by two studies [35],[36]. MYC has been shown to be expressed in mature B-cells and, thus, 
to be important for the initiation of the GC formation. But the expression of MYC is inhibited in the 
centroblasts of the DZ likely due to the expression of BCL6, which can bind to the MYC promoter. In 
the LZ the expression of MYC is induced in a small subset of B-cells likely by a T-cell- and antigen-
dependent interaction of the respective centrocytes [35]. This small subset of LZ B-cells is likely 
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positively selected for and, thus, expresses a high-affinity B-cell receptor (BCR). Subsequently, these 
B-cells can reenter in a MYC-dependent manner the DZ for an additional round of proliferation to 
acquire more mutations increasing the BCR affinity for its antigen. The other centrocytes, not re-
expressing MYC, exit the germinal center and become either plasma cells or memory B-cells. 
Different factors direct the cell fate of the plasma cells. Plasma cells express low levels of PAX5 and 
BCL6 but high levels of IRF4 [37]. IRF4 induces the expression of PRDM1, which is also called BLIMP1. 
PRDM1 is a transcriptional repressor that switches off genes required for B-cell proliferation and 
affinity maturation [38]. Some of the plasma cells migrate into the bone marrow where a subset lives 
for a long period due to pro-survival signals by the surrounding stroma cells. Others migrate into the 
medullary cords in the lymph nodes or in the spleen. Irrespective of their location, they produce high 
levels of antibody. Memory B-cells are long-lived and divide - if at all - very slowly [39]. They recircle 
within the peripheral blood and migrate into the bone marrow [40] or splenic marginal zone [41]. In 
the initial phase of the secondary immune response memory B-cells provide the antigens to 
pathogens and, thus, are an important part of the adaptive immune response [42]. 
 
1.2.2 Molecular processes remodeling the immunoglobulin genes 
 
The BCR undergoes complex rearrangements during B-cell development. In the following, the 
structure of the BCR and the molecular processes of the remodeling will by briefly presented.  
Antibodies or immunoglobulins are the secreted form of the BCR. In Figure 2 the structure of an 
immunoglobulin is exemplary depicted. IGs are Y-shaped and consist of two heavy and two light 
chains which are made of four and two immunoglobulin domains, respectively [43]. The variable 
domains of the light chain (VL) and of the heavy chain (VH) make up the variable region which confers 
the ability to bind specific antigens [43]. The constant domains of the heavy chain (CH1-3) and light 
chain (CL) make up the constant region which is important for the interaction with the effector cells 
and molecules [43]. The BCR harbors in addition a C-terminal polypeptide which anchors the receptor 
in the membrane of the cells [44],[45]. 
The heavy and light chains are encoded by separate multigene families localized on different 
chromosomes. Two different types of light chains exist: lambda (λ) light chain encoded on 
chromosome 22q11 and kappa (κ) light chain encoded on chromosome 2p11. The heavy chain is 
encoded by a gene cluster on chromosome 14q32. Each of these gene clusters contains several 
coding sequences, so called gene segments. The light chains contain variable (V), joining (J) and 
constant (C) gene segments, whereas the heavy chains contain additionally a diversity (D) gene 
segment. The C gene segment in the heavy chain does not only contain a single gene segment but a 
series of regions as μ, δ, γ, α and ε which correspond to the different isotypes IgM, IgD, IgG, IgA and 
IgE of the immunoglobulins [39].  
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Figure 2: Exemplary structure of an immunoglobulin molecule (IgG). The Y-shaped immunoglobulin consists of two heavy 
chains and two light chains, the latter are indicated by the lighter color. The heavy and the light chains are made of four and 
two immunoglobulin domains, respectively. The variable domains of the light chain (VL) and of the heavy chain (VH) make 
up the variable region, whereas the constant domains of the heavy chain (CH1-3) and light chain (CL) make up the constant 
region. Modified from [39]. 
 
The V-J in the light chain and the V-D-J gene segments in the heavy chain build the variable region 
and the C gene segment the constant region of the immunoglobulin gene. As the gene segments are 
separated by non-coding and other coding gene segments, a rearrangement of the DNA sequence is 
necessary to generate a functional coding exon of the immunoglobulin. This process is called V(D)J 
rearrangement and takes place during the B-cell maturation in the bone marrow [46]. This random 
recombination is carried out by a complex of enzymes called V(D)J recombinase. This protein 
complex binds to the conserved recombination signal sequences which lie adjacent to each gene 
segment and joins initially the D to the J gene segment in the heavy chain. In a second step the V 
gene segment is joined to the DJ gene segment (Figure 3A). In the light chain, the V gene segment is 
directly joined to the J segment. Due to the high number of functional gene segments, many 
combinations for the V(D)J recombination are possible leading to a high combinatorial diversity of 
immunoglobulins. This diversity is further increased by the so called junctional diversity, as during the 
recombination processes nucleotides at the joint region between two gene segments might be 
added or deleted [47]. 
Additional mechanisms taking place in the germinal center reaction lead to secondary diversification 
of the immunoglobulins. Among these mechanisms is the somatic hypermutation of the 
immunoglobulin genes (Figure 3B). During the germinal center reaction point mutations are 
introduced in centroblasts at a high rate into the gene segment encoding the V region [48]. The 
process of somatic hypermutation is mainly conducted by the activation induced deaminase (AID) 
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which is expressed in activated germinal center B-cells [49],[50]. Upon binding of this enzyme to 
single stranded DNA, it deaminates cytosine to uracil [49]. The deamination induces mismatch repair 
or base-excision repair mechanisms which further alter the DNA sequence [51]. Alterations of the 
DNA sequence do not only diversify the immunoglobulins but also alter the affinity of the BCR for the 
antigen. The survival of those B-cells is favored which harbor IG mutations increasing the affinity of 
the immunoglobulin. 
 
 
Figure 3: Overview on the molecular processes remodeling the immunoglobulin genes using the example of the 
immunoglobulin heavy chain (IGH) locus. A: Depicted is the schematic overview on the VDJ recombination. Initially the D 
gene segment is joined randomly to one of the J gene segments. In a next step one of the V gene segments is joined to the 
DJ segment. B: After VDJ recombination and after encounter of an antigen, the somatic hypermutation machinery is 
activated in the germinal center. This leads to the introduction of mutations at a high rate in the V region of the heavy and 
the light chain (indicated by the lollipops). C: The final step in the affinity maturation of the immunoglobulin genes is the 
class switch which only occurs on the heavy chain locus. This mechanism is based on a type of non-homologous end joining 
between the so called switch regions (here shown for sμ and sγ). These lie adjacent to each C gene segment and direct the 
class switch. Modified from [4]. 
 
Another mechanism which leads to the diversification of the immunoglobulins is the so called class 
switch recombination or class switching (Figure 3C). During this process - occurring following antigen 
Introduction 
9 
encounter of the B-cell - the constant gene segment of the heavy chain is switched. Initially, the naïve 
B-cell express IgM or IgD immunoglobulins. During affinity maturation, the IG class switches in the 
majority of cases to IgG resulting in an antibody with different effector functions [52]. Class switching 
involves irreversible DNA recombination, which is a type of non-homologous DNA recombination 
[53]. Switching is guided by stretches of repetitive DNA, so called switch regions, which lie in the 
intron between the JH and the Cμ gene segment as well as upstream of the other C gene segments 
[54]. AID induces single-strand nicks in these switch regions leading to double-strand breaks [55]. By 
non-homologous recombination between the switch regions the breaks are repaired leading to a 
joining of the VDJ segment with the switched C segment [53]. 
 
1.2.3 Cellular origin of germinal center B-cell lymphomas 
 
The cell-of-origin is defined as the cellular stage (normal stage of B-cell differentiation) resembling 
best the phenotype of a tumor cell. The analysis of the cell-of-origin in malignant B-cell lymphoma is 
based on the finding that the tumor cells seem to be frozen at a particular differentiation stage [56]. 
This does not necessarily reflect the real cell of origin as has been shown for FL. Although in this 
lymphoma the initiating translocation of the BCL2 gene is likely created during the VDJ 
recombination in the bone marrow [57],[58], FL cells display features of mature germinal center B-
cells [1]. Despite this, for the sake of convenience, the term cell-of-origin is used in the following.  
The analysis of the cell-of-origin is important as it will likely influence the physiology of the tumor 
cell. Therefore, its definition is important to understand the biology of the tumor. Nevertheless, the 
approach to define the cell-of-origin has changed in the last decades. 
Initially, the definition of the cell-of-origin was based on the fact that the BCR of mature B-cells 
undergoes affinity selection within the germinal center of secondary lymphoid organs, which is 
reflected by an increase of mutations within the IG genes [59]. Based on the IG mutation status the 
origin of the lymphoma used to be defined. In general, lymphomas harboring no IG gene mutations 
were defined to derive from pre-GC B-cells. Lymphomas harboring mutated IG genes on the other 
hand were defined to derive from B-cells of the GC or post-GC [56]. But this is not a reliable definition 
as for example a group of memory B-cells has been described to have acquired IG mutations by 
somatic hypermutation outside the GC [60]. Thus, the presence of IG mutations in a lymphoma does 
solely indicate that it derives from cells which had passed through a differentiation stage during 
which somatic hypermutation occurred [61]. Furthermore, some lymphoma show ongoing somatic 
hypermutation of the IG genes due to the high AID activity, as has been described for FL [62] and 
germinal center like DLBCL [63].  
Later on, gene expression analyses of lymphomas in comparison to normal B-cells of different 
maturation stages have been used to define the cell of origin. This was based on the finding that at 
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distinct stages of differentiation a specific set of marker genes is expressed [64],[65]. Using this 
approach, the majority of mature B-cell lymphomas including BL have been described to harbor a 
gene expression signature similar to normal germinal center B-cells [66],[67]. 
Victora et al. [68] have shown that based on differential expression of a few genes, dark zone cells 
can be differentiated from light zone cells. Included in this gene expression signature were for 
example CXCR4, CCND3, AURKA which were up-regulated in DZ cells as well as CD40, MYC or EGR3 
which were up-regulated in LZ cells [68]. Using these expression signatures, the majority of analyzed 
germinal center derived B-cell lymphomas like FL and DLBCL were shown to harbor a gene expression 
signature similar to light zone B-cells. The majority of analyzed BL (75 %) on the other hand have 
been shown to be more similar with regard to their gene expression signature to dark zone B-cells. 
Remarkably, the remaining 25 % of BL had a higher likelihood to derive from light zone B-cells [68]. 
Refer to Figure 4 for an overview on the cell of origin of germinal center B-cell lymphoma. 
 
 
Figure 4: Cellular origin of germinal center B-cell lymphoma. The majority of Burkitt lymphomas have been suggested to 
derive from dark zone B-cells, whereas the diffuse large B-cell lymphomas and follicular lymphomas are supposed to derive 
from light zone B-cells [68]. Modified from [4]. 
 
As described in 1.2.1, MYC is an important regulator of the cyclic reentry of centrocytes into the dark 
zone. Strikingly, it is lowly expressed within cells of the dark zone. Thus, the finding that most of the 
BL derive from DZ B-cells seems paradox. The MYC translocation might take place within the LZ B-
cells probably as a result of abnormal AID activity [69],[70]. This is in line with the finding that some 
of the BL harbor a LZ phenotype [68]. Those cells which harbor a high MYC expression due to the 
translocation might (re)enter the DZ. In the DZ the downregulation of MYC is either prevented due to 
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the loss of the BCL6 binding site during the translocation event. Alternatively or cooperating, the 
induction of MYC expression by the IG enhancers is stronger than the repression by BCL6 [71]. As a 
consequence, MYC expression is uncoupled from the positive selection within the light zone. Due to 
the reentry within the DZ, a DZ-specific gene expression pattern is activated which is reflected by the 
DZ phenotype in BL [68]. Among the genes of the DZ signature is the bHLH transcription factor TCF3 
which induces several downstream pro-survival signaling pathways. These contribute to the 
tolerance against MYC induced apoptosis and, thus, the survival of the transformed GC B-cell [72]. 
Moreover, Schmitz et al. [72] identified activating TCF3 mutations in BL, supporting the role of TCF3-
activated pathways within the development of BL. 
 
1.3 Molecular pathomechanisms in lymphomagenesis 
 
As described above, MYC has been shown to be important for the germinal center reaction by 
regulating the cyclic reentry of activated B-cells. In BL, the IG-MYC translocation and subsequent MYC 
overexpression has been described as its hallmark alteration. In the following, the mechanisms and 
the role of MYC deregulation in BL will be introduced as well as tumorigenic pathomechanisms which 
could be already linked to Burkitt lymphomagenesis. Initially, the general concepts of oncogene 
activation and tumor suppressor gene inactivation will be presented. 
 
1.3.1 Oncogene activation 
 
Genes, which promote the tumorigenesis by mediating a proliferative advantage upon 
overexpression or –activity are called oncogenes [73]. Thus, the general function of oncogenes is to 
promote the proliferation and the consequent uncontrolled cell division further supports the 
accumulation of genomic lesions. Oncogenes belong to different protein families like growth factors 
and their receptors, proteins with GTPase-activity, tyrosine kinase receptors, DNA-binding 
transcription factors and proteins of the cell cycle control like cyclin dependent kinases or kinase 
inhibitors. Furthermore, oncogenes can be classified depending on their physiological functions in 
proliferation or differentiation [74]. 
An oncogene becomes activated by a dominant gain-of-function [75], meaning that the alteration of 
one allele is sufficient to exert the oncogenic effect. Different gain-of-function mechanisms are 
known: (i) Amplification of a gene, not changing the gene structure, might contribute to its 
overexpression [76]. (ii) A translocation might place the proto-oncogene under the influence of the 
promoter or enhancer of another gene. This could lead either to a constitutive overexpression, like in 
the case of translocations involving the IG locus, or to an expression in tissues or in differentiation 
stages in which the gene is normally silenced. Furthermore, the fusion of two genes can lead to the 
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generation of an abnormal protein which is more active than the non-fused genes as in the case of 
the BCR-ABL1 fusion due to the so called Philadelphia translocation [77]. (iii) Various types of 
mutations can be activating by increasing the stability or functionality of the protein. Alternatively, 
like in the case of a nonsense mutation, mutations might lead to the ablation of interaction domains 
with binding partners or regulatory sites [75]. (iv) Finally, several genes including MYC [78] have been 
described to become activated upon insertion of tumor viruses. 
Classical proto-oncogenes in B-cell lymphoma are MYC [79],[80], BCL2 [81],[82], CCND1 [83],[84] and 
REL [85]. 
 
1.3.2 Tumor suppressor gene inactivation 
 
Tumor suppressor genes are important negative regulators of the cell cycle as well as cell division 
and, thus, are important counter-actors of oncogenes [86]. Tumor suppressors control genes which 
are essential for regulating progression through the cell cycle, connect the cell cycle to the DNA 
damage response and promote apoptosis in case of not repairable damage [75]. Additionally, they 
are caretakers of the genomic integrity and, hence, reduce the mutation frequency which influences 
the cancer onset. Thus, important tumor suppressors belong to genes encoding proteins important 
for genome stability (ATM) [87], to negative regulators of cell cycle (CDKN2A, TP53) [88],[89] and to 
chromatin remodelers (ARID1A) [90],[91]. 
According to Knudson´s two hit theory [92], both alleles of a tumor suppressor need to be inactivated 
before its function is lost and the cells become constitutively mitotic active. This is nowadays partially 
obsolete. Recent findings have shown that the loss of one allele can give the cells for example a 
selective growth advantage [93],[94],[95] if the expression of the remaining allele cannot 
reconstitute the wildtype condition [96]. This mechanism is called haploinsufficiency. 
Several inactivating mechanisms can lead to a so called loss-of-function: (i) Missense mutations 
might alter functional important domains of the protein; (ii) nonsense mutations truncating the 
protein might lead to a loss of important domains or to nonsense mediated decay (NMD); (iii) 
frameshift deletions or insertions might disrupt the gene structure and (iv) epigenetic mechanisms 
might silence the transcription [75].  
Initial descriptions of tumor suppressors were based on the finding that they were localized within 
focal homozygous deletions [97],[98]. In line with this most of the tumor suppressors are inactivated 
due to a deletion of one allele or loss of heterozygosity whereas the remaining allele harbors 
inactivating mutations or was epigenetically silenced. Some tumor suppressors are already mutated 
in the germline, leading to a higher cancer predisposition, as in the case of ATM germline mutations 
which are associated with the development of lymphomas [99],[100]. Typical tumor suppressor 
genes in B-cell lymphoma are TP53 [101],[102] or ATM [103]. 
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1.3.3 MYC deregulation in Burkitt lymphoma 
 
1.3.3.1 Mechanisms of MYC deregulation in Burkitt lymphoma 
 
The genetic hallmark of BL is the translocation of the MYC gene which is identified in 90-100 % of 
cases [104],[105]. The translocation leads to the juxtaposition of the MYC gene to sequences from 
immunoglobulin (IG) genes. In 80 % of the BL the translocation partner is the immunoglobulin heavy 
chain (IGH) gene whereas in 20 % the translocation partner is either the gene encoding the 
immunoglobulin κ or λ light chain locus. Three classes of breakpoints in MYC exist and the position of 
the breakpoints correlates with the BL variants: Class I breakpoints map within the first exon or 
intron of the MYC gene. This class predominantly occurs in sporadic as well as in AIDS-associated BL. 
Class II breakpoints map immediately within a few kilobases (kb) 5’ to the MYC gene. These are 
predominantly detected in endemic BL. Class III breakpoints are located in some distance upstream 
to the MYC gene [105].  
The breakpoints in the light chain gene loci map 5’ of the constant region gene segments [104]. The 
breakpoints in the IGH locus differ between the BL variants. In eBL the breakpoints occur mainly in 
the JH gene segments, indicating that the IG-MYC translocation was created during a VDJ 
rearrangement as suggested by Haluska et al. [106],[107]. This further suggests that this initiating 
event of the eBL does not occur in the germinal center itself which is the supposed cell of origin 
(1.2.3) but rather in bone marrow precursor B-cells. In contrast, the breakpoint region in sBL and 
AIDS-associated BL was determined to fall within the IGH sμ switch region [104]. This indicates that 
these translocations are created during class switch recombination in the light zone of the germinal 
center. In line with this, several studies have shown that the induction of IG-MYC translocations in 
vitro and in vivo are dependent on AID which induces double-strand breaks during class switching 
and somatic hypermutation [69],[70]. Hence, although several studies described BL as a homogenous 
lymphoma entity [67],[108], it seems that the B-cell stage, at which the malignant transformation is 
induced, differs between eBL and sBL or AIDS-associated BL. 
Subsequent to the IG-MYC translocation, the expression of MYC is regulated by the enhancers of the 
IG genes, which are especially active in mature B cells [109],[110]. Of note is that the “normal” MYC 
allele is usually transcriptionally silenced in BL and the transcribed MYC derives solely from the 
translocated allele [109],[110]. MYC itself becomes target of the somatic hypermutation machinery 
by AID due to the translocation into the IG locus and the subsequent increased transcription [111]. 
The mutations within MYC contribute to its deregulation, as mutations within the promoter region, 
first exon or intron prevent the inhibition of MYC transcription by other transcription factors as for 
example BCL6 (1.2.3) [112],[113]. Furthermore, mutations within the MYC coding sequence, like e.g. 
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mutations affecting threonine 58 prevent its degradation induced by GSK3β and, thus, increase the 
stability of the MYC protein [114]. 
 
1.3.3.2 Impact of MYC deregulation in Burkitt lymphoma 
 
All of the above described genetic alterations lead to the overexpression of MYC which belongs to 
the basic helix-loop-helix (bHLH) family of transcription factors [115]. The MYC gene, also named C-
MYC to differentiate it from the other MYC family members N-MYC and L-MYC [116], consists of 
three exons [117]. Only the second and third exons are coding. The long first exon contains several 
negative regulatory sequences. The first intron harbors binding sites for nuclear proteins [104]. MYC 
has been proposed to be a general amplifier of the active transcriptional program of the cell 
[118],[119]. This might explain the observation that the MYC-regulated transcriptional gene profile 
differs in the various studied cell types [120]. In contrast, around one third of the MYC target genes 
are transcriptionally repressed [118]. But this might be an indirect effect, as for example EZH2 is 
upregulated by MYC but represses subsequently the expression of other genes [121]. Nevertheless, 
the main functions of MYC are implicated within the cellular homeostasis. Thus, it regulates as a 
heterodimer complex with the MYC-associated factor X (Max) the transcription of genes involved in 
protein synthesis, cell cycle, translation or proliferation [122],[123]. Paradoxically, among the MYC 
target genes are the pro-apoptotic genes TP53 and CDKN2A (p14ARF) which are directly or indirectly 
upregulated [124],[125]. This is thought to be a protective regulatory feedback mechanism by the cell 
to counteract the oncogenic activation and prevent the transformation of the cell. Thus, the MYC 
overexpression in primary cells including lymphocytes results in apoptosis or cell cycle arrest [125]. 
To overcome this pro-apoptotic program, the cells need to acquire secondary alterations to survive 
and transform. In line with this, inactivating mutations within the TP53-ARF-MDM2 tumor suppressor 
pathway have been described for BL [126]. The necessity for secondary alterations to induce 
lymphomagenesis in addition to the MYC deregulation is further supported by the study of 
transgenic Eμ-MYC mouse models. In these mouse models the human IG-MYC translocation is 
mimicked leading to the development of pre B-cell and B-cell lymphoma [127],[128]. Furthermore, 
Park et al. [129] have shown in their transgenic Eμ-MYC mouse model that the development of B-cell 
and plasma neoplasms was accompanied by inactivating mutations of the already above described 
TP53-ARF-MDM2 pathway. In line with this, further studies in Eμ-MYC mice showed that mutations in 
for example TP53 [130] accelerated the development of lymphoma. Thus, the IG-MYC translocation 
alone is not sufficient to induce full-blown lymphomagenesis. Instead, additional secondary 
alterations are necessary to induce Burkitt lymphomagenesis. In line with this, a few recurrent 
secondary alterations in BL have been described. On chromosomal level, recurrent copy number 
gains in chromosome 1q, 7 and 12 as well as losses in 6q, 13q32 and 17p were identified in BL 
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[131],[132]. On mutational level, BL have been shown to carry recurrent mutations in the TP53-ARF-
MDM2 pathway as already described above. Recurrent activating mutations in CCND3 have been 
identified in BL [133]. Moreover, epigenetic inactivation of the cell cycle regulator CDKN2A has been 
described in BL [134]. A major drawback of those analyses was that only single genes were analyzed 
for recurrent mutations. Thus, usage of high throughput sequencing techniques will help to decipher 
the global mutational landscape and hence to identify genetic mutations contributing in addition to 
the IG-MYC translocation to Burkitt lymphomagenesis. 
As mentioned in 1.2.3, the majority of BL have been suggested to derive from the DZ. This is in 
contrast to the finding that MYC-translocations of sBL seem to occur during class switch 
recombination in the LZ of the germinal center (1.3.3.1). But as MYC plays a role in the cyclic reentry 
of the cells (1.2.1), it is conceivable that IG-MYC translocation induced MYC overexpression leads to a 
reentry of the cells in the DZ. In the DZ, MYC augments the transcription of those genes within the B-
cells which are already actively transcribed at this stage. Thus, the amplification of the transcriptional 
program of the centroblasts might hence lead to the DZ cell phenotype of BL [135]. 
Taken together, the MYC overexpression in BL is a key oncogenic mechanism augmenting the 
proliferative and survival pathways whereas further alterations are needed for full transformation of 
the B-cells. 
 
1.3.4 Other molecular pathomechanisms in Burkitt lymphoma 
 
In addition to the above described chromosomal and genetic alterations, several additional 
molecular pathomechanisms, most of them induced by MYC, have been described to contribute to 
the Burkitt lymphomagenesis. Refer to Figure 5 for a schematic overview on the already described 
MYC-related functions (1.3.3) and the associated pathomechanisms in BL which will be presented in 
the following. 
The attrition of the telomeres is an intrinsic life span clock. Thus, when the telomeres reach a critical 
length after several rounds of replication, the cells normally progress into senescence [136]. The 
telomerase activity is normally restricted to embryonic cells as well as to some fast dividing cells of 
the immune system as for example the extensive proliferating cells of the germinal center 
[137],[138]. Due to the high telomerase activity those cells are protected from telomere shortening. 
Lymphoma cells overcome this restricted telomerase activity as has been described for BL by Klapper 
et al. [139]. Hence, BL have been shown in comparison to for example FL or DLBCL to harbor a 
significant higher activity of the telomerase [139]. Furthermore, the high activity correlated with a 
high expression of the telomerase reverse transcriptase (TERT) in BL which is the catalytic subunit of 
the telomerase [140],[141],[142]. The high expression of TERT might be a result of the 
overexpression of MYC in BL, as a MYC-dependent activation of TERT expression in lymphocytes has 
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been described [143],[144]. Hence, this finding indicates a link between MYC deregulation and 
increased telomerase activity, contributing to the immortalization of BL cells.  
 
 
Figure 5: Schematic overview on MYC-related functions with regard to the pathomechanisms in BL. Blue boxes depict the 
physiological functions of MYC as general amplifier of transcription inducing cell cycle, proliferation, protein synthesis and 
apoptosis, as well as its role in the cyclic reentry in the germinal centre during affinity maturation. Alterations and 
pathomechanisms related to BL with regard to MYC are depicted by orange boxes.  
 
The infection with EBV is a risk factor for the development of BL. Almost in all cases of eBL, as well as 
in 15-30 % of sBL, the genome of this virus is detectable [16]. The role of EBV in BL is still unclear. 
Although EBV has been shown to be able to induce the proliferation of resting human B cells [145], it 
is not sufficient to induce their malignant transformation as has been shown in a mouse model [146]. 
It is thought that EBV inhibits apoptotic signal pathways in BL and might hence contribute to the 
lymphomagenesis [147],[148],[149]. 
Furthermore, an oncogenic role for the PI3 kinase (PI3K) pathway has been implicated in the 
pathogenesis of BL. A link between BL and PI3K activity has been long proposed [150],[151],[152] as 
well as the dependence of BL on the signalling for proliferation and survival [153]. But a study by 
Sander et al. was the first to show in a mouse model that constitutively expressed MYC together with 
PI3K activity in B-cells undergoing GC reaction leads to the formation of BL-like tumors [133]. Further 
evidence for a role of PI3K in BL comes from the analysis of gene expression signatures of the PI3K 
activity which is higher in human BL biopsies than in other lymphoma subtypes [72],[133]. Figure 6 
gives a schematic overview on the PI3K signaling in B-cells and BL which is shortly outlined in the 
following. Interaction of an antigen with the BCR or in the case of BL tonic BCR signaling [72] 
activates the tyrosine kinase SYK. This kinase activates the co-receptor CD19 which is one of the main 
regulators of PI3K activity in B cells [154] and the B-cell adaptor for PI3K (BCAP). Both activate 
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subsequently PI3K. Upon activation, PI3K produces phosphatidylinositol 3,4,5-triphosphate (PIP3) 
from phosphatidylinositol 4,5-diphosphate (PIP2) which is a lipid second-messenger. PIP3 mediates 
the recruitment of effector proteins including the serine-threonine protein kinase Akt, also known as 
protein kinase B. In this manner Akt becomes activated and promotes via various downstream 
effectors cell growth, survival and differentiation [155].  
A counter-actor of the PI3K signaling is the phosphatase and tensin homolog (PTEN). PTEN 
dephosphorylates PIP3 and thereby inhibits the PI3K-induced signaling pathway. Thus, PTEN is an 
important tumor suppressor gene frequently inactivated in many solid tumors as well as in 
lymphoma [156],[157]. Recently, Schmitz et al. [72] have described sporadic mutations of PTEN in BL, 
likely augmenting the PI3K activity in these lymphomas.  
 
 
Figure 6: Schematic overview on PI3K activation and signaling in B-cells and BL. Stimulation of the BCR activates PI3K 
signaling via CD19 and BCAP. Active PI3K synthesizes PIP3 which supports the recruitment of effector proteins to PI3K 
including Akt. In this manner, Akt becomes activated and induces several downstream effectors mediating differentiation, 
cell cycle and growth as well as the inactivation of anti-proliferative proteins and, thus, supports the survival. A counter-
actor of PI3K is PTEN, which dephosphorylates PIP3 to PIP2. Furthermore, PI3K signaling has been shown to stabilize the 
MYC protein, thus, promoting its tumorigenic effect. Modified from [158]. 
 
In addition to mediating the downstream signaling pathway, PI3K has been shown to promote the 
stabilization of MYC via inhibition of GSK3β which mediates its degradation [159]. This finding further 
supports an oncogenic role for the cooperation of PI3K signaling with MYC deregulation. 
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Although all above described mechanisms have been linked to Burkitt lymphomagenesis, the 
underlying mechanisms leading for example to the tonic BCR signaling and, thus, to the constant 
activation of PI3K signaling remain unclear. It might be possible that secondary genetic alterations 
like inactivating or activating mutations of the PI3K pathway members might contribute to the PI3K 
activity. Thus, the study of the complete mutational landscape in BL might be a conclusive approach 
to identify such secondary alterations contributing to Burkitt lymphomagenesis. In line with this, the 
systematic studies of more than 25,000 cancer genomes of in total 50 different cancer types 
including BL is the aim of the International Cancer Genome Consortium [160]. 
 
1.3.5 MYC properties in stemness 
 
MYC is one of the four reprogramming genes sufficient for transformation of somatic cells to 
inducible pluripotent stem cells [161]. The induction of pluripotency in somatic cells shares several 
molecular mechanisms with malignant transformation. Remarkably, it has been shown in studies of 
chicken´s bursa of Fabricia that myc overexpression induces preneoplastic lesions which 
subsequently give rise to lymphoma in a cell population which is only present during B-cell 
differentiation at the bursal stem cell age [162],[163]. Furthermore, the incidence peak of BL 
between the ages of 5 and 10 years at diagnosis might indicate an early initiating transforming event 
like for example in neuroblastoma which have a median incidence peak at 2 years of diagnosis. Based 
on this, it is conceivable that pediatric BL might derive from or resemble B-lymphoid cells with –
potential- stem cell features. 
 
1.4 MYC-negative Burkitt-like lymphoma 
 
In addition to MYC-positive Burkitt lymphoma, the newly identified subtype of the MYC-negative 
Burkitt-like lymphoma was extensively studied within this thesis. The identification and 
characterization of this new lymphoma subtype is presented in the following.  
 
1.4.1 Identification of MYC-negative Burkitt-like lymphoma 
 
As described above the hallmark of BL is the IG-MYC translocation. There is an ongoing discussion if a 
subset of true BL might exist lacking an IG-MYC or non-IG-MYC translocation and, thus, are MYC-
negative. In the literature 2-22 % of BL have been described to be MYC-negative [67],[108], 
[164],[165]. The discrepant frequencies might be due to a high rate of false-negative classification, as 
the breakpoints in the MYC and IG loci scatter widely. This renders the identification of a MYC break 
difficult and sometimes impossible unless an extensive set of FISH probes is used. Thus, the 
discrimination between true MYC-positive and MYC-negative BL is difficult. Recently, our group at 
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the Institute of Human Genetics, Kiel has shown the existence of a group of MYC-negative Burkitt 
lymphomas which displays a recurrent pattern of alteration on chromosome 11q [166]. In the 
following the approach leading to the identification of this lymphoma subtype is presented. 
Initially, two gene expression classifiers: the mBL index [108] and the BL-PAP index [167], were 
applied to identify molecular BL (mBL). A total of 58 genes make up the mBL gene expression 
signature which has been defined by Hummel et al. [108]. This mBL index is used to classify mature 
aggressive B-cell lymphomas in mBL (mBL index >0.95), non-BL (mBL index<0.05) and intermediate B-
cell lymphoma (0.05<mBL index<0.95) [108]. The BL-PAP index developed by Bentink et al. [167] 
identifies BL (BL-PAP) as well as four distinct groups of non-BL based on a signature of eight 
oncogene-inducible pathways. Applying these classifiers on the gene expression of the 754 
aggressive B-cell lymphomas of the Molecular Mechanisms in Malignant Lymphoma (MMML) 
network in combination with data of their MYC translocation status, revealed that 90 % of the mBL 
and 92 % of the BL-PAP carried an IG-MYC translocation or non-IG-MYC translocation. Hence, a total 
of 6 mBL and 4 BL-PAP cases lacked a MYC-translocation. After excluding those cases which were 
only defined as molecular BL by one classifier, two cases lacking a MYC-translocation remained. 
Interestingly, both cases harbored a peculiar pattern of 11q22-q24 copy gain and 11q24-qter copy 
loss. In line with this, cytogenetic studies have described MYC-negative lymphoma classified as either 
intermediate lymphoma or BL which also harbored recurrent abnormalities within chromosome 11 
such as dup(11)(q23q13) or der(11)(q) [168],[169]. Including five MYC-negative BL of the Pienkowska-
Grela et al. study [168] and seven additional MYC-negative lymphomas identified at our Institute, a 
cohort of 14 B-cell lymphomas was used for characterization of the alteration on chromosome 11q. 
All but one case harbored an interstitial gain in 11q23.2-q23.3 within a minimal region of gain 
chr11:114,530,818-117,939,359 bp (hg18). Four cases harbored a focal high-level amplification in this 
minimal region in 11q23.3 leading to the detection of a minimal region of amplification in 
chr11:117,107,631-117,939,359 bp (hg18). Furthermore, all cases harbored a telomeric loss in 
11q24.1-qter, defined as minimal region of loss chr11:126,977,015-134,445,937 bp (hg18). Strikingly, 
one case harbored a focal region of homozygous loss located at chr11:127,322,011-128,846,569 bp 
(hg18). After defining the aberration on 11q, the array-comparative genomic hybridization (CGH) 
data of cases from the MMML cohort have been mined for these alterations leading to the 
identification of three additional cases lacking a MYC-translocation. Taken together, in total 17 MYC-
negative B-cell lymphomas have been identified which harbored a recurrent gain-and-loss pattern on 
chromosome 11q.  
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1.4.2 Molecular and pathological characteristics of MYC-negative Burkitt-like lymphoma 
 
To further characterize these 17 B-cell lymphomas with 11q alteration, diverse molecular and 
pathological data were collected. The lymphomas were identified in children and young adults 
(median age at diagnosis: 16 years ranging from 6 to 76 years). The majority of patients were male 
(male:female ratio 4.7:1). The survival was excellent. In comparison to an age-matched group of 
MYC-positive BL (<40 years at diagnosis) no significant differences regarding the prognosis were 
observed. 
The presentation of MYC-negative lymphoma was more often nodal (82 %, 14/17) than in patients 
with BL younger than 40 years at diagnosis (55 %) [166]. Other than that, the cases resembled BL 
with regard to (i) morphological features including “starry sky” pattern, many mitoses and few 
infiltrating reactive lymphocytes, (ii) cytogenetic features including lack of IGH-BCL2 translocations 
and BCL2 breaks and (iii) immunophenotype being CD20+, CD10+, BCL2- and showing Ki67 positivity in 
>90 % of cells. Based on the available gene expression data from six cases of the MMML cohort the 
cell of origin could be defined as germinal center-like as it has been for BL (1.2.3). Furthermore, those 
cases showed a low MYC expression, confirming that MYC is not genomically activated in those cases.  
The array-CGH data showed a significantly higher genomic complexity in the MYC-negative 
lymphomas than in mBL and DLBCL. Concomitant to the 11q alteration, recurrent gains were 
observed in 7q34-qter, 12pter-p12.2, 18q21.2, 19pter-p13.2 and a recurrent loss in 6q14.3-q22.2. 
All these data show that the MYC-negative lymphomas resemble more BL than DLBCL, suggesting 
that this group might represent a genetic variant of the BL. Hence, they were termed “MYC-negative 
high grade B-cell lymphoma resembling Burkitt lymphoma” or shortened as MYC-negative Burkitt-like 
lymphoma (mnBLL). 
The alteration on chromosome 11q consists of a copy number gain and loss. Thus, it is conceivable 
that due to the amplification an oncogene is activated whereas due to the loss a tumor suppressor 
becomes inactivated which might provide to the lymphomagenesis of mnBLL. Combining gene 
expression data of the cases from the MMML cohort with the copy number data led to the 
identification of a few potent candidate genes like PAFAH1B2 or ETS1. Nevertheless, the underlying 
pathomechanisms of these potential candidate genes remained unclear. Thus, the aims of the 
studies conducted within this thesis are (i) to screen the region for additional potential candidate 
genes and (ii) to analyze the role of these potential candidate genes for the development or 
progression of mnBLL.  
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1.5 Aims of this thesis 
 
The aim of this thesis is the identification and characterization of new functionally relevant candidate 
genes in two mature, aggressive B-cell lymphomas of the childhood: MYC-positive Burkitt lymphoma 
and MYC-negative Burkitt-like lymphoma. 
The hallmark aberration of Burkitt lymphoma is the IG-MYC translocation. Nevertheless, it is known 
that secondary alterations are necessary to induce full-blown lymphomagenesis. Furthermore, as 
MYC is one of the four reprogramming factors sufficient to transform somatic cells to pluripotent 
stem cells, it was questioned if an association between pluripotency and BL does exist. 
Thus, the aims of the analyses of MYC-positive Burkitt lymphoma were: 
• Determination if MYC-positive Burkitt lymphoma possess potential traces of pluripotency 
• Analysis of the expression of the alternative transcripts of the TERT gene and their implications 
for BL 
• Identification of recurrently mutated genes and analysis of their tumorigenic role for BL 
 
The existence of MYC-negative Burkitt-like lymphoma, abbreviated as mnBLL, has been recently 
described by our group. The main focus has been on the characterization of this new B-cell 
lymphoma subtype. Thus, the aims of the analyses of MYC-negative Burkitt-like lymphoma were: 
• Analysis of the chromosomal landscape 
- Characterization of the alteration on chromosome 11q of newly recruited mnBLL 
- Definition of the minimal gain and loss region in 11q based on all mnBLL cases 
- Identification of further recurrent, secondary genomic alterations and involved genes  
• Analysis of the mutational landscape 
- Identification of recurrently mutated genes within the altered 11q region indicating roles as 
oncogenes or tumor suppressors 
- Identification of secondary alterations potentially contributing to the lymphomagenesis of 
mnBLL 
• Analysis of the transcriptional landscape 
- Identification of differentially expressed genes of the altered 11q region potentially 
contributing to the pathogenesis of mnBLL 
• Characterization and functional analyses of possible candidate genes and their potential role in 
the lymphomagenesis of mnBLL 
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2 Materials and Methods 
 
This chapter presents the materials used and methods applied in this thesis. Standard laboratory 
equipment, reagents and instruments are not mentioned. It is important to note, that the molecular 
genetic analyses at the Institute of Human Genetics of the Christian-Albrechts-University of Kiel were 
performed according to the determinations of the DIN EN ISO 15189:2007 and, thus, the respective 
protocols of the standard operating procedures have been used within this thesis. 
 
2.1 Materials 
 
2.1.1 Patient materials 
 
Most of the material from patients analyzed within this thesis was provided in the framework of the 
Molecular Mechanism in Malignant Lymphoma (MMML) project (n=31 B-cell lymphomas) and the 
International Cancer Genome Consortium (ICGC) MMML-Seq project (n=27 B-cell lymphomas). Some 
of the Burkitt lymphomas (BL) as well as MYC-negative Burkitt-like lymphomas (mnBLL) which were 
analyzed in the framework of this thesis have been extensively studied in already published 
manuscripts [108],[166],[170]. Thus, the reader is referred to the respective publications for an 
overview on the molecular and pathological characteristics of those cases. 
The ICGC MMML-Seq study was approved by the Institutional Review Boards of the Medical Faculty 
of the University of Kiel (A150/10) and of the recruiting centers. The protocols of the MMML network 
have been approved by central (University of Göttingen) and local review boards (Institutional 
Review Boards) of the Medical Faculty of the University of Kiel (D403/05). The lymphomas included 
in both projects were partly derived from the Berlin-Frankfurt-Münster (BFM) clinical trials which 
have also been approved by central and local institutional review boards. 
 
2.1.1.1 Characteristics of MYC-positive Burkitt lymphomas  
 
The material from 21 patients with Burkitt lymphoma (male to female ratio 6:1, median age at 
diagnosis 10 years, range 4-18 years) was provided for this study in the framework of the ICGC 
MMML-Seq (case identifier with seven-digit ID). Furthermore, material from 31 patients with Burkitt 
lymphoma (male to female ratio 2.75:1, median age 12.5 years at diagnosis, range 2-76 years at 
diagnosis) from the MMML project (case identifier starting with MPI) was studied. The tumor 
material for the analyses was obtained from the affected tissue of the patients´ lymph nodes, other 
lymphatic tissues or tumor manifestations. For an overview on the cases analyzed in this thesis refer 
to the appendices 8.1 and 8.2. 
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Moreover, whole-genome and transcriptome data, as well as the clinico-pathological data of the 
analyzed BL samples of the ICGC MMML-Seq project were available for further analyses in the 
framework of this thesis. Clinico-pathologic data of the analyzed cases of the MMML cohort were 
kindly provided by Dr. Markus Kreuz, Institute for Medical Informatics, Statistics and Epidemiology, 
University of Leipzig. 
In this thesis the number of analyzed BL cases in the different projects differed as the recruitment of 
new cases within the ICGC MMML-Seq project has been still ongoing. 
 
2.1.1.2 Characteristics of MYC-negative Burkitt-like lymphomas  
 
Table 2 gives an overview on the characteristics of the mnBLL and the techniques applied for their 
characterization performed in this study. Some of those cases have been already described by our 
Institute [166].  
Table 2: Overview on characteristics of mnBLL. 
Case Initial diagnosis 
Age 
(yrs) 
Sex Tissue/ material 450k 
Onco 
Scan 
NGS 
1
1,2
 (MPI-626) Aggressive B-NHL, BL 7 m LN/ Cryo x  x
3
 
2
1
 BL 7 m LN/ Cryo x  x
4
 
3
1
 High-grade B-NHL, atypical BL 16 f LN/ Cryo x  x
4
 
8
1
 
Mature B-cell lymphoma/ 
lymphoblastic B-lymphoma 
11 m LN/ Cryo x 
 
x
4
 
MPI-078
1,2
 Centroblastic, DLBCL 8 m LN/ Cryo x   
MPI-086
1,2
 High-grade B-cell lymphoma 14 m LN/ Cryo x   
MPI-148
1,2
 Atypical BL 26 m extranodal/ Cryo x   
MPI-315
1,2
 Centroblastic, DLBCL 49 f intestine/ Cryo x   
18 Atypical BL 14 m nasopharynx/ FFPE  x  
19 BL 4 m LN/ FFPE  x  
20 Aggressive B-cell lymphoma 23 f BM/ FFPE  x  
21 BL 8 m LN/ FFPE  x  
22 BL 27 m LN/ FFPE  x  
23 FL grade IIIb, DLBCL 17 m LN/ FFPE  x  
24 ALL 10 m BM/ FFPE  x  
25 
B-cell lymphoma, 
unclassifiable 
13 m LN/FFPE  x  
Cases denoted with 
1
 were published as part of the initial cohort [166]. Cases denoted with 
2
 were analyzed within the 
framework of the MMML project. Age, patients´ age in years (yrs) at diagnosis; sex, m for male and f for female; 
material/tissue is denoted as LN for lymph node, BM for bone marrow, cryo for cryopreserved tissue and FFPE for formalin-
fixed, paraffin-embedded tissue; initial diagnosis denotes the diagnosis of the patients before classification as mnBLL: BL, 
Burkitt lymphoma; DLBCL, diffuse-large B-cell lymphoma; FL, follicular lymphoma; NHL, non-Hodgkin lymphoma; ALL, acute 
lymphoblastic leukemia; Techniques used for the analyses: 450k, analysis of the global DNA methylation using 
HumanMethylation 450k Bead Chip; OncoScan, analyses of chromosomal imbalances using the OncoScan DNA microarray; 
NGS, next generation sequencing; 
3
 whole-genome sequencing performed within the framework of the ICGC-MMML-Seq 
project; 
4
 targeted resequencing using the TruSight
TM
 One Sequencing panel. 
 
The cases which were not part of the initial cohort (cases 18-25) were initially analyzed for the 
existence of the specific 11q alteration using fluorescence in situ hybridization (FISH) diagnostic 
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before further analyses were performed. Some cases have been identified in routine diagnostics in 
the laboratories of the Institute of Human Genetics, Kiel, Germany and by Prof. Dr. Wolfram Klapper 
(Section Hematopathology, Kiel, Germany), others were supplied by Dr. Elaine Jaffe (Laboratory of 
Pathology, National Cancer Institute, Bethesda, USA), Dr. Itziar Salaverria (Department of Pathology, 
Hematopathology Unit, Barcelona, Spain) and Dr. Kristian Schafernak (Ann & Robert H. Lurie 
Children´s Hospital of Chicago, Department of Pathology, Chicago, USA).  
 
2.1.1.3 Sera from patients with Burkitt lymphoma or Burkitt-like lymphoma  
 
Serum of a patient with mnBLL (case 10, 2.1.1.2) was used to analyze the IL10 level in comparison to 
sera of six patients with BL (BL controls) of the peripheral blood (pB) or bone marrow (bm). 
Characteristics of patients are given in Table 3. Sera were kindly provided by Dr. Christine Damm-
Welk (Department of Pediatric Hematology and Oncology, Justus-Liebig University, Giessen) in the 
framework of the NHL-BFM and MMML project. Material for FISH diagnostics was available for the BL 
controls 1, 3-4 and 6. Those cases were screened at our Institute for the existence of a MYC-break 
and 11q aberration as part of routine FISH work-up. 
Table 3: Characteristics of patients analyzed for IL10 levels in serum. 
Case Initial diagnosis Age (yrs) Sex Material MYC-break 11q alteration 
Case 10  Pediatric FL
1
 6 f pB EDTA negative positive
2
 
BL control 1 BL 14 m pB Heparin positive negative 
BL control 2 BL 3 m pB EDTA na na 
BL control 3 BL 9 m bm EDTA positive negative 
BL control 4 BL 9 m pB Heparin positive negative 
BL control 5 BL 2 m bm EDTA na na 
BL control 6 BL 11 m pB EDTA positive negative 
Age denotes patient age in years (yrs) at diagnosis; sex is denoted m for male and f for female; initial diagnosis is denoted 
BL for Burkitt lymphoma and FL for follicular lymphoma; material is denoted pB for peripheral blood and bm for bone 
marrow; na, not analyzed. 
1
 as described in [166] case 10 was classified as follicular lymphoma displaying a follicular and 
diffuse growth pattern but the cytological features were Burkitt-like. Hence it was included in the series of MYC-negative 
Burkitt-like lymphoma. 
2
 as published in [166]. 
 
2.1.2 Cell lines 
 
The identity of all cell lines used within this thesis has been validated by STR-profiling using the Stem 
Elite ID Kit as described in 2.2.5.5. 
 
2.1.2.1 Burkitt lymphoma cell lines 
 
All cell lines were obtained from the Leibniz Institute DSMZ-German Collection of Microorganisms 
and Cell Culture (Braunschweig, Germany). The only exception was the BL-30 cell line which was 
kindly provided by Dr. R. Schmitz, National Cancer Institute, NIH, Bethesda, USA. Cell line 
characteristics and first description are listed in Table 4. 
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Table 4: Characteristics of Burkitt lymphoma cell lines. 
Cell line Diagnosis Age (yrs) Sex MYC translocation EBV Status Reference 
BALM-16 Burkitt leukemia 42 m t(8;22)(q24;q11)
 1
 negative [171] 
BALM-18 Burkitt leukemia 35 m t(8;14)(q24;q32)
 2
 negative [172] 
BL-2 BL 7 m t(8;22)(q24;q11)
 1
 negative [173] 
BL-30 BL 19 m t(8;14)(q24;q32)
 2
 negative [174] 
BL-41 BL 8 m t(8;14)(q24;q32)
 1
 negative [175] 
BL-70 BL 16 m t(8;14)(q24;q32)
 1
 negative [175] 
BLUE-1 BL 29 m t(8;14)(q24;q32)
 1
 negative [176] 
Ca46 BL 16 m t(8;14)(q24;q32)
 1
 negative [177] 
DAUDI BL 16 m t(8;14)(q24;q32)
 1
 positive [178] 
DG-75 BL 10 m t(8;14)(q24;q32)
 1
 negative [179] 
EB-1 BL 9 f t(8;14)(q24;q32)
 2
 positive [180] 
EB-3 BL 3 m t(8;14)(q24;q32)
 3
 positive [181] 
Namalwa BL 3 f t(8;14)(q24;q32)
 2
 positive [178] 
Raji BL 12 m t(8;14)(q24;q32)
 1
 positive [182] 
Ramos BL 3 m t(8;14)(q24;q32)
 1
 negative not published 
U-698-M BL 7 m t(8;14)(q24;q32)
 4
 negative [183] 
Age denotes patient age in years (yrs) when cell line was established, sex is denoted m for male and f for female, reference 
refers to the first description, information of MYC translocation: 
1
from the DSMZ (http://www.dsmz.de/home.html, 
10/11/2014), 
2
 published in Murga-Penas et al. [184], 
3
 published in Berger et al. [181], 
4
 analyzed at our Institute. 
 
2.1.2.2 Non-Burkitt lymphoma cell lines 
 
The cell line MLMA was obtained from the Japanese Collection of Research Bioresources Cell Bank 
(JCRB). All other cell lines were obtained from the Leibniz Institute DSMZ-German Collection of 
Microorganisms and Cell Culture (Braunschweig, Germany). Cell line characteristics and first 
description are listed in Table 5. The data of the hallmark chromosomal aberrations were taken from 
the homepage of the DSMZ (http://www.dsmz.de/home.html, 10/11/2014). The exception was the 
data of the MLMA cell line which are in-house data. 
Table 5: Characteristics of non-Burkitt lymphoma cell lines. 
Cell line Diagnosis 
Age 
(yrs) 
Sex Hallmark chromosomal aberration Reference 
Su-DHL-6 GCB-DLBCL
1
 43 m t(14;18)(q32;q21) (IGH:BCL2) [185] 
Su-DHL-10 GCB-DLBCL
1
 25 m 
der(14)t(8;14)(q24;q32) (IGH:MYC), 
der(18)t(14;18)(q32;q21) (IGH:BCL2) 
[185] 
Karpas422 GCB-DLBCL
1
 72 f t(14;18)(q32;q21) (IGH:BCL2) [186] 
RIVA ABC-DLBCL
1
 57 f der(18)amp(18)(q21)dup(18)(q21) [187] 
Su-DHL-5 GCB-DLBCL
1
 17 f +12, del(6)(q13) [185] 
HT GCB-DLBCL
1
 70 m dup(11)(?q23qter) [188] 
MLMA malignant lymphoma
3
 32 f der(11)dup(11)(q22q25)hsr(11)(q22~23) not published 
L-428 Hodgkin lymphoma
2
 37 f complex hyperdiploid karyotype [189] 
MC-116 B-cell lymphoma
2
 n.d. n.d. t(8;14)(q24;q32) (IGH:MYC) [177] 
OCI-LY7 DLBCL
1
 48 m t(8;14)(q24;q32) (IGH:MYC) [190] 
Hek293 
Human embryonic 
kidney cell
2
 
n.d. n.d. none [191] 
Diagnosis are denoted GCB-DLBCL for germinal center B-cell like diffuse-large B-cell lymphoma and ABC-DLBCL activated B-
cell like diffuse-large B-cell lymphoma; age denotes patient age in years (yrs) when cell line was established; sex is denoted 
m for male and f for female; Reference refers to the first description of the cell lines; n.d., no data available. 
1 
diagnosis as 
defined by Schuetz et al. [192]; 
2
 diagnosis as defined on the homepage of the DSMZ (http://www.dsmz.de/home.html, 
10/11/2014), 
3
 diagnosis as defined in this thesis as described in 3.2.2.1. 
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2.1.2.3 Characterization of a cell line panel used for functional studies 
 
All functional experiments described in 3.2 were performed using a cell line panel consisting of six 
Burkitt lymphoma cell lines (BL-2, BL-41, BL-70, BLUE-1, Ca46, U-698-M), four diffuse-large B-cell 
lymphoma cell lines which can be further separated in three germinal center B-cell-like DLBCL           
(Su-DHL-6, Su-DHL-10, Karpas422) and one activated B-cell-like DLBCL (RIVA), as well as three in 3.2.2 
described mnBLL cell line models (HT, Su-DHL-5, MLMA). All DLBCL and BL cell lines were chosen 
based on the criteria that those are cell line models frequently used and published by the scientific 
community. Moreover, the BL and DLBCL cell lines were analyzed for the presence of the mnBLL-
typical gain and loss pattern on chromosome 11. To this end available SNP 6.0 array data from the 
COSMIC database and the available karyotype data from the DSMZ 
(http://www.dsmz.de/home.html, 10/11/2014) were mined for chromosomal aberrations on 
chromosome 11 as summarized in Table 6. Refer to the appendix 8.3 for the complete karyotypes of 
the cell lines. Furthermore, all BL and DLBCL cell lines were screened using a FISH assay specific for 
the gain and loss pattern on chromosome 11. Table 6 gives an overview on the characteristics of the 
reference cell line panel.  
Table 6: Overview on characteristics of the BL and DLBCL cell line of the reference cell line panel. 
 Cell line  Diagnosis 
 Karyotype 
aberration involving 
chr11q23-q25 
 SNP 6.0 array chromosome 
11q 
 11q 
gain/loss 
(FISH)
1
 
 Typical 
11q 
alteration 
BL-2 BL del(11)(q24.2) n.a. 
subclonal 
del(11q25) 
no 
BL-41 BL negative negative negative no 
BL-70 BL negative negative negative no 
BLUE-1 BL negative n.a. negative no 
Ca46 BL negative negative negative no 
U-698-M BL dup(11)(q23q13) chr11:108038477-111222713,gain negative no 
Su-DHL-6 GCB-DLBCL dup(11)(q24q25) chr11:127435602-127770927,loss 11q25 loss no 
Su-DHL-10 GCB-DLBCL der(11)t(Y;11)(q11;q25) negative negative no 
Karpas422 GCB-DLBCL negative 
chr11:110931477-117046760,gain 
chr11:125071926-125083705,loss 
11q24 
gain, 
11q25 loss 
yes 
RIVA ABC-DLBCL negative n.a. negative no 
Karyotype data available at the DSMZ homepage at (http://www.dsmz.de/home.html, 10/11/2014); SNP 6.0 array data of 
chromosome 11, available at COSMIC database (http://cancer.sanger.ac.uk/cancergenome/ projects/cell_lines/, 
10/11/2014); n.a., not available; 11q gain/loss (FISH), screening for 11q aberration pattern using FISH; positive, detection of 
11q aberration; negative, no detection of 11q aberration. 
1
The FISH analysis was performed as part of the routine FISH 
work-up at the Institute of Human Genetics, Kiel and the data were kindly provided by Dr. med. Susanne Bens. 
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2.1.3 Cell culture media 
 
Table 7: Cell culture media used in this study. 
Reagent Manufacturer 
D-MEM GIBCO Life Technologies, Carlsband, USA 
FBS, South American (CE) GIBCO Life Technologies, Carlsband, USA 
L-Alanyl-L-Glutamin (200 mM) Biochrome AG, Berlin, Germany 
RPMI-1640 GIBCO Life Technologies, Carlsband, USA 
 
2.1.4 Antibodies  
 
Table 8: Antibodies used in this study. 
Antibody [clone] Manufacturer 
Primary antibodies: 
CDw210 [3F9] BD Bioscience, Franklin Lake, New Jersey, USA 
ETS1 [EPR546(2)] Epitomics, California, USA 
FLI1 [C19] Santa Cruz Biotechnology, Texas, USA 
GAPDH [GT239] GeneTex, Irvine, CA, USA 
Goat IgG Control-PE R&D Systems, Minneapolis, USA 
ID3 [C20] Santa Cruz Biotechnology, Texas, USA 
IL10 (ab34843) Abcam, Cambridge, UK 
IL10RA (T3431) Epitomics, California, USA 
IL-10Rα-Phycoerythrin (FAB6280P) R&D Systems, Minneapolis, USA 
Lamin B1 (ab16048) Abcam, Cambridge, UK 
PAFAH1B2 (M01A) [2FA-1C10] Abnova, Taipei City, Taiwan 
β-Actin [AC-15] Sigma Aldrich, St. Louis, USA 
Secondary antibodies: 
Donkey anti-Mouse IgG (H&L), HRP Conjugate Immuno Reagents, Inc., Raleigh, USA 
Donkey anti-Rabbit IgG (H&L), HRP Conjugate Immuno Reagents, Inc., Raleigh, USA 
 
2.1.5 Primers for Sanger sequencing 
 
The initial step in the primer design was the download of the genomic sequence of the gene from the 
UCSC genome bioinformatics site (http://genome.ucsc.edu/). The primers were designed to have an 
optimal length of 18-20 bp, a GC content between 45-60 % and to harbor no repeats or run of a 
single bases. The uniqueness of the primers in the human genome was rechecked by BLAT analyses 
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) against the NCBI build 37/hg19. 
Oligonucleotides were obtained from Biomers, Ulm, Germany as lyophilisates and resuspended in 
ddH2O to a final concentration of 200 pmol/µl.  
 
2.1.5.1    Primers for Sanger sequencing of TP53 
 
The following primers were designed to screen B-cell lymphoma cell lines for mutations within exon 
4-9 of the TP53 gene on chromosome 17p13.1. 
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Table 9: Primer sequences for Sanger sequencing of TP53. 
TP53 chromosome 17p13.1 
Primer name Exon 
Primer Sequence 
(5’… 3’) 
Start (hg19) in bp Product 
Size 
Annealing 
temp. End (hg19) in bp 
TP53_Ex4_F 
4 
CGTTCTGGTAAGGACAAGGG 7,579,223 
484 bp 60 °C 
TP53_Ex4_R GGAATCCCAAAGTTCCAAAC 7,579,706 
TP53_Ex5-6_F 
5-6 
TAGTGGGTTGCAGGAGGTG 7,578,076 
594 bp 65 °C 
TP53_Ex5-6_R TCAAATAAGCAGCAGGAGAAAG  7,578,669 
TP53_Ex7_F 
7 
CCTGCTTGCCACAGGTC  7,577,384 
288 bp 55 °C 
TP53_Ex7_R GAGGTGGATGGGTAGTAGTATGG  7,577,671 
TP53_Ex8-9_F 
8-9 
TGGTTGGGAGTAGATGGAGC 7,576,758 
492 bp 60 °C 
TP53_Ex8-9_R GCCCCAATTGCAGGTAAAAC 7,577,249 
 
2.1.5.2    Primers for Sanger sequencing of CCND3 
 
The following primers were designed to screen different B-cell lymphoma cell lines for mutations 
within the hot spot mutation region in exon 5 of the CCND3 gene on chromosome 6p21.1. 
Table 10: Primer sequences for Sanger sequencing of CCND3. 
CCND3 chromosome 6p21.1 
Primer name Exon 
Primer Sequence 
(5’… 3’) 
Start (hg19) in bp Product 
Size 
Annealing 
temp. End (hg19) in bp 
CCND3_5_F 
5 
CCATGTGTTGGGAGCTGTC  41,903,607 
328 bp 65 °C 
CCND3_5_R CTGGAGGCAGGGAGGTG  41,903,934 
 
2.1.5.3    Primers for Sanger sequencing of CDKN2A 
 
The following primers were designed to screen B-cell lymphoma cell lines for mutations in exon 3-5 
of the CDKN2A gene on chromosome 9p21.3 
Table 11: Primer sequences for Sanger sequencing of CDKN2A. 
CDKN2A chromosome 9p21.3 
Primer name Exon 
Primer Sequence 
(5’… 3’) 
Start (hg19) in bp Product 
Size 
Annealing 
temp. End (hg19) in bp 
CDKN2A_Ex3_F 
3 
CACAAGCTTCCTTTCCGTCA 21,970,789 
484 bp 55 °C 
CDKN2A_Ex3_R CTGAGGCAAGACCGGAGAC  21,971,272 
CDKN2A_Ex4_F 
4 
GCAAATGCTCCCTCAGGAAT  21,968,595 
333 bp 63 °C 
CDKN2A_Ex4_R AAGATGTGGCCTTTCCCTTC  21,968,927 
CDKN2A_Ex5_F 
5 
TAGGGACGGCAAGAGAGGAG  21,968,162 
166 bp 60 °C 
CDKN2A_Ex5_R CCTGTAGGACCTTCGGTGAC  21,968,327 
 
2.1.5.4    Primers for Sequencing of ID3 
 
The following primers for the ID3 gene on chromosome 1p36.12 were designed to screen B-cell 
lymphoma cell lines for mutations within this gene as has been published by Richter et al. [170]. The 
primer pair covers the complete coding region of the gene including parts of the 3’UTR and the 
complete 5’UTR as well as the complete intron 1.  
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Table 12: Primer Sequences for Sanger Sequencing of ID3. 
ID3 chromosome 1p36.12 
Primer name 
Primer Sequence 
(5’… 3’) 
Start (hg19) in bp 
Product Size Annealing temp. 
End (hg19) in bp 
ID3_F TCCAGGCAGGCTCTATAAGTG  23,885,341 
694 bp 65 °C 
ID3_R CCGAGTGAGTGGCAATTTTT  23,886,034 
 
2.1.5.5    Primers for Sanger sequencing of CREBBP 
 
The following primers were designed to screen B-cell lymphoma cell lines for mutations in the 
CREBBP gene on chromosome 16p13.3. 
Table 13: Primer sequences for Sanger sequencing of CREBBP. 
CREBBP chromosome 16p13.3 
Primer name Exon 
Primer Sequence 
(5’… 3’) 
Start (hg19) in bp Product 
Size 
Annealing 
temp. End (hg19) in bp 
CREBBP_Ex1_F 
1 
GCTCCTCTCCCTCGCAG  3,929,763 
253 bp 65 °C 
CREBBP_Ex1_R CCGGACGCTCTCTTTCAG  3,930,015 
CREBBP_Ex2a_F 
2 
CATAGAAACGTGGCAGTTGG  3,900,593 
490 bp 60 °C 
CREBBP_Ex2a_R GTGGCAGGGCTGCTAGTC  3,901,082 
CREBBP_Ex2b_F CCTAAACAGGCAGCCAGC  3,900,229 
468 bp 60 °C 
CREBBP_Ex2b_R TTTACGCATTACTCGGAGGG  3,900,696 
CREBBP_Ex3_F 
3 
GAAACTGTGTGAGCATTTCCC  3,860,489 
374 bp 55 °C 
CREBBP_Ex3_R CCTATCACCTACTGACACACTTTTAG 3,860,862 
CREBBP_Ex4_F 
4 
GTGGTCGGTATTATCCATCAGC  3,843,336 
400 bp 65 °C 
CREBBP_Ex4_R GGCAAATTCTTCCTGACCTC  3,843,735 
CREBBP_Ex5_F 
5 
GGTCTGCCTATACTGTGTTATGG  3,841,838 
390 bp 60 °C 
CREBBP_Ex5_R TGTACCTTGGGCTGCTGTC  3,842,227 
CREBBP_Ex6_F 
6 
AAATCATTCGTGGGCTTCTC 3,832,600 
397 bp 60 °C 
CREBBP_Ex6_R CTGAAAACTGCCTTGGGTTC  3,832,996 
CREBBP_Ex7_F 
7 
ATGGTGGCATGTTGGTTATC  3,831,138 
257 bp 60 °C 
CREBBP_Ex7_R CAGTTTTGTGTGGTTCTCAGTC  3,831,394 
CREBBP_Ex8_F 
8 
TGGTGGCAGAAGAACCTTAC  3,830,629 
332 bp 60 °C 
CREBBP_Ex8_R AAGCACGTGACTTGTATAGGC  3,830,960 
CREBBP_Ex9_F 
9 
AGGTGATTCTCCCGCCTCAG  3,828,551 
401 bp 65 °C 
CREBBP_Ex9_R ATCTGGGAAGTCTCCTTGGTC  3,828,951 
CREBBP_Ex10_F 
10 
GTTAGAACCTACAACACAGATCATTC 3,827,942 
320 bp 60 °C 
CREBBP_Ex10_R ATACACCCCAAACACGAAGG  3,828,261 
CREBBP_Ex11_F 
11 
GCTTTTGGACCTATTGGCTG  3,827,410 
378 bp 60 °C 
CREBBP_Ex11_R TTGGAAGATCTTTCCTATAATCTCC  3,827,787 
CREBBP_Ex12_F 
12 
TTCTGTTGCCTGTGCGTTC  3,824,487 
320 bp 55 °C 
CREBBP_Ex12_R CAAGTGACATGAATTCTGCTGC  3,824,806 
CREBBP_Ex13_F 
13 
CATCCTCTGGGGTTGTGAAG  3,823,635 
399 bp 55 °C 
CREBBP_Ex13_R CATGAAATGTGCATTCTGGA  3,824,033 
CREBBP_Ex14_F 
14 
TCCATTTCTGGTAGGGACAGGTGC  3,820,539 
463 bp 60 °C 
CREBBP_Ex14_R GGCCCAAAAACAGCAGAGACAGA  3,821,001 
CREBBP_Ex15_F 
15 
TTGTAGGTTGCATGAGCAGC  3,819,081 
356 bp 55 °C 
CREBBP_Ex15_R CAGGGATACCCATGGCAG  3,819,436 
CREBBP_Ex16_F 
16 
CTTCCCGTGAGGTTGCG  3,817,651 
329 bp 55 °C 
CREBBP_Ex16_R TCCTCCACATGGAATCCTAAC  3,817,979 
CREBBP_Ex17_F 
17 
CTTAGGAGCATCGTGGCTG  3,808,746 
342 bp 60 °C 
CREBBP_Ex17_R ACAATCTTCAAGGCAGGGG  3,809,087 
CREBBP_Ex18_F 
18 
TTGGGAATGGAAGTTATTTTGG  3,807,688 
484 bp 60 °C 
CREBBP_Ex18_R CACCAGACAGCAGATTGCAC  3,808,171 
CREBBP_Ex19_F 
19 
TCACATGCTATCCCAAAATGTC  3,807,172 
369 bp 60 °C 
CREBBP_Ex19_R GCCTGAAATTGGGCCAC  3,807,540 
CREBBP_Ex20_F 
20 
TTGCTTGGGTGGCTGTG 3,801,630 
241 bp 60 °C 
CREBBP_Ex20_R ATGGCACCGGTACCTTCC 3,801,870 
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Table 13 continued 
Primer name Exon 
Primer Sequence 
(5’… 3’) 
Start (hg19) in bp Product 
Size 
Annealing 
temp. End (hg19) in bp 
CREBBP_Ex21_F 
21 
GTTACAAAATAACATTCCAGAGACC 3,799,547 
227 bp 60 °C 
CREBBP_Ex21_R CCCACAACCCACTCCATAAG  3,799,773 
CREBBP_Ex22-23_F 
22-23 
GGACGCACACACAGACTTCTAC  3,794,816 
621 bp 60 °C 
CREBBP_Ex22-23_R AACCAAAGAACAATGGGGAC 3,795,436 
CREBBP_Ex24_F 
24 
ATCCCAGAGTCCACCTTTCC  3,790,319 
424 bp 60 °C 
CREBBP_Ex24_R CAAGAGCTTTGCAGAGAGCA  3,790,740 
CREBBP_Ex25_F 
25 
GGTGTGCAGAAGCACCTTG  3,789,484 
306 bp 65 °C 
CREBBP_Ex25_R GAAGGCTCACAGGCTCCTC  3,789,789 
CREBBP_Ex26_F 
26 
AATGACAGAGCAAGACCCTG  3,788,475 
315 bp 55 °C 
CREBBP_Ex26_R TTAAAATACCCATTATTTCACGG  3,788,788 
CREBBP_Ex27_F 
27 
TAACTCCTTAAAGGCAGGGC  3,786,584 
300 bp 55 °C 
CREBBP_Ex27_R AAAAGGCACACAAATATCCTCC  3,786,883 
CREBBP_Ex28_F 
28 
CATGGGACTCTGCCACAC  3,785,931 
388 bp 60 °C 
CREBBP_Ex28_R GACACCACCACAGGAAGGAC  3,786,318 
CREBBP_Ex29_F 
29 
TGACCTACTTTGGCCTGAGC  3,781,671 
377 bp 65 °C 
CREBBP_Ex29_R ACTTCCCTCCCACCACAGAC  3,782,047 
CREBBP_Ex30_F 
30 
CTATTCTGCAGGCTGGGTG  3,781,127 
442 bp 60 °C 
CREBBP_Ex30_R AAAGGGACAGGATGCTTCG  3,781,568 
CREBBP_Ex31.1_F 
31 
GCACAGACCCAGACTTAGC  3,779,394 
580 bp 55 °C 
CREBBP_Ex31.1_R GGAGAAGGCAGACTCTGC  3,779,973 
CREBBP_Ex31.3_F CCTGTACCGGGTGAACATCAAC  3,778,459 
 677 bp  60 °C 
CREBBP_Ex31.3_R GCTGCCTCCGTAACATTTCTCG  3,779,135 
CREBBP_Ex31.4_F CCAAGTACGTGGCCAATCAG  3,778,015 
717 bp 65 °C 
CREBBP_Ex31.4_R ACCGCACCTGGTTACTAAGG  3,778,731 
CREBBP_Ex31.5_F CAACATCCAGCAAGCCC 3,777,646 
548 bp 65 °C 
CREBBP_Ex31.5_R GAACCTAGATGCCTGGATTTTC  3,778,193 
 
2.1.5.6    Primers for Sanger sequencing of PCBP1 
 
The following primers for the PCBP1 gene on chromosome 2p13.3 were designed to validate 
mutations detected by whole-genome sequencing in BL and to screen for mutations in cell lines as is 
denoted in a manuscript accepted for publication in the journal Genes, Chromosomes and Cancer. 
Table 14: Primer sequences for Sanger sequencing of PCBP1. 
PCBP1 chromosome 2p13.3 
Primer name Exon 
Primer Sequence 
(5’… 3’) 
Start (hg19) in bp Product 
Size 
Annealing 
temp. End (hg19) in bp 
PCBP1_part1_F 
 1 
GCCAGCCGCCAAAGACTTGA  70,314,811 
711 bp 65 °C 
PCBP1_part1_R CCTCCAGGTCATGGGTGGCATG  70,315,521 
PCBP1_part2_F GGATATGCTGCCCAACTCCACCG  70,315,280 
748 bp 60 °C 
PCBP1_part2_R CCTGGAATCACTGACCAG  70,316,027 
 
2.1.5.7    Primers for Sanger sequencing of SMARCA4 
 
The following primers for SMARCA4 on chromosome 19p13.2 have been published by 
Schneppenheim et al. [193] and were used for validation of mutations detected by whole genome 
sequencing and for screening of mutations in the helicase domain of SMARCA4 in B-cell lymphoma 
cell lines. 
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Table 15: Primer sequences for Sanger sequencing of SMARCA4. 
SMARCA4 chromosome 19p13.2 
Primer name Exon 
Primer Sequence 
(5’… 3’) 
Start (hg19) in 
bp 
Product 
Size 
Annealing 
temp. 
End (hg19) in bp 
SMARCA4_Ex9_F 
9 
GCCTTGCGGGGAGATGTGTCCACCATGCTG 11,105,437 
315 bp 65°C  
SMARCA4_Ex9_R GGGGAGTGACCCCTGGAGCCCGCAGTACC 11,105,751 
SMARCA4_Ex15_F 
15 
GTCAGGAGCCAGCACATTGTCACAGATAG 11,120,988 
287 bp 65°C 
SMARCA4_Ex15_R CGCACCACCTGGGAACACCTGCACCGAGG 11,121,274 
SMARCA4_Ex16_F 
16 
AGGACCCTCTGGTGTCCGACCCGGCCTTC 11,123,565 
311 bp 65°C 
SMARCA4_Ex16_R TTGTGGTATTCTACTGCGGCAAACTTAGG 11,123,875 
SMARCA4_Ex17_F 
17 
TTGCACAGTGAGCCATTGATGAGAGACCG 11,129,573 
215 bp 65°C 
SMARCA4_Ex17_R TCACTGTCCAGAGGTATGTGTGGACGTC 11,129,787 
SMARCA4_Ex18_F 
18 
GTGCCTGTGCCCCTCTTGCCACCTGGCC 11,130,195 
273 bp 65°C 
SMARCA4_Ex18_R AACTTGTAGGGGCTTTGGAGGAGACGGGC 11,130,467 
SMARCA4_Ex19_F 
19 
CTCCCCATGTGCCGGGCCACCTGCTGCCC 11,132,340 
392 bp 65°C 
SMARCA4_Ex19_R CCAGCTGTAGCTGGTGCTCAACACGTTCC 11,132,731 
SMARCA4_Ex20_F 
20 
CCTTCTAGTGAGACCTCTGTCGCCCTCC 11,134,124 
271 bp 65°C 
SMARCA4_Ex20_R TGGGGAGAGGCCCTGAGCACGCCCAGCCC 11,134,394 
SMARCA4_Ex21_F 
21 
GGGTTCGGATGGGGGGAGTCAGGCCTCAA 11,134,938 
243 bp 65°C 
SMARCA4_Ex21_R CTGCCTGCCACGCTGCCGGCCTTGGACAC 11,135,180 
SMARCA4_Ex22_F 
22 
AGCCCACCCCACCCCAGGAGGGCAAGACC 11,136,039 
227 bp 65°C 
SMARCA4_Ex22_R GAGCTGTCGAGGAGAAGCCAGCTCTGCC 11,136,265 
SMARCA4_Ex23_F 
23 
GGACCGCAGCGGGGCCCGGTGGCCTGCTC  11,136,911 
189 bp 60°C 
SMARCA4_Ex23_R GCAATAAAGCCAACAAAACGACAGAAAAC  11,137,099 
SMARCA4_Ex24_F 
24 
CCTGCCTTACCTGCCTGCAGGGTTCCAGG  11,138,388 
307 bp 60°C 
SMARCA4_Ex24_R GTGAGGAGCTTCTGTGGCAGCCACAACAAC 11,138,694 
SMARCA4_Ex25_F 
25 
TCCTTGGTGTCCCCACTCTACCCCTGAGG  11,141,340 
299 bp 65°C 
SMARCA4_Ex25_R GGCCGTCTCCTCGAGGTTTTGCAGGCACC  11,141,638 
SMARCA4_Ex26_F 
26 
CAGAGGCCACCTTCCCTTTTATGACCTCC  11,143,899 
357 bp 65°C 
SMARCA4_Ex26_R GAAAGCCGCTCACGCGTCCACCATTCACGC 11,144,255 
SMARCA4_Ex27_F 
27 
AACTGCTGGTGAAAGACGCCGGATTGACA 11,144,380 
233 bp 65°C 
SMARCA4_Ex27_R GGCCCTTGCTGGCCGTCTCAGCCGAGAAG  11,144,612 
SMARCA4_Ex28_F 
28 
GCTCGGCCGCCGCCCACCCCGGCCCCTCC  11,144,739 
234 bp 65°C 
SMARCA4_Ex28_R CTAGGGATACCACCATGGGCACTAGGACG  11,144,972 
SMARCA4_Ex30_F 
30 
CGGCCTCTGCTTGTCGACCTGGGTGCTGG  11,151,923 
383 bp 65°C 
SMARCA4_Ex30_R GAGTGCAGATGCCAGGCCTGCTCCCACGG  11,152,305 
SMARCA4_Ex33_F 
33 
GGCCGGGCAGGCAGCCCTCCAGTCGGGCC 11,170,368 
262 bp 65°C 
SMARCA4_Ex33_R AAAGCTGGGGCCTTGGGGGCTCTCGGGCC 11,170,629 
 
2.1.6 Primers for validation of TERT transcripts on cDNA level 
 
The following primers were designed to validate the existence and expression of a new exon of the 
TERT gene (NM_198253.2) on chromosome 5p15.33, as well as for Sanger sequencing of the PCR 
product.  
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Table 16: Primer for validation of existence and expression of a new exon of the TERT gene. 
TERT chromosome 5p15.33 
Primer used for  
Primer name 
Primer Sequence 
(5’… 3’) 
Start (hg19) in bp 
Product 
Size 
Annealing 
temp. End (hg19) in bp 
sequencing of 5’ 
end of new exon 
TERT_Ex2_F 
CTCCAGGCACAACGAACGC  
1,287,089 
176 bp 60 °C 
TERT_Ex 
new_R1 
GATCAACACACACTCGGCAGG  
1,293,564 
detection of TERT 
new exon and 
exon2V transcript 
TERT_Ex2V2_F 
CGAGTGGACACGGTGATCTC  
1,285,577 
296 bp 60 °C 
TERT_Ex 
new_R1 
GGCAACCCAAGAGGTGGTGAG 
1,294,834 
detection of splice 
variants of TERT 
new exon, 
sequencing of 3’ 
end of new exon 
TERT_Ex new_F CCAGCTTTACCTGTGCTGG  1,282,669 447 bp, 
222 bp, 
181 bp 
65 °C 
TERT_Ex3_R CAGCCAGTGCAGGAACTTGG  1,286,390 
detection of basal 
TERT expression 
TERT_Ex3_F 
CGTCGTCGAGCTGCTCAGGTC  
1,253,287 
137 bp 60 °C 
TERT_Ex4_R 
GCTGCACCCTCTTCAAGTGC 
1,283,125 
 
2.1.7 Primers for quantitative real-time PCR (qPCR) 
 
2.1.7.1    Self-designed qPCR primers 
 
Primers were designed and the uniqueness in the human genome was rechecked by BLAT analyses 
(http://genome.ucsc.edu/cgi-bin/hgBlat?command=start) against the NCBI build 37/hg19. 
Oligonucleotides were obtained from Biomers, Ulm, Germany as lyophilisates and resuspended in 
ddH2O to a final concentration of 200 pmol/µl. The primers were designed to have an optimal 
annealing temperature at 58°C. 
 
Table 17: Self-designed primers for qPCR. 
Gene Primer name 
Detected 
Transcript 
Primer Sequence  
(5’… 3’) 
Chr 
Start (hg19) in bp Product 
Size End (hg19) in bp 
IL10 
IL10_qPCR_F 
NM_000572.2 
CTACGGCGCTGTCATCGAT  
1 
206,940,948 
110 bp 
IL10_qPCR_R CTCATGGCTTTGTAGATGCC  206,945,839 
KMT2A 
KMT2A_qPCR_F NM_001197104.1 
NM_005933.3  
CCAGTAGTGGGCATGTAGAG  
11 
118,355,671 
156 bp 
KMT2A_qPCR_R GATGTTGCCTTCCACAAACG  118,359,464 
 
2.1.7.2    Pre-designed qPCR primers 
 
Predesigned oligonucleotides were obtained from Qiagen, Hilden, Germany as lyophilisates and 
resuspended in ddH2O according to manufacturer´s instruction. 
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Table 18: Predesigned qPCR primers obtained from Qiagen. 
Gene Detected transcript(s) QuantiTect Primer Assay 
ETS1 NM_005238 Hs_ETS1_1_SG 
FLI1 NM_001167681, NM_002017 Hs_FLI1_1_SG 
IL0RA NM_001588 Hs_IL10RA_1_SG 
PAFAH1B2 NM_002572 Hs_PAFAH1B2_1_SG 
GUSB NM_000181 Hs_GUSB_1_SG 
HPRT1 NM_000194 Hs_HPRT1_1_SG 
 
2.1.8 Plasmids 
 
Commercially available vectors were obtained as DNA solutions. Table 19 lists plasmid DNA used in 
this study. Refer to 8.5 for the vector maps of the respective plasmids. 
Table 19: List of plasmid DNA used in this study. 
Plasmid DNA Function Manufacturer 
ID3-pCMV6-AC-GFP 
(RG200583) 
expression of ID3 (NM_002167.2) in B-
cell lymphoma cell lines 
OriGene Technologies, Rockville, USA 
pMD.G 
Packaging plasmids for generation of 
lentiviral vectors 
Kindly provided by Dr. rer. nat. E. Murga 
Penas, Institute of Human Genetics, Kiel 
pCMV-dR8.91 
Packaging plasmids for generation of 
lentiviral vectors 
Kindly provided by Dr. rer. nat. E. Murga 
Penas, Institute of Human Genetics, Kiel 
pLKO_IPTG_3xLacO 
non-targeting control 
shRNA 
Negative control for baseline cellular 
response to knock down experiments 
Sigma Aldrich, St. Louis, USA 
pLKO_IPTG_3xLacO 
PAFAH1B2 shRNA1 
(TRCN0000218283) 
Knock down of PAFAH1B2 expression in 
B-cell lymphoma cell lines 
Sigma Aldrich, St. Louis, USA 
pLKO_IPTG_3xLacO 
PAFAH1B2 shRNA2 
(TRCN0000218878) 
Knock down of PAFAH1B2 expression in 
B-cell lymphoma cell lines 
Sigma Aldrich, St. Louis, USA 
pLKO_IPTG_3xLacO 
PAFAH1B2 shRNA3 
(TRCN0000230674) 
Knock down of PAFAH1B2 expression in 
B-cell lymphoma cell lines 
Sigma Aldrich, St. Louis, USA 
pmax 
Control of transfection efficiency, 
contains GFP gene 
Amaxa/Lonza, Cologne, Germany 
 
2.1.9 Special laboratory equipment 
 
Laboratory equipment, which was specifically used for experiments in this study, is listed in Table 20. 
Standard laboratory equipment is not separately listed. 
Table 20: Lab equipment used in this study. 
Equipment Manufacturer 
Amersham Hyperfilm
TM
 ECL (5x7 inch) GE Healthcare, Munich, Germany 
Criterion TGX Precast Gel Any kD  Bio-Rad, Munich, Germany 
Criterion TGX Precast Gel 18 % Resolve Bio-Rad, Munich, Germany 
Hypercassette
TM
 GE Healthcare, Munich, Germany 
Immobilin-P PVDF membrane Merck Millipore, Darmstadt, Germany 
Magnetic beads Agencourt, Beverly, MA, USA 
Neubauer hematocytometer Brand, Wertheim, Germany 
Polystrene Round-Bottom Tube (FACS) BD Bioscience, Franklin Lake, New Jersey, USA 
Tissue culture flasks T25 Sarstedt, Newton, USA 
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Table 20 continued 
Equipment Manufacturer 
Tissue culture flasks T75 Sarstedt, Newton, USA 
Tissue culture plate, 6-well Sarstedt, Newton, USA 
Tissue culture plate, 24-well Sarstedt, Newton, USA 
Tissue culture plate, 96-well Sarstedt, Newton, USA 
Whatman filter paper GE Healthcare, Munich, Germany 
 
2.1.10 Chemicals and reagents 
 
The following Table 21 lists all chemicals and reagents used in this study and their manufacturers. 
Standard chemicals are not separately listed. 
Table 21: Chemicals and reagents used in this study. 
Chemicals and reagents Manufacturer 
Acetic acid J.T. Baker, Griesheim, Deutschland 
Agar-Agar Merck Millipore, Darmstadt, Germany 
Agarose Biozym, Hessisch Oldendorf, Germany 
Aqua bidest (ddH2O) Fresenius Kabi AG, Bad Homburg, Germany 
BKM120 Selleckchem, Houston, USA 
Blotto, non-fat dry milk powder Santa Cruz Biotechnology, Texas, USA 
Bromphenol Blue Serva, Heidelberg, Germany 
Carbenicillin Sigma Aldrich, St. Louis, USA 
Cell Titer Blue reagent Promega, Mannheim, Germany 
cOmplete
TM
 Protease Inhibition cocktail (PIC) Tablet Roche, Rotkreuz, Switzerland 
Denhardt´s solution Sigma Aldrich, St. Louis, USA 
DMSO Sigma Aldrich, St. Louis, USA 
dNTP Roche, Rotkreuz, Switerland 
EB-buffer Qiagen, Hilden, Germany 
Ethanol J.T. Baker, Griesheim, Deutschland 
Ethidiumbromide Sigma Aldrich, St. Louis, USA 
Glycerol Sigma Aldrich, St. Louis, USA 
Glycine Sigma Aldrich, St. Louis, USA 
Hering Sperm DNA Promega, Mannheim, Germany 
Human Cot-1 Life Technologies, Carlsband, USA 
Human Total RNA Master Panel II Clontech, Daint-Germain-en-Laye, France 
HyperLadder I Bioline, Taunton, USA 
IGEPAL CA-630 Sigma Aldrich, St. Louis, USA 
IPTG Sigma Aldrich, St. Louis, USA 
Isopropyl alcohol Sigma Aldrich, St. Louis, USA 
LB broth base Life Technologies, Carlsband, USA 
Luminata
TM
 Forte Western HRP Substrate Merck Millipore, Darmstadt, Germany 
MES hydrate Sigma Ultra Sigma Aldrich, St. Louis, USA 
MES sodium salt Sigma Aldrich, St. Louis, USA 
Methyl alcohol J.T. Baker, Griesheim, Deutschland 
Methylated DNA Merck Millipore, Darmstadt, Germany 
Nsp I New England Biolabs, Frankfurt a.M., Germany 
NuPAGE LDS loading buffer (4x) Life Technologies, Carlsband, USA 
Paraformaldehyde Sigma Aldrich, St. Louis, USA 
PBS GIBCO Life Technologies, Carlsband, USA 
Polybrene Merck Millipore, Darmstadt, Germany 
Ponceau Red Sigma Aldrich, St. Louis, USA 
Precision PlusPotein Standard DualXtra  Bio-Rad, Munich, Germany 
Puromycin Sigma Aldrich, St. Louis, USA 
RNase A Qiagen, Hilden, Germany 
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Table 21 continued 
Reagents Manufacturer 
Roentoroll 25, part 1 and part2 Tetenal, Norderstedt, Germany 
Roti®-Histol Carl ROTH, Karlsruhe, Germany 
SDS Serva, Heidelberg, Germany 
S.O.C. medium Life Technologies, Carlsband, USA 
Sodium cholorid (NaCl) Merck Millipore, Darmstadt, Germany 
Sodium deocycholat (Na-DOC) Sigma Aldrich, St. Louis, USA 
Streptavidin coated Sepahrose beads GE Healthcare, Munich, Germany 
Sty I New England Biolabs, Frankfurt a.M., Germany 
Superfix 25 Tetenal, Norderstedt, Germany 
T4 DNA Ligase New England Biolabs, Frankfurt a.M., Germany 
10x TBE buffer Life Technologies, Carlsband, USA 
TITANIUM Taq Polymerase Takara Clontech, Daint-Germain-en-Laye, France 
TMACL Sigma Aldrich, St. Louis, USA 
TriDye ladder New England Biolabs, Frankfurt/Main, Germany 
TritonX-100 Sigma Aldrich, St. Louis, USA 
TRIS Merck Millipore, Darmstadt, Germany 
TRIS-HCl Sigma Aldrich, St. Louis, USA 
Trypan blue solution (0.4 %) Sigma Aldrich, St. Louis, USA 
Trypsin EDTA (1x) GE Healthcare, Munich, Germany 
Tween®20 Sigma Aldrich, St. Louis, USA 
 
2.1.11 Buffers and solutions 
 
The following table enlists all buffers and solutions used in this study as well as their composition. If 
not other specified the buffers were used at room temperature. 
 
Table 22: Buffers and solutions used in this study. 
Buffers and solutions Composition 
Agarose gel loading buffer  1.9 mM Bromphenol blue  
3.1 M glycerol  
add ddH2O to 100 ml  
store at 4°C 
Antibody diluent (WB) 1.5 g Blotto, non-fat milk powder 
TBS-T to 50 ml 
Bjerrum Schäfer transfer buffer, 10x 480 mM TRIS 
380 mM glycine 
ddH2O to 1 l 
Bjerrum Schäfer transfer buffer, 1x 100 ml 10x Bjerrum Schäfer transfer buffer 
100 ml methyl alcohol 
ddH2O to 1 l, store at 4 °C 
Blocking Solution (WB) 3 g Blotto, non-fat milk powder 
TBS-T to 50 ml 
FACS wash buffer 0.5 % FBS 
PBS to 50 ml 
FACS wash buffer II 0.5 % FBS 
0.5 % Tween®20 
PBS to 50 ml 
Freezing media 10 % DMSO 
FBS to 50 ml 
Store at 4 °C 
LB medium 20 g LB 
ddH2O to 1 l, 
autoclave and store at 4 °C 
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Table 22 continued 
Buffers and solutions Composition 
LB agar 10 g LB 
15 g Agar-Agar 
ddH2O to 0.5 l 
autoclave and store at 4 °C 
Paraformaldehyde solution 1 % in PBS 1 g paraformaldehyde 
PBS to 100 ml 
Boil until dissolved and store at 4 °C 
Permeabilization buffer 0.5 % Tween20 
PBS to 50 ml 
Ponceau Red Staining Solution 0.5 % Ponceau S 
1 % acetic acid 
ddH2O to 100 ml 
RIPA 50 mM TRIS-HCl (pH8) 
150 mM NaCl 
1 % IGEPAL 
0.5 % Na-DOC 
0.1 % SDS 
1 cOmplete
TM
 PIC Tablet 
ddH2O to 50 ml 
store at -20 °C 
SDS-running buffer, 10x 250 mM TRIS 
2 M glycine 
1 % SDS 
ddH2O to 1 l 
SDS-running buffer, 1x 100 ml 10x SDS-running buffer 
ddH2O to 1 l 
TBE, 1x  100 ml 10x TBE buffer 
ddH2O to 1 l 
TBS, 10x 5 M NaCl 
0.2 TRIS 
ddH2O to 1 l 
TBS, 1x 100 ml TBS 
ddH2O to 1 l 
TBS-T 0.1 % Tween®20 
1 l 1x TBS 
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2.1.12 Kits 
 
The kits which have been used in this study and their manufacturer are listed in Table 23.  
Table 23: Name and manufacturer of the kits used in this study. 
Kits Manufacturer 
AccuPrime Polymerase System Life Technologies, Carlsband, USA 
AmpliTaq Gold Polymerase System Life Technologies, Carlsband, USA 
BCA Macro Assay Kit Serva, Heidelberg, Germany 
Big Dye Terminator® v1.1 Cycle Sequencing Kit Applied Biosystems, Foster City, USA 
Cell Line Nucleofector® Kit V Amaxa/Lonza, Cologne, Germany 
EasyPure DNA Purification Kit Biozym, Hessisch Oldendorf, Germany 
Experion® RNA StdSens Analysis Kit Bio-Rad, Munich, Germany 
EZ-96 DNA Methylation
TM
 Kit Zymo Research, Freiburg, Germany 
Genome wide human SNP NSP/STY Assay Kit 5.0/6.0 Affymetrix, Santa Clara, USA 
Human IL-10 ELISA Kit Thermo Scientific, Waltham, Massachusetts, USA 
Human Methylation 450k Beadchip Kit Illumina, San Diego, USA 
jetPEI transfection reagent Polyplus-transfection, Illkirch, France 
Lenti-X
TM
 GoStix
TM
 Clontech, Daint-Germain-en-Laye, France 
Montage 96 Well Sequencing Reaction Cleanup kit Merck Millipore, Darmstadt, Germany 
NucleoBond Xtra Maxi EF plasmid purification kit Machery-Nagel, Düren, Germany 
OncoScan
TM
 FFPE Assay Kit  Affymetrix, Santa Clara, USA 
One Shot® TOP10 Chemically Competent E.coli Life Technologies, Carlsband, USA 
PARIS
TM
 kit Life Technologies, Carlsband, USA 
PUREGENE DNA Isolation Kit (Gentra Systems) Qiagen, Hilden, Germany 
RNeasy Mini kit Qiagen, Hilden, Germany 
QIAmp DNA FFPE tissue kit Qiagen, Hilden, Germany 
Qiagen MiniElute 96 PCR Purification Kit Qiagen, Hilden, Germany 
OncoScan
TM
 FFPE Assay Kit Affymetrix, Santa Clara, USA 
QuantiTect®Reverse Transcription Kit Qiagen, Hilden, Germany 
QuantiTect®SYBR®Green PCR Kit Qiagen, Hilden, Germany 
Qubit® dsDNA BR assay Life Technologies, Carlsband, USA 
Qubit RNA HS assay Life Technologies, Carlsband, USA 
STEM ELITE ID Promega, Mannheim, Germany 
TruSightTM One Sequencing Panel Illumina, San Diego, USA 
 
2.1.13 Instruments 
 
The following table lists the instruments used in this study. Standard instruments are not separately 
listed. 
Table 24: Instruments used in this study. 
Instruments Model Manufacturer 
Autoclave V-Autoklav Webeco, Fridolfing, Germany 
Centrifuge (Cell culture) Centrifuge 5810 Eppendorf, Hamburg, Germany 
Centrifuge (Cell culture) Multifuge 1L-R (rotor: 75002000) Heraeus, Hanau, Germany 
Centrifuge (DNA, Eppendorf tube) Biofuge primo R (rotor: 7593) Heraeus, Hanau, Germany 
Centrifuge (DNA, 15 ml falcon tube) Megafuge 1.0 R (rotor: BS4402/A) Heraeus, Hanau, Germany 
Centrifuge (Methylation, plate) Megafuge 40R (rotor: 75003607) Heraeus, Hanau, Germany 
Centrifuge (Eppendorf tubes) Mikro 200 (rotor: 1195-A) Hettich, Tuttlingen, Germany 
Centrifuge (Protein, bacteria 
harvest) 
Multifuge X1R (rotor: 75003602, 
75003658) 
Heraeus, Hanau, Germany 
Centrifuge (Preparation of 
recombinant bacteria) 
SORVALL SUPER T21 (rotor: SL-
50T) 
Thermo Scientific, Waltham, 
Massachusetts, USA 
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Table 24 continued 
Instruments Model Manufacturer 
CO2 incubator for cell culture Galaxy B nunc
TM
 RS Biotech, Irvine, UK 
Electroporator Nucleofector I device Lonza, Cologne, Germany 
ELISA plate reader Synergy HT BioTek, Luzern, Switzerland 
Flow cytometer AccuriC6 
BD Bioscience, Franklin Lake, 
New Jersey, USA 
Flow cytometer FACS Calibur Analyzer 
BD Bioscience, Franklin Lake, 
New Jersey, USA 
Fluorescence microscope Eclipse TS100 Nikon, Tokyo, Japan 
Fluorometer Qubit 2.0 Life Technologies, Carlsband, USA 
Gene-Chip Washing Station Gene Chip® Fluidics Station 450 Affymetrix, Santa Clara, USA 
Gel chamber Model 41-2026 Promega, Mannheim, Germany 
Gel chamber 
Hoefer HE 33 mini horizontal 
submarine unit 
Amersham Bioscience, Munich, 
Germany 
Gel chamber for SDS-Page Criterion Cell Bio-Rad, Munich, Germany 
Gel documentation device BioDoc Analyzer Biometra, Göttingen, Germany 
Hybridization Oven 
GeneChip® Hybridization Oven 
645 
Affymetrix, Santa Clara, USA 
Hybridization Oven (450k array) Hybrid oven Illumina, San Diego, USA 
Incubator Function Line Heraeus, Hanau, Germany 
Incubator with shaking device for 
bacteria 
SM30 Edmund Bühler GmbH, Tübingen 
Incubator for bacteria B5025 Heraeus, Hanau, Germany 
Incubator (450k array) Hybex-microsample incubator Illumina, San Diego, USA 
Microfuidics system Experion® Electrophoresis System Bio-Rad, Munich, Germany 
Microscope Photo Zoom inverted microscope 
Cambridge Instruments, Wetzlar, 
Germany 
Microwave M500 Philips, Hamburg, Germany 
Plate shaker MS 3 basic IKA, Staufen, Germany 
Plate shaker (450k array) High-Speed Microplate Shaker Illumina, San Diego, USA 
Power Supply for western blot Power Pac HC
TM
 Bio-Rad, Munich, Germany 
Power Supply for agarosegel ST606 Life Technologies, Carlsband, USA 
quantitative real-time PCR 
instrument 
LightCycler® 480 II Roche, Rotkreuz, Switzerland 
Tube Roller Mixer RMS V-30 
Bibby Scientific limited group, 
Staffordshire, UK  
Safety Cabinet 
Nuaire Biological Safety Cabinet 
Class II 
Zapf Instruments, Sarstedt, 
Germany 
Scanner GeneChip® Scanner Affymetrix, Santa Clara, USA 
Scanner (450k array) iScan Illumina, San Diego, USA 
Sequencer, 4-capillary 
ABI PRISM®3100/3130 Genetic 
Analyzer 
Applied Biosystems, Foster City, 
USA 
Sequencer  MiSeq desktop sequencer Illumina, San Diego, USA 
Tank for western blot Criterion Blotter Bio-Rad, Munich, Germany 
Thermocycler T3000 Thermocycler Biometra, Göttingen, Germany 
Thermomixer Thermomixer Comfort Eppendorf, Hamburg, Germany 
Vacuum tool Vacuum Prep Tool Biotage, Uppsala, Sweden 
Vortexer REAX 2000 Heidolph, Schwabach, Germany 
Weighing device LC621P Sartorius, Göttingen, Germany 
X-ray film processor  Curix 60 Agfa HelthCare, Berlin, Germany 
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2.1.14 Software 
 
The following table lists the software used in this study. Standard software is not enlisted in the 
following Table 25. 
Table 25. Software used in this study. 
Software Manufacturer used for 
BD C Sampler Software BD Bioscience, Franklin Lake, New Jersey, USA 
Analyses of flow 
cytometry data 
BioDoc Analyze Applied Biosystems, Foster City, USA Photodocumentation 
Cell Quest Software BD Bioscience, Franklin Lake, New Jersey, USA 
Analyses of flow 
cytometry data 
Command Console Affymetrix, Santa Clara, USA 
Analyses of Human 
SNP 6.0 array data 
Experion® Software Bio-Rad, Munich, Germany Experion® RNA assay 
Gen5
TM
 Software BioTek, Luzern, Switzerland 
Control console for 
Synergy HT 
GeneMapper 5 Software Applied Biosystems, Foster City, USA Sequence analyses  
Genome Studio Software 2011.1 Illumina, San Diego, USA 
Analyses 450k array 
data 
Genotyping Console Affymetrix, Santa Clara, USA 
Analyses of Human 
SNP 6.0 arrays 
Graphpad Prism 5 Graphpad Software, San Diego, CA, USA Statistical analyses 
Integrative Genomics Viewer 2.3 Broad Institute, Cambridge, Boston, USA Viewing of BAM files 
Lightcycler®480 SW 1.5.1 Roche, Rotkreuz, Switerland 
Control console and 
analyses of qPCR data 
Microsoft Office 2007 Microsoft, Unterschleißheim, Germany Digital documentation 
MiSeq Reporter Illumina, San Diego, USA 
Analyses of TRUE Sight 
Panel 
Nexus Express for OncoScan 3.0 Affymetrix, Santa Clara, USA 
Analyses of OncoScan 
copy number data 
Sequencing Analyses Software 
6.0 
Applied Biosystems, Foster City, USA 
Analyses of obtained 
sequences 
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2.1.15 Online databases and algorithms 
 
Online databases and tools that were used in this study are listed in Table 26. As the databases have 
been continuously used, a single date of accession can sometimes not be given. If analyses or data 
extractions have been performed at a specific time point, this will be mentioned in the text. 
Table 26: Online databases and algorithms used in this study. 
Name URL Reference 
BLAT https://genome.ucsc.edu/cgi-bin/hgBlat?command=start  [194] 
CCLE http://www.broadinstitute.org/ccle/home  
COSMIC v69 http://cancer.sanger.ac.uk/cancergenome/projects/cosmic  
dbSNP (build 141) http://www.ncbi.nlm.nih.gov/projects/SNP/  
DSMZ homepage http://www.dsmz.de/home.html  
ExPASy translate tool http://web.expasy.org/translate/  
GeneCards® http://www.genecards.org/  
Human Genome Variation Society http://www.hgvs.org/mutnomen/ [195] 
ICGC data portal https://dcc.icgc.org/  
LALIGN http://www.ch.embnet.org/software/LALIGN_form.html [196] 
Mechismo http://mechismo.russelllab.org/ [197] 
NHLBI Exome Sequencing Project 
(ESP6500SI-V2) 
http://evs.gs.washington.edu/EVS/ 
 
Online STR Analyses http://www.dsmz.de/STRanalyses [198] 
Pfam 27.0 http://pfam.xfam.org/ [199] 
PolyPhen-2 http://genetics.bwh.harvard.edu/pph2/index.shtml [200] 
PubMed http://www.ncbi.nlm.nih.gov/pubmed/  
SMART http://smart.embl-heidelberg.de/ [201] 
UCSC Genome Bioinformatics http://genome.ucsc.edu/ [202] 
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2.2 Methods 
 
2.2.1 Preparation and analyses of DNA 
 
2.2.1.1 Extraction of genomic DNA 
 
2.2.1.1.1   DNA extraction from FFPE-embedded tissue 
 
DNA from formalin-fixed, paraffin-embedded (FFPE) tissue was extracted using the QIAmp DNA FFPE 
tissue kit. For preparation of DNA from FFPE blocks, 8-10 tissue sections of ~8 µm were used. For 
removal of the paraffin, Roti®-Histol was added to the sections and mixed thoroughly. The mixture 
was centrifuged and washed once more with Roti®-Histol. Afterwards the tissue was washed twice 
with absolute ethanol to remove any remaining Roti®-Histol. After drying the pellet at room 
temperature, the pellet was resuspended in ATL buffer and proteinase K. The lysate was incubated at 
56 °C overnight (o/n). The next day, the lysate was incubated at 90 °C for 1 h to remove any 
modifications of the formaldehyde on the DNA. After adding AL buffer, the lysate was mixed and the 
DNA was precipitated using absolute ethanol. The lysate was then loaded onto a Mini Elute column 
and centrifuged. The column was washed with AW1 buffer and AW2 buffer by centrifugation at 
8,000 rpm (Mikro 200). Finally, the DNA was eluted using ddH2O and stored at 4 °C. The 
concentration was measured as described in 2.2.1.2. 
 
2.2.1.1.2   DNA extraction from cell lines 
 
DNA from cell lines in culture was extracted using the PUREGENE DNA Isolation Kit. The protocol is 
outlined in the following. 
Cells from cultured cell lines were harvested by centrifuging for 3 min at 1500 rpm (Multifuge 1L-R) 
at room temperature. The supernatant was discarded and the pellet resuspended in Cell Lysis 
Solution corresponding to the amount of starting material. The lysate was incubated o/n at room 
temperature. The next day RNase A-solution was added to the lysate and incubated for another 
30 min at room temperature. Then Protein Precipitation Solution was added to the lysate and mixed 
thoroughly for 1 min and afterwards incubated on ice for 15 min. The lysate was centrifuged at 
4500 rpm for 30 min (Megafuge 1.0R). After transferring the supernatant to a fresh Eppendorf tube, 
the DNA was precipitated using the same volume of absolute isopropyl alcohol. The DNA became 
visible as a white thread and was transferred into a fresh Eppendorf tube. The DNA was washed once 
with 70 % ethanol and then dried at room temperature. Dependent on the DNA pellet size, ddH2O 
was added and resolved o/n at room temperature. The DNA was stored afterwards at 4 °C and the 
concentration was measured as described in 2.2.1.2. 
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2.2.1.2 Measurement of DNA concentration using Qubit®dsDNA BR assay 
 
The DNA concentration was measured using Qubit® dsDNA BR assay. The advantage of this assay is 
that it is a fluorescence-based technique which is highly selective for double stranded (ds) DNA over 
RNA. Therefore there is no bias of any leftover RNA when measuring DNA concentration as it might 
be the case using conventional spectrophotometric DNA measurement methods. The measurement 
was performed according to manufacturer´s protocol (Life Technologies, Carlsband, USA). 
 
2.2.1.3 Plasmid propagation and transformation of E. coli 
 
For each transformation one vial chemically competent TOP10 E.coli was thawed on ice. Up to 1 µg 
of plasmid DNA was added to each vial and tube content was mixed by gentle agitation. The 
transformation mixture was incubated for 30 min on ice, then at 42 °C for 30 s and afterwards 
immediately put on ice for at least 2 min. Afterwards, 250 µl of pre-warmed S.O.C. media was added 
to the transformation mix and incubated at 37 °C under constant shaking at 225 rpm in a horizontal 
shaking incubator for 1 h. 25 µl of the transformation mix was plated onto LB agar plates containing 
100 µg/ml carbenicillin. Plates were incubated at 37 °C o/n. Single clones were picked and grown at 
37 °C for at least 8 h in an initial solution of 5 ml LB media containing 100 µg/ml carbenicillin. To 
generate glycerol stocks, 0.5 ml glycerol was added to 0.5 ml of this bacteria suspension. Stocks were 
stored at -80 °C. The left-over of the bacteria suspension was used for the preparation of plasmid 
DNA (2.2.1.4). 
 
2.2.1.4 Preparation of plasmid DNA from recombinant E. coli 
 
Plasmid DNA was prepared using the NucleoBond® Xtra Maxi EF kit according to manufacturer´s 
instruction. After adding 4 ml of the mini initial solution (2.2.1.3) to 300 ml LB containing 50 µg/ml 
carbenicillin, the bacteria suspension was incubate o/n at 37 °C under vigorous shaking. The next day, 
the bacteria suspension was centrifuged at 5500 rpm (Multifuge X1R) for 15 min to pellet the cells. 
The supernatant was discarded and the pellet resuspended in RES-EF buffer + RNase A. LYS-EF buffer 
was added, mixed by inverting and incubated for 5 min at room temperature. NEU-EF buffer was 
added, mixed by inverting and loaded onto an equilibrated filter column. After the solution had 
passed through the filter completely, FIL-EF buffer was added to wash and run through. The filter 
was discarded and the column was washed with ENDO-EF buffer and WASH-EF buffer. Plasmid DNA 
was eluted with ELU buffer. To the elute half of the volume absolute isopropyl alcohol was added 
and mixed thoroughly to precipitate the DNA. The suspension was centrifuged at 18,500 g (SORVALL 
SUPER T21) for 45 min at 4 °C. Discarding the supernatant, the pellet was washed with 70 % ethanol 
and centrifuged at 15,000 g (Multifuge X1R) for 15 min at room temperature. The supernatant was 
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discarded carefully and the pellet dried at room temperature. After resuspension of the pellet in 
ddH2O, plasmid DNA was dissolved o/n at 4 °C. The DNA concentration was determined as described 
in 2.2.1.2. 
 
2.2.1.5 Amplification of DNA fragments by PCR 
 
Amplification of fragments from genomic DNA (gDNA), plasmid DNA or complementary DNA (cDNA) 
was performed using either the AmpliTaq Gold Polymerase system or the Accuprime Polymerase 
system in case of GC-rich target DNA. Reactions were set up in volumes of 25 µl. 
For a typical PCR of gDNA each 25 µl reaction mix contained: 
AmpliTaq Gold Polymerase System     Accuprime Polymerase System 
1 µl gDNA (100 ng/µl) 1 µl gDNA (100 ng/µl) 
0.5 µl sense-primer (20 pmol/µl) 0.5 µl sense-primer (20 pmol/µl) 
0.5 µl antisense-primer (20 pmol/µl) 0.5 µl antisense-primer (20 pmol/µl) 
1 µl dNTP solution (5 mM per nucleotide) 2.5 µl 10x buffer 
2.5 µl 10x buffer II 0.3 µl Accuprime Polymerase 
2 µl MgCl2 (25 mM) 20.2 µl ddH2O 
0.2 µl AmpliTaq Gold Polymerase   
17.3 µl  ddH2O   
The amount of DNA, cDNA or plasmid DNA used for the PCR was dependent on the experimental 
setting. Thus, the amount of ddH2O was adjusted not to exceed the final reaction volume of 25 µl. 
In order to achieve PCR condition yielding the specific product, cycling was performed at the highest, 
most stringent annealing temperature which was determined for each primer pair by test reaction 
runs. 
A typical PCR program was run as follows: 
Denaturation 95 °C 5 min 
 95 °C 30 s 
Annealing 55-65 °C 30 s 
Elongation 68 °C Accuprime Polymerase/ 
72 °C AmpliTaq Gold Polymerase 
30 s 
 68 °C or 72 °C 5 min 
Cooling 4 °C on hold 
PCR products were checked by agarose gel electrophoresis (2.2.1.6). 
 
 
 
36 cycles 
Materials and Methods 
44 
2.2.1.6 Agarose gel electrophoresis 
 
Agarose gel electrophoresis was performed depending on the size of the expected PCR product in 
agarose gels differing in their agarose concentration. 2 % gels were used in case of PCR products 
smaller than 1,000 bp in size, 1 % gels in case of larger fragments as in the case of plasmid DNA and 
3 % gels in case of fragments about 100 bp in size. Agarose was boiled in TBE buffer in a microwave 
until the solution became transparent and then cooled down until lukewarm. Ethidiumbromide was 
added to a final concentration of ~1µM and mixed well. The agarose was poured into a horizontal gel 
chamber and a comb was placed into the gel to create wells. After becoming solid again the PCR 
products were loaded. 3.5 µl of gel loading buffer were added to 10 µl of PCR product. Depending on 
the size of the expected PCR product, the 100 bp TriDye ladder was used as site standard for 
products smaller 800 bp and the HyperLadder standard was used for PCR products bigger than 
800 bp. 2-3 % agarose gels were run 10 V/cm and 1 % agarose gels 5 V/cm until single marker bands 
were clearly visible. Gels were documented using the BioDoc Analyzer. The size of the fragment was 
determined by comparison of bands relative to the standard. 
 
2.2.1.7 Purification of PCR products from agarose gels 
 
To analyze a biallelic involvement of ID3 mutations in BL-70 cells, the ID3 cDNA was amplified as 
described in 2.2.1.5. The PCR yielded two bands on the agarose gel. The two bands were extracted 
using the EasyPure DNA Purification Kit according to manufacturer’s instructions. The target PCR 
bands were cut out from the agarose gel. The cut-out gel band was weight and the volume of the gel 
was estimated at 100 µg gel responding to ~100 µl gel. MELT buffer - half of the gel volume- as well 
as SALT buffer - 4.5 of the gel volume- was added. The mixture was boiled at 55 °C until the agarose 
was completely dissolved. 10 µl BIND was added to the mixture and incubated for 5 min at room 
temperature. The mixture was centrifuged at 10,000 rpm for 5 s (Micro 200) and the supernatant 
was discarded. The pellet was resuspended in 1 ml WASH buffer and mixed well for 5-10 s using a 
vortexer. After centrifugation at 10,000 rpm for 5 s (Micro 200), the supernatant was discarded and 
the pellet was dried at room temperature. Finally, the pellet was resuspended in 20 µl ddH2O and 
incubated for 5 min at room temperature. After an additional centrifugation step as described above, 
the supernatant containing the PCR product was transferred into a fresh tube. The sequence of the 
PCR product was analyzed by Sanger sequencing as described in 2.2.1.9. 
 
2.2.1.8 Post reaction purification of PCR products 
 
Prior to sequencing, amplified products were subjected to a cleanup step for removal of nucleotides, 
polymerase and salts. This step was processed in a 96-well plate using the Qiagen MiniElute 96 PCR 
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Purification Kit. A volume of 40 µl ddH2O was added to the PCR product and mixed well. The mixture 
was loaded onto the 96-well plate and a vacuum was applied to draw the liquid through the 
membrane until completely dry. The plate was removed and put on a paper towel to remove any 
leftover liquid from underneath. For repeated washing, another 50 µl of ddH2O were added to each 
well and drawn though the membrane as above until the membrane was dry. Another 20 µl of ddH2O 
were added to each well. For DNA recovery, the plate was sealed with a plastic foil and put on a 
horizontal plate shaker for 5 min at 1,000 rpm. Purified PCR-products were transferred into a fresh 
tube. 
 
2.2.1.9 DNA sequencing 
 
The didesoxy-method described by Sanger et al. [203] was used for sequencing of PCR products or 
plasmid DNA. The determination of the nucleotide sequence was performed by capillary 
electrophoresis according to fragment length and detection of the fluorescent dye. 
Sequencing reactions were set up using the Big Dye Terminator® v1.1 Cycle Sequencing Kit in 
volumes of 20 µl as follows: 
  1 µl  Big Dye Terminator 
  2 µl  5x Big Dye Terminator reaction buffer 
  1 µl  primer (20 pmol/µl) 
  1 µl  purified PCR product 
  15 µl  ddH2O 
The PCR reaction was run under the following conditions: 
Denaturation 96 °C 2 min 
 96 °C 10 s 
Annealing 57 °C 5 s 
Elongation 60 °C 4 min 
Cooling 4 °C on hold 
 
Prior to electrophoretic separation, a cleanup step was performed using the Montage 96 well 
Sequencing Reaction Cleanup Kit to remove any leftover nucleotides, buffer and salts. A volume of 
20 µl injection solution was added to the reaction and loaded onto the plate. A vacuum was applied 
to draw the liquid through the membrane until completely dry. The plate was removed and dried 
from underneath using a paper towel. To wash the membrane another 20 µl injection solution was 
loaded and again it was drawn through the membrane as described above. Finally 20 µl ddH2O were 
loaded, the plate sealed with plastic foil and put on a horizontal plate shaker for 5 min at 1,000 rpm 
25 cycles 
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for recovery of the sequencing products. Purified sequencing products were transferred into fresh 
tubes. 
Sequencing was done on ABI PRISM® 3100 or 3130 Genetic Analyzer. The sequencing products were 
diluted between 3x-5x in ddH2O. Injection time varied from 5 s to 15 s according to product 
concentration; run time varied between 18 min to 30 min according to fragment length. The analyses 
of the sequence raw data was performed using the Sequencing Analyses Software Version 6.0 and 
afterwards compared manually against references sequences of the NCBI build 37/hg19. Variances 
from the reference sequence were described according to HGVS mutation nomenclature 
recommendations [195]. Every detected single nucleotide variant (SNV) was screened for annotation 
as single nucleotide polymorphisms (SNP) in the dbSNP 141 database. The consequences of 
mutational changes on the protein code were derived from the DNA codon table which is attached in 
the appendix (8.4). 
 
2.2.1.10 High-throughput sequencing 
 
Using high-throughput sequencing it is possible to decipher the sequence of the whole-genome, 
exome, transcriptome and epigenome. Different sequencing techniques exist today depending on 
the provider, platform and applied kit. In this study exome sequencing and targeted-resequencing 
was performed for three mnBLL cases (cases 2, 3 and 8) and selected cell lines as listed in Table 27. 
Table 27: Cell lines analyzed with high-throughput sequencing. 
Cases Enrichment Sequencing platform Custom/In-house Analyses performed 
BL-2 cells Nimbl-SeqCapEZ-
V2 (Roche) 
HiSeq2000 (Illumina) 
Cologne Center for 
Genomics (CCG), 
Cologne, Germany 
Varbank (CCG) 
MLMA cells 
Su-DHL-5 cells TruSeq
TM
 Exome 
Enrichment Kit 
(Illumina) 
HiSeq2000 (Illumina) 
AROS Applied 
Biotechnology, Arhus, 
Denmark 
Dr. Matthias 
Schlesner (DKFZ) HT cells 
mnBLL cases 
2, 3 and 8 
TruSight
TM
 One 
Sequencing Panel 
(Illumina) 
MiSeq (Illumina) In-house In-house 
BL-70, BLUE-1, 
U-698-M cells 
All three enrichment techniques are based on hybrid capture. The differences of the enrichment 
panels and platforms, as well as the bioinformatic analyses are described in the following sections. 
 
2.2.1.10.1   Custom exome sequencing 
 
Custom exome sequencing of the BL-2 and MLMA cell lines was accomplished at the Cologne Center 
for Genomics (CCG). They used the Nimbl-SeqCapEZ-V2 kit for library preparation and enrichment 
which is a hybrid capture technique. This means that input DNA strands are hybridized to 
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complementary DNA fragments which carry a bead. With this panel more than 20,000 genes are 
covered including microRNA genes. The sequencing was performed on a HiSeq2000 platform which is 
based on the sequencing-by-synthesis method. The bioinformatic analyses were performed by CCG. 
The pipeline for the analyses is called varbank and the complex workflow can be seen on the 
homepage of varbank (http://varbank.ccg.uni-koeln.de/). 
Custom exome sequencing of Su-DHL-5 and HT cell lines was accomplished at the AROS Applied 
Biotechnology Company. They used the TruSeqTM Exome Enrichment Kit for library preparation. This 
enrichment technique is based as well on hybrid capture. This panel includes 20,794 genes and 
targets more than 200,000 exons. In contrast to the Nimble-SeqCapEZ enrichment it targets also 5’- 
and 3’-UTR, as well as non-coding RNAs. The sequencing was also performed on a HiSeq2000. The 
bioinformatic analyses of this data set was performed by Dr. Matthias Schlesner, German Cancer 
Research Center (DKFZ), Division Theoretical Bioinformatics, Heidelberg, Germany in the framework 
of the ICGC MMML-Seq as already described [170]. 
 
2.2.1.10.2   Targeted-resequencing 
 
Targeted-resequencing of the mnBLL cases 2, 3 and 8 as well as of the cell lines BL-70, BLUE-1 and   
U-698-M was performed at our Institute using the TruSightTM One Sequencing Panel. This panel 
targets 4,813 genes associated with human diseases based on information in the human gene 
mutation database and the online Mendelian inheritance in man catalog. M.Sc. Ulrike Paul of the 
high-throughput sequencing core facility of the Institute of Human Genetics, Kiel, performed the 
assay and provided the data for the further analyses. The applied protocol is explained briefly in the 
following. DNA samples were prepared by tagmentation using transposomes which cut the DNA 
strands into 300 bp fragments. In a PCR reaction oligonucleotides containing sequencing primers, 
indices unique to each sample and primers for binding to the flow cell were synthesized to the DNA 
fragments which were also amplified in parallel. In this panel three sample libraries were pooled. The 
enrichment of the target genes was achieved using a hybrid capture technique. In this panel 
biotinylated probes which are complementary to the target regions were hybridized to the samples 
and the enrichment was performed using streptavidin beads. After washing the samples to eliminate 
all non-bound DNA fragments, the enriched DNA was eluted from the beads. The prepared libraries 
were loaded onto a flow cell for sequencing on a MiSeq sequencer. The sequencing method is the 
same as for the HiSeq2000 (2.2.1.10.1). In the MiSeq workflow the removal of the indices, the 
alignment of the reads to the GRCh37/hg19 reference genome and production of so called BAM files 
was already included. The BAM files were used to produce the variance call files (VCF) using the 
MiSeq Reporter Software. The VCF files contain the information about the type of single nucleotide 
variant (SNV) as well as if it has already been annotated as a SNP in the dbSNP or a COSMIC SNP 
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databases. Additionally, the variants were selected according to the quality. Variants which (i) did not 
pass the filter, (ii) had a read depth lower than 20-fold and (iii) a mutated allele frequency (MAF) 
below 0.1 were excluded from further analyses. To eliminate false-positive variants from the filtered 
list, the BAM files were uploaded in the Integrative Genomics Viewer (version 2.3) which is a 
freeware program launched by the Broad Institute [204]. Each variant read was analyzed individually 
for artifacts, e.g. a read harboring many SNV is likely of bad quality especially when other samples 
show at the same position many SNV as well. 
 
2.2.2 Preparation and analyses of RNA 
 
2.2.2.1 Extraction of RNA from cell lines 
 
Two different protocols for extraction of RNA from cell lines were used as described in the following.  
 
2.2.2.1.1   RNA extraction with RNeasy Mini Kit 
 
RNA extraction from cell lines was performed using the RNeasy Mini Kit according to manufacturer´s 
instructions. The principle is outlined in the following. Between 1x106 - 3x106 cells were pelleted and 
lysed using RLT Buffer supplemented with 10 % β-mercaptoethanol. Lysates were loaded onto a 
QIAshredder spin column for homogenization of the lysate. To the homogenate, 70 % ethanol was 
added and loaded onto RNeasy mini column. The column was washed once with RW1 buffer and 
then twice with RPE buffer, to wash out any leftover protein and DNA. The RNA was eluted using 
RNase-free water and stored at -80 °C. The RNA extracted with this method was used for the 
expression analysis of the alternative transcripts of the TERT gene. 
 
2.2.2.1.2   RNA extraction with PARIS Kit 
 
RNA from 1x106 cells was extracted using the PARISTM Kit. The extraction was performed according to 
the manufacturer´s protocol which is outlined in the following. Overall 1x106 Cells were lysed in ice-
cold Cell Disruption Buffer. The lysate was homogenized in Lysis/Binding Buffer. Afterwards, absolute 
ethanol was added to the mixture and loaded onto a column to purify the RNA. The column was 
washed once with wash solution 1 and then twice with wash solution 2/3, to wash out any leftover 
protein and DNA. RNA was eluted using elution buffer. The RNA was stored at -80 °C. The RNA 
extracted with this method was used for the expression analysis using qPCR. 
 
2.2.2.2 Determination of RNA quality using Experion® RNA StdSens analysis kit 
 
RNA samples were measured using the Experion® electrophoresis system and the Experion® RNA 
StdSens analyses kit according to manufacturer´s instructions. The purity and integrity of the RNA 
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was reported as a RNA quality indicator (RQI), which was calculated by the Experion software. A RQI 
value of 8-10 denotes RNA with a good quality. RNA with a RQI below 8 was not used for further 
experiments. 
 
2.2.2.3 Determination of RNA concentration using Qubit® RNA HS Assay 
 
For a quick control of the quantity of the RNA samples, they were measured using the Qubit® RNA HS 
Assay which is a fluorescence-based assay. It is a much faster method to determine the RNA 
concentration than using the Experion® electrophoresis system. An advantage of this fluorometric 
quantification of RNA in comparison to spectrophotometric approaches is the high selectivity of the 
fluorescent dye for RNA over DNA or free nucleotides. The measurement was performed according 
to manufacturer´s protocol. 
 
2.2.2.4 Reverse transcription 
 
Synthesis of cDNA from RNA was performed using the QuantiTect Reverse Transcription Kit according 
to manufacturer´s instructions. For each reaction 1 µg RNA extract was used. Prior to reverse 
transcription, RNA was subjected to a gDNA wipeout step to digest any left-over DNA. The cDNA 
synthesis was set up in a volume of 20 µl: 
  1 µl  RT Primer Mix (consisting of long random and oligo dT primer) 
  1 µl  Reverse Transcriptase (RT) 
  4 µl  5x Quantiscript RT buffer 
  14 µl  Template RNA diluted in dH2O (after gDNA elimination) 
The synthesis was performed at 42 °C for 30 min with a final inactivation step of the reverse 
transcriptase at 95 °C for 3 min. The cDNA was diluted 1/5 or 1/10 depending on the subsequent 
applied assay. cDNA was short-term stored at 4 °C or long-term at -20 °C. 
 
2.2.2.5 Quantitative real-time PCR 
 
Quantitative real-time PCR (qPCR) is a fluorescence-based PCR used to simultaneously amplify and 
quantify target DNA molecules. This technique is commonly used in gene expression analyses. The 
qPCR reaction mix contains the intercalating fluorophore SYBR® Green which is a cyanine dye. The 
maximum excitation wavelength of SYBR® Green is 497 nm and fluorescence emission of SYBR® 
Green I-DNA complex is at 520 nm wavelength which was detected using the Light Cycler ® 480 II. 
The concentration of the cDNA was not measured, as after the cDNA synthesis, the reaction mix 
contains not only the cDNA but also RNAs and nucleotides. Therefore, 1 µl of a 1:10 diluted cDNA 
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was used per qPCR reaction. Thus, as 1 µg RNA was initially applied for the cDNA synthesis, each 
qPCR reaction contained about 5 ng RNA. 
The qPCR reaction was set up using the QuantiTect® SYBR® Green PCR Kit. A typical qPCR was set up 
in a volume of 20 µl: 
  1 µl  1:10 diluted cDNA  
  10 µl  2x QuantiTect SYBR Green PCR Master Mix 
  2 µl  QuantiTect Primer Assay 
  7 µl  ddH2O 
In some cases self-designed primers obtained from Biomers were used instead of the QuantiTect 
Primer Assay: 
  1 µl  1:10 diluted cDNA  
  10 µl  2x QuantiTect SYBR Green PCR Master Mix 
  0.5 µl  sense-primer (20 pmol/µl) 
  0.5 µl  antisense-primer (20 pmol/µl) 
  8 µl  ddH2O 
 
The qPCR was run under the following conditions: 
Denaturation 95 °C 15 min 
 95 °C 30 s 
Annealing 58 °C 30 s 
Elongation 72 °C 30 s 
Melting curve 72-95 °C continuous 
At the end of every qPCR reaction a melting curve analysis was performed as a quality control to 
detect unspecific PCR products. In the melting curve analysis the dissociation-characteristics of 
double stranded DNA is assessed which is dependent on the length and the GC-content of each DNA 
fragment. The dissociation is measured as a reduction of fluorescence signal. The temperature at 
which 50 % of the dsDNA is denatured is called the melting point (Tm). Thus, each qPCR product has 
a specific melting point. In case of unspecific amplification, several varying melting points would be 
detected in the melting curve analysis. The respective Cq values were excluded from further 
analyses. 
To quantify the initial amount of target DNA, the so called quantification cycle (Cq) value was used, 
which has formerly been called crossing point (CP). In an ideal PCR reaction the efficiency is 2, 
meaning that with every cycle the DNA amount is doubled, which is reflected by a doubling of the 
fluorescence intensity. In reality the efficiency differs for every PCR reaction depending for example 
on the primers and target DNA sequence. Therefore, the efficiency of every primer set was 
determined using the slope of the log-linear portion of the calibration curve. Each calibration curve 
40-45 cycles 
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was set up using a serial dilution of self-prepared BL-2 or MLMA cDNA from 0.5 ng to 500 ng in 
triplicates. For most of the assays cDNA from BL-2 was used, as the analyzed genes were not located 
in a region of chromosomal aberration in this cell line. The sole exception was the calibration curve 
for the IL10 transcript, for which the MLMA cDNA was used. The calibration curve qPCR was run at 
least two times. The efficiency of the qPCR (E) was calculated using the formula: E=10-1/slope. The 
mean of the efficiencies was used for further quantification of the gene expression. An example of a 
calibration curve is given in Figure 7. 
 
 
Figure 7: Calibration curve for calculation of PCR efficiency. The squares depict the calibration curve using the HPRT1 
QuantiTect Primer Assay and the rhombuses depict the calibration curve for the PAFAH1B2 QuantiTect Primer Assay for 
one run. The slope and the efficiency (E) are given for this PCR reaction. 
 
The gene expression of the target gene was normalized to the expression of the reference genes 
GUSB and HPRT1 using the following formula: Ratio= ERef
Cq(Ref)/Etarget
Cq(target) [ERef: PCR efficiency of the 
reference gene; Etarget: PCR efficiency of the target gene; Cq(Ref): Cq value of the reference gene; 
Cq(target): Cq value of the target gene]. The ratios of normalizations to either GUSB or HPRT1 were 
averaged (Ratio mRNA expression). The qPCR was repeated at least three times. Using the averaged 
ratios, the mean ratio and the standard deviation was calculated. The above described approach for 
gene expression quantification is recommended by the MIQE Guidelines for qPCR [205]. As the PCR 
efficiencies of the reference gene and target gene must be the same for the ΔΔCq method in order to 
generate an accurate comparison, which is often not warranted, the here described method is the 
means of choice. 
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2.2.3 Array-based techniques 
 
2.2.3.1 Human SNP array 6.0 - DNA microarray 
 
Using the genome-wide human SNP array 6.0 it is possible to analyze more than 900,000 SNPs, 
distributed throughout the whole genome, as well as the same number of copy number alterations 
(CNA) in a single experiment for one DNA sample. On the slide of the SNP array 25 mer 
oligonucleotides, which are called probes, are spotted. Each CNV locus is detected by one probe on 
the array. The SNP array loci are detected by allele-specific probes, meaning that one probe binds 
either to allele A or allele B of the respective SNP. 
Using the human SNP array 6.0, the cell line MLMA was analyzed. The assay was performed by 
Claudia Becher, technician of the array-core facility at our Institute who supplied the data for the 
subsequent analyses which were performed in the framework of this thesis. The genome-wide 
human SNP array 6.0 analyses have been performed using the Genome wide human SNP NSP/STY 
assay kit 5.0/6.0 according to manufacturer´s instructions. The workflow is outlined shortly in the 
following. Prior to hybridization of the DNA samples to the array, the complexity of the genome was 
reduced by digestion using a restriction enzyme followed by an adapter-ligation and PCR-
amplification. The DNA fragments were labeled with biotin and hybridized to the array where they 
bound to their respective probes. DNA fragments, which were not bound, were washed away. After 
staining of the biotin-labeled DNA fragments, the array was scanned using the GeneChip Scanner and 
the CN status was analyzed using the Genotyping Console software. 
The analyses of CNA were performed using the following settings: only those CNAs were included 
which were larger than 100 kb, contained more than 20 markers and which overlapped with known 
copy number variations (CNV) less than 70 %. 
 
2.2.3.2 OncoScan - DNA microarray 
 
Using the OncoScanTM FFPE Assay Kit it is possible to obtain whole-genome copy number and somatic 
mutation information from FFPE DNA samples. The method is based on the DNA microarray 
technique which covers SNPs and, thus, can extract genomic aberrations and loss-of-heterozygosity 
(LOH) information. The advantage of the OncoScan assay is that it is possible to use FFPE DNA which 
is often too degraded to obtain good results in conventional DNA microarray systems. The OncoScan 
assay is based on the molecular inversion probe (MIP) technology. Refer to Figure 8 for detailed 
description of the MIP technology. The assay was performed according to manufacturer´s 
instructions by Claudia Becher, technician of the array-core facility of our Institute. The data were 
supplied for the subsequent analysis of the mnBLL cases 18-25 which was performed in the 
framework of this thesis. The workflow is outlined shortly in the following. 
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The sample-DNA was diluted to a final concentration of 12 ng/µl and incubated o/n to anneal with 
the MIP probe. The following day the gap fill reaction was performed. For this the total volume was 
divided into two reactions to which either the AT- or the GC nucleotide mix was added. The gap was 
filled using special gap fill enzymes. Adding exonucleases, unligated probes which were not-gap filled, 
were removed. Afterwards the samples were cleaved using the cleavage enzyme to linearize the gap-
filled, now circular MIP probes. Afterwards the gap-filled, linearized MIP probes were amplified to 
enrich the MIP product. After an additional cleavage step, the hybridization target was obtained 
which consists of the tag sequence and the primer sequence. This product is hybridized to the 
OncoScanTM array overnight (o/n). After washing the array at the Gene Chip® Fluidics Station 450 to 
remove unbound products, the array was stained using Streptavidin, R-Phycoerythrin Conjugate 
(SAPE). The fluorescence signals of the arrays were scanned using the Gene Chip® Scanner and so 
called CEL files were generated. 
 
 
Figure 8: The MIP technology uses a MIP linear probe which contains homologous genomic regions adjacent to the target 
SNP as well as universal primer binding sites, cleavage sites and a tag sequence. This MIP probe binds to the homologous 
genomic region with the SNP position left out. The MIP probes form a circular structure. In a next step, the gap is filled-in. 
After subsequent ligation which can only take place if a nucleotide was incorporated, exonucleases are added which digest 
unligated probes. Afterwards the circular structure is linearized using an enzymatic digestion of one of the cleavage sites. 
The linearized products are amplified with the universal primer and cleaved a second time at the cleavage site 2. The 
product is hybridized to the array. During the hybridization step the digested product binds to the probes on the array and 
becomes simultaneously biotin-labeled. From http://www.affymetrix.com, 15/10/2014. 
 
The CEL files were uploaded to the OncoScanTM Console which converted the CEL files to OSCHIP 
files. The converted files were uploaded to the Nexus Express for OncoScan 3.0 software to analyze 
the chromosomal aberrations. DNA samples derived from FFPE have generally a worse quality than 
DNA samples derived from cryo material or fresh tissues which is reflected by a higher number of 
CNA. To exclude false positive CNA, stringent filter criteria were applied. Thus, those CNA were 
excluded from further analyses which showed copy number gains and losses smaller than 100 kb, 
LOG2 ratios between -0.3 and 0.3 and overlap of more than 70 % with described CNV. 
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2.2.4 Analyses of global DNA methylation 
 
The assays for analyses of DNA methylation were performed by Lorena Valles under the supervision 
of Dipl. Molmed. Julia Kolarova and Prof. Dr. rer. nat. Ole Ammerpohl within the epigenetic core 
facility of the Institute of Human Genetics, Kiel. They provided the data of the cases as listed in 
2.1.1.2, 8.1 and 8.2 for the analyses described in this study. The protocols used are outlined in the 
following. 
 
2.2.4.1 Bisulfite conversion of gDNA for HumanMethylation 450k Bead Chip 
 
The first step to the analyses of DNA methylation is the conversion of unmethylated cytosine to uracil 
using sodium bisulfite. Methylated cytosine on the other hand becomes not deaminated by the 
sodium bisulfite treatment. The conversion is followed by an amplification reaction in which uracil is 
replaced by thymine. Thus, unmethylated cytosine is detected as thymine in subsequent sequencing 
reactions. The conversion was performed using the EZ-96 DNA MethylationTM Kit according to 
manufacturer´s instruction. Briefly, 1 µg of gDNA was diluted in 45 µl ddH2O and 5 µl M-dilution 
buffer was added. The samples were incubated at 37 °C for 15 min in a thermocycler. 100 µl of the CT 
Conversion reagent were added and mixed well. The conversion reaction was performed in a 
thermocycler using the following program: 
  95 °C  30 s 
  50 °C  60 min 
  4 °C  on hold 
400 µl binding buffer and converted sample were loaded onto the Zymo-spin columns and mixed by 
pipetting. After centrifugation at 10,000 g for 30 s, the supernatant was discarded. After applying 
100 µl M-Wash buffer to the columns, they were centrifuged at 10,000 g for 30 s and the 
supernatant was discarded. 200 µl M-Desulphonation buffer was added and incubated at room 
temperature for 15-20 min. After centrifugation at 10,000 g (Mikro 200) for 30 s, the supernatant 
was discarded. 200 µl M-Wash buffer was added to every column and centrifuged at 10,000 g 
(Mikro 200) for 30 s. The washing step was repeated and the columns transferred to new reaction 
tubes. The converted DNA was eluted in 10 µl ddH2O by centrifugation at 10,000 g (Mikro 200) for 
30 s. The converted DNA was stored at -20 °C. 
 
2.2.4.2 HumanMethylation 450k Bead Chip analysis 
 
To determine the methylation landscape of mnBLL, they were analyzed using the HumanMethylation 
450k Bead Chip. The results were compared to the available methylation data of BL and DLBCL, which 
have been already analyzed in the framework of the ICGC MMML-Seq and MMML projects. The quite 
16 cycles 
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recently obtained data are still undergoing statistical analysis, but the data to determine the 
methylation status of the IL10 locus were available for initial analysis. The principle of the 
HumanMethylation 450k Bead Chip is shortly outlined in the following: 
The HumanMethylation 450k Bead Chip allows the parallel analyses of 485,577 different cytosine-
guanine-dinucleotides (CpGs) corresponding to 21,231 genes. The principle of the array is based on 
two different bead-type assays: Infinium I assay and Infinium II assay. The Infinium I assay uses two 
different bead types which have probe sequences either matching the methylated or unmethylated 
CpG site. If a CpG target site matches with the respective probe, a single nucleotide is extended 
which is labeled with biotin or dinitrophenyl (DNP). The level of methylation for a CpG site is 
determined by the ratio from fluorescent signals from the methylated bead vs. the unmethylated 
bead. The Infinium II assay on the other hand has only one bead type corresponding to one CpG site. 
The 3’-end of the probe sequence stops one base before the query CpG target site. Thus, in a single-
nucleotide extension either a biotin-labeled cytosine or guanine in case of a methylated CpG site or a 
DNP-labeled adenine or thymine in case of an unmethylated CpG site is incorporated. Thus, other 
than in the Infinium I assay the level of methylation for a CpG site is determined by the ratio of 
fluorescent signal from the methylated CpG vs. fluorescent signal from the unmethylated CpG.  
The analyses of the DNA-methylation of mnBLL was performed using the “Illumina Infinium HD 
MethylationAssay” manual (state 2011) and the Human Methylation 450k Bead Chip Kit which is 
shortly outlined in the following. The bisulfite converted DNA was enzymatically fragmented. The 
DNA was precipitated using absolute isopropyl alcohol and subsequently resuspended in 
hybridization buffer. The samples were loaded onto the Human Methylation 450k Bead Chip and 
incubated in a Hybrid oven at 48 °C for 16-22 h. During this time the fragmented DNA binds to its 
complementary probes. DNA molecules which were not bound were removed by a washing step. 
During the single strand elongation a biotin-labeled cytosine or guanine or a DNP-labeled adenine or 
thymine was incorporated. Different fluorescence-labeled antibodies interact with the either biotin- 
or DNP-labeled nucleotide and the fluorescence signal was measured using the iScan. The 
methylation status was given as AVG-β values which correspond to the ratio of methylated signal to 
the sum of methylated and unmethylated signals at one CpG. 
 
2.2.5 Cell biology methods 
 
2.2.5.1 Cultivation of cells 
 
The cultivation of eukaryotic cell lines was performed under sterile conditions using a laminar flow 
hood, sterile instruments and sterile growth media. RPMI-1640 medium supplemented with 10 % 
(v/v) Fetal Bovine Serum (FBS) and glutamine (2 mM) was used for cultivation of the cell lines BL-2, 
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BL-30, BL-41, BL-70, BLUE-1, Ca46, DAUDI, DG-75, EB-1, EB-3, Namalwa, Raji, Ramos, U698-M,           
Su-DHL-5, MLMA, Su-DHL-10 and RIVA. The percentage of FBS was raised to 20 % in the media for 
the Karpas422 and Su-DHL-6 cell lines and to 15 % for the HT cells. The cell line Hek293 was 
cultivated in D-MEM and 10 % FBS (v/v). The cell lines were cultivated in T25 flasks using an 
incubator with humidified atmosphere containing 5 % CO2 at 37 °C. Cells were split every two or 
three days to prevent an overgrowth. To split the adherent Hek293 cells, they were washed once 
with PBS and then treated with 1 ml trypsin until the cells were detached from the bottom of the 
flask. The trypsin was inactivated with media containing 10 % FBS and the cells were pelleted at 
1,300 rpm for 3 min (Multifuge 1L-R). The supernatant was discarded, the cells supplemented with 
their respective fresh media and a part of the cells were used for continued cultivation. Suspension 
cells were split by diluting them with fresh complete medium. 
 
2.2.5.2 Freezing and thawing of cells 
 
In order to freeze cells, they were pelleted at 1,300 rpm for 3 min (Multifuge 1L-R). The supernatant 
was discarded and the pellet resuspended in 1 ml freezing medium (90 % FBS, 10 % DMSO). The cell 
suspension was transferred into a cryo vial and frozen at -80°C o/n. The next day the vial was 
transferred into a -145 °C freezer. 
To thaw cells the content of the cryo vial was diluted in 5 ml of the respective cell line cultivation 
media. The cells were pelleted at 1,300 rpm for 3 min (Multifuge 1L-R) and the supernatant was 
discarded. After resuspension of the cell pellet in fresh medium, the cells were transferred into a T25 
flask and cultivated in an incubator. 
 
2.2.5.3 Cell counting 
 
The cell number was determined using a Neubauer hemocytometer. 10 µl cell suspension was mixed 
with 10 µl trypan blue solution and half of the mixture was applied to the hemocytometer. Four of 
the nine quadrants were counted. The number of cells in the growing culture was estimated using 
the following formula: number of cells per milliliter of culture= (number of cells in each quadrant/4) x 
10,000 x 2 (to take into account the dilution factor due to the volume of trypan blue solution added). 
Based on this number, the volume of cell suspension for every experiment was calculated. 
 
2.2.5.4 Mycoplasma test 
 
Mycoplasmas are intracellular bacteria. Upon infection they can influence the cell physiology as 
inhibition of cell proliferation or alteration of gene expression. Therefore regular testing of the cell 
culture for Mycoplasma contamination is essential. To screen the cell lines for possible mycoplasma 
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contamination a PCR-based assay was performed. This assay detects the 16S rRNA gene of 
Mycoplasma genus which is well preserved in prokaryotes. Primer sequences were as follows:            
5’-CACCATCTGTCACTCTGTTAACC-3’ and 5’-GGAGCAAACAGGATTAGATACCC-3’ published by [206]. 
The cell lines were cultured for at least two days in the same media and 1 ml cell supernatant was 
centrifuged at 250 g (Multifuge X1R) for 3 min to remove any remaining cells. Afterwards, the 
supernatant was transferred into a fresh tube and centrifuged again at 15,000 rpm (Multifuge X1R) 
for 10 min. After discarding the supernatant, the pellet was resuspended in 50 µl ddH2O and heated 
to 95 °C for 3 min in a thermomixer. 5 µl of this solution were used in a PCR set up as described in 
2.2.1.5. The PCR products were analyzed on an agarose gel. The presence of a 270 bp sized band 
indicated a Mycoplasma-positive sample. 
 
2.2.5.5 Authentication of cell lines using STR profiles 
 
Inter- and intraspecies cross-contamination of human and animal cells and misidentification are 
among the major problems in biological studies based on cell cultures and usually lead to the 
production of false data [207],[208]. Consequently, regular authentication of the cell lines in culture 
as well as when obtaining new cell lines is crucial. The authentication of the cell lines was performed 
using microsatellite loci in the human genome harboring short tandem repeat (STR) DNA markers. 
The usage of nine different STR loci allows the individualization of cell lines at the DNA level. The 
analyses were performed using the StemElite™ ID System according to manufacturer´s instructions. 
In this assay, nine STR loci are amplified in a multiplex PCR. The primers for the amplification of the 
nine loci are labeled either with fluorescein, carboxytetramethylrhodamine or 6-carboxy-4’,5’-
dichloro-2’,7’-dimethoxy-fluorescein. Thus, based on the various lengths of the PCR products and 
fluorescence-labels the loci can be differentiated by capillary electrophoresis and three-fluorescence-
color detection. The DNA of the cell lines was isolated as described before (2.2.1.1). Capillary 
electrophoresis was performed on an ABI PRISM® 3130 Genetic Analyzer. Allele analyses were done 
using the GeneMapper 5 Software. The resulting STR profiles were compared to the online STR 
Analyses database for cell lines (http://www.dsmz.de/STRanalyses). Only cell lines with correct STR 
profiles were used for further analyses. 
 
2.2.5.6 Ectopic expression of genes of interest 
 
Transfection is a process of introducing nucleic acids such as plasmid DNA into eukaryotic cells. In this 
study electroporation was used to transfect human B-cell lymphoma cell lines. Electroporation uses 
an electric field generated by an electroporator to disrupt the permeability of the cell membrane. If 
the electroporation is performed in presence of nucleic acids, these will enter the cells due to the 
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change in permeability. The pulse duration and shape of the electric field can be set manually, in 
order to obtain the ideal transfection condition. The best electroporation conditions are those that 
achieve a high transfection efficiency and high cell viability. The electroporation protocol needed to 
be optimized for each cell line. The optimization was performed by testing different transfection 
programs of the Nucleofector I device using the pmax vector included in the transfection kit, which 
harbors a gene encoding the green fluorescent protein (GFP). Three days after the electroporation, 
the transfection efficiency was determined. In total 100 cells were counted using a fluorescence 
microscope and the amount of GFP-expressing cells was determined. Additionally, cells were stained 
with trypan blue solution (2.2.5.3) to determine the number of viable cells. 
In this study the BL cell lines BL-2 and DG-75 were transfected with the commercially available 
human ID3-pCMV6-AC-GFP plasmid (2.1.8). The nucleofection protocol is described in the following. 
At the day of the transfection cells were harvested and counted. Per transfection reaction 1x106 cells 
were used. The appropriate number of cells was pelleted at 90 g (Multifuge 1L-R) for 5 min. The cell 
pellet was resuspended carefully in nucleofection solution V supplemented with 18 % nucleofection 
supplement. 5 µg of plasmid DNA were added to the cell suspension and mixed carefully. The cell-
DNA suspension was transferred to nucleofection cuvettes using the supplied transfer pipette. The 
transfection program of the Nucleofector I device was set to C-09 for BL-2 and to R-13 for DG-75. 
After nucleofection cells were directly transferred into a well of a 6-well plate and supplemented 
with medium. To ensure proper expression of ID3-GFP, cells were cultivated for two days before 
further experiments were performed. 
 
2.2.5.7 Knock down of target genes 
 
In this study three different, commercially available short hairpin RNA (shRNA) constructs 
(pLKO_IPTG_3xLacO) were used, targeting PAFAH1B2 (PAFAH1B2 shRNA1-3) (2.1.8). ShRNAs use the 
endogenous cellular processing system of microRNAs (miRNAs) to form the effector complex for RNA 
interference. 
A lentiviral vector system was used to transfer foreign DNA in human B-cell lymphoma cell lines. This 
gene delivery method is called transduction. To generate lentiviral particles, two different 
components are needed: packaging constructs which make up the structural components of the 
vector and a transgene construct containing the shRNA targeting the gene of interest as well as an 
resistance gene for an antibiotic. The structural components consist of the structural protein gag 
which forms the viral capsid and the nucleoprotein complex, the reverse transcriptase and integrase 
protein pol and the viral glycoprotein env which is displayed on the surface of the vector and defines 
the tropism. The packing constructs pCMV-dR8.91 [209] and pMD.G [210] were kindly provided by 
Dr. rer. nat. Eva Murga-Penas, Institute of Human Genetics, Kiel. 
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In the following the transduction protocol is explained in detail. The following experiments were 
performed according to S2 gene technology safety regulations at the respective S2-laboratory of the 
Department of Pediatrics, group of Dr. med.  Denis Schewe, Christian-Albrechts University Kiel & 
University Hospital Schleswig Holstein, Kiel. 
 
2.2.5.7.1   Production of lentiviral vectors 
 
Due to its high transfection efficiency, Hek293 cells are commonly used for production of lentiviral 
particles. At day one, the Hek293 cells were seeded at a density of 3.5 million cells in a 10 cm dish. 
The following day the cells were transfected with 5 µg of each the packaging constructs pMD.G and 
pCMV-dR8.91 as well as 10 µg of the pLKO_IPTG_3xLacO construct carrying the shRNA sequence. The 
jetPEI DNA transfection kit was used for the transfection of the Hek293 cells in a 10 cm culture dish. 
For each transfection, all three plasmid constructs were diluted in 150 mM NaCl to a final volume of 
250 µl in one mixture. In an additional mix, 40 µl of the cationic polymer of the jetPEI Kit were diluted 
in 150 mM NaCl to a final volume of 250 µl. The two solutions were mixed and incubated for 30 min 
at room temperature, to let the nucleic acids and polymer complex build up. The plasmid/polymer 
complexes were added drop wise to the Hek293 cells. The transfected cells were incubated for 24 h 
in the incubator before the medium was changed. 48 h after transfection the viral titer was described 
to be the highest and the viral vector was harvested. The supernatant was collected and centrifuged 
for 5 min at 1,100 rpm (Centrifuge 5810) to remove any remaining dead cells. The medium was 
sterile filtered using a 0.45 µm membrane to remove any cell debris. The filtered virus-containing 
medium was aliquoted and stored at -20°C. The transduction was performed shortly afterwards as 
the virus titer decreases during long time storage. 
The presence of lentivirus in the supernatant was confirmed using the lentiviral titer test Lenti-XTM 
GoStixTM according to manufacturer´s instructions. This rapid strip test detects the lentiviral p24 
capsid protein. The supernatant is applied to the GoStix cassette and Chase Buffer is added. If the 
sample contains sufficient levels of lentivirus, a band will appear in the cassette after 30-180 s. The 
lower detection limit of this assay is about 5x105 infectious units/ml. 
 
2.2.5.7.2   Transduction of target cells with lentiviral vectors 
 
Prior to the transduction, Su-DHL-5 cells were seeded at a density of 2x105 cells/well/1 mL in a 6-well 
plate. After at least 6 h, 2 µl polybrene (10 mg/ml) was added to the cells. Polybrene is a polycation 
which facilitates the interaction between the negatively charged viral particles and their target cells 
and therefore increases the transduction efficiency. Afterwards, 1 ml of either freshly produced or 
thawed medium containing the viral particles were added to the target cells. The transduced cells 
were incubated for 24 h in the incubator. The following day the medium was changed and fresh 
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medium added. Two days after transduction the selection of the Su-DHL-5 cells was started using 
medium supplemented with 2 µg/ml puromycin. The puromycin concentration, which effectively kills             
Su-DHL-5 cells, has been defined beforehand in a titration curve. 
After one week of puromycin selection only those cells survived which had taken up the lentiviral 
shRNA construct. 
 
2.2.5.7.3   Induction of shRNA expression using IPTG 
 
The expression of the shRNA of interest from the pLKO_IPTG_3xLacO vector is controlled by a 
modified human U6 promoter construct containing LacO (operator) sequences. Furthermore, the 
vector contains a LacI (repressor) gene (refer to the appendix 8.5 for an overview on the vector map). 
The LacI protein is expressed from the lentiviral vector and in the absence of isopropyl-β-D-
thiogalactoside (IPTG) it is bound to the LacO promoter region. Hence, it prohibits the expression of 
the shRNA. Binding of IPTG to the LacI leads to a conformation change of LacI and subsequent 
release from the LacO sequence. Hence, the RNA polymerase can bind to the U6 promoter and the 
shRNA is transcribed. 
To determine the IPTG concentration giving the best knock down efficiency, the transduced cells 
were treated with various concentrations ranging from 10 µM to 1 mM IPTG diluted in sterile ddH2O 
for three days. To ensure that IPTG had no impact on the gene expression of the target gene and/or 
cell viability, cells transduced with a non-targeting control (NTC) shRNA were included in the 
analyses. The knock down efficiency was analyzed using Western blot. The best knock down 
efficiency was obtained after treatment of Su-DHL-5 cells with 100 µM and 250 µM IPTG. These 
concentrations were used in subsequent experiments. To determine whether a knock down of 
PAFAH1B2 had an impact on cell viability, three days after induction cells were analyzed using a cell 
viability assay (2.2.5.10). 
 
2.2.5.8 Treatment of cell lines with neutralizing antibodies 
 
2.2.5.8.1  IL10 inhibition 
 
To test if neutralizing IL10 in the cell culture supernatant has an impact on cell viability, cells were 
treated with a neutralizing IL10 antibody (ab34843). The analyses were performed in BL (BL-2, BL-70), 
mnBLL (HT, Su-DHL-5, MLMA) as well as in one non-BL (RIVA) cell lines. Cell lines were harvested, 
centrifuged at 1,100 rpm for 3 min (Multifuge 1L-R) and supplemented with fresh medium to remove 
any remaining IL10. Cells were counted and seeded at a density of 15,000 cells/well in a 96-well 
plate. The cell lines were treated with various concentrations of IL10 antibody ranging from 50 µg/ml 
to 1 mg/ml, which was diluted in PBS if necessary, in duplicates. For each cell line an untreated 
control was included in the experiment. After two days of treatment in an incubator, cells were 
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analyzed using the cell viability assay (2.2.5.10). The experiment was repeated three times as 
biological replicate. 
 
2.2.5.8.2  IL10RA inhibition 
 
The inhibition of IL10RA with a neutralizing antibody was performed using two different antibodies: 
• CDw210 (3F9) has been published to neutralize IL10RA [211],[212] 
• IL10RA (T3431) was used for IL10RA Western blot 
The analyses were performed in a BL (BL-2) and a mnBLL (Su-DHL-5) cell line. Cell lines were 
harvested, centrifuged at 1,100 rpm for 3 min (Multifuge 1L-R) and supplemented with fresh 
medium. Cells were counted and seeded at a density of 15,000 cells/well in a 96-well plate. Cells 
were treated in duplicate with various concentration of antibody ranging from 2.5 µg/ml to 10 µg/ml 
diluted in PBS. The experiment was performed as biological triplicate. For each cell line an untreated 
control was included in the experiment. After two days of treatment in an incubator, cells were 
analyzed using the cell viability assay (2.2.5.10). The experiment was repeated three times as 
biological replicate. 
 
2.2.5.9 Treatment of cell lines with BKM120 
 
In order to analyze if the mnBLL cell lines depend on the downstream signaling of the IL10 receptor 
for survival, PI3K signaling was inhibited using the selective PI3K inhibitor BKM120, which is also 
termed Buparlisib. This compound has been recently published to successfully inhibit the 
proliferation of BL cell lines, which were shown to depend on the PI3K signaling for cell survival [72]. 
The analyses were performed in BL (BL-2, BL-41, BL-70), mnBLL (HT, Su-DHL-5, MLMA) as well as non-
BL (Su-DHL-10, Karpas422) cell lines. Cells were seeded in duplicate at a density of 6,000 cells/well in 
a 96-well plate and treated with various concentration of BKM120 ranging from 0.15 µM to 2 µM 
BKM120 diluted in DMSO. For each cell line an untreated control was included in the experiment. 
After three days of treatment in an incubator, cell viability was analyzed using the cell viability assay 
(2.2.5.10). The experiment was repeated three times as biological replicate. 
 
2.2.5.10 Cell viability assay 
 
The determination of the amount of viable cells was performed using the Cell Titer Blue reagent. This 
assay is based on the reduction of resazurin to resorufin which is highly fluorescent (579Ex/590Em). 
The reduction becomes furthermore visible as a “blue shift” from blue to pink (absorbance maximum 
resazurin: 605 nm and resorufin: 573 nm). Only metabolically active cells are capable of this reaction 
which is an indicator for cell viability. 
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After treating cells in a 96-well plate using the above described assays, 20 µl of cell titer blue reagent 
was added to the cells. Depending on the cell type, the cells were incubated between one to three 
hours in an incubator until the reduction became visible as described above. The fluorescence of 
resorufin was measured at 540Ex/590Em using the Synergy HT ELISA plate reader. The fluorescence 
signals were displayed by the Gen5TM Software and subsequent exported as an excel document. In 
each experiment a medium control (blank) was included, which was used to determine the 
background fluorescence of the medium. Initially the fluorescence signal of the blank was subtracted 
from every fluorescence signal. As every treatment condition was performed in duplicate, the mean 
of the fluorescence signals was calculated. The relative viability was calculated as ratio of 
fluorescence signal from treated samples to untreated control. 
 
2.2.5.11 Cell cycle measurement 
 
Cell cycle analyses were performed using propidium iodide according to a published protocol [213] 
and with the help of Prof. Dr. rer. nat. S. Adam, Institute of Immunology, Kiel. Propidium iodide is an 
intercalating agent which binds to DNA. When bound to DNA, propidium iodide has its fluorescence 
excitation maximum at 535 nm and the emission maximum at 617 nm. In cell cycle analyses the 
nuclear DNA content of a cell is quantitatively measured using flow cytometry, based on the principle 
that the incorporated amount of propidium iodide is proportional to the amount of DNA [214]. Thus, 
based on the detected fluorescence signal, the cells can be assigned to the various cell cycle phases 
(in cells without polyploidy= G0/1-phase: diploid chromosomal DNA content, S-phase: between 1x to 
2x chromosomal DNA content, G2/M-phase: tetraploid chromosomal DNA content).  For the analysis, 
1x106 cells were harvested and centrifuged at 1,100 rpm for 3 min (Multifuge 1L-R). The supernatant 
was discarded and the cells were washed with 1 ml of ice-cold PBS, followed by centrifugation at 
1,100 rpm for 3 min (Multifuge 1L-R). This washing step was repeated once more. After discarding 
the supernatant the cells were resuspended in ice-cold 500 µl PBS. For fixation of the cells, the same 
volume of absolute ethanol was added dropwise under constant mixing on a vortex mixer. 
Afterwards, the cells were incubated for 30 min on ice. Cells were centrifuged at 1,100 rpm for 3 min 
(Multifuge 1L-R), the supernatant discarded and the cells resuspended in 200 µl PBS. To remove 
cellular RNA, 8 µl RNase A (1 mg/ml, diluted in ddH2O) were added. Finally, 200 µl propidium iodide 
(50 µg/ml, diluted in ddH2O) were added and cells were incubated for 30 min at room temperature in 
the dark. Cell cycle analysis was performed by flow cytometry using a FACS Calibur Analyzer and the 
Cell Quest software. The workflow of the analyses as depicted in Figure 9 is briefly described in the 
following. In each cell cycle analysis 1x104 cells were analyzed. To exclude dead cells and debris from 
the following analysis, the cell population was initially analyzed in a two-parameter dot plot of the 
signals from the forward scatter (FSC) and side-scatter (SSC) (Figure 9A). The viable cell population 
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was gated and the emitted fluorescent light of propidium iodide which was recorded in the FL2 
channel was analyzed. A common problem of the DNA analysis is the findings of doublets. Doublets 
are two cells with G1-phase DNA content which are recorded as one event and are hence, similar to 
cells with G2/M-phase DNA content. These doublets can be excluded by analyzing the pulse-width 
(FL2-W) of the fluorescent signal of propidium iodide (PI), as FL2-W increases with the diameter of 
the particle. Thus, G1-phase doublets have a higher FL2-W signal. Hence, in a dot plot graph 
depicting the FL2-W vs. the FL2-A (pulse area), the latter representing the relative DNA amount, a 
gate was set around the single cell population (Figure 9B). This gated cell populations were shown in 
a histogram depicting the FL2-A signal vs. the count of cells. Furthermore, the four distinct phases of 
a proliferating cell population can be identified (Figure 9C). Using the Cell Quest software the amount 
of cells in each cell cycle phase is calculated. 
 
 
Figure 9: Example of cell cycle analysis of BL-2 cell line. A: Dot blot graph of forward-scatter (FSC) vs. side-scatter (SSW) 
signals of the cell population. B: Depicts the two-parameter dot blot of FL2-W vs. FL2-A. The gate, depicted here as box with 
R2 label, contains solely single cells. C: Histogram of FL2-A, representing the relative DNA amount vs. the count of cells 
(counts). The cell cycle phases are indicated by the respective lines and labeled as G1 (G1-phase), S (S-phase) and G2/M 
(G2/M-phase). The table shows the amount of cells in the respective cell cycle phases. % Gated refers to the amount of cells 
gated in G1-, S- and G2/M-phases in the histogram. FL2-W, fluorescence channel 2 width; FL2-A, fluorescence channel 2 
area; counts, number of cells. 
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2.2.6 Proteinbiochemical analyses 
 
2.2.6.1 Protein extraction from cell lines 
 
To obtain whole protein extracts from cell lines, cells were harvested and washed once with PBS. 
Depending on the size of the cell pellet, the cells were lysed in 40-100 µl RIPA buffer. The lysate was 
incubated on ice for 30 min and mixed from time to time. After centrifugation of the lysate at 
14,000 rpm (Multifuge X1R) for 10 min at 4 °C, the supernatant was transferred into a new tube and 
stored at -80 °C. 
 
2.2.6.2 Determination of protein concentration 
 
The protein concentration was determined using the BCA Macro assay kit. The analyses were 
performed in a 96-well plate and each sample was measured in duplicate. In each measurement a 
standard curve according to manufacturer´s protocol was included. To obtain a 1/5 dilution, 10 µl 
water were added to 2.5 µl of the protein solution. 100 µl master mix, consisting of 1/50 dilution of 
solution A in solution B, was added, mixed and incubated for 30 min at 37 °C. The absorption was 
measured at 562 nm using the Synergy HT and the data were analyzed using the Gen5TM Software. 
Using the standard curve the protein concentrations of the samples were interpolated. 
 
2.2.6.3 Western blot analyses  
 
2.2.6.3.1  SDS-polyacrylamid gel electrophoresis 
 
10-20 µg of each protein sample was diluted in 4x NUPAGE® LDS sample buffer and boiled at 95 °C 
for 5 min. Afterwards they were centrifuged shortly to collect the liquid at the bottom of the tube. 
Premade Criterion TGX Precast gels were inserted into the Criterion Cell gel chamber, which was 
filled with SDS-Running buffer according to manufacturer´s instructions. Depending on the size of the 
protein of interest a gradient gel, termed Criterion TGX Precast Any kD gel or the Criterion TGX 
Precast 18 % Resolving gel was used. The protein samples were loaded and the separation was 
performed at 100 V for 20 min until the electrophoretic front had entered the stacker gel completely. 
Afterwards the voltage was set to 150 V and separation completed through the running gel. The gel 
was taken out of the unit and the plastic case was broken to uncover the gel for blotting. 
 
2.2.6.3.2  Gel Transfer 
 
Proteins were blotted onto a PVDF-membrane using a tank blot cell transfer device according to 
manufacturer´s instructions. Prior to blotting, the PVDF-membrane was activated using absolute 
methyl alcohol for 30 s, afterwards, it was equilibrated together with Whatman filter papers in the 
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Bjerrum-Schäfer transfer buffer for at least 10 min. Blotting was performed at 100 V and 0.5 Amp for 
1 h. To monitor a successful transfer, the membrane was stained with Ponceau S which binds 
reversible to the amino-residues of the proteins. For the staining, the membrane was incubated for 
at least 2 min at room temperature with Ponceau Red Staining Solution. Afterwards, the membrane 
was washed with H2O until the protein bands were clearly visible. Subsequently, the membrane was 
washed with H2O until the staining came off. 
 
2.2.6.3.3  Immunoblot 
 
The membrane was incubated in blocking solution for at least 1 h at room temperature or o/n at 
4 °C. The specific antibody against the protein of interest was diluted in antibody diluent based on 
the manufacturer´s instructions or previous results. The antibody solution was added to the 
membrane and incubated at room temperature on a tube roller mixer for 1 h. The membrane was 
washed twice with antibody diluent for 5 min at room temperature. HRP-coupled secondary 
antibody was diluted 1/2,000 in antibody diluent and added to the blot. Incubation was performed 
for 1 h at room temperature on a tube roller mixer. The membrane was washed three times with 
TBS-T for 10 min each at room temperature and then in TBS for 5 min at room temperature for 
detergent removal. 
 
2.2.6.3.4  Chemiluminescence  
 
Luminata Forte was added to the membrane for 1-2 min to induce the horseradish peroxidase 
reaction. The liquid was drawn off until the membrane ran dry. The membrane was put into a X-ray 
film box. An Amersham HyperfilmTM ECL was exposed for 1-60 s depending on signal intensity and 
developed using the Curix 60. 
 
2.2.6.4 Enzyme-Linked Immunosorbent Assay for IL10 expression analyses 
 
To determine the IL10 protein amount in cell culture supernatant, the cell lines BL-2, BL-41, BL-70, 
BLUE-1, Ca46, U-698-M, HT, Su-DHL-5, MLMA, Su-DHL-6, Su-DHL-10, Karpas422 and RIVA were 
seeded at a density of 250,000 cells/well in a 24-well plate. After two days, cell supernatant was 
harvested and stored at -80°C. Two different media conditions were tested: media supplemented 
with 5 % FBS or 10 % FBS. For detection of IL10 protein the human IL-10 Enzyme-linked 
Immunosorbent Assay (ELISA) Kit was used according to manufacturer´s instructions. The protocol is 
outlined in the following. 50 µl of the cell supernatant sample was added per well in duplicate. In the 
same plate different concentrations (0-600 pg/ml) of purified IL10 were also added in order to create 
a reference standard curve. 50 µl of biotinylated antibody reagent was added and incubated for 2 h 
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at room temperature. Solution was discarded and each well washed three times with 1x wash buffer 
at room temperature. 100 µl streptavidin-HRP solution was added and incubated for another 30 min 
at room temperature. The solution was discarded and washed again three times with 1x wash buffer. 
To each well 100 µl TMB substrate solution was added and incubated for 30 min at room 
temperature in the dark. After adding 100 µl of stop solution to each well, the color change was 
measured at 450 nm and at the reference wavelength 550 nm to correct for background signal using 
the Synergy HT. The measured absorbance was displayed by the Gen5TM Software and subsequent 
reported as an excel data sheet. The average absorbance in nm obtained for each concentration of 
the standard curve was plotted on the vertical axis and the corresponding IL10 concentration in 
pg/ml was plotted on the horizontal axis. Using linear regression, a best-fit straight line was plotted 
through the data points. The equation of the linear regression was: y=mx+b [y: absorbance (nm); m: 
coefficient, rate and slope of line; x: concentration (pg/ml) and b: point at which standard curve 
crosses vertical-axis). This equation was used to determine the IL10 concentration of each sample. 
Initially, as the experiment was performed in duplicates, the mean of the measured absorbance from 
each sample was calculated. Using the average absorbance the IL10 concentration was interpolated 
from the above described equation.  
The IL10 protein amount was analyzed also in sera from Burkitt lymphoma and MYC-negative Burkitt-
like lymphoma patients using the same protocol as outlined above. Refer to 2.1.1.3 for an overview 
on the cases.  
 
2.2.6.5 Expression analyses of IL10RA using flow cytometry 
 
2.2.6.5.1  Cell surface staining of IL10RA 
 
To analyze the surface IL10RA expression on cell lines, 5x105 cells per staining were used. All 
centrifugation steps were performed at 1,300 rpm for 3 min using the Multifuge X1R.  
The counted cells were centrifuged. The supernatant was discarded and the cells resuspended in 
500 µl FACS wash buffer. The cells were centrifuged again and the washing step was repeated once 
more. Finally, the cell pellet was resuspended in 15 µl FACS wash buffer and either 125 ng IL10Rα-PE 
antibody or goat IgG control-PE antibody were added. The cells were incubated for 35 min on ice in 
the dark. Afterwards, cells were washed twice with FACS wash buffer as described above. The cell 
pellet was resuspended in 250 µl 1 % PFA solution and stored at 4 °C in polystyrene round-bottom 
tubes until the measurement was performed. The amount of IL10RA-positive cells was determined 
by flow cytometry counting at least 1x104 cells using the Accuri C6 at the Department of Pediatrics, 
group of Dr. Denis Schewe, Christian-Albrechts University Kiel & University Hospital Schleswig-
Holstein, Kiel. The workflow of the analyses using the BD C Sampler Software is briefly described in 
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the following. To exclude dead cells and debris from following analysis, the cell population was 
initially analyzed in a two-parameter dot plot of the signals from the forward scatter (FSC) and side-
scatter (SSC). A gate was set on the viable cells. The viable cell population was subsequent analyzed 
using a two-parameter dot plot of the FSC vs. the FL2A in which the fluorescence signal of the PE-
conjugated antibody was detected. Initially, the cells stained with the isotype control (Goat IgG 
control-PE antibody) were analyzed to determine the background fluorescence signal. Using these 
settings as a cut-off, the cells stained with the IL10Rα-PE antibody were analyzed. Those cells which 
showed higher fluorescence intensity than the isotype control were defined as IL10RA-positive. The 
amount of IL10RA-posivie cells was used for further analysis. Moreover, for visualization of the 
IL10RA-positive cells, the cell population stained with IL10Rα-PE antibody were displayed in the same 
histogram (FL2A vs. count of cells) as the cell population stained with the isotype control.  
The analysis of the IL10RA cell surface expression was performed in duplicate. The number of IL10RA-
positve cells of each experiment was averaged.  
 
2.2.6.5.2  Intracellular staining of IL10RA 
 
The analyses of the intracellular IL10RA expression in cell lines was performed using the same 
antibodies as described in 2.2.6.5.1. For each staining 5x105 cells were used. All centrifugation steps 
were performed at 1,300 rpm for 3 min using the Multifuge X1R.  
After the counted cells were centrifuged, the supernatant was discarded and the cells resuspended in 
500 µl PBS. After an additional centrifugation step, the cell pellet was fixed in 1 ml 1 % 
paraformaldehyde solution for 20 min on ice. Cells were pelleted by centrifugation and the 
supernatant was discarded. Cells were washed once with PBS as described above and the cell 
membranes were permeabilized using 1 ml permeabilization buffer for 2 min on ice. Cells were 
washed twice as described above using 500 µl FACS wash buffer II. After resuspension of the cell 
pellet in 15 µl FACS wash buffer II, 125 ng IL10Rα-PE antibody or goat IgG control-PE antibody were 
added and incubated for 35 min on ice in the dark. Afterwards, cells were washed twice with FACS 
wash buffer II. The cell pellet was resuspended in 250 µl 1 % PFA solution and stored at 4 °C in 
polystyrene round-bottom tubes until the measurement was performed. The amount of IL10RA-
positive cells was determined as described above (2.2.6.5.1) using the Accuri C6 at the Department of 
Pediatrics, group of Dr. Denis Schewe, Christian-Albrechts University Kiel & University Hospital 
Schleswig-Holstein, Kiel. 
The analysis of the intracellular IL10RA expression was performed in duplicate. The number of 
IL10RA-positve cells of each experiment was averaged. 
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2.2.7 Bioinformatics 
 
2.2.7.1 Modeling of open reading frames  
 
Using the ExPASy translation tool the transcript sequences of TERT (NM_198253.2) including the 
different splice variants from the new exon in combination with exon 2 or exon 2V were uploaded to 
obtain the open reading frames (ORF). For each uploaded CDS three 5’-3’ reading frames (frame 1-3) 
and the included ORFs were reported. Of note is that it is possible that one reading frame contains 
more than one ORF. Only ORFs longer than 100 amino acids were considered for further analysis. 
Furthermore, to determine if the ORFs contain domains similar to TERT or even the same domains, 
the predicted protein sequences were uploaded in the SMART tool which compares the protein 
sequence with a database of protein domain sequences. Afterwards, the predicted protein domains 
of each ORF were compared using the LALIGN tool to the protein sequence of the so called wildtype 
TERT protein to decipher similarities and differences. 
 
2.2.7.2 Pluripotency plot 
 
The pluripotency plot was provided by M.Sc. Michael Lenz, Joint Research Center for Computational 
Biomedicine, RWTH Aachen University. The pluripotency plot depicts the median expression level for 
each gene/tag of the U133A microarray of all ESC and all mBL samples. Every microarray tag is 
represented by a grey dot whereas the genes of the pluripotency signature are depicted by red-
circled black dots. Furthermore, the log-fold change was calculated. The log-fold change of 1 and -1 
was used as cut-off for definition of differentially expressed genes. 
 
2.2.7.3 Statistical analyses 
 
Based on the data of the experiments the mean and the standard deviation were calculated.  
The significance of the differences in the cell cycle measurement (3.1.3.2) has been calculated using 
the unpaired, parametric t-test as published [170]. P-values were denoted as: not significant p> 0.05, 
*p < 0.05, **p < 0.01, ***p < 0.001. 
The gene expression data and the gene expression analyses were performed and provided by M.Sc. 
Christian Kohler, Institute of Functional Genomics, Statistical Bioinformatics, University of 
Regensburg as has been published in [166]. In brief, the expression levels were compared by 
Student´s t-test using R package multitest. The false discovery rates (FDR) were calculated according 
to Benjamini and Hochberg and a FDR cut-off of 0.1 was applied. 
The methylation value of the IL10 locus (3.2.3.4.2) was analyzed in mnBLL in comparison to BL and 
DLBCL. The mean of each CpG for each entity as well as for the respective cell lines was calculated. 
The significance of the differences of the methylation was calculated using the unpaired, parametric 
t-test (p>0.05 not significant). 
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3 Results 
 
The aim of this thesis was the identification and characterization of new functionally relevant 
candidate genes in pediatric B-cell lymphoma. The focus was on the most common subtype of 
pediatric B-cell lymphoma: MYC-positive Burkitt lymphoma, and its counterpart MYC-negative 
Burkitt-like lymphoma. With respect to the diverse questions raised in each lymphoma subtype, 
different techniques or combinations of those were used in the analyses. Figure 10 outlines the 
structure of findings presented in the results section. 
 
 
Figure 10: Overview on the herein conducted analyses of MYC-positive Burkitt lymphoma and MYC-negative Burkitt-like 
lymphoma. 
 
3.1 Investigation and characterization of MYC-positive Burkitt lymphomas 
 
3.1.1 Investigation of potential traces of pluripotency in Burkitt lymphomas 
 
The hallmark of MYC-positive Burkitt lymphomas (BL) is the IG-MYC translocation leading to an 
overexpression of the MYC protein. Different hypotheses about the origin of the cell in which the 
MYC translocation is initiated have been proposed (1.3.3.1). One of these hypotheses suggests that 
MYC activation occurs within hematopoietic stem cells or cells with stem-cell like capacities which 
might be precursor cells of BL. This hypothesis is supported by the fact that the MYC gene is one of 
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the four reprogramming factors sufficient to transform somatic cells into inducible pluripotent stem 
cells. To test this hypothesis, BL were analyzed for potential traces of pluripotency in collaboration 
with the Centrum for Integrative Psychiatry, Kiel. Results of these analyses, which will be detailed 
below, are accepted for publication in the journal Blood Cancer Journal reflecting in a first 
authorship. 
In order to identify traces of pluripotency in BL a recently published bioinformatic assay called 
PluriTest [215] was applied. Thus test is based on the analysis of the gene expression of a defined set 
of pluripotency signature genes. The bioinformatic procedures of this test were performed by M.Sc. 
Michael Lenz, Joint Research Center for Computational Biomedicine, RWTH Aachen University. Gene 
expression data of 221 mature aggressive B-cell lymphomas including molecular BL (mBL, n=44; MYC-
positive n=38; MYC-negative n=4; non-IG-MYC positive n=1; not analyzed n=1), non-mBL (n=129) and 
lymphomas with a gene expression signature intermediate between mBL and non-mBL (intermediate 
lymphomas, n=48), published by the MMML project [108] were studied. The 177 non-mBL were 
classified into three groups according to their MYC translocation status: MYC-positive, non-IG-MYC-
positive or MYC-negative. To improve the context of interpretation in the PluriTest, gene expression 
data of 173 primary germ cell tumors (GCT) [216],[217],[218] as well as of a large expression atlas 
consisting of a variety of somatic tissues [219] were also included in the analyses. Figure 11 gives an 
overview on the results of the analyses. The PluriTest is based on two classifiers termed pluripotency 
and novelty score. The pluripotency score describes to what extent a sample contains the 
pluripotency signature. The novelty score reports the extent of dissimilarity of the sample to the 
pluripotent sample models.  
The B-cell lymphomas analyzed regardless of their diagnosis had a strikingly lower pluripotency score 
and higher novelty score than the GCT (Figure 11A). Thus, clearly showing a closer resemblance of 
most GCT expression profiles to human pluripotent stem cells (hPSC) than any of the analyzed B-cell 
lymphomas. To get a better overview on the single disease subgroups with regard to their MYC 
status, only the 44 mBL were initially compared to 115 MYC-negative non-mBL. As shown in Figure 
11B, the mBL have a slightly higher pluripotency score and a lower novelty score than the MYC-
negative non-mBL, leading to an effective separation of these tumor entities in two groups (p<10-17, 
Mann-Whitney-U-test). Inclusion of all the other subgroups, using the mBL and MYC-negative non-
mBL as empirical density map, showed that the MYC-positive intermediate and non-mBL do not have 
a higher pluripotency score than their MYC-negative counterpart but are intermingled between mBL 
and MYC-negative non-mBL (Figure 11C). 
 
Results 
71 
 
Figure 11: PluriTest analysis of MYC-positive and –negative B-cell lymphomas. A: PluriTest results of B-cell lymphomas in 
comparison to germ cell tumors and somatic tissues. The red and blue background encodes an empirical density map 
indicating the location of pluripotent (red) and somatic (blue) cells in the reference data set. B: Zoom into the PluriTest 
results, now only shown for the all mBL and MYC-negative non-mBL. C: The mBL and MYC-negative non-mBL were used as 
empirical density maps, into which the MYC-positive and MYC-negative intermediate B-cell lymphomas and non-mBL were 
integrated. Modified from Wagener et al., Blood Cancer Journal, accepted for publication. 
 
To determine which genes of the pluripotency signature differ between the embryonic stem cells 
(ESC) and the mBL, the gene expression was compared in a pluripotency plot (Figure 12). In total 181 
genes (=279 oligonucleotide tags) build up the pluripotency signature [215]. The genes coding for 
more than one transcript can be covered by more than one oligonucleotide tag. Hence, it is possible 
that the transcripts of one gene might be differentially expressed. A total of 18 oligonucleotide tags 
(=13 genes, 6 %) were higher expressed in the mBL than in the ESC (log-fold change>1). Among those 
were genes related to increased cell cycle and proliferative activity like BCL11A [220] or PLCG2 [221]. 
In contrast, 163 oligonucleotide tags (=114 genes, 58 %) were higher expressed in the ESC than in the 
mBL (log-fold change< -1). Among them were genes such as NANOG, POU5F1, and SOX2 which are 
mechanistically linked to pluripotency [222]. A total of 98 tags (=81 genes, 35 %) were expressed at 
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comparable levels in mBL and ESC. Among those were genes which are related to cell cycle and 
proliferative activity as CDC25A [223] and AURKB [224]. 
 
 
Figure 12: Pluripotency plot comparing the median gene expression of 44 mBL and 43 ESC with regard to the expression of 
pluripotency signature genes. The grey empirical density map is based on all genes analyzed on the respective gene 
expression platform. Red-circled dots mark genes of the pluripotency signature, green-circled dots mark genes 
mechanistically linked to pluripotency and the blue-circled dot depicts the MYC gene. The red dashed lines denote the log-
fold change of ±1. Modified from Wagener et al., Blood Cancer Journal, accepted for publication. 
 
Taken together, the PluriTest algorithm showed that mBL map closer to human pluripotent stem cells 
(hPSC) than non-mBL and intermediate lymphomas. Nevertheless, based on data presented one can 
conclude that mBL do not resemble cells with pluripotent stem cell features. 
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3.1.2 Identification and characterization of a new exon in the TERT gene 
 
As described in 1.3.4, TERT is part of the telomerase complex, which is highly active in embryonic 
cells and BL. A recent analysis confirmed the high TERT expression in BL using gene expression arrays, 
and hence, led to the inclusion of this gene in a newly defined molecular gene expression classifier 
for BL [108].  
Within the ICGC MMML-Seq project, RNA-sequencing of primary BL was performed. Analysis of these 
RNA-sequencing data as well as of normal germinal center B-cells, performed by Dr. Stephan 
Bernhart from the Bioinformatics, LIFE Research Center for Civilization Diseases in Leipzig, again 
confirmed significantly higher expression of TERT in BL than in the GCB-controls (BL vs. GCB-controls 
log2FC 2.21, adj. p-value 3.94
-10, t-test p-value corrected according to Benjamini and Hochberg). 
Strikingly, mining the transcriptome data of BL revealed reads within the second intron of the TERT 
gene mapping to chr5:1,286,281-1,287,202 bp (hg19). In contrast, these reads were barely present in 
the GCB-controls (Figure 13A). This suggests that, lying between exon 2 and exon 3, a new, so far not 
described exon exists. This exon, hereinafter called “new exon”, might be part of the coding 
sequence of an alternatively spliced transcript variant of TERT. As TERT contributes to the 
immortalization of BL (1.3.4), alternative splicing of TERT might be an event in Burkitt 
lymphomagenesis secondary to MYC-translocation which might influence TERT function. Thus, in the 
framework of this thesis the validation of the existence and further molecular analyses of this new 
exon were performed which are presented in the following. 
To exclude that the reads of the new exon were misaligned repetitive elements, the region of the 
new exon was analyzed using the RepeatMasker track from the UCSC browser (Figure 13B). This 
showed that a large part of the new exon overlaps with short and long interspersed nuclear elements 
(SINE and LINE). Nevertheless, a BLAT search of the putative exon sequence derived from the 
transcriptome analysis confirmed the uniqueness of the sequence in the human genome. 
The transcriptome data also revealed that the new exon has three different splice sites at the 3’-
terminus leading to different exon sizes. The variants of the new exon are termed hereinafter V1-V3 
with V1 being the shortest and V3 the longest variant (Figure 13B).  
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Figure 13: Differential expression of TERT gene on chromosome 5p15 (localized on the reverse strand). A: Depicted are 
from the top to the bottom: scale bar in kb, genome base position in bp, the UCSC gene track showing all transcripts of the 
TERT gene (reading direction exon 1 on the right to last exon on the left), and the mean read density obtained in the ICGC 
MMML-Seq project given as reads per million of the transcriptome data of all analyzed GCB-cell samples (control_expr) and 
BL samples (BL_expr). Highlighted in blue is the newly identified exon (chr5:1,286,281-1,287,202 bp, hg19) which is visible 
in the ICGC MMML-Seq samples but is not annotated yet in the UCSC gene track. B: Magnification of the region surrounding 
the new exon. Depicted are from the top to the bottom: scale bar in kb, genome base position in bp, the UCSC gene track 
showing all transcripts of the TERT gene (reading direction from the right (exon 1) to the left), the transcriptome track of BL 
(BL_expr), a track in which the black bars indicate position of repetitive elements (RepeatMasker) and a track in which the 
red bars depict the position and the length of the three splice variants (V1-V3) of the new exon identified in BL. 
 
The existence of the new exon and its three variants, as well as the basal expression of TERT was 
analyzed in eleven BL cell lines as well as in eight primary BL on mRNA level. All BL cell lines and 7/8 
primary BL expressed detectable amounts of TERT, as well as the three splice variants of the new 
exon (Figure 14), thus, confirming its existence.  
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Figure 14: Basal expression of the TERT gene and validation of the new exon using PCR. (A) Depicted are from the top to the 
bottom: the UCSC gene track showing all transcripts of the TERT gene (reading direction from the right (exon 1) to the left), 
the transcriptome track of BL (BL_expr, in reads per million) in which the new exon is highlighted in blue as well as a 
schematic overview on the location of the PCR products with regard to the TERT gene. In latter track the red symbol depicts 
the PCR product detecting all three variants of the new exon in one PCR. The size of the PCR products were as follows: 
V1=181 bp, V2=222 bp and V3=447 bp. The green symbol represents the PCR product (137 bp) applied for analysis of basal 
TERT expression. Expression analysis was performed in eleven BL cell lines (B) and eight BL (C). Agarose gel analysis in the 
top panel depicts the expression of the three variants of the new exon, the middle panel shows basal TERT expression. 
Additionally, the integrity of the used cDNA was analyzed using the cDNA-specific primers for the reference gene GUSB 
(99 bp) (lower panel). Genomic DNA (gDNA) and water (no DNA) were used as negative controls. The arrows indicate the 
band corresponding to the size of the respective PCR products. 
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After confirmation of the expression of the new exon, its 5’ and 3’ exon borders were determined in 
the BL cell line DG-75 using Sanger sequencing (Figure 15). Based on the sequencing results, the 
exact coordinates of all three splice variants of the new exon were determined as follows: new exon 
V1 chr5:1,286,280-1,287,201 bp, new exon V2 chr5:1,286,239-1,287,201 bp and new exon V3 
chr5:1,286,014-1,287,201 bp (referring to hg19). Refer to 8.6 for the sequences of the new exon 
variants. 
 
 
Figure 15: Validation of the 5’ and 3’ exon borders of the new exon of the TERT gene in the DG-75 cell line using Sanger 
sequencing. A: Schematic overview on the exon 2 - new exon and exon 3 -new exon junctions (note the inverse orientation 
as compared to Figure 13 and Figure 14 as focused on RNA). The letters indicate the four nucleotides adjacent to the 
junction as can be seen in the electropherograms of B-E. B: 3’end of exon 2 and 5’end of the new exon. C-E: 3’ end of the 
new exon V1 (C), V2 (D) and V3 (E) and 5’ end of exon 3. 
 
In addition to the new exon, the transcriptome data of the BL from the ICGC MMML-Seq indicated 
the existence of a splice variant of exon 2, termed in the following exon 2V (Figure 16A). In particular, 
an alternative splice site seems to be used extending exon 2 into the second intron. To analyze if this 
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variant of exon 2 is transcribed together with the new exon PCR was performed on a panel of eleven 
BL cell lines. All BL cell lines expressed a TERT transcript harboring exon 2V and the new exon (Figure 
16B/C). The 3’end of this exon 2 variant was analyzed using Sanger Sequencing (Figure 16D). The 
genomic coordinates of the exon 2V were determined as chr5:1,293,079-1,294,781 bp (hg19). Refer 
to 8.7 for the sequence of the splice site variant of exon 2. 
 
 
Figure 16: Validation of the expression of the variant of exon 2 together with the new exon. A: Depicted are from the top to 
the bottom: scale bar in kb, genome base position in bp, the UCSC gene track showing all transcripts of the TERT gene 
(reading direction from the right (exon 1) to the left), and the mean read density obtained in the ICGC MMML-Seq project 
given as reads per million of the transcriptome data of all analyzed GCB-cell samples (control_expr) and BL samples 
(BL_expr) as well as a schematic overview on the location of the PCR product with regard to the TERT gene. In latter track 
the green symbol represents the PCR product (296 bp) detecting expression of exon 2V together with the new exon. 
Highlighted in blue is the newly identified exon and highlighted in red is 3’end of exon 2V which is visible in the ICGC 
MMML-Seq samples but is not annotated yet in the UCSC gene track. B: Agarose gel analysis depicts expression of the 
exon 2V together with the new exon performed on eleven BL cell lines. C: Agarose gel analysis of the reference gene GUSB 
(99 bp PCR product) in the BL cell lines. D: Electropherogram showing exon borders of the 5’ end of the new exon and 3’ 
end of exon 2V. Genomic DNA (gDNA) and water (no DNA) were used as negative controls. The arrows indicate the band 
corresponding to the respective size of the PCR products. 
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As an additional exon as well as an alternative splice site might change the open reading frame (ORF) 
of the gene and, hence, altering the respective protein, the impact of the new exon variants on the 
TERT protein sequence was analyzed. Using the ExPASy translation tool the ORFs of the three 5’-3’ 
reading frames of the coding sequence of the alternative TERT transcript were modeled (2.2.7.1). 
These included the alternative transcripts of the three different variants of the new exon in 
combination with either exon 2 or exon 2V. Table 28 summarizes for each of these six alternative 
TERT transcripts the predicted ORFs in the respective reading frames (frame 1-3). Interestingly, two 
ORFs were predicted in the first reading frame of the alternative transcripts including the new exon 
variants V2 and V3. Remarkably, overall only four different ORFs (ORF1-4) were identified in the six 
alternative transcripts as depicted in Figure 17. 
Table 28: Overview on four predicted ORFs (ORF1-4) in the three frames of the respective alternative transcripts of TERT. 
TERT transcripts Frame 1 Frame 2 Frame 3 
New exon V1 ORF1 ORF4 / 
New exon V2 ORF1 + ORF3 / / 
New exon V3 ORF1 + ORF3 / / 
New exon V1 + ex2V ORF2 / ORF4 
New exon V2 + ex2V ORF2 ORF3 / 
New exon V3 + ex2V ORF2 ORF3 / 
TERT transcripts: alternative TERT transcripts including the different splice variants of the new exon (new exon V1-V3) 
without or in combination with the alternative splice variant of exon 2 (ex2V); frame, reading frame; ORF, open reading 
frame. 
 
The predicted protein sequences of all ORFs were compared to the ORF of the assumed wildtype (wt) 
TERT protein to identify altered regions. As mentioned above, overall four different ORFs were 
identified. The features of each of these ORFs as summarized in Figure 17 are presented in the 
following. 
The first ORF (ORF1), 606 aa in length, is encoded in the first reading frame of the alternative 
transcripts including the new exon variants V1-V3. This ORF shares the same start codon with the wt 
TERT protein whereas a premature stop codon is localized within the new exon. The first 524 aa of 
this ORF1 match to the first 524 aa of the wt TERT protein. Overall, ORF1 lacks the C-terminal domain 
including the domains of the reverse transcriptase (RT), the C-terminal extension domain (CTE) as 
well as of the T-motif. Furthermore, only 46 aa of the TERT RNA binding domain (TRBD) domain are 
present.  
The ORF2, encoded in the first reading frame of the transcripts including the new exon variants as 
well as the exon 2V, also lacks the same C-terminal domain as ORF1. Furthermore, as ORF1, ORF2 
shares the start codon with wt TERT protein, whereas a premature stop codon maps within exon 2V. 
The first 525 aa match with the first 525 aa of the wt TERT protein. The remaining 49 aa at the C-
terminal of ORF2 do not overlap with wt TERT protein. 
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In contrast, the ORF3 and ORF4 are predicted to lack the N-terminal domain. The start codon of ORF3 
maps within the third exon of the transcript, whereas the stop codon is the same as in the wt TERT 
protein. The 584 aa of ORF3 match completely to the amino acids 549-1132 of the wt TERT protein. 
This ORF lacks the TERT essential N-terminal (TEN) domain, the QFP motif as well as the first 90 aa of 
the TRBD domain.  
The start codon of ORF4 maps within the new exon of the transcript, whereas the stop codon is as in 
ORF3 the same as in the wt TERT protein. Overall 606 aa of the ORF4 match to amino acids 526-1132 
of the wt TERT protein sequence whereas the first 15 aa do not match. ORF4 lacks the same N-
terminal domains as ORF3. 
 
 
Figure 17: Overview on the four predicted ORFs (ORF1-4) of the six TERT transcripts including the three variants of the new 
exon and exon 2V. A: Summary of characteristics of the four ORFs: Position of the start and stop codon within the coding 
sequence of the ORF, length of ORF in aa, overlap with TERT wt protein sequence, overall identity to TERT wt protein 
sequence as well as overview on domains which are retained in the ORFs. B: On the top the domains of the wildtype TERT 
protein are depicted: TEN, TERT essential N-terminal; TRBD, TERT RNA binding domain; RT, reverse transcriptase and CTE, 
C-terminal extension. Within the TRBD two motifs are localized: QFP and T motif [225]. The lower part illustrates the four 
predicted ORFs (ORF1-4). The same color code in the ORFs as in the wt TERT protein indicates overlapping sequences 
whereas the grey colored boxes display amino acid sequences which differ from the wt TERT protein sequence. The 
numbers indicate the amino acids (aa). The * indicates a premature stop codon.  
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Taken together, analysis of the transcriptome data of the TERT gene in BL led to the identification of 
a new exon which used three different splice sites and, thus, had three different splice variants. 
Moreover, a new splice variant of exon 2 was detected. Thus, the novel findings presented herein led 
to the identification of six splice variants of the TERT gene. The expression of the various transcripts 
could be validated in BL cell lines as well as in primary BL. The ICGC MMML-Seq data show that these 
variants are also expressed in normal GCB-cells, though at lower levels as BL. Inclusion of the new 
splice variants in the reading frame of the TERT transcripts lead to a disruption of the wt ORF. Overall 
four different ORFs were predicted in the alternative transcripts, either lacking the N- or C-terminal 
domain. 
 
3.1.3 The mutational landscape in Burkitt lymphoma 
 
In the following, the results of the analyses of the mutational landscape in MYC-positive BL will be 
presented. This chapter is divided into (i) results derived from screening of BL cell lines for mutations 
within genes previously associated with lymphomagenesis of BL and/or DLBCL and (ii) results of the 
analyses of genes newly identified to be recurrently mutated in BL and BL cell lines. 
 
3.1.3.1 Investigation of recurrently mutated genes in Burkitt lymphoma cell lines 
 
Cell lines are widely used as models to study human cancers. A range of BL cell lines is worldwide 
available. Nevertheless, these BL cell lines differ like primary BL in their mutational landscape. 
Therefore, it is reasonable to characterize mutations in BL-related genes to be able to choose the 
appropriate cell line for further functional studies. 
In the framework of this thesis, a panel of twelve cell lines (BL-2, BL-41, BL-70, BLUE-1, Ca46, DAUDI, 
DG-75, EB-1, Namalwa, Raji, Ramos, U-698-M) derived from children with BL was analyzed (2.1.2.1). 
These cell lines were screened by Sanger sequencing for mutations in genes described to be 
recurrently mutated in BL, i.e. TP53 [91] and CCND3 [133], as well as in genes described to be 
recurrently altered in DLBCL, i.e. CREBBP [226] and CDKN2A [227]. Figure 18 shows examples of the 
mutation screening using Sanger sequencing and Table 29 gives an overview on the results of this 
screening. The details will be presented in the following. 
In 10/12 (83 %) BL cell lines overall 13 mutations were detected within the TP53 gene. Of these, the 
majority were missense mutations (12/13) whereas the remaining was a nonsense mutation. All 
mutations were described to be probably damaging by PolyPhen. Despite this, six mutations (6/13, 
46 %) were described as SNP in the dbSNP database.  
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Figure 18: Overview on mutations detected in BL cell lines. A-C: Electropherograms showing the sequences around the 
mutational sites within the TP53 (A), CCND3 (B) and CREBBP (C) genes. The upper part of each panel shows the sequence 
derived from the forward primer (F) and the lower part of the reverse primer (R). The letter highlighted in red marks the 
nucleotide which is mutated. D: Plot showing the coverage of the CDKN2A gene in BL-2 as analyzed by whole-exome 
sequencing. The red bars of the Refseq track depict the various exons of those transcripts of CDKN2A with a consensus 
coding sequence or Refseq ID. The average exon coverage was between 0 to 5.46 reads per exon.  
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A total of 4/12 (33 %) BL cell lines harbored mutations within the fifth exon of the CCND3 gene. Three 
of those mutations were insertions or deletions which lead to a frameshift and subsequent 
truncation of the protein. The remaining change was a missense mutation, which has been described 
as possibly damaging by PolyPhen. All mutations have not been reported as SNP in the dbSNP 
database. 
Table 29: Overview on the mutations and alterations detected in 12 BL cell lines using Sanger sequencing. 
Gene Cell line 
genomic position 
(hg19) in bp 
mutation 
consequence on 
protein 
PolyPhen 
TP53 
NM_001126114 
chr17p13.1 
BL-41 chr17:7,577,538 c.743G>A p.Arg248Gln
1
 damaging 
BL-70 chr17:7,577,121 c.817C>T p.Arg273Cys
2
 damaging 
BLUE-1 chr17:7,577,120 c.818G>A p.Arg273His
3
 damaging 
Ca46 chr17:7,577,538 c.743G>A p.Arg248Gln
1
 damaging 
DAUDI 
chr17:7,578,212 c.637C>T p.Arg213* n.p. 
chr17:7,577,141 c.797G>A p.Gly266Glu damaging 
DG-75 
chr17:7,577,548 c.733G>A p.Gly245Ser
3
 damaging 
chr17:7,577,090 c.848G>A p.Arg283His damaging 
Namalwa chr17:7,577,538 c.743G>A p.Arg248Gln
1
 damaging 
Raji 
chr17:7,578,211 c.638G>A p.Arg213Gln damaging 
chr17:7,577,581 c.700T>C p.Tyr234His damaging 
Ramos 
chr17:7,577,520-
7,577,521 
c.760_761AT>GA p.Ile254Asp 
damaging 
U-698-M chr17:7,578,190 c.659A>G p.Tyr220Cys damaging 
CCND3 
NM_001760.4 
chr6p21.1 
BL-41 
chr6:41,903,711-
41,903,759 
c.798_846del(#) p.Pro267Leu fs*21 n.p. 
BL-70 
chr6:41,903,788-
41,903,789 
c.801_802insC p.Lys268Gln fs*56 n.p. 
BLUE-1 chr6:41,903,688 c.869T>G p.Ile290Arg 
possibly 
damaging 
DG-75 
chr6:41,903,746-
41,903,747 
c.811_812insG p.Ser273Leu fs*51 n.p. 
CREBBP 
NM_004380 
chr16p13.3 
DG-75 
chr16:3,817,721-
3,817,727 
c.3244_3250insA p.Ile1084Asn*2 n.p. 
CDKN2A 
ENSG00000147889 
chr9p21.3 
 
BL-2 
 
chr9:21,967,753-
21,995,301 
homozygous 
deletion 
 n.p. 
Sanger sequencing was performed on a panel of 12 BL cell lines (BL-2, BL-41, BL-70, BLUE-1, Ca46, DAUDI, DG-75, EB-1, 
Namalwa, Raji, Ramos, U-698-M). Genomic position (in bp) refers to the genomic build hg19; mutation, affected nucleotide 
in cDNA; (#), complex aberration; consequence on protein, amino acid change introduced by mutation; all mutations were 
revised for a SNP annotation in the dbSNP database (Build 141, 15/12/2014); six TP53 mutations had a dbSNP annotation: 
1
, 
rs11540652, 
2
, rs121913343, 
3
, rs28934576; PolyPhen: n.p., not predictable with PolyPhen. 
 
Only one BL cell line (DG-75) (1/12, 8 %) carried a mutation within the CREBBP gene. This mutation 
was an insertion leading to a frameshift and premature stop codon in exon 16 of the gene.  
None of the cell lines carried a point mutation within the CDKN2A gene. Nevertheless, no PCR 
product was obtained for the BL-2 cell line indicating a homozygous loss or mutation of the primer 
binding sites in the gene. Further, analysis of this cell line by whole-exome sequencing failed to 
produce reads of the CDKN2A locus indicating a homozygous deletion of CDKN2A (Figure 18D). The 
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size of the homozygous deletion is unclear, as the exact breakpoints of the homozygous loss cannot 
be determined by whole-exome sequencing. But based on the read coverage of adjacent genes, the 
homozygous loss seems to encompass two more genes: CDKN2B (chr9:22,002,903-22,009,362 bp, 
hg19) and DMRTA1 (chr9:22,446,840-22,452,472 bp, hg19) which lie downstream from the CDKN2A 
locus. Refer to 8.8 for an overview on the chromosomal region encompassing the homozygous loss. 
Taken together, the BL cell lines showed a high frequency of mutations in TP53 (83 %) and CCND3 
(33 %). CDKN2A and CREBBP, which are genes recurrently mutated in DLBCL, were each solely 
mutated in one of twelve BL cell lines (8 %). 
 
3.1.3.2 Identification and characterization of recurrent ID3 mutations in Burkitt lymphoma 
 
In the framework of the ICGC MMML-Seq project, our group has recently described mutations within 
the ID3 (Inhibitor of DNA Binding 3, Dominant Negative Helix-Loop-Helix Protein) gene in 68 % 
(36/53) of BL [170]. The in vitro analyses of the functional consequences of the ID3 mutations 
presented in the publication were performed in the framework of this thesis and are outlined below. 
This contribution led to a co-authorship in the manuscript published in the journal Nature Genetics.  
Initially, a panel of 18 aggressive B-cell lymphoma cell lines was screened for ID3 mutations using 
Sanger sequencing. This panel consisted of twelve BL- (BL-2, BL-41, BL-70, BLUE-1, Ca46, DAUDI,          
DG-75, EB-1, Namalwa, Raji, Ramos, U-698-M) and six non-BL (MC-116, HT, Karpas422, Su-DHL-5,           
Su-DHL-6, Su-DHL-10) cell lines. The results of the mutation analyses of ID3 are summarized in Table 
30. 
Table 30: Mutation analyses of ID3 in B-cell lymphoma cell lines by Sanger sequencing. Adapted from Richter et al.[170]. 
Cell line Diagnosis 
genomic position (hg19) in 
bp 
mutation 
consequence on 
protein 
bi-
allelic 
BL-2 BL 
chr1:23,885,618 c.300G>A (sm) splicing 
 
chr1:23,885,617 c.300+1G>C splicing 
BL-41 BL chr1:23,885,716 c.202G>C p.Glu68* Y 
BL-70 BL 
chr1:23,885,654-23,885,778 c.139_264del p.Cys47Pro*32 
Y 
chr1:23,885,617 c.300+1G>A splicing 
BLUE-1 BL chr1:23,855,678-23,885,682 c.236_240delACCTG p.Asp79Alafs*13  
Ca46 BL 
chr1:23,885,758 c.160C>G p.Leu54Val 
 
chr1:23,885,728 c.190C>T p.Leu64Phe 
DAUDI BL 
chr1:23,885,758 c.160C>G p.Leu54Val 
 
chr1:23,885,697 c.241C>T p.Gln81* 
Namalwa BL chr1:23,885,385-23,885,708 c.210_360+66del(#) p.Ile74Val*26  
U-698-M BL 
chr1:23,885,752 c.166C>T p.Pro56Ser 
 
chr1:23,885,685 c.233T>C  p.Leu78Pro 
MC-116 
B-cell 
lymphoma 
chr1:23,885,618 c.300G>A(sm) splicing  
chr1:23,885,617 c.300+1G>A splicing  
Diagnosis: BL, Burkitt lymphoma; mutation, affected nucleotide in cDNA; wt, wildtype; sm, silent mutation affecting last 
base of ID3 exon1; (#), complex aberration; consequence on protein, amino acid change introduced by mutation; y, biallelic 
status was confirmed. All consequences of the mutations on cDNA and protein level were described referring to the ID3 
transcript NM_002167. The genomic positions (in bp) refer to the hg19 reference genome. 
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Overall, 8/12 (67 %) BL cell lines and one cell line classified as B-cell lymphoma (MC-116) harbored 
mutations within the ID3 gene. The eight mutated BL cell lines carried in total 13 mutations within 
the ID3 gene of which two cell lines harbored biallelic mutations. The 13 mutations in the BL cell lines 
were classified as missense mutations (5/13, 39 %), nonsense mutations (2/13, 15 %), frameshift 
deletions (3/13, 23 %) and splice site mutations (3/13, 23 %). 
Remarkably, all three splice site mutations affected the end of exon 1, with the mutation c.300+1G>C 
occurring in two cell lines (BL-2, BL-70). Further analysis of the two ID3 mutations in the BL-70 cells 
by RT-PCR and Sanger sequencing (2.2.1.7), revealed that the mutations were biallelic as two bands 
were detectable in the agarose gel analysis after the amplification. Both bands were analyzed by 
Sanger sequencing. Sequence analysis identified on the one allele the deletion but normal splicing of 
exon 1 on exon 2 (Figure 19A) whereas on the other allele a truncated exon 1 was spliced on exon 2 
(Figure 19B). Thus, the splicing mutation led to an in-frame message with a loss of the 57 bp at the 3’ 
end of exon 1. 
 
 
Figure 19: Biallelic involvement of ID3 mutations in BL-70 cell line analyzed by Sanger sequencing. A: Electropherogram 
showing the cDNA sequence of the ID3 allele harboring the deletion c.139_264del. The blue arrow indicates the position of 
the 125 bp deletion. The exon border is indicated by the black line confirming normal splicing. B: Electropherogram showing 
the cDNA sequence of the ID3 allele with the splicing mutation (c.300+1G>A). This mutation leads to the usage of an 
alternative splice site within exon 1 and, thus, to an in-frame loss of 57 bp at the 3’ end of the exon 1. Adapted from [170]. 
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In summary, the screening of cell lines showed a predominant occurrence of ID3 mutations in cell 
lines derived from BL of which two-third were affected, as well as a tendency to deleterious 
mutations.  
To examine if the ID3 mutations might lead to a decreased ID3 protein expression, Western blot 
analysis was performed using protein extracts of a panel of 14 B-cell lymphoma cell lines, consisting 
of ten BL- and four non-BL cell lines with known ID3 mutation status. The results of the analysis are 
shown in Figure 20.  
 
 
Figure 20: Western blot analyses of ID3 protein in B-cell lymphoma cell lines. The table at the top summarizes the mutation 
status of each cell line (+, one mutation, ++ two mutations) Depicted are the Immunoblots for the ID3 protein (13 kD) and 
the reference protein Actin (42 kD). Adapted from Richter et al. [170]. Although the ID3 antibody detected additional 
unspecific bands, it was determined as the best available antibody after screening of various commercially, available ID3 
antibodies. 
 
Based on the ID3 protein expression level detected by Western blot, the cell lines can be separated 
into different groups: cell lines with no ID3 expression (BL-2, BL-41, BL-70), cell lines (Ca-46, 
Namalwa) expressing ID3 at comparable levels as the cell lines with wildtype ID3 (Raji, DG-75, EB-1) 
as well as cell lines with lower ID3 expression (BLUE-1, U-698-M) than the ID3-wildtype cell lines. The 
ID3 expression status correlated only partly with the ID3 mutation status. For example, Namalwa 
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cells harbored a frameshift deletion but expressed ID3 at comparable levels as ID3-wildtype cell lines, 
whereas in BL-2 cells, harboring splice site mutations, no ID3 expression was detectable at all. The 
non-BL cell lines on the other hand showed a barely detectable or no ID3 expression at all. But it 
should be also taken into consideration that the detection of the expression depends on the 
presence of the epitope of the antibody. Thus, a here described loss of expression might be also 
attributable to a loss of the epitope due to an alteration of the ID3 protein sequence. 
To test if a complete abolishing of ID3 function due to loss of expression or inactivating mutations 
might give a selective growth advantage, BL-2 cells with ID3 mutation and complete loss of ID3 
expression and DG-75 cells with wildtype-ID3 and detectable ID3 expression were transfected with 
an ID3-GFP construct to re-/overexpress the ID3 protein. 
The amount of ID3-GFP positive cells was determined using flow cytometry. Figure 21A and C shows 
that the overall ID3-GFP positivity was low for both cell lines (11.5-18 % for DG-75 and 4-5 % for BL-2 
cells).  
 
 
Figure 21: Cell cycle analyses of BL-cell lines transfected with an ID3-GFP construct. The ID3-wildtype DG-75 (A,B) and ID3-
mutated BL-2 (C,D) cell lines were transfected with ID3-pCMV6-AC-GFP. A,C: Depict the results of the flow cytometry. The 
ID3-GFP-expressing (R3) and ID3-GFP-negative (R4) cells were gated into different populations. B,D: Depicts the cell cycle 
analyses of ID3-GFP-positive (black) and ID3-GFP-negative (grey) cell populations. The graphs depict the mean and the 
standard deviation. FL1-H, fluorescence channel 1 height; FSC-H, forward scatter height; G1, Gap 1 phase, S, synthesis 
phase, G2/M, Gap 2/Mitosis phase. Adapted from Richter et al. [170].  
 
Results 
87 
Analysis of the cell cycle (Figure 21B,D) showed that in both cell lines most of the ID3-GFP negative 
cell population was in G1 phase (DG-75 40.4 %, BL-2 ~48.6 %) and less than 10 % of the cells were in 
the apoptotic phase or pre-G1 phase. 52.6 % of BL-2 cells re-expressing the ID3 protein were in the 
pre-G1 phase, which is a significant increase as compared with ID3-GFP-negative cells (52.6 5 vs. 
3.3 %, p<0.001, t-test). The other half of the ID3-GFP-positive BL-2 cells were in the G1 or S phase of 
the cell cycle. Only 3.2 % of those cells were in the G2/M phase which is a significant reduction in 
comparison to the ID3-GFP-negative BL-2 cells (3.2 % vs. 19.6 %, p<0.001, t-test). The majority of ID3-
GFP-negative DG-75 cells were within the G1 phase (40.4 %) whereas in ID3-GFP-positive DG-75 cells 
53.7 % were in the pre-G1 phase. This increase of cells in the pre-G1 phase in comparison to ID3-GFP-
negative DG-75 cells is significant (53.7 % vs. 8.2 %, p<0.001, t-test).  
Taken together, 67 % of the Burkitt lymphoma cell lines carried ID3 mutations, from which the 
majority were deleterious and possibly inactivating. Some of the mutations led to a complete loss of 
the ID3 expression as shown by Western blot analysis. Re-expression or overexpression of ID3-GFP in 
BL cell lines with a mutated-ID3 gene (BL-2) or wildtype ID3 gene (DG-75) led to a significant increase 
of the number of cells in the pre-G1 phase of the cell cycle (p<0.001, t-test). Thus, ID3 might be a 
novel tumor suppressor gene in MYC-positive Burkitt lymphoma. 
 
3.1.3.3 Identification and characterization of recurrent SMARCA4 mutations in Burkitt lymphoma 
 
Further analysis of the mutational landscape of BL within the framework of the ICGC MMML-Seq 
project revealed the SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4) gene to be mutated in 43 % of BL (9/21). The results of the 
identification and characterization of the SMARCA4 mutations as presented below were embedded 
within a study on integrated analyses of the genome, methylome and epigenome in BL. The results of 
this study are currently under revision in the journal Nature Genetics and the data presented in this 
thesis lead to a co-authorship. 
Initially, the focus was on the SMARCA4 mutations identified in nine BL all analyzed within the ICGC 
MMML-Seq project. Based on the lack of these mutations within the respective germline, these 
mutations were described as somatic. The mutations were validated using Sanger sequencing as part 
of this thesis. After reviewing the nine mutations at the dbSNP141 and ESP6500 databases, they 
were confirmed as single nucleotide variants (SNV). Additionally, to elucidate a possible 
exclusiveness of SMARCA4 mutation to BL, the whole-genome sequencing data of 99 non-BL of the 
ICGC MMML-Seq project were screened for mutations within the SMARCA4 gene. Only 6 % of the 
non-BL (6/99) harbored SMARCA4 mutations. 
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To identify additional cases with mutations and asses the frequency of SMARCA4 mutations in 
independent cohorts, the published next generation sequencing data of BL from Schmitz et al. [72] 
and Love et al. [228] were mined. Schmitz et al. [72] have performed RNA-sequencing of 28 BL. Of 
those eleven BL (11/28, 39 %) were described to carry a SMARCA4 mutation of which one mutation 
was described as SNP in the dbSNP141 database. Love et al. [228] performed whole-exome 
sequencing of 51 primary BL, of which eight (8/51, 16 %) carried SMARCA4 mutations. Refer to Table 
31 for an overview on the mutations. 
Additionally, the whole-exome data of 13 BL cell lines available at the COSMIC database 
(http://cancer.sanger.ac.uk/cancergenome/projects/cell_lines/), published by Schmitz et al. [72] or 
by Love et al. [228] were reviewed for mutations within the SMARCA4 gene. Using this approach, five 
BL cell lines (DAUDI, DG-75, EB-3, JIYOYEP and Ramos) were identified to harbor SMARCA4 
mutations. Two of the cell lines (Ramos, EB-3) harbored mutations which were reported in the dbSNP 
database as SNP and, hence, they were subsequently excluded. Using Sanger sequencing the 
SMARCA4 mutation in DG-75 was confirmed. The SMARCA4 mutation in DAUDI cells on the other 
hand could not be confirmed. The latter could be attributed to the fact that the whole-exome 
sequencing (data available at COSMIC cell line database, http://cancer.sanger.ac.uk/cell_lines/, 
31/01/2014) and the in-house Sanger sequencing have been performed on DAUDI cells obtained 
from varying suppliers (American Type Culture Collection (ATCC) vs. DSMZ, respectively). Thus, 
DAUDI cells have likely been cultured for varying periods of time and the SMARCA4 mutation 
reported in the COSMIC cell line database could represent a mutation acquired during the culturing 
of the cell line. As we do not possess the JIYOYEP cell line or DNA from this cell line, the validation of 
the mutation in this cell line was not possible. 
In addition to the mining of available data, targeted resequencing using the TruSight One panel 
covering the SMARCA4 gene was performed in three BL cell lines for which neither whole-exome nor 
whole-genome sequencing data were available (BL-70, BLUE-1, U-698-M). Only the cell line BLUE-1 
carried a SMARCA4 mutation but this was reported as SNP in the dbSNP database. Taken together, in 
two out of 16 BL cell lines (13 %) SMARCA4 mutations could be identified and verified. Refer to Table 
31 for a complete overview on the SMARCA4 mutations. Figure 22A shows examples of the mutation 
validation using Sanger sequencing. 
A total of 29 mutations were identified in SMARCA4 of which all except one were missense mutations 
(28/29, 97 %). One mutation probably affects splicing (1/29, 3 %) (Table 31). All 28 missense 
mutations were described by PolyPhen as damaging.  
Recurrent sites of substitutions were amino acids 973, 1192 and 1232 each altered in three cases, as 
well as the amino acid 1243 which was substituted in two cases. A total of 18 mutations  affected the 
SNF2 family N-terminal domain (SNF2_N) and Helicase conserved C-terminal domain (Helicase_C), 
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(38 % and 24 %, respectively). Refer to Figure 22B for an overview on the distribution of the 
mutations in the SMARCA4 encoded BRG1 protein which clearly depicts the accumulation of 
mutations within the SNF2_N and Helicase_C domains. 
The Mechismo tool was used to analyze if the here described mutations might affect protein-protein, 
protein-DNA/RNA or protein-small molecule interaction. None of the 28 SMARCA4 missense 
mutations was reported to alter any of the above mentioned interactions.  
Table 31: Overview on SMARCA4 (NM_001128844.1) mutations in primary BL and BL cell lines. 
 
PID 
Genomic 
position (hg19) 
in bp 
Mutation 
Consequence 
on protein 
Affected 
domain 
Validated 
using Sanger 
sequencing 
PolyPhen 
IC
G
C
 c
o
h
o
rt
 
4125240 chr19:11,105,679 c.1593+2T>C Splicing HSA validated n.p. 
4194218 chr19:11134,251 c.2917C>T p.Arg973Trp SNF2_N  validated damaging 
4182393 chr19:11,134,252 c.2918G>A p.Arg973Gln SNF2_N  validated damaging 
4194891 chr19:11,134,252 c.2918G>A p.Arg973Gln SNF2_N  validated damaging 
4127766 chr19:11,134,254 c.2920C>T p.Pro974Ser SNF2_N validated damaging 
4146289 chr19:11,134,275 c.2942A>G p.Lys981Glu SNF2_N validated damaging 
4108627 chr19:11,141,498 c.3475G>A p.Gly1159Arg Helicase_C validated damaging 
4177856 chr19:11,144,113 c.3694G>A p.Gly1232Ser  validated damaging 
4112512 chr19:11,144,146 c.3727C>T p.Arg1243Trp  validated damaging 
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SLN2448 chr19:11,094,973 c.146C>T p.Pro49Leu  validated by 
1
 damaging 
SLN2386 chr19:11,105,645 c.1561C>T p.Arg521Trp HSA validated by 
1 damaging 
SLN2389 chr19:11,132,500 c.2716C>T p.Arg906Cys SNF2_N validated by 
1 damaging 
SLN2402 chr19:11,132,516 c.2732G>A p.Gly911Asp SNF2_N validated by 
1 damaging 
SLN2391 chr19:11,134,230 c.2896C>T p.Arg966Trp SNF2_N validated by 
1 damaging 
SLN2540 chr19:11,141,508 c.3485G>T p.Gly1162Val Helicase_C validated by 
1 damaging 
SLN2536 chr19:11,143,976 c.3556C>T p.Ala1186Val Helicase_C validated by 
1 damaging 
SLN2528 chr19:11,143,999 c.3580G>A p.Gly1194Arg Helicase_C validated by 
1 damaging 
SLN2448 chr19:11,144,113 c.3694G>A p.Gly1232Ser  validated by 
1 damaging 
SLN2430 chr19:11,144,146 c.3727C>T p.Arg1243Trp  validated by 
1 damaging 
Lo
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1060 chr19:11,132,428 c.2644G>A p.Glu882Lys SNF2_N validated by 
2
 damaging 
1064 chr19:11,132,513 c.2729C>T p.Thr910Met SNF2_N  damaging 
324 chr19:11,143,993  c.3574C>T p.Arg1192Cys Helicase_C  damaging 
510 chr19:11,143,993  c.3574C>T p.Arg1192Cys Helicase_C  damaging 
1090 chr19:11,143,993  c.3574C>T p.Arg1192Cys Helicase_C  damaging 
403 chr19:11,144,113 c.3694G>A p.Gly1232Ser   damaging 
508 chr19:11,144,131 c.3712T>C p.Ser1238Pro   
possibly 
damaging 
1063 chr19:11,144,152 c.3733G>A p.Ala1245Thr 
  possibly 
damaging 
C
e
ll 
lin
e
s 
JIYOYEP
3 
chr19:11,132,426 c.2642A>G p.Asp881Gly SNF2_N  damaging 
DG-75
3
 chr19:11,152,098 c.4286G>A p.Arg1429His  validated damaging 
PID: patient identification; Affected domain: HSA, Helicases and associated with SANT domains; SNF2_N, SNF2 family N-
terminal domain; Helicase_C, Helicase conserved C-terminal domain; mutation, affected nucleotide in cDNA based on 
transcript NM_006196; consequence, amino acid change introduced by mutation The genomic positions (in bp) refer to the 
hg19 reference genome. If not otherwise indicated the validation using Sanger sequencing has been performed in the 
framework of this thesis. 
1
 Validation by Sanger sequencing by Schmitz et al. [72], 
2
 Validation by Sanger sequencing by Love 
et al. [228], 
3
 data from COSMIC Cell Line Project data base (http://cancer.sanger.ac.uk/cancergenome/projects/cell_lines/). 
PolyPhen: n.p., not predictable with PolyPhen. 
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Figure 22: Overview on SMARCA4 mutations. A: Electropherograms showing the sequences around the mutational sites 
within the SMARCA4 gene in three BL and one BL cell line (DG-75). The upper panel shows the sequence derived from the 
forward primer (F) and the lower panel of the reverse primer (R). The site of mutation is indicated by the arrow. The letter 
highlighted in red marks the nucleotide which is mutated; the underlined letters mark the mutated codon. B: Overview on 
the mutation sites in BRG1 of all mutated BL (refer to Table 31) and BL cell lines. The protein model is based on Pfam 
domains. 
Results 
91 
Taken together, analyses of three independent BL-cohorts, with in total exactly 100 BL, led to the 
detection of SMARCA4 mutations in 27 % of BL. The majority of these mutations were missense 
mutations of which 62 % affected either the SNF2_N domain or the Helicase_C domain. 
 
3.1.3.4 Identification and characterization of recurrent PCBP1 mutations in Burkitt lymphoma 
 
In the framework of this thesis the Poly(rC) binding protein 1 (PCBP1) gene was newly identified as 
recurrently mutated gene in BL. The results of the identification and characterization of the PCBP1 
mutations in BL as detailed below were summarized in a manuscript which is accepted for 
publication in the journal Genes, Chromosomes and Cancer. 
Initially, analysis of whole-genome sequencing data of 17 BL from the ICGC MMML-Seq cohort 
revealed three BL to harbor mutations within the PCBP1 gene (3/17, 18 %). The mutations were 
verified using Sanger sequencing. Moreover, by screening of the corresponding germline tissue of the 
patients the mutations were shown to be of somatic origin. All mutations were confirmed as SNV by 
comparison to the dbSNP141 and ESP6500 databases.  
In order to identify additional cases with PCBP1 mutations and to determine the frequency of 
mutations in this gene in an independent series, a cohort consisting of 28 IG-MYC-positive mBL from 
the MMML-network project [108] was screened using Sanger sequencing (MMML cohort). In this 
cohort, three BL carried PCBP1 mutations (3/28, 11 %) which were also shown to be SNV. Thus, 
combining the discovery cohort of the ICGC MMML-Seq and the validation cohort of the MMML, we 
identified PCBP1 mutations in 13 % (6/45) of BL.  
Moreover, a panel consisting of 16 BL cell lines (BALM-16, BALM-18, BL-2, BL-30, BL-41, BL-70,       
BLUE-1, Ca46, DAUDI, DG-75, EB-1, EB-3, Namalwa, Raji, Ramos, U-698-M) was screened for 
alterations of PCBP1. Six BL cell lines carried mutations within PCBP1 (6/16, 38 %) which were also 
shown to be SNV. Refer to Table 32 for an overview on the mutations. Figure 23A shows examples of 
electropherograms of identified mutations. 
In total twelve mutations within the PCBP1 gene were identified. The majority (7/12, 58 %) were 
missense mutations. The mutation p.Cys293Tyr occurred in two cases (MPI-017, BL-70 cell line). The 
other mutations were nonsense mutations (3/12, 25 %) as well as an insertion and deletion leading 
to a premature stop codon (2/12, 17 %). Two of the nonsense mutations affected adjacent amino 
acids (Gln184* and Tyr183*). The majority (6/7) of the seven missense mutations were defined by 
PolyPhen as possibly or even probably damaging. Only the mutation p.Val267Met was predicted to 
be benign.  
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Table 32: Overview on the mutations in PCBP1 (NM_006196) identified in BL and BL cell lines. 
 
PID 
Genomic 
position (hg19) 
in bp 
Mutation 
Consequence on 
protein 
Affected domain PolyPhen 
IC
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 c
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4193278 
chr2:70,314,913
-70,314,914 
c.41_42delTC p.Leu14fs*22 Truncating in KH I n.p. 
4177434 chr2:70,315,476 c.601_602insT p.Cys201Leufs*12 Truncating after KH II n.p. 
4127766 chr2:70,315,425 c.550C>T p.Gln184* Truncating after KH II n.p. 
M
M
M
L 
co
h
o
rt
 
MPI-017 chr2:70,315,753 c.878G>A p.Cys293Tyr KH III 
possibly 
damaging 
MPI-005 chr2:70,315,759 c.884T>C p.Ile295Thr KH III 
possibly 
damaging 
MPI-101 chr2:70,315,848 c.973A>G p.Arg325Gly KH III/NLS I 
probably 
damaging 
C
e
ll 
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e
s 
BL-30 chr2:70,315,779 c.907A>G p.Asn303Asp KH III 
possibly 
damaging 
BL-41 chr2:70,315,674 c.799G>A p.Val267Met NLSI benign 
BL-70 chr2:70,315,753 c.878G>A p.Cys293Tyr KH III 
possibly 
damaging 
DAUDI chr2:70,315,312 c.437T>G p.Ile146Ser KH II 
probably 
damaging 
EB-3 chr2:70,315,424 c.549C>G p.Tyr183* Truncating after KH II n.p. 
Namalwa chr2:70,315,236 c.361A>T p.Lys121* Truncating after KH II n.p. 
PID: patient identification; mutation, affected nucleotide in cDNA based on transcript NM_006196; consequence, amino 
acid change introduced by mutation. Affected domains: KH, K-Homology domain; NLS, nuclear localization signal. PolyPhen: 
n.p., not predictable with PolyPhen. The genomic positions refer to the hg19 reference genome.  
 
The PCBP1 protein consists of three K-homology (KH) domains (KH I-III) and two nuclear localization 
signals (NLS I-II). The majority of mutations affected the KH III domain (10/12, 83 %) due to a 
complete loss of the domain (5/10) or an amino acid substitution. Moreover, 58 % of the mutations 
affect the NLS I and/or NLS II due to a loss of both NLS or a missense mutation in one of them (Figure 
23B). Five of the six missense mutations affected directly the KH III domain or lay next to it 
(p.Val267Met). The mutation p.Ile146Ser was the exception, as it lay within the KH II domain. The 
four mutations lying within the KH III domain were predicted by the Mechismo tool to have an effect 
on DNA/RNA interaction. The substitution p.Arg325Gly was predicted to have a strong disabling 
effect on oligonucleotide binding due to a loss of the positive charge while the other three 
mutations, p.Cys293Tyr, p.Ile295Thr and p.Asn303Asp, were predicted to have weaker effects. 
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Figure 23: Overview on the PCBP1 mutations. A: Electropherograms showing the sequence around the mutational sites 
within PCBP1 gene in two primary BL cases and one BL cell line (BL-41). The site of mutation is indicated by the arrow. The 
upper panel shows the sequence derived from the forward primer (F) and the lower panel of the reverse primer (R). The 
letter highlighted in red marks the mutated nucleotide; the underlined letters mark the mutated codon. B: Overview on the 
mutational sites in PCBP1 with regard to its subdomains. KH, K-homology domain; NLS, nuclear localization signal. The 
numbers indicate the amino acid (aa). Modified from Wagener et al., Genes, Chromosomes and Cancer, accepted for 
publication. 
 
To analyze if the mutations have an impact on the PCBP1 expression, the transcriptome data 
available for the three cases of the ICGC MMML-Seq cohort were analyzed. This analysis revealed a 
balanced expression of the mutated and wildtype PCBP1 alleles in cases 4177434 and 4127766 
(relative expression of the mutated allele in case 4177434=0.47 and in case 4127766=0.55). Case 
4193278 on the other hand, which carried a frameshift mutation leading to a truncation within the 
KH I domain, showed a more than five-fold lower expression of the mutated allele than of the 
wildtype allele (relative expression of the mutated allele=0.16). This points to a possible degradation 
of the mutated allele by nonsense mediated decay (NMD). 
Analysis of the available clinico-pathological data of the BL with wildtype or mutated PCBP1 of the 
ICGC MMML-Seq and MMML cohorts showed no striking differences between the two groups. The 
only significant difference was that the PCBP1 mutated cases showed a higher frequency of 
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MUM1/IRF4 expression than the wildtype-PCBP1 cases (6/6, 100 % vs. 12/32, 39 %, p=0.008, Fisher’s 
exact test). Refer to 8.9 for an overview on immunohistochemical variables. 
Taken together, 6 of 45 (13 %) investigated BL carried PCBP1 mutations. The mutations 
predominantly affected the KH III domain of the PCBP1 protein (10/12, 83 %) either due to a 
complete loss or by an amino acid substitution. Four of the missense mutations might alter the RNA 
interaction efficiency of PCBP1. All PCBP1 mutated cases expressed MUM1/IRF4. 
 
3.1.3.5 Summary of the mutational landscape in MYC-positive Burkitt lymphoma cell lines 
 
Figure 24 summarizes the results of the analyses of the mutational landscape in the BL cell line 
models. The most frequently mutated genes were TP53 and ID3 genes in 10/12 (83 %) and 8/12 
(67 %) BL cell lines, respectively. 6/16 BL cell lines (38 %) carried PCBP1 mutations and 4/12 (33 %) 
carried CCND3 mutations. In 8 % of BL cell lines, corresponding to one BL cell line, mutations within 
SMARCA4 (1/13), CREBBP (1/12) and CDKN2A (1/12) were detected. The overview on the mutational 
status of the respective genes shows that every cell line, besides the EB-1, BALM-16 and BALM-18, 
harbored at least one mutation in one of the above mentioned genes. Of note is, that only PCBP1 
mutation screening was performed for the BALM-16 and BALM-18 cell lines. Thus, the existence of 
mutations in the other six analyzed genes for these two cell lines cannot be excluded. Moreover, the 
frequency and distribution of PCBP1 and SMARCA4 mutations in the BL cell line models resembled 
that in primary BL. 
 
 
Figure 24: Overview on mutation status of the seven analyzed genes identified or verified by Sanger sequencing in overall 
16 BL cell lines investigated as potential models for functional analyses. The five genes of the upper panel are frequently 
mutated in primary Burkitt lymphomas whereas the genes of the lower panel are more frequently mutated in primary 
DLBCL. 
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3.2 Identification and characterization of MYC-negative Burkitt-like lymphomas 
 
In 2014, our group described the existence of a subtype of B-cell lymphomas termed MYC-negative 
high grade B-cell lymphoma resembling Burkitt lymphoma [166]. As already described in 1.4, these 
MYC-negative Burkitt-like lymphomas (mnBLL) were characterized by a common pattern of 
aberration on chromosome 11q consisting of interstitial gains and telomeric losses.  
The aim of the analyses of mnBLL presented in the following was the characterization of the 
chromosomal, mutational and transcriptional landscape. These analyses should pave the way for the 
identification of genes which might contribute to the pathogenesis of these lymphomas. Moreover, 
cell line models for mnBLL were identified and characterized. These models were subsequently used 
for functional analyses of the potential candidate genes involved in the pathogenesis of this 
lymphoma subtype. 
Part of the characterization of mnBLL was performed in the framework of this thesis leading to a 
shared first authorship in the above mentioned work published in the journal Blood [166]. The data 
presented below are extended follow-up analyses of this publication taking into account the data 
published in Blood [166] as well as data acquired afterwards. 
 
3.2.1 Characterization of newly recruited MYC-negative Burkitt-like lymphomas 
 
In addition to the 17 mnBLL already published in Blood, eight new mnBLL (cases 18-25) were 
identified in the routine tumor genetic diagnostics of the Institute of Human Genetics, Kiel, Germany 
or were referred to by other institutions for reference diagnostics. These cases were recognized by 
the referring pathologist to harbor features of BL. Furthermore, they were identified based on the 
cytogenetic analyses showing that they did not carry a break within the MYC gene, but harbored the 
gain and loss pattern on chromosome 11. All newly recruited cases were characterized as mnBLL 
based on the following published criteria: 
Cytogenetic analysis: Immunophenotype: 
Presence of 11q gain/loss Coexpression of CD20 and CD10 
Lack of MYC break  
Lack of BCL2 break  
Lack of BCL2 expression 
>90 % Ki67 positivity 
The information concerning the cytogenetic findings and immunophenotype were obtained from the 
clinical records and/or referring institutions. The results are summarized in Table 33. The BCL2 break 
status was missing for three cases. Nevertheless, as the BCL2 translocation is associated with an 
overexpression, the BCL2-negative immunophenotype of those cases suggested for a lack of a BCL2 
break. 
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Table 33: Cytogenetic features and immunophenotype of mnBLL cases investigated in this thesis but not reported in 
[166]. 
 Case 
Cytogenetics Immunophenotype 
11q 
gain/loss 
IGH-MYC 
fusion 
MYC 
break 
BCL2 
break 
CD20 CD10 BCL2 Ki67 
Case 18 positive n.d. negative n.d. + + - ~ 100 % 
Case 19 positive negative negative negative + + -/+ > 95 % 
Case 20 positive negative negative negative +/- + - > 95 % 
Case 21 positive negative negative n.d. + + - 90 % 
Case 22 positive negative negative n.d. n.d. + - > 95 % 
Case 23 positive negative negative negative n.d. + +/- 95 % 
Case 24 positive negative negative n.d. + + - 100 % 
Case 25 positive negative negative negative + + - 100 % 
+, positive; -, negative; +/-, majority positive with negative fractions; -/+, majority negative with positive fractions; n.d., no 
data available. 
 
After confirmation that the newly recruited cases harbor the typical cytogenetic and 
immunophenotypical features of the mnBLL, array-based analyses using the OncoScan DNA-
microarray were performed to further characterize the alteration on chromosome 11 as well as the 
global chromosomal landscape. The results of these analyses are presented in the following. 
 
3.2.1.1 Array-based characterization of chromosome 11 aberrations in MYC-negative Burkitt-like 
lymphoma 
 
In the following, the alterations on chromosome 11 observed in the eight novel mnBLL are described. 
Findings are summarized in Figure 25. For a complete list of all copy number alterations (CNA) in 
these eight mnBLL cases refer to appendix 8.10. 
Seven of the eight mnBLL (cases 18-21 and 23-25) carried the typical copy number pattern of gain 
and loss on chromosome 11 (Figure 25A). The exception was case 22 which solely harbored a loss of 
11q24.2-q25. Interestingly, cases 19 and 24 showed in contrast to all the other previously described 
mnBLL cases a complete gain of chromosome 11 with a telomeric loss in 11q25. Cases 18 and 20 
carried in addition to the interstitial gains in 11q22.3-q23.3 a focal high-level amplification in 
11q23.3. 
Based on the breakpoints in chromosome 11 the minimal regions of gain and loss in the eight 
analyzed mnBLL cases were defined (Figure 25B). The minimal region of gain in 11q23.3 was defined 
as chr11:106,233,094-118,966,521 bp and the minimal region of amplification as chr11:117,127,159-
118,966,521 bp. Telomeric losses of 11q affecting 11q24-qter were present in all eight samples. The 
minimal region of loss was defined as chr11: 127,799,447-132,877,670 bp. Moreover case 25 
harbored a homozygous loss in 11q24.2-q24.3, spanning 1.95 Mb (chr11:127,621,020-
129,572,876 bp). 
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Figure 25: Chromosomal view of chromosome 11 analyzed by OncoScan DNA-microarray in eight newly recruited mnBLL. A: 
Depicted from top to the bottom: Ideogram of chromosome 11, diagram showing the cumulative percentage of cases 
sharing the copy number alteration and chromosome 11 profiles of cases 18-25. Blue color represents copy number gains, 
red color represents copy number losses. The height of the bars refers to the copy number state. B: Breakpoints of the 
alterations in chromosome 11. Highlighted breakpoints mark the minimal region of gain (blue) and loss (red). Start and end 
refer to the genomic position according to hg19 in bp.  
 
Next, the minimal regions for the newly recruited mnBLL cases were compared to those of the 
published cases. Refer to Table 34 for an overview on the new and published minimal regions. 
The minimal region of gain, defined in the newly recruited mnBLL, was 9 Mb larger than the already 
published minimal region. Therefore, the data from the newly recruited cases did not reduce the size 
of the already published minimal region of gain. In some of the published as well as in two of the 
newly identified mnBLL amplifications within the minimal gain region were detected. Thus, a minimal 
region of amplification was defined. The newly defined minimal region of amplification was ~1 Mb 
larger and the breakpoints lay outside of the already published minimal region. Thus, the minimal 
region of amplification did not alter either. 
In contrast, on the basis of the results of the newly recruited mnBLL the size of the minimal region of 
loss could be reduced to chr11:127,799,447-132,877,670 bp. Thus, the size of the minimal region of 
loss was reduced by approximately 2.4 Mb now being ~ 5.1 Mb in size. 
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Intriguingly, in addition to the previously described case 9, a second mnBLL case (case 25) also 
harbored an homozygous loss in 11q. Based on those two cases the minimal homozygous loss region 
was defined as chr11:127,816,801-129,341,359 bp which is part of the minimal region of loss. 
Table 34: Overview on minimal gain and loss regions in chromosome 11q. 
 Chromosome 11 Published breakpoints (bp) New breakpoints (bp) Final breakpoints (bp) 
Minimal gain region 115,025,608-118,434,149 106,233,094-118,966,521 115,025,608-118,434,149 
Minimal 
amplification region 
117,602,151-118,434,149 117,127,159-118,966,521 117,602,151-118,434,149 
Minimal loss region 127,471,805-134,940,727 127,799,447-132,877,670 127,799,447-132,877,670 
Minimal homozygous 
loss region 
127,816,801-129,341,359 127,621,020-129,572,876 127,816,801-129,341,359 
Published breakpoints: Minimal regions already published by Salaverria et al. [166]; New breakpoints: Minimal regions 
defined based on the eight newly recruited mnBLL cases; Final breakpoints: Newly defined minimal regions based on the 
new and published regions. All genomic positions in bp refer to the hg19 reference genome. The underlined genomic 
positions define breakpoints of the final minimal regions. 
 
Taken together, extension of the published cohort of 17 to a total of 25 mnBLL led to a re-definition 
of the minimal region of loss, which is now defined as chr11:127,799,447-132,877,670 bp (11q24.2-
q25) which includes a minimal homozygous loss region at chr11:127,816,801-129,341,359 bp 
(11q24.3). The already described minimal regions of gain and amplification did not change. 
 
3.2.1.2 Genome-wide array-based characterization of chromosomal imbalances in MYC-negative 
Burkitt-like lymphoma 
 
After characterization of the aberration in chromosome 11, the OncoScan DNA-microarray data of 
the 25 mnBLL were mined for concomitant and recurrent CNA. The median number of CNA in the 
recently acquired cases (cases 18-25) was 6. The 17 cases already published have been analyzed with 
different platforms, thus, the median number of CNA differed. Cases 1-3 and 8 analyzed with SNP 
array 6.0 harbored a median of 18.5 CNA. Cases 4-7 and 9-12, whose DNA was derived from FFPE 
tumor material, were analyzed with array-CGH and harbored a median of 4 CNA. The MPI cases 
analyzed with array-CGH harbored a median of 11.5 CNA. Thus, the median number of CNA in the 
new cases lay in the range of described of a median 4-18.5 CNA. 
Concomitant to the chromosome 11 alterations, the most abundant copy number alterations in all 
25 mnBLL cases, defined as imbalances detected in at least five cases, were a trisomy 12, as well as 
losses in 6q14.3-q21 and gains in 13q31.3 and 18q21.2 (Table 35). 
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Table 35: Overview on concomitant CNA occurring in more than five of the in total 25 mnBLL cases. 
  
 PID Breakpoints in bp (hg19) 
Minimal region of imbalances 
in bp 
Copy number loss 
6q14.3-q21 
Case 1 chr6:74,937,191 - 118,113,917 
chr6:86,450,066 - 110,118,776 
Case 3 chr6:86,450,066 - 145,479,373 
Case 22 chr6:67,759,432 - 110,118,776 
MPI-078 chr6:80,425,984 - 110,631,941 
MPI-315 chr6:46,810,436 - 170,958,026 
MPI-382 chr6:80,425,984 - 170,957,975 
Copy number gain  
13q31.3 
Case 1 chr13:77,877,525 - 106,193,991 
chr13:91,967,744 - 92,150,929 
Case 2 chr13:91,967,744 – 92,361,860 
Case 18 chr13:91,359,736 - 92,328,701 
Case 20 chr13:89,614,856 - 92,150,929 
MPI-382 chr13:51,430,518 - 114,914,704 
Copy number gain 
18q21.2 
Case 1 chr18:40,819,075 - 62,093,468 
chr18:51,129,489 - 53,141,537 
Case 2 chr18:51,050,447 – 53,141,537 
Case 3 chr18:45,252,881 - 77,920,288 
Case 20 chr18:51,129,489 – 74,637,067 
Case 24 chr18:18,554,307 – 53,950,927 
Trisomy 12 
Case 5 
Whole chromosome  
Case 7 
Case 18 
Case 21 
Case 23 
Case 24 
PID: patient identification. All genomic positions in bp refer to the hg19 reference genome. Highlighted in bold letters are 
the breakpoints which define the minimal region of loss or gain. 
 
The most frequent alteration was a copy number loss in 6q14.3-q21 which was identified in six out of 
25 cases (24 %) (cases 1, 3, 22 and MPI-078, MPI-315, MPI-382). The minimal loss region was 
chr6:86,450,066-110,118,776 bp. Two tumor suppressor genes in lymphoma map within this 24 Mb 
large region of copy loss: EPH Receptor A7 (EPHA7) [229] and PR domain containing 1, with ZNF 
domain (PRDM1) [230]. A total of 24 % (6/25) of the mnBLL harbored a complete trisomy 12 (cases 5, 
7, 18, 21, 23 and 24). A copy number gain in 13q31.3 was identified in five out of 25 cases 
(20 %)(cases 1, 2, 18, 20 and MPI-382). Within the 0.2 Mb minimal region of gain in 13q31.31 
(chr13:91,967,744-92,150,929 bp) maps the miR-17-92 cluster which has been for example described 
to be gained and overexpressed in pediatric BL [231]. Additionally, a recurrent copy number gain in 
18q21.2 was detected which affected five out of 25 cases (20 %) (cases 1, 2, 3, 20 and 24). Within the 
minimal region of gain, which encompassed ~ 2 Mb (chr18:51,129,489-53,141,537 bp), map seven 
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genes including the Transcription Factor 4 (TCF4). This gene belongs, as its homologue TCF3, to the 
bHLH family of transcription factor and plays a major role in the Wnt/β-catenin signaling pathway in 
various cancer types [232],[233]. 
 
3.2.2 Cell line models for the functional study of MYC-negative Burkitt-like lymphoma 
 
Cell line models are crucial tools for functional studies. Thus, to perform functional studies for 
mnBLL, such cell line models were indispensable. The two cell lines HT and Su-DHL-5 have already 
been identified as mnBLL cell line models [166]. In the following, the identification and 
characterization of new possible cell line models for mnBLL with the typical 11q alteration is 
described.  
 
3.2.2.1 Identification and characterization of cell line models for MYC-negative Burkitt-like 
lymphoma 
 
To identify further cell line models the available Affymetrix SNP array 6.0 data at the COSMIC 
database (http://cancer.sanger.ac.uk/cell_lines/, 11/09/2012) were mined for B-cell lymphoma cell 
lines harboring the peculiar alteration pattern on chromosome 11 characteristic for mnBLL. Using this 
approach, the two cell lines MLMA and Karpas422 were identified to carry a mnBLL-typical gain and 
loss pattern on chromosome 11. 
Karpas422 has been described to be a germinal-center B-cell-like DLBCL cell line, harboring a 
translocation t(14;18) juxtaposing the BCL2 gene to the IGH gene resulting in a BCL2 overexpression. 
In line, this cell line has been described to have a high BCL2 protein expression [234]. But as 
described in 3.2.1 the criteria for the diagnosis of mnBLL is a lack of a BCL2 break as well as a lack of 
BCL2 expression. Thus, Karpas422 is not an appropriate cell line model for mnBLL. 
The MLMA cell line has been described to have been established from a patient with human 
malignant lymphoma being IgD, IgM positive with hairy B-cells (http://cellbank.nibio.go.jp/english/, 
15/12/2014). This differs from the diagnosis of mnBLL which have mostly been diagnosed as high 
grade B-cell lymphoma or atypical BL (2.1.1.2). To elucidate if the MLMA cell line has been 
established from hairy cell leukemia or from another B-cell malignancy and if it is indeed an 
appropriate mnBLL cell line model, the cells were characterized at our Institute by routine 
cytogenetic and molecular analyses. A hallmark of hairy cell leukemia is the mutation p.Val600Glu 
within the BRAF gene, which can be detected in nearly all typical cases [235]. MLMA cells did not 
carry this typical p.Val600Glu mutation. Thus, indicating that MLMA cell line has not been established 
from classical hairy cell leukemia. Immunophenotyping of MLMA cells was performed by Dr. 
Sebastian Böttcher at the II. Medical Clinic, Kiel. The immunophenotyp showed coexpression of 
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CD20, CD10, CD38, CD45 and CD43, whereas CD5, CD103 and CD138 were not expressed. Especially 
the lack of CD103 expression distinguished the cell line from the typical hairy cell leukemia [1]. 
Instead, the high coexpression of the other markers was indicative for a classification as mature B-
cell non-Hodgkin-lymphoma. The CD10, CD20 and CD38 expression is well in line with a typical BL 
phenotype as also most mnBLL show. 
Furthermore, cytogenetic analyses performed in routine tumor genetic diagnostics of the Institute of 
Human Genetics, Kiel revealed that the MLMA cell line did not harbor a MYC or a BCL2 break which is 
in line with the established mnBLL criteria (3.2.1). 
Our own SNP array 6.0 analyses of MLMA cells revealed extensive and complex rearrangements 
(overall 77 CNA). Refer to appendix 8.11 for a complete overview on the CNA. In agreement with the 
data in the COSMIC database, MLMA cells were shown to carry the typical gain and loss pattern on 
the long arm of chromosome 11 (Figure 26).  
 
 
Figure 26: Overview on chromosome 11 analyzed by SNP array 6.0 in the MLMA cell line. The y-axis depicts the log2 ratio 
copy number and the x-axis the chromosomal positions in Mb. The blue highlighted region marks the copy number gain 
region, the red region marks the copy number loss regions.  
 
The gain region covered chr11:93,756,820-118,962,816 bp (11q21-q23.3) which included three high 
level copy number gain regions 11q21.2-q22.1, 11q22.1 and 11q23.3. The gain region in MLMA cell 
line is 4-fold larger than the previously defined minimal region of gain, spanning 12 Mb. The terminal 
loss in MLMA cells spans chr11:118,970,202-134,944,770 bp (11q23.3-q25) which covers completely 
the minimal loss region (11q24.2-q25) defined for the primary mnBLL. 
Since the analyses indicate that MLMA cell line was established from a mature B-cell non-Hodgkin-
lymphoma and that it carries the typical chromosomal alteration on chromosome 11, it qualified as a 
novel mnBLL cell line model. 
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3.2.3 Identification and characterization of possible candidate genes contributing to the 
development of MYC-negative Burkitt-like lymphomas 
 
After extensive chromosomal characterization of the primary mnBLL as well as the corresponding cell 
line models, the next aim was to identify possible candidate genes and pathogenetic mechanisms 
which might contribute or lead to the development of mnBLL. In the following the identification of 
possible candidate genes by global expression profiling, mutation analyses and text mining as well as 
subsequent functional characterization in the cell line models is described. 
 
3.2.3.1 Identification of possible candidate genes on chromosome 11 in MYC-negative Burkitt-
like lymphomas 
 
We consider the 11q alteration as pathogenetic and likely primary event in the pathogenesis of 
mnBLL. Thus, to identify possible candidate genes involved in the pathogenesis of mnBLL, the 
analyses were focused on those genes mapping to the minimal regions of gain and loss on 
chromosome 11. These regions encompassed in total 54 protein coding genes and 8 genes of non-
coding RNA (refer to Appendix 8.12 for the complete list of genes and to 8.13 for the complete list of 
non-coding RNAs mapping to the critical regions). Three different criteria have been applied to 
identify possible candidate genes: differential expression (3.2.3.1.1), recurrent mutations (3.2.3.1.2) 
and already published association with lymphomas (3.2.3.1.3). The results of the selections are 
summarized in the following. 
 
3.2.3.1.1 Differentially expressed genes in MYC-negative Burkitt-like lymphomas 
 
The first criterion applied to attenuate the list of possible candidate genes was the identification of 
those genes which map to the regions of alteration in 11q and are also differentially expressed at the 
mRNA level in mnBLL in comparison to IG-MYC positive, molecular BL (mBL) or DLBCL. For this 
analysis the available gene expression data of six mnBLL cases of the MMML cohort in comparison to 
46 IG-MYC mBL and 198 DLBCL have been analyzed. Bioinformatic evaluations were supported by 
M.Sc. Christian Kohler, Institute of Functional Genomics, Statistical Bioinformatics, University of 
Regensburg.  
The results of the analyses of the gene expression data of those genes which are mapping to the 
minimal region of gain are summarized in Figure 27.  
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Figure 27: Expression analyses of the genes mapping to the minimal region of gain in 11q in mnBLL. Comparison of 
transcript expression in mnBLL vs. mBL (A) and vs. DLBCL (B). The mean expression is indicated by a dot and the vertical 
lines depict 95 % confidence intervals for the fold changes between the two compared groups. Significant differentially 
expressed genes (adj. p-value <0.1) are highlighted in red. Comparison of the differentially expressed genes of the minimal 
region of gain, revealed eight genes to be significantly higher expressed in mnBLL than in mBL and eight genes higher than 
in DLBCL. Six genes showed higher expression in mnBLL as compared to both contrasting groups. Modified from [166]. 
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Overall, eight genes were significantly higher expressed in mnBLL than in mBL and eight genes were 
significantly higher expressed in mnBLL than in DLBCL (adj. P-values <0.1, t-test p-value corrected 
according to Benjamini and Hochberg). Of those genes, six genes (ZNF259, PAFAH1B2, PCSK7, 
CEP164, UBE4A, ATP5L) were higher expressed in mnBLL as compared to both contrasting groups. 
The IL10RA gene stood out in the gene expression comparison mnBLL vs. mBL, as it showed the 
highest mean gene expression difference from all genes of the 11q region (adj. p-value 5.51E-09, t-
test p-value corrected according to Benjamini and Hochberg). 
 
Figure 28 depicts the results of the analyses of the gene expression data of those genes which are 
mapping to the minimal region of loss. The comparison revealed six genes to be significantly lower 
expressed on mRNA level in mnBLL than in mBL and four genes to be lower expressed than in DLBLC 
(adj. P-values <0.1, t-test p-value corrected according to Benjamini and Hochberg). Two of those 
genes (FLI1 and SNX19) were lower expressed in mnBLL as compared to both contrasting groups. 
Besides these two genes, the PRDM10 gene stood out in the analysis comparing mnBLL vs. mBL 
showing a significantly reduced expression comparable to FLI1 (adj. p-value 0.013, t-test p-value 
corrected according to Benjamini and Hochberg). 
 
Taken together, using transcriptional expression analyses, ten genes were identified to be 
differentially expressed at the mRNA level in mnBLL in comparison to BL and DLBCL. These genes 
were subsequently included in the list of possible candidate genes: ZNF259, PAFAH1B2, PCSK7, 
CEP164, UBE4A, ATP5L, FLI1, SNX19, IL10RA and PRDM10. 
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Figure 28: Expression analyses of the genes mapping to the minimal region of loss in 11q in mnBLL. Comparison of 
transcript expression in mnBLL vs. mBL (A) and vs. DLBCL (B). The mean expression is indicated by a dot and the vertical 
lines depict 95 % confidence intervals for the fold changes between the two compared groups. Significant differentially 
expressed genes (adj. p-value <0.1) are highlighted in red. Comparison of the differentially expressed genes of the minimal 
region of loss, revealed six genes to be significantly lower expressed in mnBLL than in mBL and four genes lower than in 
DLBCL. Two genes were lower expressed in mnBLL as compared to both contrasting groups. Modified from [166]. 
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3.2.3.1.2 Identification of recurrently mutated genes in MYC-negative Burkitt-like lymphomas 
 
To get an overview on the mutational landscape in the mnBLL, next generation sequencing data of 
four mnBLL (cases 1-3 and 8) and the three mnBLL cell lines (HT, Su-DHL-5, MLMA) were analyzed.  
Initially, the sequencing data were examined for recurrent mutations within the 54 genes of the 
minimal region of gain and loss on chromosome 11. Recurrency was defined as a gene being affected 
by protein changing mutations in at least two cases. To note is, that cases 2, 3 and 8 were analyzed 
by targeted resequencing using a gene panel in which only 22 of those 54 genes were covered. In the 
list of recurrently mutated genes were included (i) only nonsynonymous mutations affecting the 
coding sequence (CDS) of a gene (ii) mutations with a mutated allele frequency (MAF) higher than 0.1 
and (iii) mutations which have no dbSNP annotation (build 141, 27/01/2015). According to these 
definitions none of the 54 genes of the minimal region of gain and loss was found to be recurrently 
mutated in the analyzed mnBLL and cell lines. Nevertheless, nine genes of the minimal regions were 
affected by protein coding mutations in one of the respective cases (summarized in Table 36).  
Table 36: Overview on genes affected by protein coding mutations mapping to the minimal region of gain and loss on 
chromosome 11. 
 PID Gene 
Genomic Position 
(hg19) in bp 
Mutation 
Consequence 
on protein 
MAF PolyPhen 
G
ai
n
 r
e
gi
o
n
 
HT 
BUD13  
NM_032725 
chr11:116,633,542 c.763A>T p.Thr255Ser 0.14 benign  
HT 
SIK3 
NM_025164 
chr11:116,730,273 c.2155A>T p.Ile719Phe 0.24 benign  
Su-DHL-5 
TAGLN 
NM_003186 
chr11:117,074,158 c.316G>T p.Val106Phe 0.19 damaging  
HT 
DSCAML1 
NM_020693 
chr11:117,299,170 c.4842C>A p.Cys1614* 0.15 damaging 
HT 
TMPRSS13 
NM_001077263 
chr11:117,789,189 c.386C>T p.Ala129Val 0.26 damaging  
HT 
IL10RA 
NM_001558 
chr11:117,860,284 c.316A>G p.Ser106Gly 0.13 benign  
HT 
TMPRSS4 
NM_019894 
chr11:117,984,012 c.772G>A p.Val258Met 0.16 damaging  
Lo
ss
 r
e
gi
o
n
 
Case 8 
ETS1 
NM_005238.3 
chr11:128,355,983 c.532T>A p.Tyr154* 0.56 damaging 
HT 
SNX19 
NM_014758 
chr11:130,785,119 c.716T>G p.Val239Gly 1 benign  
PID, patient identification; genomic position refers to the human reference genome hg19 in bp; MAF, mutated allele 
frequency. Gain region, minimal region of gain; loss region, minimal region of loss. 
 
Among those nine mutated genes was the V-Ets Avian Erythroblastosis Virus E26 Oncogene 
Homolog 1 (ETS1) gene which maps within the minimal region of homozygous loss in chromosome 
11q in mnBLL. The mnBLL case 8 carried a mutation within the ETS1 gene, showing a MAF of 0.56, 
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which leads to a premature stop codon. This mutation was verified by Sanger sequencing. Sanger 
sequencing of ETS1 in 15 additional mnBLL revealed six mutations in three of 15 cases (20 %) [166]. 
Three ETS1 mutations detected in case 5 and case 7 were missense mutations, of which two were 
predicted by PolyPhen to be benign and one to be probably damaging. Case 3 harbored a splice site 
mutation. The other two mutations occurring in case 5 and case 7 were silent mutations. In total four 
of sixteen (25 %) analyzed mnBLL carried mutations within ETS1. Please refer to Table 37 for an 
overview on all ETS1 mutations. 
Table 37: Overview on ETS1 mutations detected in 16 analyzed mnBLL cases. 
ETS1 (NM_005238.3) 
PID 
Genomic Position 
(hg19) in bp 
Mutation 
Consequence 
on protein 
MAF PolyPhen detected by 
Case 3 chr11:128,391,807 c.82+1G>A splicing  n.p. Sanger sequencing 
Case 5 
chr11:128,391,865 c.25C>G p.Pro9Ala  
probably 
damaging 
Sanger sequencing 
chr11:128,333,521 c.993C>T p.Gly331Gly  benign Sanger sequencing 
Case 7 
chr11:128,391,826 c.64G>A p.Glu22Lys  benign Sanger sequencing 
chr11:128,350,277 c.800C>T p.Ser267Phe  benign Sanger sequencing 
chr11:128,354,796 c.653C>T p.Thr218Ile  benign Sanger sequencing 
Case 8 chr11:128,355,983 c.462T>A p.Tyr154* 0.56 n.p. 
Targeted 
Resequencing, Sanger 
sequencing 
PID, patient identification; genomic position refers to the human reference genome hg19; MAF, mutated allele frequency; 
n.p., not predictable with PolyPhen. Modified from [166]. 
 
The remaining eight genes were solely mutated within the mnBLL cell lines. The HT cell line carried 
seven and the Su-DHL-5 cell line one mutations within genes of the minimal gain and loss region. 
Seven of the eight mutations had a MAF lower than 0.3 suggesting for a subclonal origin and, thus, a 
minor role in lymphomagenesis. The mutation with a higher MAF was detected within the SNX19 
gene in HT cells, mapping to the minimal region of loss. Remarkably, as described previously, SNX19 
was lower expressed in mnBLL than in mBL and DLBCL (3.2.3.1.1). The SNX19 missense mutation 
c.716T>G had a MAF of 1 meaning that only one mutated copy of the gene was present in the cell 
line. Nevertheless, by using PolyPhen, the mutation was classified as benign indicating that the 
mutation has probably no major impact on the protein function.  
To elucidate if genes outside the minimal region of gain and loss in chromosome 11 are targeted by 
recurrent mutations, the analyses were expanded to the whole-exome. 
Initially, the whole-genome sequencing data from case 1 and the exome sequencing data from the 
three mnBLL cell lines were screened for genes which were mutated in more than two cases and 
which have not been described as SNP in the dbSNP141 database. This analysis resulted in the 
detection of 63 recurrently mutated genes which are enlisted in the appendix 8.14. Of those 
recurrently mutated genes only four were mutated in case 1. The mnBLL cell lines on the other hand 
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showed a high mutation frequency. About 90 % (57/63) of these recurrently mutated genes were 
mutated in the HT cells. Thus, the list of recurrently mutated genes might be biased by the high 
mutation load in the mnBLL cell lines. To further reduce the list of recurrently mutated genes, the 
targeted resequencing data of three mnBLL, were analyzed for mutations within those 63 genes. To 
note is, that of those only 22 were covered in the targeted resequencing panel. None of the three 
mnBLL cases harbored a mutation in those 22 genes.  
To sum up, next generation sequencing analysis of four mnBLL and three mnBLL cell lines, did not 
lead to the identification of recurrently mutated genes in mnBLL other than the already described 
ETS1 gene. ETS1 was therefore added to the list of possible candidate genes. 
 
3.2.3.1.3 Examination of candidate genes for published association with lymphomagenesis  
 
All 54 genes of the minimal gain and loss region were examined for a published association or 
function with regard to lymphomagenesis using the PubMed library. In the following only those 
genes will be mentioned for which an association with lymphomas has been published. 
Only for three of the ten possible candidate genes identified in the gene expression analyses 
(3.2.3.1.1) (PAFAH1B2, IL10RA and FLI1) a role with regard to lymphomagenesis has been published. 
PAFAH1B2 has been described to be a recurrent target of chromosomal rearrangement in lymphoma 
[236]. The expression of the IL10RA gene has been published to be regulated by MYC in MYC-induced 
B-cell lymphomas in mice [237] and to be overexpressed in mantle cell lymphoma [238]. The FLI1 
gene has been described to be recurrently deregulated in DLBCL [239]. 
Additionally, the lysine (K)-specific methyltransferase 2A (KMT2A) gene, formerly known as MLL, and 
the ETS1 gene were added to the list of possible candidate genes based on their published 
association with lymphoma. The KMT2A gene maps to the minimal region of amplification and is 
known to be frequently translocated in acute lymphoblastic leukemia and lymphoblastic lymphoma 
[240],[241]. Furthermore, translocations and complex alterations involving KMT2A have been 
identified in DLBCL [242],[239],[243],[244],[245]. Although the difference of KMT2A expression was 
not significant (adj. p-value >0.1) the mnBLL cases showed a slightly higher expression than the BL 
and DLBCL. The sole exception was one oligonucleotide tag covering a transcript variant of KMT2A 
(212076_at) which was significantly higher expressed in mnBLL than in DLBCL (adj. p-value 0.0018, t-
test p-value corrected according to Benjamini and Hochberg). ETS1 has been described to contribute 
to the regulation of plasmacytic differentiation in normal B-cells via negative regulation of BLIMP1 
which is encoded by PRDM1 [246]. BLIMP1 is a regulator of the plasmacytic differentiation in the 
germinal center [247]. ETS1 has been proposed to be a tumor suppressor gene in Hodgkin lymphoma 
[248] and an oncogene in a subset of DLBCL with terminal 11q gains [239]. Figure 29 gives an 
overview on the identified candidate genes after applying the three different filtering criteria. 
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Figure 29: Overview on identified candidate genes after applying three different filter criteria. 
 
After applying the three different criteria, the final list of candidate genes on chromosome 11 
potentially involved in the pathogenesis of mnBLL encompassed five possible genes: PAFAH1B2, 
IL10RA, FLI1, ETS1 and KMT2A. Table 38 summarizes the features of these candidate genes. 
Table 38: Overview on the identified candidate genes in mnBLL. 
 Gene Function 
Differential expression 
mnBLL Mutated in 
association with 
lymphoma 
(examples) vs. BL vs. DLBCL 
G
ai
n
 
PAFAH1B2 
catalytical subunit of 
PAFAH, inactivation of 
platelet activating 
factor 
significantly 
higher 
expressed 
significantly 
higher 
expressed 
0/16 cases 
 
0/3 cell lines 
recurrent 
chromosomal 
alterations in 
lymphoma [243], 
[244],[239],[245] 
A
m
p
lif
ic
at
io
n
 
IL10RA 
Subunit of interleukin 
10 receptor, mediation 
of immunosuppressive 
signals 
significantly 
higher 
expressed 
no 
difference 
0/16 cases 
 
1/3 cell lines 
role in BL [237], 
overexpressed in 
mantle cell 
lymphoma [238] 
KMT2A 
transcriptional 
coactivator, 
methyltransferase 
activity 
higher 
expressed 
higher 
expressed 
0/16 cases 
 
0/3 cell lines 
recurrent 
translocation in 
lymphoblastic 
lymphoma [243] 
H
o
m
o
zy
go
u
s 
lo
ss
 
FLI1 
member of ETS family 
of transcription factors 
significantly 
lower 
expressed 
significantly 
lower 
expressed 
0/16 cases 
 
0/3 cell lines 
deregulated in 
DLBCL [239] 
ETS1 
member of ETS family 
of transcription factors 
no 
difference 
no 
difference 
4/16 cases  
 
0/3 cell lines 
deleted and 
downregulated in 
Hodgkin lymphoma 
[248], amplified in 
DLBCL [239]  
Gain, minimal region of gain; amplification, minimal region of amplification; homozygous loss, minimal region of 
homozygous loss 
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3.2.3.2 Expression of MYC-negative Burkitt-like lymphoma-related candidate genes in cell line 
models 
 
To analyze the expression of the five candidate genes on mRNA and protein level in the mnBLL cell 
line models quantitative real-time PCR (qPCR) and Western blot were performed in three mnBLL, six 
BL- and five DLBCL cell lines (2.1.2.3). The results of the expression analyses of the three candidate 
genes mapping to the minimal region of gain are summarized in Figure 30.  
The expression of PAFAH1B2 on mRNA level was higher in the mnBLL cell lines than in the BL and 
DLBCL cell lines (mean ratio mRNA expression 1.12 vs. 0.77 and 0.51, respectively). Notably, half of 
the analyzed BL cell lines (BLUE-1, Ca46, U-698-M) showed PAFAH1B2 expression levels comparable 
to the mnBLL cell lines HT and Su-DHL-5. In comparison to the other mnBLL cell lines, the MLMA cells 
exhibited a low expression (ratio mRNA expression 0.45). On protein level, the mnBLL cell lines 
exhibited a much higher PAFAH1B2 expression than the BL and DLBCL cell lines. The DLBCL cell lines 
particularly had a barely detectable PAFAH1B2 expression. Taken together, these findings are in 
agreement with the array-based gene expression analyses in the mnBLL showing a significant higher 
expression of PAFAH1B2 in mnBLL than mBL and DLBCL (3.2.3.1.1). 
Quantification of the IL10RA mRNA level in the cell lines showed a higher expression in the mnBLL 
cell lines than in the BL and DLBCL cell lines. In latter the IL10RA mRNA expression was barely 
detectable (mean ratio mRNA expression 1.15 vs. 0.03 and 0.11, respectively). The mnBLL cell line 
MLMA exhibited the highest IL10RA mRNA expression level (ratio mRNA expression 2.33). On the 
protein level, IL10RA was not only highly expressed in the mnBLL cell lines, but also in four BL cell 
lines (BL-2, BL-41, BLUE-1, Ca46) and in two DLBCL cell lines (Karpas422, RIVA) which differs from the 
findings on mRNA level. Furthermore, IL10RA protein expression was not detectable in the BL cell 
line BL-70. Taken together the results in the cell lines on mRNA level confirm the array-based gene 
expression analyses showing an increased expression level in mnBLL (3.2.3.1.1). On the protein level 
the ten analyzed cell lines, irrespective of the lymphoma entity, exhibited a comparable IL10RA 
expression level. 
The expression of KMT2A in the cell line panel was solely analyzed on mRNA level, as a suitable 
antibody for detection of the KMT2A protein was not available. The mnBLL cell lines exhibited a 
higher KMT2A expression than the BL and DLBCL cell lines on mRNA level, (mean ratio mRNA 
expression 9.22 vs. 2.53 and 1.85, respectively). The mnBLL cell line MLMA exhibited the highest 
KMT2A expression (ratio mRNA expression 18.1), showing a ~3.5-fold higher expression than the 
other mnBLL cell lines HT and Su-DHL-5 (ratio mRNA expression 4.3 and 5.3 respectively). This is in 
agreement with the array-based gene expression analysis of the mnBLL, showing a slightly, though 
not significant, higher expression level in comparison to BL and DLBCL (3.2.3.1.1).  
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Figure 30: Expression analyses of candidate genes mapping to the minimal region of gain in mnBLL. The three panels depict 
expression analyses in B-cell lymphoma cell lines of PAFAH1B2 (A), IL10RA (B) and KMT2A (C) on mRNA level using qPCR and 
on protein level using Western blot. The qPCR graphs depict the mean of the relative expression and the standard deviation 
of three independent technical replicates. The Western blot which is displayed is an example of at least two performed 
technical and biological replicates. The complete Western blot is depicted in the appendix (8.15). The PAFAH1B2 Western 
blot figure has been adapted from Salaverria et al. [166]. 
 
Subsequently, the expression levels of the candidate genes FLI1 and ETS1 mapping to the minimal 
region of loss, more precisely into the minimal region of homozygous loss, were analyzed. The 
findings are documented in Figure 31. 
The mean FLI1 expression on mRNA level was lower in the mnBLL than in the BL cell lines and slightly 
lower than in the DLBCL cell lines (mean mRNA expression ratio 3.25 vs. 5.15 and 3.44, respectively). 
Nevertheless, considerable heterogeneity in the expression level was observed. The MLMA cell line 
exhibited a much higher expression (ratio mRNA expression 6.3) than the other two mnBLL cell lines 
HT and Su-DHL-5 (ratio mRNA expression 1.2 and 2.2, respectively). Moreover, the DLBCL cell line 
Karpas422 exhibited a very low FLI1 expression (ratio mRNA expression 0.3) in comparison to the 
other DLBCL cell lines, which showed comparable FLI1 expression levels to the BL cell lines. To note 
is, that the FLI1 antibody used for protein expression analyses detects two protein isoforms of 48 kD 
and 51 kD size [249]. The BL cell lines expressed both isoforms at comparable levels, whereas in the 
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DLBCL cell lines the 48 kD isoform was higher expressed than the 51 kD isoform. The mnBLL cell lines 
HT and Su-DHL-5 seemed to have lost the expression of both isoforms whereas the MLMA cell line 
solely expressed the 48 kD isoform but at comparable levels to the DLBCL cell lines. Taken together, 
the analyses of FLI1 mRNA and protein expression revealed a lower expression in the mnBLL cell lines 
than in the BL and DLBCL cell lines. This is in agreement with the findings of the array-based gene 
expression analyses of the mnBLL which exhibited a significant lower FLI1 mRNA expression than the 
mBL and DLBCL (3.2.3.1.1). 
Furthermore, the expression levels of ETS1 were analyzed. At mRNA level the mean ETS1 expression 
in the mnBLL cell lines was lower than in the BL cell lines but slightly higher than in the DLBCL cell 
lines (mean ratio mRNA expression of 13.39 vs. 21.36 and 10.96, respectively). At protein level the 
expression was comparable in all cell lines, whereas some of the BL cell lines (BL-2, Ca46, U-698-M) 
showed a slightly higher expression than the other cell lines. Overall the ETS1 expression differences 
in the different cell line entities were minor which is in line with the qPCR and array-based analyses 
(3.2.3.1.1). 
 
 
Figure 31: Expression analyses of candidate genes mapping to the minimal region of loss in mnBLL. The panel depicts 
expression analyses of FLI1 (A) and ETS1 (B) on mRNA level using qPCR and on protein level using Western blot in B-cell 
lymphoma cell lines. The qPCR graphs depict the mean and the standard deviation of three independent technical 
replicates. The Western blot shown is an example of at least two performed technical and biological replicates. The 
complete Western blot is depicted in the appendix (8.15).  
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Taken together, the expression analyses of the candidate genes in the mnBLL cell lines in comparison 
to BL and DLBCL cell lines confirmed PAFAH1B2 and IL10RA to be higher and FLI1 to be lower 
expressed. 
 
3.2.3.3 Knock down study of the candidate gene PAFAH1B2 
 
The first candidate gene chosen for the functional studies was the PAFAH1B2 gene for which, as 
reported in 1.4, an oncogenic function has been assumed. PAFAH1B2, mapping to the minimal region 
of gain, was constitutively up-regulated on mRNA as well as on protein level in mnBLL. Moreover, it 
has been described to be an oncogenic target of a translocation involving the IGH locus in lymphoma 
[236]. PAFAH1B2, also called PAF-AH1b Alpha 2 subunit, encodes the beta subunit of the platelet-
activating factor acetylhydrolase (PAF-AH) which inactivates the platelet activating factor (PAF). 
Among others, it has been described to have anti-apoptotic functions [250].  
To elucidate if PAFAH1B2 could be indeed a potential oncogene in mnBLL, knock down analyses of 
this gene were performed using lentiviral shRNA constructs. The analyses were initially based on the 
hypothesis that if PAFAH1B2 plays a vital role in mnBLL, the induced loss of expression might lead to 
a loss of viability or growth suppression. The Su-DHL-5 cell line was used for the knock down analyses 
which were performed as described in 2.2.5.7. In total three different shRNAs targeting PAFAH1B2 
(PAFAH1B2 shRNA1-3) as well as a non-targeting control (NTC) shRNA were delivered to the             
Su-DHL-5 cells using lentiviral vectors. Three days after induction of shRNA expression using IPTG the 
knock down efficiency of the PAFAH1B2 shRNA constructs in comparison to the non-targeting control 
shRNA was analyzed by Western blot as depicted in Figure 32A. All PAFAH1B2 shRNA constructs 
repressed the PAFAH1B2 expression almost completely. However, PAFAH1B2 shRNA1 seemed to be 
expressed even without IPTG induction, indicating a leakiness of the construct. 
To determine if the knock down had an influence on the viability, the transduced cells were analyzed 
using a cell viability assay. This analysis showed that although the expression of PAFAH1B2 was 
almost completely reduced, the cell viability of the cells was not altered in comparison to the NTC 
control (Figure 32B).  
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Figure 32: Knock down of PAFAH1B2 expression in Su-DHL-5 cell line. A: Example of knock down efficiency of PAFAH1B2 in 
the Su-DHL-5 cell line using Western blot. Cells have been treated with 100 µM IPTG or 250 µM IPTG and the expression of 
PAFAH1B2 was compared to cells not treated with IPTG (w/o IPTG) and to cells expressing the NTC shRNA. Treatment 
condition is indicated by + in a grey box. Detection of Lamin B1 protein was used as loading control. Refer to the appendix 
8.15 for the complete Western blot figure. B: Analyses of cell viability after knock down of PAFAH1B2. Depicted are the 
mean and the standard deviation of three independent experiments.  
 
The results of the PAFAH1B2 knock down experiments indicate that PAFAH1B2 expression and 
function is not essential for the viability of the mnBLL cell line Su-DHL-5 under the experimental 
conditions tested. This suggests that PAFAH1B2 might not be on its own a driving oncogenic force in 
the tumorigenesis of mnBLL. 
 
3.2.3.4 Analyses of the IL10R pathway in MYC-negative Burkitt-like lymphomas 
 
The next candidate gene studied was IL10RA. IL10RA, mapping to the minimal region of 
amplification, was significantly higher expressed on mRNA level in mnBLL than in mBL, though at 
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protein level the expression was more homogenous in the cell lines. The IL10 receptor (IL10R) 
consists of an α-subunit which is encoded by IL10RA and a β-subunit which is encoded by IL10RB. The 
ligand of the IL10R is interleukin 10 (IL10). Upon binding of the ligand, the IL10 receptor activates 
among others the downstream PI3K signaling pathway [251]. PI3K signaling and its components have 
been introduced in 1.3.4 as an oncogenic signaling pathway in BL. 
 
3.2.3.4.1 Expression analysis of IL10RA  
 
As shown in Figure 30, mRNA expression of IL10RA was higher in the mnBLL cell lines than in BL and 
DLBCL cell lines. Only the overall IL10RA protein expression level was analyzed in the B-cell 
lymphoma cell lines by Western blot (3.2.3.2). Thus, since the main site of function of IL10R is on the 
cell surface, the cell surface expression of IL10RA was examined. To this end, cell surface and 
intracellular staining of IL10RA in a cell line panel consisting of three mnBLL (HT, Su-DHL-5, MLMA), 
three BL (BL-2, BL-41, BL-70) and three DLBCL (Su-DHL-6, Karpas422, RIVA) cell lines was performed 
and evaluated using flow cytometry (2.2.6.5). The results are summarized in Figure 33. 
The highest IL10RA cell surface expression exhibited the BL cell lines showing a median of 22.5 % 
IL10RA-positive cells in comparison to 14.6 % in mnBLL cell lines and 5.9 % in DLBCL cell lines. The BL 
cell line BL-2 and the mnBLL cell line MLMA had the lowest amount of IL10RA positive cells (2.1 % 
and 3.3 %, respectively) (Figure 33A). 
The intracellular IL10RA staining revealed on the other hand, that the mnBLL cell lines exhibited a 
higher median IL10RA-positivity of 73.7 % in comparison to 59.2 % in BL and 54.1 % in DLBCL cell 
lines (Figure 33A). The amount of IL10RA-positivity is influenced by the overall expression, which has 
been shown by Western blot to differ between the cell lines entities (Figure 30). Therefore, the ratio 
of IL10RA cell surface expression to the overall expression, which is reflected by the intracellular 
expression, was calculated. Figure 33B shows that the BL cell lines had the highest relative surface 
expression (median 0.41) whereas the mnBLL and DLBCL cell lines exhibited solely half of the relative 
surface expression (0.21 and 0.11 respectively). To note is that the BL cell line    BL-70 and the DLBCL 
cell line RIVA exhibited the highest surface expression ratio with 0.63 and 0.54 respectively. Oddly, 
the BL-70 cell line showed in the Western blot analyses the lowest IL10RA expression (Figure 30). 
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Figure 33: Analyses of IL10RA cell surface and intracellular expression using flow cytometry. A: Representative histograms 
of the IL10RA expression analysis with FACS in a BL (BL-2), a mnBLL (Su-DHL-5) and a DLBCL (Su-DHL-6) cell line. The upper 
and the lower panel depict the cell surface and the intracellular expression analysis, respectively. The black peaks represent 
the isotype control measurement and the red peaks the IL10RA measurement. FL2-A, fluorescence channel 2 area; count, 
number of cells. B: Percentages of cells expressing IL10RA on the cell surface or intracellular. The measurements have been 
repeated at least two times. Depicted are the mean and the standard deviation. C: Ratio of mean IL10RA cell surface 
expression to intracellular expression. The higher the ratio the higher the relative amount cell surface expression.  
 
Taken together, the flow cytometry analyses of the IL10RA cell surface expression did not indicate 
that the mnBLL cell lines have a higher IL10RA cell surface expression than the BL and DLBCL cell 
lines. Nevertheless, mnBLL cell lines tended to have a higher intracellular IL10RA expression which is 
in line with the results of the qPCR analyses (3.2.3.2). 
 
3.2.3.4.2 Expression analysis of IL10 
 
Next, the differential expression of the IL10R ligand, IL10, was analyzed in the mnBLL as well as in the 
mnBLL cell lines. The gene expression data of six of the mnBLL were provided by the MMML project. 
The data and statistical analysis were provided by M.Sc. Christian Kohler, Institute of Functional 
Genomics, Statistical Bioinformatics, University of Regensburg. Strikingly, IL10 which maps to 
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chromosome 1q32.1 showed a significantly higher expression in the mnBLL than in the mBL analyzed 
based on U133A gene expression array data (adjusted p-value 0.003, t-test p-value corrected 
according to Benjamini and Hochberg) (Figure 34A). 
Analyses of the mRNA level of IL10 in the mnBLL cell lines in comparison to BL and DLBCL cell lines 
showed an extraordinary high expression of IL10 (mean ratio mRNA expression 0.372) whereas 
within the BL and the DLBCL cell lines its expression was barely detectable (mean ratio mRNA 
expression 0.002 and 0.0004, respectively). Of note is that the mnBLL cell lines Su-DHL-5 and MLMA 
showed a 20-90 fold higher IL10 expression than the other cell lines (Figure 34B) whereas the mnBLL 
cell line HT exhibited a barely detectable expression. 
 
 
Figure 34: IL10 expression in B-cell lymphoma cell lines and sera of patients with B-cell lymphoma. A: U133A gene 
expression microarray data of 6 mnBLL, 46 BL and 198 DLBCL. The mnBLL show a significant higher IL10 mRNA than the BL 
(adjusted p-value 0.003). Lines indicate the median. B: Mean and standard deviation of three independent technical 
replicates of the IL10 mRNA expression analyses in the cell lines by qPCR. C: Mean and standard deviation of three 
independent measurements of IL10 level in the cell culture supernatant of different B-cell lymphoma cell lines by ELISA. D: 
Results of two measurements of IL10 level (#1, #2) by ELISA which have been performed on the serum from initial diagnosis 
of one patient with mnBLL (case 10) and six patients with BL (BL control 1-6). 
 
The extracellular IL10 protein expression level was analyzed using ELISA (2.2.6.4). The cell lines with 
the highest IL10 concentration in the cell supernatant were the mnBLL cell lines Su-DHL-5 
(730 pg/ml) and MLMA (299 pg/ml). Besides the BL cell line BL-2 (41 pg/ml), the other cell lines 
showed only a barely detectable or no expression of IL10 protein in the supernatant at all (Figure 
34C). Thus, the results of the IL10 protein expression analysis in the cell lines were in line with the 
findings of the IL10 qPCR. 
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Furthermore, the IL10 protein level was analyzed in the serum of one mnBLL patient (case 10), of 
whom material was available, in comparison to sera of six patients with primary BL from initial 
diagnosis (Figure 34D). The IL10 level within the serum from the patient with mnBLL presentation 
was about ~14 pg/ml. In four of the BL control sera, no IL10 was detectable at all. The other two BL 
control sera (BL control 2 and 6) exhibited comparable IL10 level to the mnBLL.  
To sum up, two of the three mnBLL cell lines exhibited a high IL10 concentration in the cell culture 
supernatant whereas in the BL and DLBCL cell lines IL10 was not expressed or below the detection 
limit. Within the serum of the patient with mnBLL, IL10 was detectable at comparable levels to that 
of two of the four sera from patients with BL. These findings suggest that both IL10 and IL10RA are 
regularly expressed in the mnBLL. 
The finding that the IL10RA gene is overexpressed in mnBLL can be explained by the recurrent 
chromosomal gain on 11q. To unravel the reason for the high IL10 expression in mnBLL, several 
approaches were used: (i) analyses of chromosomal alterations of IL10 locus; (ii) identification of 
mutations within IL10 gene and (iii) analyses of methylation status of IL10 locus. 
By mining the CNA data, only two mnBLL were identified to exhibit chromosomal alterations 
affecting 1q32.1 including the IL10 locus: MPI-315 carried a chromosomal loss (1q32.1-qter) and MPI-
382 carried a chromosomal gain (1q21.1-qter). Hence, solely for the mnBLL case MPI-382 a higher 
IL10 expression might be explainable by a copy number gain covering the IL10 locus (Figure 35A). 
Thus, analyses of the CNA render chromosomal alterations as a cause for the high IL10 expression in 
mnBLL unlikely. 
The already described whole-genome, exome and targeted re-sequencing data of the mnBLL and the 
mnBLL cell lines exhibited no mutations affecting IL10 rendering also oncogenic mutations unlikely. 
Thus, using the HumanMethylation 450k Bead Chip array data the IL10 gene locus was analyzed for 
differential methylation comparing eight mnBLL with 18 BL and seven DLBCL, as well as the 
corresponding cell line subtypes. Ten CpGs at the IL10 gene locus including CpGs ~20 kb up- and 
downstream of the gene, were covered on the 450k array. The mnBLL showed a mean methylation of 
the complete IL10 locus of 0.27 and the BL and DLBCL of 0.25 and 0.35, respectively. The mean 
methylation of the respective cell lines models was 0.23, 0.47 and 0.45 in mnBLL, BL and DLBCL cell 
lines, respectively. Overall, the methylation status of none of the CpGs linked to the IL10 gene 
differed significantly in mnBLL compared to BL or DLBCL (p> 0.05, t-test) (Figure 35B). 
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Figure 35: Chromosomal and methylation landscape of the IL10 gene locus in mnBLL. A: Plots showing the alterations on 
chromosome 1 for the mnBLL cases MPI-315 and MPI-382. The x-axis depicts the position on the chromosome in Mb and 
the y-axis the normalized log2Ratio. The blue line outlines the chromosomal profile. The red line indicates the position of 
the IL10 gene locus. B: The heatmap shows the methylation values (mean AVG-β value) of the single CpGs at the IL10 gene 
locus of eight mnBLL, three mnBLL cell lines, 18 BL, twelve BL cell lines, seven DLBCL and three DLBCL cell lines. The blue 
color indicates low methylation and the yellow color high methylation. The localization of each CpG is given as “upstream” 
of the gene, ”gene body” within the gene and “downstream” of the gene. 
 
Taken together, the increased expression of IL10 in the mnBLL in comparison to the BL and DLBCL 
can yet neither be explained by chromosomal or mutational alterations nor by changes at the 
methylation level. 
 
3.2.3.4.3 Functional analyses of the IL10 signaling pathway 
 
The overexpression of IL10RA and IL10 might indicate a possible autocrine signaling via the IL10 
receptor pathway leading to a subsequent self-stimulation of growth and survival. To test this 
hypothesis, single components of this putative autocrine signaling pathway were inhibited: (i) the 
IL10 receptor subunit IL10RA, (ii) the ligand IL10 and (iii) the IL10R-downstream PI3K signaling. 
IL10R inhibition was performed in the mnBLL cell line Su-DHL-5 and in the BL cell line BL-2 as 
described in 2.2.5.8. Two different IL10RA antibodies were used: T3431, which has been also used for 
IL10RA Western blot analyses and 3F9 for which neutralizing properties have already been described 
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[211],[212]. Treatment with the T3431 antibody led to a loss of viability in both cell lines. The highest 
concentration applied of 10 µg/ml antibody led to 80 % reduction of cell viability in BL-2 cells and 
~90 % in Su-DHL-5 cells (Figure 36A). Treatment with 3F9 antibody on the other hand, had no impact 
at all on the cell viability of BL-2 and Su-DHL-5 cells (Figure 36B). 
 
 
Figure 36: Treatment of different components of the IL10 signaling pathway. A,B: Treatment of BL-2 (BL cell line) and        
Su-DHL-5 (mnBLL cell line) cells with varying concentration of two different IL10RA antibodies (T3431 and 3F9). C: 
Treatment of BL cell lines (BL-2, BL-70), mnBLL cell lines (HT, Su-DHL-5, MLMA) and DLBCL cell line (RIVA) with various 
concentrations of neutralizing IL10 antibody (ab34843). D: Impact of cell line treatment with BKM120 on cell viability. 
Studied were three BL cell lines (BL-2, BL-41, BL-70), three mnBLL cell lines (HT, Su-DHL-5, MLMA) and two DLBCL cell lines 
(Su-DHL-10, Karpas422). The graphs depict the mean and the standard deviation of three experiments.  
 
Inhibition of IL10 was performed using various concentrations (0.1 mg/ml-1 mg/ml) of neutralizing 
IL10 antibody (ab34843) on two BL cell lines (BL-2, BL-70), three mnBLL cell lines (HT, Su-DHL-5, 
MLMA) and one DLBCL cell line (RIVA) as outlined in 2.2.5.8. After two days of treatment the impact 
on cell viability was analyzed (2.2.5.10). The only cell line showing clearly reduced cell viability was 
the mnBLL cell line Su-DHL-5 (Figure 36C). Treatment of Su-DHL-5 cells with 0.25 mg/ml IL10 antibody 
reduced the viability about 40 %. The highest applied concentration of 1 mg/ml IL10 antibody 
reduced the viability by about 90 %. The BL cell lines BL-2 and BL-70 had a reduced cell viability of 
about 30 % and 45 %, respectively, after treatment with 1 mg/ml IL10 antibody. Otherwise, the IL10 
antibody treatment had no impact on cell viability on all the other cell lines. 
Finally, the IL10 receptor downstream PI3K signaling pathway has been inhibited. The compound 
Buparlisib (BKM120) has been reported to be a potent inhibitor of the PI3K class IA in different 
clinical trials [252],[253]. Moreover, Schmitz et al. [72] showed that BKM120 is toxic to BL cell lines. 
Using their treatment protocol as outlined in 2.2.5.9 the impact of BKM120 on the mnBLL cell lines 
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was analyzed. The BKM120 treatment was performed in three BL cell lines (BL-2, BL-41 and BL-70), 
two DLBCL cell lines (Su-DHL-10 and Karpas422) and the three mnBLL cell lines (HT, Su-DHL-5 and 
MLMA). Figure 36D summarizes the results of three independent experiments. The highest applied 
concentration of 2 µM BKM120, led to a complete loss of cell viability in the BL cell lines, the DLBCL 
cell line Su-DHL-10 and the mnBLL cell lines. Lower BKM120 concentrations as 1 µM reduced the cell 
viability of the same cell lines about 50 %. These results indicate that like the BL cell lines, the cell 
survival of mnBLL cell lines seems to depend among others on PI3K signaling. 
Taken together, the inhibition of IL10RA reduced the cell viability in the tested mnBLL cell line but as 
well in the BL cell line. Treatment with the inhibiting IL10 antibody lead to a nearly complete loss of 
cell viability within the mnBLL cell line Su-DHL-5. Inhibition of the IL10R downstream PI3K signaling 
pathway led to the complete loss of cell viability of all mnBLL cell lines. Thus, the findings indicate a 
role of the IL10 signaling in the pathogenesis of mnBLL. 
 
3.2.4 Integrative analysis of the findings in MYC-negative Burkitt-like lymphomas 
 
In the following, as well as in Figure 37 the results of the analysis of the genomic, genetic and 
expressional landscape of the mnBLL are summarized. 
The hallmark characteristics of the mnBLL is the chromosomal alteration on chromosome 11q 
consisting of a copy number gain (11q23.3) including a minimal region of amplification and a 
telomeric copy number loss (11q24.3-q25) including a minimal region of homozygous loss. These 
alterations were present in 23 of 25 analyzed mnBLL (92 %). Two cases solely harbored the telomeric 
loss. Additionally, recurrent copy number alteration as copy loss in 6q14.3-q21 involving the EPHA7 
and PRDM1 genes, copy gains affecting 13q31.3 and 18q21 involving miR-17-92 gene cluster and 
TCF4 gene respectively, might cooperate with the 11q alteration in the pathogenesis of mnBLL. 
No recurrently mutated gene could be identified by gene-wide sequencing approaches. But recurrent 
mutation of ETS1 mapping to the minimal region of homozygous loss in mnBLL was observed by 
Sanger sequencing. 
Expression analysis on mRNA and protein level combined with data mining approaches led to the 
identification of PAFAH1B2, IL10RA and KMT2A as oncogene candidates and of FLI1 and ETS1 as 
tumor suppressor gene candidates in mnBLL. 
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Figure 37: Summary of recurrent genomic and genetic alterations in mnBLL, as well as differential gene expression on 
mRNA and protein level in mnBLL in comparison to BL and DLBCL. Blue color indicates copy number gains, red color 
indicates copy number losses, green color indicates genes significantly higher expressed whereas yellow color indicates 
genes significantly lower expressed in mnBLL than in comparison to BL and DLBCL. Gene names highlighted in red represent 
identified possible candidate genes contributing to the lymphomagenesis of the mnBLL. 
 
Thus, based on these comprehensive analyses, five possible candidate genes contributing to the 
lymphomagenesis of mnBLL were described: PAFAH1B2, IL10RA, KMT2A, FLI1 and ETS1. 
Functional studies of PAFAH1B2 in a mnBLL cell line suggested that this gene plays a minor role in the 
lymphomagenesis of this tumor, whereas functional studies of IL10RA and its related ligand (IL10) as 
well as the downstream signaling pathway points toward a specific role in mnBLL. 
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4 Discussion 
 
The analyses of this thesis focused on two mature aggressive B-cell lymphomas of childhood: MYC-
positive Burkitt lymphoma (BL), and its MYC-negative counterpart, MYC-negative Burkitt-like 
lymphoma (mnBLL).  
The aims of the analyses of BL were to decipher if BL possesses traces of pluripotency and to study 
the expression of a newly identified alternative spliced isoforms of TERT in BL. Moreover, BL should 
be investigated for recurrently mutated genes and their role in Burkitt lymphomagenesis studied. 
Furthermore, the aim of this thesis was to analyze the chromosomal, mutational and transcriptional 
landscape of the mnBLL in order to identify potential candidate genes which might have a 
tumorigenic role in their lymphomagenesis.  
The following discussion will in the first part focus on the findings in BL and in the second part on 
those in mnBLL. Thereafter, the characteristics of both lymphoma subtypes will be compared. 
 
4.1 MYC-positive Burkitt lymphoma 
 
The discussion of the MYC-positive Burkitt lymphoma can be roughly divided into two parts: analyses 
based on gene expression data and analyses of the mutational landscape which led to the 
identification of secondary alterations occurring concomitant to the MYC deregulation in BL. The 
major findings of this thesis in BL are: 
• The PluriTest algorithm showed a higher similarity of BL to hPSC than of non-BL. Nevertheless, an 
origin from or resemblance to cells with PSC features for the BL could not be established. 
• The existence of a new exon in the TERT gene could be verified. Modeling of the effects of the 
splice variant including this new exon predicted (i) translation of proteins with either a loss of the 
N-terminal or C-terminal domain or (ii) due to the introduction of a premature stop codon the 
degradation of the mRNA by NMD. 
• The BL cell lines showed a high frequency of mutations in genes known to be recurrently mutated 
in BL (TP53, CCND3), whereas genes recurrently mutated in DLCBL (CREBBP, CDKN2A) were less 
frequently mutated. 
• Three genes were identified to be recurrently mutated in BL and BL cell lines:  
- ID3 was identified to harbor inactivating mutations and subsequent functional analyses point 
towards a tumor suppressive function in BL. 
- SMARCA4 missense mutations recurrently affecting its catalytic domain were identified in BL. 
- PCBP1 was identified to be recurrently mutated in BL likely leading to a loss-of-function. 
In the following these major results are discussed. 
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4.1.1 Traces of pluripotency in Burkitt lymphoma 
 
As already mentioned in 1.3.3, the MYC-translocation is the initiating event in the pathogenesis of BL 
and different theories exist at which stage of the B-cell development transformation might occur. 
One hypothesis has been that pediatric BL might derive from or resemble cells with – potential- stem 
cell features. To test this hypothesis, BL were analyzed herein for traces of pluripotency using the 
PluriTest. 
The PluriTest showed that the B-cell lymphomas, regardless of their subtype, had in comparison to 
germ cell tumors (GCT) or in particular teratomas, which have pluripotent capacities [254], a 
strikingly lower pluripotency score and higher novelty score. But taking the MYC-status into account, 
mBL could be efficiently separated from MYC-negative non-mBL showing a higher pluripotency score 
and novelty score. The MYC-positive and –negative intermediate B-cell lymphomas and MYC-positive 
non-mBL intermingled between both indicating that the MYC-status alone does not explain the shift 
of the mBL towards hPSC. This might be due to the fact that in non-mBL the MYC translocation is a 
secondary event occurring during the progression of the tumor [255],[256]. 
Comparison of the expression of the 181 genes, which make up the pluripotency signature, between 
mBL and ESC revealed that about 41 % of these genes were expressed at similar or higher levels in 
mBL. hPSC showed just as mBL a rapid proliferation rate driven by certain genes [162],[257] probably 
leading to the described shared gene expression pattern between mBL and ESC which is in 
agreement with recent findings by Ben-Porath et al. [258]. Moreover, Kim et al. [259] have shown 
that the similarities of hPSC and some tumor-associated signatures are contributed by a regulatory 
network of the MYC gene. The findings that the major pluripotency genes like NANOG or POU5F1 
[260],[261] were lower expressed in mBL whereas genes related to increased cell cycle and 
proliferation were expressed at comparable levels or even higher in mBL, further indicates that the 
high similarity is based on a shared proliferation signature in the mBL and hPSC. Thus, it seems as if 
the pluripotency score and the novelty score of mBL is shifted towards hPSC due to a MYC-driven 
proliferation signature. Overall the results suggest that the cell in which the IG-MYC translocation is 
initiated, seems not derive from a B-lymphoid progenitor cell with stem-cell like features. This is 
further supported by the findings of the IGH breakpoint analyses in the BL variants, which suggest 
either a origin of the translocation in bone marrow precursor B-cells during VDJ rearrangement 
particularly in endemic BL [106],[107] or in mature germinal center B-cells during class switch 
recombination [104] or during somatic hypermutation in sporadic BL [262] as described in 1.3.3.1. 
Taken together, the results summarized in this thesis show that mBL resemble more hPSC than non-
mBL and intermediate B-cell lymphomas. Nevertheless, this finding could not be associated to an 
origin or resemblance of mBL to B-lymphoid progenitors with stem cell features. 
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4.1.2 Possible implications of the new exon of TERT gene for Burkitt lymphoma 
 
Analysis of the transcriptome data of primary BL within the ICGC MMML-Seq project revealed a new, 
so far undescribed exon within the TERT gene lying between the second and third exon. The 5’ and 3’ 
exon borders as well as the expression of the three splice variants of this new exon were herein 
verified in a panel of eleven BL cell lines, as well as in seven primary BL. Moreover, the expression of 
a new, so far undescribed splice variant of exon 2 (exon 2V) could be confirmed. The possible 
implications of the expression of the alternative TERT transcripts for BL will be discussed in the 
following. 
The TERT gene maps to chromosome 5p15 and harbors diverse functions. It is the catalytic subunit of 
the telomerase complex [140],[141]. In addition, the telomerase consists of a telomerase RNA (TERC) 
which directs the telomere synthesis [142]. The canonical function of the telomerase is the 
maintenance of the telomere ends [140],[141]. Furthermore, non-telomeric functions have been 
described in the last years which include amongst others regulation of gene expression 
[263],[264],[265],[266], regulation of the cell cycle [267] and inhibition of apoptosis 
[268],[269],[270]. With regard to these various cellular functions, oncogene-like features have been 
attributed to TERT likely contributing to malignant phenotypes [271]. This is supported by the 
findings that the vast majority of cancers express high levels of TERT [272],[273],[274] which is 
correlated with high telomerase activity [139]. In line with this, BL have been shown to have the 
highest telomerase activity among malignant B-cell lymphoma [139] which is reflected by a likely 
MYC-induced TERT expression [275],[276],[277]. Due to its high expression it is one of the genes 
defining the gene expression signature of BL [108]. In line with these findings, TERT expression was 
detectable in all BL cell lines as well as in all but one primary BL. Reviewing the available karyotype 
and SNP array data as well as the whole-genome sequencing data which were available within the 
ICGC MMML-Seq project failed to explain the lack of TERT expression in this single BL case. 
As described in 3.1.2 overall six alternative TERT transcripts might occur due to the inclusion of the 
three variants of the new exon in combination with either exon 2 or exon 2V in the reading frame of 
the wildtype TERT transcripts. Prediction of the open reading frames (ORFs) showed that overall four 
different ORFs might occur, encoding proteins of which either two lack the N-terminal or the C-
terminal domain of the wildtype TERT protein. But it should be noted that based on this modeling, it 
is not clear if these proteins are translated at all. The ORFs encoding proteins lacking the C-terminal 
domain harbor premature stop codons. Alternative splicing of TERT has been already reported n 
several studies leading to the detection of more than 20 splice variants [278],[279],[280],[281],[282]. 
Remarkably, most of them have a premature stop codon [283] making the transcripts more prone to 
NMD [284]. This is thought to be one of the mechanisms regulating TERT activity [285],[286]. In line 
with this, a recent study has shown that the TERT upregulation during lymphomagenesis is counter-
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regulated by a switch of alternative splicing towards transcripts with premature stop codon 
subjected to NMD [287]. Thus, the inclusion of the new exon could also be a counter-regulating 
mechanism and the predicted ORFs lacking the C-terminal domain might be not translated at all. 
However, if transcripts with premature stop codons are dedicate to NMD, their expression is 
normally difficult to detect without inhibition of the NMD machinery as has been reported for other 
transcripts [288]. Thus, as the alternative TERT transcripts can be easily detected in the here studied 
cases, it is also conceivable that the particular high TERT expression in BL might overrun this negative 
feedback regulation. Alternatively, the alternative transcripts might not be subjected to NMD. In line 
with this, Wang et al. [289] have reported that high MYC expression inhibits NMD in B-cells and, 
hence, MYC-target genes were stabilized and upregulated. Hence, due to the high MYC expression in 
the BL cells, NMD might be suppressed and the alternative transcripts harboring a premature stop 
codon might be translated. 
Thus, assuming that the N-terminal and the C-terminal truncated proteins are translated, different 
functions are conceivable which are shortly discussed in the following. 
The C-terminal domain of TERT, which is lost in ORF1 and ORF2, contains two important domains: (i) 
the reverse transcriptase (RT) domain which is responsible for telomerase activity [290] and (ii) the 
TERT C-terminal extension (CTE) domain which participates in protein-protein or protein-DNA 
interactions and regulates the enzyme location [291],[292]. Furthermore, the T-motif is lost which is 
important for maintenance of enzymatic activity [293] by mediating TERT-TERC binding interaction 
and, thus, influences the elongation of the telomeres. Thus, TERT proteins lacking these domains 
have lost their catalytic activity which is needed for its diverse functions [294]. But the N-terminal 
TEN domain which is also called RNA interaction domain-1 (RID1) [295] is retained. This domain has 
been reported to bind single-stranded telomeric DNA [296],[297]. Various studies have analyzed the 
properties of TERT proteins lacking the C-terminus. Some have postulated a dominant-negative 
effect on wildtype-TERT function for example by competing for TERC binding [278],[298],[299]. Other 
studies have shown that TERT variants lacking the catalytic domain retain the ability to induce 
proliferation [279] or anti-apoptotic effects [278]. Thus, the C-terminal truncated proteins encoded 
by the ORF1 and 2 might counteract the function of the physiological TERT in a dominant-negative 
manner or might even have alternative functions. 
The N-terminal truncated TERT proteins encoded by ORF3 and ORF4 retain the functionally 
important catalytic RT domain. But the above described TEN domain is lost and only half of the 
sequence of the TRBD domain is retained in those N-terminal truncated proteins. The TRBD domain 
has a high affinity for TERC and, hence, is important for the TERT-TERC interaction promoting a stable 
assembly of the telomerase complex [300],[301]. Thus, as the truncated protein cannot be directed 
to the telomeric DNA and the assembly with TERC is also likely impaired, it might have no function. 
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Nevertheless, to elucidate the function of the alternative TERT proteins in BL, further functional 
studies need to be performed. 
Taken together, based on the existing data it is yet not possible to conclude if a truncated TERT 
protein is expressed. Furthermore, the function of these truncated proteins remain unclear although 
it is conceivable that the expression of the alternative transcript including the variants of the new 
exon might (i) be a mechanism to negatively regulate the TERT expression (NMD) or function 
(dominant negative effect) or (ii) contribute to wildtype TERT function mediating additional 
functions. Thus, further functional studies need to be conducted to unravel if the alternative 
transcripts are indeed translated and what kind of function they have in BL cells.  
 
4.1.3 Analysis of the mutational landscape in Burkitt lymphoma 
 
The first step in the analysis of the mutational landscape in BL was the identification of appropriate in 
vitro models for BL. Thus, a panel of twelve BL cell lines was screened for mutations using Sanger 
sequencing of two genes described to be recurrently mutated in BL (TP53, CCND3) as well as of two 
genes described to be recurrently mutated in DLBCL (CREBBP and CDKN2A). The results of these 
mutational analyses will be discussed in the following.  
The transcription factor TP53, which is a tumor suppressor, has the highest mutation frequency of all 
analyzed genes by whole-genome sequencing among the 50 cancers analyzed within the ICGC project 
(https://dcc.icgc.org/, 15/01/2015). Inactivating mutations in TP53, which are in the majority 
missense mutations, have been published to occur in about 33 % of primary BL 
[72],[101],[170],[228]. Screening of the twelve BL cell lines revealed that 83 % carried TP53 
mutations of which the majority (12/13) were missense mutations. Various reasons for the 
discrepant TP53 mutation frequencies between BL and BL cell lines are conceivable: (i) high passage 
time of cell lines might lead to acquisition of growth-advantage mutations [302]. (ii) Within the 
processing of the NGS data annotated SNPs as well as germline SNV were excluded in the primary BL. 
The latter was not possible in the cell lines due to the lack of germline material. (iii) DNA from 
primary BL were derived from pretreatment tissue whereas cell lines may derive from tumor tissues 
after treatment which might induce TP53 mutations [303],[304] as in the case of DAUDI cells [178]. 
(iv) The acquisition of TP53 mutation poses a growth advantage to the cells which might lead to a 
positive selection for culturing [125],[305]. Interestingly, the recurrent TP53 mutations at positions 
245, 248 and 273, described as damaging SNPs by PolyPhen and the dbSNP 141 database, 
correspond to six already defined “hot spot” residues which have been defined by Freed-Pastor and 
Prives [306] based on TP53 missense mutation data of 25,902 human cancer patients. These hot spot 
mutations, as well as the other seven identified mutations all map within a conserved DNA-binding 
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domain of the TP53 protein [307]. The mutations affecting this domain have been shown to lead to a 
prolonged half-life of the protein [308],[309],[310]. TP53 is activated upon cellular stress like e.g. 
DNA damage leading to a negative regulation of the cell cycle [311] and induction of apoptosis 
[312],[313],[314]. Thus, a stable mutated-TP53 protein can exert a dominant-negative effect leading 
to an abrogation of the wildtype TP53 function in the cells [315]. The selective acquisition of TP53 
mutations is important for MYC-positive cancers like BL, since cells with a MYC overexpression, which 
represents already a cellular stress factor [316], are more prone to TP53-dependent apoptosis 
[317],[318].  
The CCND3 gene mapping to chromosome 6p21 has been identified to be recurrently mutated in 
primary BL, showing mutation frequencies between 24 % and 38 % [133],[170]. Those studies have 
shown that the mutations cluster in a region which is encoded by the fifth exon of CCND3. Four of 
twelve screened BL cell lines (33 %) carried CCND3 mutations within this exon. The majority of these 
mutations led to a frameshift and a loss of the C-terminal domain of the protein which includes the 
phosphorylation motif. This is in concordance with the findings in primary BL [133],[170]. The only 
missense mutation detected within the BL cell lines affected the residue Ile290 which has been 
described to be part of the phosphorylation motif that regulates among others the protein stability 
[319],[320]. Thus, all four mutations identified in BL cell lines affected the phosphorylation site of the 
protein. CCND3 encodes cyclin D3, which regulates the G1-S cell cycle transition by binding to the 
cyclin-dependent kinases CDK4 and CDK6 [321] in germinal center B-cells [322],[323]. In functional 
studies, Schmitz et al. [72],[135] have shown that CCND3 mutations led to a stabilization of the 
protein and consequently to a longer half-life. Based on those findings they suggested that BL cell 
lines as well as primary BL likely rely on CCND3 signaling which is augmented upon activating CCND3 
mutations [72]. Thus, the here identified CCND3 mutations in BL cell lines harbor the same kind of 
activating mutations as the published primary BL. 
CREBBP, mapping to chromosome 16p13.3, is recurrently mutated or deleted in DLBCL with 
frequencies between 8-41 % [324],[325],[326]. In contrast, CREBBP is barely (4 %) or not at all 
mutated in BL [72],[170]. Furthermore, screening of the CONAN database for copy number analyses 
in cell lines revealed that none of the herein studied BL cell lines carried CNA affecting the CREBBP 
locus (http://cancer.sanger.ac.uk/cell_lines/conan/search, 03/04/2015). Based on this, CREBBP 
mutations are a possible criterion to differentiate between BL and DLBCL. Among the BL cell lines 
screened for CREBBP mutations, only the DG-75 cell line (1/12, 8 %) carried a mutation 
(p.Ile1084Asn*2). The main function of CREEBP is the acetylation of histones [327],[328] which is 
important for the regulation of transcription [329],[330]. Half of the mutations identified in DLBCL 
affected the histone acetyltransferase (HAT) domain which has been described to reduce the activity 
of the protein [324]. The CREBBP mutation identified in DG-75 led to a loss of the functional HAT 
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domain of the protein. Anyhow, this does not implicate that DG-75 cells are DLBCL-like. CREBBP is a 
large gene with 31 exons spanning 155 Mb, hence, the probability for a mutational event increases. 
The probability is even higher in a cell line as DG-75 which has been shown to harbor microsatellite 
instability (http://cancer.sanger.ac.uk/cell_lines/, 03/04/2015). This is in line with the findings by 
Wagener et al. [331] who showed that the cells show a high mutation load which is associated with 
DNA MMR deficiency (Figure 38).  
 
 
Figure 38: Relative contribution of signature 6 (DNA MMR deficiency associated) to the mutation load in 12 BL cell lines. 
The DG-75 cells have the highest mutation load associated with signature 6 in comparison to the other BL cell lines. Data 
from [331]. 
 
The CDKN2A gene maps to a tumor suppressor gene locus on chromosome 9p21 [332]. CDKN2A 
encodes two alternative proteins: (i) p16INK4a has been described to inhibit CDK4 and CDK6 
[333],[334] which interact with CCND3 [321] and (ii) p14ARF which has been described to inhibit 
MDM2 which destabilizes the TP53 protein [335]. The gene is frequently altered in malignant 
lymphomas [336], especially in DLBCL [227] and FL [337]. Three different CDKN2A inactivating 
mechanisms have been described: (i) deletion, (ii) methylational silencing and (iii) inactivating 
mutations [338],[339]. Although the overwhelming majority of inactivating alterations in DLBCL and 
FL are attributed to deletion in 9p21 including CDKN2A, a small fraction of cases harbors inactivating 
mutations [72],[227],[337],[339]. In Burkitt lymphomas the major mechanism of CDKN2A inactivation 
has been attributed to epigenetic silencing [134],[340] whereas deletions and inactivating mutations 
occur at a much lower frequencies [72],[341]. In line with these findings, none of the here analyzed 
BL cell lines carried a CDKN2A mutation. Of note is that the BL-2 cell line carried a homozygous 
deletion of the CDKN2A locus as detected by exome sequencing. After screening of the above 
described CONAN database none of the other herein studied BL cell lines harbored CNA affecting the 
CDKN2A locus (http://cancer.sanger.ac.uk/cell_lines/conan/search, 03/04/2015).  
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Figure 39 gives a mechanistic overview on the impact of the mutated genes on the physiology of the 
BL.  
 
 
Figure 39: Overview on recurrently mutated CCND3, TP53 and CDKN2A in Burkitt lymphoma and their impact on cellular 
pathways. Inactivating mutations or deletions in CDKN2A were detected in 8 % of BL cell lines. The gene encodes two 
alternative proteins: p16
INK4a
 and p14
ARF
. Inactivation of p16
INK4a 
leads to a loss of CDK4 and CDK6 inhibition, which are 
bound to CCND3, thus, increasing the CCND3-CDK induced proliferation of the cell. This pro-proliferative pathway is further 
enhanced by activating CCND3 mutations (33 % of BL cell lines) leading to a stabilization of the protein. On the other hand, 
loss of p14
ARF
 leads to a decrease in TP53 protein stability reducing the TP53-induced apoptosis. Furthermore, BL and BL cell 
lines harbor recurrent inactivating mutations within TP53 (83 % of BL cell lines). 
 
The TP53 gene was the gene with the highest mutation frequency in BL cell lines (83 %). These 
mutations lead to an inactivation of the protein and, thus, a loss of TP53-induced apoptosis. The 
inactivation of TP53 can be supported by inactivation of the CDKN2A-encoded protein p14ARF which 
regulates via MDM2 the stabilization of TP53 protein. Sánchez-Beato et al. [341] have reported that 
CDKN2A and TP53 alterations might occur mutually exclusive. These holds true for the BL cell lines 
investigated herein. Furthermore, loss of the CDKN2A-encoded protein p16INK4a leads to an increased 
activation of CCND3-CDK4/6 and subsequently higher proliferation activity. This effect is enhanced by 
activating mutations in CCND3, increasing the stability of the protein and fostering progression 
through the cell cycle. 
To sum up, the mutational landscapes of the BL cell lines and primary BL with regard to the mutation 
frequencies and types within TP53, CCND3, CREBBP and CDKN2A resemble each other. Thus, the 
selected BL cell lines are appropriate in vitro models for further functional analyses of BL. Overall, the 
mutations in the analyzed genes, lead to an increase in proliferation and an inhibition of anti-survival 
signals via TP53. 
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4.1.3.1 Recurrency of ID3 mutations in Burkitt lymphoma 
 
The analyses of the frequency and the functional impact of ID3 mutations on BL cell lines performed 
in this thesis were embedded within the published analysis of primary BL within the ICGC MMML-Seq 
project [170]. 
A total of 18 B-cell lymphoma cell lines were screened for ID3 mutations. Of those, only BL cell lines 
carried ID3 mutations (67 %, 8/12). This is in agreement with the findings in primary MYC-positive BL. 
ID3 mutations were detected in 68 % of the Burkitt lymphomas of those [170]. The latter findings of 
our group were confined in two independent NGS studies in which 58 % [72] and 34 % [228] of BL 
were described to carry ID3 mutations. In addition to the BL cell lines, only the MC-116 cell line of the 
B-cell lymphoma cell line panel (1/6, 16 %) which carried an ID3 mutation. Remarkably, this cell line 
carries a MYC-translocation [177]. In line with this finding in the cell line, also six primary MYC-
positive non-BL were identified to carry ID3 mutations (13 %, 6/45), suggesting an association 
between MYC-translocation status and ID3 mutation. 
The ID3 gene, consisting of two coding exons, is located on chromosome 1p36.12 and encodes the 
Inhibitor of DNA Binding 3, Dominant Negative Helix-Loop-Helix protein. This protein belongs to the 
Inhibitor of Differentiation (ID) family of helix-loop-helix (HLH) proteins [342] which consists of four 
members in mammals (ID1-4). Their main function is the regulation of proliferation and 
differentiation [343],[344],[345]. Some ID3 functions have been attributed to cell cycle regulation. 
Thus, ID3 has been described to induce growth arrest in B-lymphocyte progenitors [346]. One of its 
main functions is the antagonization of the DNA-binding capacity of the basic HLH (bHLH) proteins 
TCF3 and TCF4 through heterodimerization via its HLH domain [347],[348],[349]. TCF3, also known as 
E2A, plays an important role during B-cell lymphocyte development [350],[351] and is involved in the 
germinal center reaction (1.2.3). As far as yet known, TCF4 (E2-2) on the other hand plays in 
comparison to TCF3 a minor role in B-cell development [352]. Nevertheless, it is rather important for 
plasmacytoid dendritic cell development [353] and neurodevelopment [354],[355]. Generally the ID 
proteins are ubiquitously expressed [356]. However, within the hematopoietic tissue ID3 has been 
described to show a lymphoid-specific expression [357]. Within the tonsils, ID3 is higher expressed 
within the centroblasts of the dark zone than in the centrocytes of the light zone [135]. This pattern 
resembles that of TCF3 and suggests an important role in germinal center B-cell regulation. 
Remarkably, ID3 deficiency in a mouse model led to an induction of γδ T-cell lymphoma [358], 
indicating a tumor suppressive role for ID3. 
ID3 mutations have yet been described in the literature mainly within B-cell lymphoma [359],[360]. 
But overexpression of ID3 has been observed in different tumor types like prostate cancer [361] and 
medulloblastoma [362]. In these tumors, ID3 overexpression was associated with poor prognosis. 
Strikingly, ID3 is not only recurrently mutated in BL but is among those genes which are particularly 
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highly expressed in BL [108]. This strong expression might be induced by the high expression of the 
MYC oncogene in BL. Indeed, the ID3 promoter harbors a MYC binding site [363],[364]. In line with 
this, the ID3 protein expression was lower or non-detectable in non-BL cell lines which were MYC-
negative; whereas the IG-MYC positive non-BL cell line Su-DHL-6 exhibited a low ID3 expression.  
A total of 13 mutations were detected in eight BL cell lines. The majority of those mutations (8/13, 
65 %) skewed towards deleterious changes caused by nonsense mutations, deletions or splice site 
mutations. The type of ID3 mutations in primary BL described in the literature differed between the 
study cohorts: Richter et al. [170] have described an overall deleterious character of the mutations, 
whereas Schmitz et al. [72] and Love et al. [228] have described that the majority of ID3 mutations in 
BL were missense mutations. This discrepancy can be in part explained by the fact that Schmitz et al. 
used RNA-sequencing to identify SNV. Thus, transcripts harboring a nonsense mutations or 
frameshift deletion/insertion leading to a premature stop codon are probably not detected with this 
technique due to nonsense mediated decay (NMD). 
The ID3 protein expression analysis in the BL cell lines gave further evidence for the deleterious 
character of the ID3 mutations. In five of the eight ID3-mutated BL cell lines (63 %) ID3 protein 
expression was lower in comparison to ID3-wildtype BL cell lines or completely absent. Two of the BL 
cell lines with complete loss of ID3 expression carried biallelic ID3 mutations. Hence, it can be 
speculated that although the ID3 mRNA levels are increased in primary BL [108], the ID3 protein 
expression is also reduced in primary BL with biallelic ID3 mutations.  
Two BL cell lines (BL-2, BL-70) carried the same splice site mutation which leads to an aberrant 
splicing as shown for BL-70 cells. In line with this, aberrant splicing due to a splicing mutation could 
be also shown for one of the primary BL samples [170]. Protein expression analysis showed a loss of 
ID3 expression in BL-70 cells, pointing towards NMD of the aberrantly spliced mRNA. Thus, these 
findings are in line with the overall deleterious character of the mutations.  
In addition to the deleterious mutations, five missense mutations were identified in the BL cell lines. 
All of them were located within the HLH domain of the ID3 protein. The HLH domain mediates the 
protein homo- and heterodimerization of ID proteins [356]. The accumulation of missense mutations 
in the HLH domain has been also observed in the primary BL [72],[170], [228]. Furthermore, Richter 
et al. have shown that several of those mutations were predicted to affect the interaction of ID3 with 
TCF3 and/or TCF4 [170]. This might lead to an increased activity of TCF3 and maybe TCF4, giving the 
BL a selective growth and survival advantage. This hypothesis was corroborated by functional 
experiments in this thesis. These showed that overexpression of wildtype-ID3 in ID3-unmutated (DG-
75) and ID3-mutated (BL-2) BL cell lines led to a significant increase of apoptosis. This is in line with 
the findings by Love et al. [228] who showed that an overexpression of wildtype-ID3 in BL cell lines 
Discussion 
133 
reduced the cell viability whereas overexpression of mutant-ID3 did not affect the viability. These 
findings further support a possible tumor-suppressor function for ID3 in BL. 
However, although ID3 mutations have a high frequency of 34-68 % in BL, not all primary BL and BL 
cell lines carry mutations in this gene. Interestingly, Schmitz et al. have shown that 11 % of BL harbor 
activating mutations within TCF3 [72]. Mutations of TCF3 have meanwhile also been detected in 
follow up analysis of more primary BL (23 %, 3/13) within the ICGC MMML-Seq project 
(https://dcc.icgc.org/, 15/01/2015). Thus, up to 70 % of BL harbor either inactivating ID3 or activating 
TCF3 mutations [72]. In line, the BL cell lines DG-75 and Ramos, lacking ID3 mutations, carried TCF3 
mutations (p.Asp561Val and p.Asp561Glu, respectively) [72]. Remarkably, in both cell lines the 
mutation affected a residue in the bHLH domain which Schmitz et al. described as evolutionary 
conserved [72]. Moreover, Richter et al. [170] described that 28 % of BL without an ID3 mutation 
harbored a copy number gain in 18q. A minimal region of gain in chr18:51,894,728–54,354,319 bp 
(hg19) including the TCF4 gene could be defined for those cases which was, furthermore, associated 
with a higher expression of the TCF4 gene [170]. As TCF4 has been described to share targets with 
TCF3 [365], it is conceivable that the overexpression of TCF4 is another activating mechanism in BL. 
In further experimental studies, Schmitz et al. have shown that loss of TCF3 inactivation by ID3 
and/or activating TCF3 mutations led to a TCF3-dependent activation of the tonic BCR signalling and 
subsequently activation of the PI3K pathway, increasing the proliferation rate of the cells [72]. As 
mentioned in the introduction (1.3.4), the PI3K pathway plays an important role as survival 
determinant in BL [133]. This view has been further confirmed by specific inhibition of the PI3K in BL 
cell lines with the clinical trial compound BKM120 [72]. The loss of viability of BL cell lines due to 
BKM120 treatment was confirmed in functional experiments on the same BL cell lines used by 
Schmitz et al. [72] in the framework of this thesis (Figure 36D).  
To sum up, a high frequency of inactivating mutations within ID3 is specific for BL and points towards 
a tumor-suppressor function of this gene. The loss of ID3 function increases TCF3 activity and, thus, 
PI3K signaling which ultimately leads to an enforced proliferation of the cells. This is schematically 
summarized in Figure 40. 
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Figure 40: Schematic overview on the aberrations in the ID3-TCF3-PI3K signaling pathway in BL. ID3 is particularly highly 
expressed in BL which is likely induced by the high MYC oncogene expression in BL. Two mutational events lead to an 
increase of TCF3 activity: (i) inactivating mutations of ID3 as detected in 34-68 % of primary BL and 67 % of BL cell lines 
ablate its negative control of TCF3 and (ii) activating TCF3 mutations were detected in 11 % of primary BL [72]. Higher 
activity of TCF3 augments BCR signaling which subsequently enforces PI3K signaling, leading to increased survival and 
proliferation of the BL cells. Adapted from Ott et al. [71]. 
 
4.1.3.2 Recurrency of SMARCA4 mutations in Burkitt lymphoma 
 
In the following the results of the SMARCA4 mutation analysis in BL, which were embedded within 
the ICGC MMML-Seq analyses of primary BL, will be discussed. SMARCA4 is of special interest in BL as 
it is, just as ID3 (4.1.3.1), among those genes which are particularly highly expressed in BL [108]. This 
strong expression might be induced by the MYC oncogene [366].  
The aim of this study was to analyze the functional impact of the SMARCA4 mutations since so far 
only the fact that these mutations recurrently occur in BL has been described in literature 
[72],[170],[228]. 
SMARCA4 maps to chromosome 19p13.2. Mutations in SMARCA4 have been observed in 43 % (9/21) 
of primary BL within our ICGC MMML-Seq cohort and in 13 % of BL cell lines (2/16). To enlarge the 
cohort of BL, exome and RNA-sequencing data of two independent cohorts [72],[228] were included 
for the characterization of the SMARCA4 mutations. The overall SMARCA4 mutation frequency in BL 
in all three cohorts was 27 % (27/100). The mutation frequencies differed between the cohorts (ICGC 
MMML-Seq: 43 %, Schmitz: 39 %, Love: 16 %) which might be due to the different sequencing 
methods applied (whole-genome sequencing vs. RNA-sequencing vs. exome sequencing). Another 
reason might be the selection of the cohorts: all analyzed primary BL of the ICGC cohort were derived 
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from children (median age 6 years at diagnosis), whereas in the studies of Love et al. and Schmitz et 
al. also BL from adults were included [72],[228]. Furthermore, the ICGC cohort consists of molecular 
defined BL hereby excluding lymphomas with morphological features of BL but not representing BL at 
the molecular level like e.g. some double-hit lymphomas [367],[368]. 
SMARCA4 has been described as one of 15 genes being frequently mutated in a set of over 1,000 
pediatric cancers [369]. Furthermore, SMARCA4 mutations have been described in Atypical 
Teratoid/Rhabdoid Tumor (AT/RT) which primarily affect young children [193],[370] and in small cell 
carcinoma of the ovary, hypercalcemic type (SCCOHT) occurring in woman under 40 years of age 
[371]. The SMARCA4 mutations of both tumor types were predominantly nonsense mutations or 
deletions leading to a loss of the C-terminal domains and SMARCA4 expression [370],[371]. 
Moreover, SMARCA4 germline mutations have been reported in 4/7 families with SCCOHT and in 6/7 
children with AT/RT [370],[371]. On the contrary, the SMARCA4 mutations identified in BL were all 
somatic and in the overwhelming majority missense mutations (97 %). Thus, although those tumors 
share the high frequency of SMARCA4 mutations, the functional impact likely varies due to the 
different types of mutations. 
The SMARCA4 gene encodes the Brahma-related gene-1 (BRG1) protein which is the catalytic subunit 
of the ATP-dependent chromatin remodeler called SWI/SNF complex [372]. Thus, it confers the DNA-
dependent ATPase activity of the complex. Binding of SWI/SNF to the nucleosome changes the 
conformation at the transcription start site in such a manner, that the RNA polymerase II can bind 
and initiate the transcription of the gene [373],[374]. In addition to BRG-1, the SWI/SNF complex 
contains 8-10 subunits which are referred to as BRG-1 associated factors (BAF) [375],[376]. Among 
them are e.g. ARID1A (BAF250A) and ARID1B (BAF250B). The BAF subunits contain DNA-binding and 
protein binding motifs which influence the selectivity and activity of the ATPase subunits [377]. BRG1 
itself contains a Bromo domain which binds acetylated histones [378] and is necessary for the stable 
association of the complex with the chromatin [379]. Furthermore, interaction between the SWI/SNF 
complex and gene-specific transcription factors directs the complex to the target genes 
[380],[381],[382]. The BRG1 SWI/SNF complex is a master regulator of gene expression as it has been 
shown to bind to ~51,000 regions in embryonic mouse tissues [383] as well as about 15,000 islands 
across the genome in murine embryonic stem cells [384]. In line with this, BRG1 has been described 
to associate for example with the p21 promoter in a p53-dependent manner [385],[386] and, thus, 
plays an important role in cell cycle control. Furthermore, BRG1 has been reported to modulate TERT 
expression [387]. A further function of BRG1 is the regulation of differentiation of diverse tissues and 
at various developmental stages [388],[389],[390]. BRG1 has been also linked to B-cell development 
and function. Hence, as it has been described to play a role in the V(D)J recombination and BCR 
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assembly [391],[392]. Moreover, it has been recorded to be required for B-cell proliferation upon 
activation and, thus, to increase the efficiency of BCR signaling [393]. 
Furthermore, different studies have shown a tumor-suppressor function for various subunits of the 
SWI/SNF complex including BRG1 [385],[394]. Hence, BRG1 has been shown to bind to the 
retinoblastoma tumor suppressor protein (RB) and consequently control the cell cycle progression 
[394]. Moreover, BRG1 re-expression in BRG1-mutant or deficient cell lines inhibits their growth 
[385]. To elucidate the impact of the SMARCA4 mutations on its functions, the sites of mutations 
were analyzed on protein level as discussed in the following. 
Strikingly, 62 % of the missense mutations lay within the SNF_N or Helicase domains which together 
build the ATPase domain of BRG1 [372]. Different studies have revealed that mutations within the 
ATPase domain might impair the function of the protein [395]. For example, Bultman et al. [395] 
have shown that the mutation Glu1083Gly in the murine Brg1 gene does not alter the stability of the 
protein, its capability to form the SWI/SNF complex or the ATPase activity. Instead, the mutation led 
to a reduced transcription of the target gene β-globulin, as well as to a methylation of the CpGs. In 
contrast, in BL the genomic targets of SMARCA4 are hypomethylated but an increase of SMARCA4 
target genes transcription was not observed (data not shown, manuscript under revision at Nature 
Genetics). In another study it has been described that a missense mutation within the ATPase domain 
of BRG1 leads to a dominant negative inhibition of transcription due to the formation of a 
nonfunctional complex [372]. Based on this, it is conceivable that the SMARCA4 mutations identified 
in the BL ablate the ATPase activity and, thus, its function, but the ability of the complex to interact 
with the DNA is still present. The protein modeling of SMARCA4 and its mutations further 
corroborates this (Figure 41). The results suggest that the helicase function of the protein is impaired 
either due to direct interference with ATP-binding or obstruction of the interaction of the N-and C-
terminal helicase domains (data provided by Dr. rer. nat. Robert B. Russell, Cell Networks, Bioquant, 
University of Heidelberg, Heidelberg, Germany). 
In comparison to ID3, the mutation frequency of SMARCA4 is lower though a significant amount of 
cases is affected. Nevertheless, also other members of the SWI/SNF complex have been described to 
be recurrently mutated in BL. Giulino-Roth et al. [91] have shown that 17 % (5/29) of primary 
pediatric BL carry truncating ARID1A mutations and one BL harbored a mutation within SMARCB1 
(BAF47). In line with this, eight of 12 primary BL of the ICGC MMML-Seq cohort without SMARCA4 
mutation carried mutations within subunits of the SWI/SNF complex as in ARID1A (17 %, 2/12), 
ARID1B (8 %, 1/12) and SMARCB1 (8 %, 1/12) or in newly identified subunits of SWI/SNF complex 
[396] as BCL7A (17 %, 2/12) and BCL11B (8 %, 1/12). Thus, 81 % of BL (17/21) carried mutations 
within the SWI/SNF complex (data not shown, manuscript under revision at Nature Genetics). This 
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suggests that the inactivation of this complex might confer a selective pathogenic advantage for the 
BL cells. 
 
 
Figure 41: Protein model of SMARCA4 showing sites of mutations in BL. The N-terminal helicase domain (SNF2_N) is shown 
in cyan and the conserved C-terminal helicase domain (Helicase_C) is shown in grey. DNA is depicted as a cartoon and ATP 
with sticks, both colored by atom types. Residues mutated in BL are shown as spheres for C-alpha atoms, with side-chains 
as sticks colored by atom types. The model was provided by Dr. rer. nat. Robert Russell Cell Networks, Bioquant, University 
of Heidelberg, Heidelberg, Germany and is also included in Kretzmer et al., Nature Genetics, under revision. 
 
Taken together, 43 % of primary BL were identified using whole-genome sequencing and verified 
using Sanger sequencing to carry SMARCA4 mutations. The overwhelming majority of mutations 
were missense mutations which likely lead to an impaired ATPase function and, thus, might have a 
dominant negative effect on the transcription of the SMARCA4 target genes. Hence, the mutations 
further corroborate the published function of SMARCA4 within the SWI/SNF complex as tumor 
suppressor. 
 
4.1.3.3 Recurrency of PCBP1 mutations in Burkitt lymphoma 
 
Using whole-genome sequencing in a cohort of pediatric Burkitt lymphoma several genes were 
identified which are mutated at lower frequencies (9 and 20 %) than those discussed before. Among 
those genes is PCBP1 which was mutated in 3 of 17 (18 %) whole-genome sequenced BL. 
After verification of the mutations and their somatic origin using Sanger sequencing, an independent 
cohort of 28 primary BL, as well as 16 BL cell lines was screened for mutations using Sanger 
Sequencing. In total, PCBP1 mutations were identified in 13 % (6/45) of primary BL and in 38 % (6/16) 
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of BL cell lines. Of note is, that five of those cell lines (BL-30, BL-70, DAUDI, EB-3, Namalwa) have 
been already described in the literature to carry PCBP1 mutations [72],[228], thus proving the 
correctness of the here presented data. Mining of the data of the two published mutation screens in 
BL revealed that PCBP1 mutations have been observed at lower frequencies by Schmitz et al. [72] 
(2/28, 7 %) and by Love et al. [228] (2/51, 4 %) but were not further discussed in those studies. The 
lower frequency might be again explained by the different sequencing methods used (RNA- vs. 
whole-genome- sequencing) as well as by the composition of the cohorts. 
In comparison to the more frequently mutated genes like ID3 or CCND3, the significance of genes 
mutated at a lower frequency is unclear. Nevertheless, a recent meta-analysis of pan-cancer exome 
data showed that most cancer related genes are mutated at frequencies between 2 and 20 % [397]. 
It is conceivable that genes with a low mutation frequency contribute to the pathogenesis of the 
tumor by interplay with other mutations deregulating the same pathway. In line with this, TCF3 has 
been reported to be mutated in only 11 % of BL. Nevertheless, together with the above described ID3 
mutations, deregulation of the ID3-TCF3-PI3K pathway occurs in about 70 % BL [72]. Furthermore, 
SMARCA4 mutations occur in 43 % of BL but overall 81 % of BL carry mutations within subunits of the 
SWI/SNF complex (4.1.3.2). Moreover, the ras homology family member A (RHOA) gene has been 
described to be mutated in 8.5 % of pediatric BL [398]. Recently, the Gα13-dependent pathway 
signaling which also includes RHOA has been reported by Muppidi et al. [399] to be deregulated in 
BL. Frequent mutations in components of this pathway as GNA13 (7/31, 22.6 %) and P2RY8 (10/31, 
32.3 %) have been reported [399]. The Gα13 pathway inhibits the cell growth and the migration of 
GC B-cells [399]. Its deregulation has been reported to induce lymphoma formation in a mouse 
model [400]. Thus, as the above presented examples demonstrate, it is conceivable that PCBP1 
mutations also contribute to the lymphomagenesis of BL by interplay with other mutations. 
PCBP1, also called heterogeneous nuclear ribonucleoprotein E1 (hnRNP-E1) or Alpha-CP1, is a 
member of the poly(C)-binding proteins. It has a high and specific affinity for binding C-rich 
oligonucleotide sequences. The protein consists of three KH domains (KH), which act as independent 
RNA/DNA binding units [401],[402], as well as of two nuclear localization signals (NLS) [403]. The first 
NLS lies between the second and third KH, whereas the second NLS lies within the KH III. The major 
functions of PCBP1 can be attributed to transcriptional regulation of gene expression, translational 
control and modulation or pre-mRNA splicing. PCBP1 controls translation by binding to mRNA 
templates containing differentiation control elements (DICE) [404]. The silencing of pseudoexon 
splicing as part of the pre-spliceosomal complex [405] as well as the transcriptional activation of the 
eukaryotic translation initiation factor 4E (eIF4E) [404] were also attributed to PCBP1. Furthermore, 
PCBP1 has been shown to regulate the expression of DNA polymerase eta (POLH) by stabilizing its 
mRNA [406]. 
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PCBP1 protein is localized in the cytoplasm as well as in the nucleus [404]. In agreement with PCBP1’s 
function in mRNA splicing, it has been also described to accumulate in nuclear speckles [403],[407] in 
which splicing factors are generally concentrated [408]. 
In this study a total of 12 PCBP1 mutations were observed. Ten of those affected the KH III domain 
either due to a complete loss of the domain (5/10) or due to a substitution (5/10). Moreover, seven 
mutations affected the NLS I and/or NLS II due to a complete loss of both (5/7) or a substitution (2/7) 
in one of the NLS. The functional impact of the mutations might vary. Nevertheless, the nonsense 
and frameshift mutations leading to loss of functional domains are probably more damaging than the 
substitutions. For example the nonsense mutation in case 4177434, leading to a loss of KH III domain 
and both NLS, probably completely impairs the nuclear trafficking. In contrast, the missense 
mutation of BL-41 in NLS I might slightly decrease the PCBP1 expression within the nucleus. This is 
supported by the findings by Chkheidze and Liebhaber [403] showing that the depletion of only one 
NLS signal leads to the retention of some of the protein in the cytoplasm whereas the depletion of 
both NLS leads to a loss of nuclear trafficking.  
Additionally, four missense mutations were predicted by Mechismo [197] to have an effect on the 
oligonucleotide interaction. Hence, the mutation p.Arg325Gly was predicted to have a strong 
disabling effect on oligonucleotides binding. The substitutions p.Cys293Tyr, p.Ile295Thr and 
p.Asn303Asp on the other hand, were predicted to have weaker effects. Thus, the missense 
mutations might also lead to a loss-of-function. Strikingly, the mutation p.Cys293Tyr, which was 
found in MPI-017 as well as in the BL-70 cell line, has been also described in each one BL sample by 
Schmitz et al. [72] and by Love et al. [228]. 
Furthermore, the available clinico-pathological and molecular cytogenetic data, which were provided 
by the ICGC MMML-Seq and the MMML-project, were analyzed for differences in the PCBP1 mutated 
and wildtype BL groups. Interestingly, all six mutated cases expressed IRF4, whereas only 39 % of the 
PCBP1 wildtype cases expressed IRF4 (PCBP1 mutated vs. wildtype p=0.008). In the literature, IRF4 
expression is detected in 20-40 % of BL [409],[410]. IRF4, also known as MUM1, belongs to the 
interferon regulating factor (IRF) family of transcription factors. The expression of IRF4 is restricted to 
the immune system [411],[412] and it is a crucial regulatory factor in B-cell development [413]. Low 
levels of IRF4 expression have been described in the germinal center B-cells [414] whereas within the 
terminal differentiated plasma cells higher expression levels have been described [415]. The 
IRF4/MUM1 positive immunoprofile of the BL might reflect a pathological intermediate GC stage of 
differentiation [409]. This is further supported by the finding that those cases are also positive for the 
GC marker BCL6 (8.9). The implications of PCBP1 mutations in MUM1 expressing Burkitt lymphoma 
are unclear at present and the findings need further confirmation in independent cohorts. 
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To sum up, PCBP1 was found to be mutated in 13 % of primary BL. The mutations primarily affect the 
KH III domain and/or the NLS. The consequences of the mutations point to a reduction or even loss of 
function. Furthermore, PCBP1 mutations might accumulate in IRF4/MUM1 positive BL. 
 
4.1.3.4 Conclusions from the analyses of the mutational landscape in Burkitt lymphoma 
 
The aim of the analyses of the mutational landscape in BL was to identify recurrently mutated genes 
in primary BL and to determine the consequences of the mutated genes for Burkitt 
lymphomagenesis. The mutation screening was also performed in BL cell lines to identify appropriate 
cell line models for BL for further functional studies. The following figure summarizes the comparison 
of the mutation frequencies of the here analyzed genes in BL cell lines to the mutation frequencies 
determined in the framework of this thesis or published elsewhere for primary BL (Figure 42). 
 
Figure 42: Comparison of mutation frequencies in seven genes detected in BL cell lines and primary BL. The mutation 
frequency of ID3, PCBP1, SMARCA4 of the primary BL were determined within this thesis, whereas the mutation 
frequencies of TP53 [72],[101],[170],[228], CCND3 [133], [170], CREBBP [72],[170] and CDKN2A [72],[341] have been 
already published. 
 
Overall, all genes mutated in primary BL are also mutated in the BL cell lines. Nevertheless, the 
mutation frequencies of TP53 and PCBP1 are higher in the BL cell lines than in the BL whereas the 
mutation frequency of SMARCA4 is lower in the BL cell lines. A higher mutation frequency in the BL 
cell lines, as already discussed in 4.1.3, might be related to (i) the high passage number of the cell 
lines favoring acquisition of mutations which give an growth advantage as for example inactivation of 
TP53 (ii) treatment-induced mutations in BL cell lines and (iii) as in the case of TP53 inclusion of 
mutations designated as SNP in BL cell lines which were excluded in the processing of the whole-
genome data. In case of TP53 mutations, exclusion of the mutations annotated as SNPs, decreases 
the frequency to 42 % which is comparable to the mutation frequency observed in primary BL. But it 
is important to include these mutations annotated as SNPs as they have been described to have 
dominant negative effects as described in 4.1.3. Furthermore, the type of identified mutations is 
Discussion 
141 
consistent between the cell lines and the primary BL. Hence, taken together, the selected cell lines 
seem to be appropriate in vitro models for BL.  
Remarkably, some of those genes which were identified to be recurrently mutated in BL have been 
described to interact with each other leading to a mechanistic model of BL lymphomagenesis. Figure 
43 illustrates the interaction of the recurrently mutated genes in BL and the involved oncogenic 
pathways. 
 
 
Figure 43: Overview on recurrently altered oncogenic pathways in Burkitt lymphoma. Four oncogenic pathways can be 
defined: 1. Inactivation of TP53 leads to a decrease of TP53-dependent apoptosis, which is further augmented by the 
finding of recurrent inactivation of CDKN2A encoding p14
ARF
 which regulates the stability of the TP53 protein. 2. Activation 
of CCND3 mediated proliferation via CDK4 and CDK6 is enhanced due to CCND3 activating mutations. Furthermore CDKN2A 
also encodes the CDK4 and CDK6 regulating protein p16
INK4a
 and its inactivation leads to an augmentation of the pro-
proliferative pathway. 3. Inactivating mutations in ID3 lead to a loss of negative regulation of TCF3 which has been 
furthermore described to carry activating mutations [72]. TCF3 has been described to activate CCND3, thus, contributing to 
the proliferative pathway. Furthermore, it enhances BCR signaling via various mechanisms, which leads to increased 
PI3K/AKT signaling and, hence, to the survival and growth of the BL cells. 4. Inactivation of the MYC induced SWI/SNF 
catalytic subunit SMARCA4 due to mutations within the ATPase domain likely lead to a dominant negative effect with a 
subsequent decrease of SMARCA4 target gene transcription. The effect of the likely inactivating PCBP1 mutations is unclear 
to the present. But since the NLS domain of the protein is a major target of the mutations, an impaired trafficking to the 
nucleus is conceivable. 
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Strikingly, based on the analysis of the mutational landscape four major oncogenic pathways could 
be identified, which constitute promising targets for BL therapy. Among those targets is PI3K A 
specific inhibitor for PI3K is the compound BKM120 which is recently applied in several clinical trials 
[252],[416]. Schmitz et al. [72] could show that BL cell lines treated with BKM120 undergo cell death. 
This effect on BL cell lines could be reproduced in functional studies conducted within this thesis as 
described in 3.2.3.4.3. Hence, BKM120 is probably a portent BL therapeutic. A further promising 
target for BL therapy might be the cyclin-dependent kinases CDK4 and CDK6 which mediate 
proliferation. A potent inhibitor of the cyclin dependent kinases is the compound PD0332991 which 
has been shown by Schmitz et al. [72] to effectively block the G1-S-phase transition in BL cell lines. 
Moreover, this inhibitor has proven in several clinical trials its clinical benefit in the treatment of 
refractory NHL and multiple myeloma [417],[418]. Moreover, the Akt-downstream component, 
mTOR, might be a further target for BL therapy. A potent inhibitor of the mTOR complex is rapamycin 
and its derivates which have been shown in several clinical trials to be potent lymphoma 
therapeutics [419]. In line with this, treatment with rapamycin has been described to be toxic to 
most of the BL cell lines [72] or to decrease the tumor growth in a transgenic mouse model of BL 
[420]. 
 
4.2 MYC-negative high-grade lymphoma resembling Burkitt lymphoma 
 
The existence of rare MYC-negative Burkitt lymphoma or Burkitt-like lymphoma has been widely 
discussed for a long time [1],[164],[169]. Recently, by using a comprehensive genomics and gene 
expression approach our group identified a series of mBL and intermediate B-cell lymphoma lacking a 
MYC-translocation but sharing a peculiar pattern of chromosomal gain in 11q23.3 and loss in 
11q24.2-q25 [166]. The aims of this thesis were the analyses of the chromosomal, mutational and 
transcriptional landscape of these MYC-negative Burkitt like lymphoma (mnBLL) in order to identify 
potential candidate genes which might contribute to its lymphomagenesis.  
Major results of these analyses were:  
• The minimal region of loss and the included minimal region of homozygous loss were redefined by 
analysis of newly recruited mnBLL. Moreover, recurrent secondary alterations, present in more 
than 20 % of mnBLL affecting 6q, 13q and 18q as well as a trisomy 12 were identified. 
• ETS1 is recurrently mutated in 4/16 (25 %) mnBLL. 
• Ten genes of the altered 11q region were identified to be differentially expressed in mnBLL in 
comparison to BL and DLBCL.  
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• Combining the results of the analysis of the chromosomal, mutational and transcriptional 
landscape with literature search led to the identification of PAFAH1B2, IL10RA and KMT2A as 
potential oncogenes and of FLI1 and ETS1 as potential tumor suppressor genes in mnBLL. 
• Expression analysis of the five candidate genes on mRNA and protein level in mnBLL cell lines 
were in agreement with the expression profiles in the mnBLL. 
• Analysis of the IL10RA cell surface and extracellular IL10 expression in combination with inhibition 
of IL10, IL10RA and PI3K revealed the dependency of the mnBLL cell lines on PI3K signaling and 
suggests an oncogenic role for the IL10 signaling pathway. 
Hereinafter, the results of the follow up analyses with regard to the already published data in Blood 
[166] will be discussed. 
 
4.2.1 The chromosomal landscape of MYC-negative Burkitt-like lymphomas 
 
We described 17 MYC-negative Burkitt-like lymphomas sharing a special pattern of alteration on 
chromosome 11 consisting of a copy number gain (11q23.3) and a telomeric copy number loss 
(11q24.2-qter) [166]. In this thesis eight additional cases (case 18-25) were characterized. Moreover, 
in addition to the two already described cell lines with the typical mnBLL features (HT, Su-DHL-5) 
[166], the MLMA cell line was identified as an additional mnBLL cell line model. In order to identify 
potential pathogenetically relevant candidate genes, the aim of the analysis of the chromosomal 
landscape of mnBLL was the definition of the minimal gain and loss region in 11q as well as the 
identification of recurrent secondary alterations for all 25 mnBLL cases.  
Figure 44 gives an overview on the alterations of chromosome 11 in the mnBLL as well as in three 
mnBLL cell lines. Combining the breakpoint data in 11q of all 25 cases led to a re-definition of the 
minimal region of loss and homozygous loss, whereas the already described minimal regions of gain 
and amplification remained unchanged. The occurrence of imbalances on chromosome 11 as 11q23 
duplications or der(11q) have been described in MYC-negative lymphomas with Burkitt morphology 
[168],[169]. Furthermore, alterations on chromosome 11q23-qter have been described in a variety of 
hematological disorders, especially translocations involving the KMT2A gene on 11q23 [421],[422]. In 
DLBCL a gain in 11q22.3-qter or 11q24.3 is among the most frequent chromosomal rearrangements 
[239],[245]. But in contrast to the mnBLL these DLBCL harbor solely a copy number gain but nor loss 
in 11q. 
As all analyzed mnBLL harbor at least the deletion on 11q24.3, this region might contain a tumor 
suppressor gene(s) important for its pathogenesis. Remarkably, two mnBLL (case 9 and case 25) 
harbor a homozygous deletion of 11q24.3 including seven genes (8.12) and one ncRNA (8.13). 
Strikingly, among those genes are two transcription factors of the ETS-family, ETS1 and FLI1, which 
are known to play important roles in the pathogenesis of various cancers [423],[424],[425]. In 
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contrast to the here assumed tumor suppressive function, an oncogenic role has been described for 
those two genes in a subset of DLBCL [239]. In this subset of DLBCL, FLI1 and ETS1 map to a minimal 
region of gain [239]. A tumor suppressive function for ETS1 has been already suggested for Hodgkin 
lymphoma [248],[426]. This points towards an ambivalent role for ETS1 in tumors, having an 
oncogenic role in DLBCL but a tumor suppressive in mnBLL. The potential impact of those two genes 
on the pathogenesis of mnBLL will be discussed in further detail in 4.2.4.3 and 4.2.4.4. 
 
 
Figure 44: Genomic profile of chromosome 11 analyzed by SNP 6.0 array and OncoScan in mnBLL (n=23) and mnBLL cell 
lines (n=3). Depicted are the ideogram of chromosome 11, the cumulative percentage of cases sharing this copy number 
alteration and the analyzed cases: case 1-12 and 18-25, MPI-cases and cell lines HT, Su-DHL-5 and MLMA. Missing are three 
MPI cases, which have been analyzed using an array-CGH platform. Blue color represents copy number gains, and red color 
represents copy number losses.  
 
A major hallmark of BL is the low genomic complexity harboring less than five CNA in addition to the 
MYC-translocation [170],[427],[428]. Hence, the genomic complexity of the mnBLL was used to 
determine if mnBLL resemble BL also at chromosomal level. As already described in 3.2.1.2 the 
genomic complexity of mnBLL varied strongly among the cases with a range of 2 – 28 CNA per case. 
The big difference in the amount of CNA might be attributed to the different platforms used for the 
CN analyses or to the different fixation methods of the tissue of which DNA was extracted. It is 
known that DNA derived from FFPE material has a lower quality due to degradation [429], leading to 
a higher background in the CN analyses. Thus, more stringent criteria needed to be applied which 
might lead to reduced detection sensitivity for smaller alterations. Therefore, it is only possible to 
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compare the CNA analyzed with the same platform and using DNA derived from the same fixation 
procedure. This has been already performed for the initial mnBLL cohort showing that the mnBLL 
have a high amount of CNA in comparison to BL (11.5 vs. 4) and DLBCL (11.5 vs. 6) [166]. Thus, the 
higher genomic complexity is not in agreement with the Burkitt-like phenotype. Hence, as the MYC 
deregulation in BL is already such a crucial alteration for the malignant transformation, the low 
genomic complexity in mnBLL might be an indicator that the mnBLL do not harbor such a potent 
alteration. And, thus, more alterations are necessary to induce full blown lymphomagenesis. This is in 
line with the observation that the absence of MYC-rearrangements in B-cell lymphoma has been 
described to be associated with higher genomic complexity [169]. 
Thus, the chromosomal landscape of the mnBLL was analyzed for secondary recurrent alterations 
concomitant to the 11q alteration. Recurrency of secondary alterations was defined as alterations 
occurring in more than 5 of the 25 (20 %) mnBLL. Hence, following secondary alterations were 
identified: deletion on 6q14.3-q21 and gains in 13q31.3, 18q21 as well as trisomy 12. 
Trisomy 12 was identified in 20 % of mnBLL. A partial or a complete trisomy 12 has been described to 
be common in BL [131],[132], DLBCL [430] and CLL. In the latter, trisomy 12 has been associated with 
a favorable overall survival [431]. Based on cytogenetic studies in B-cell lymphoproliferative 
malignancies a “minimal duplication region” 12q13-q22 has been identified in cases with partial 
trisomy 12 [432]. Five mnBLL (cases 1, 8 and MPI-078, MPI-086, MPI-315) as well as the mnBLL cell 
lines Su-DHL-5 and MLMA harbor copy number gains in this minimal gain region on chromosome 12. 
Hence, a total of eleven mnBLL (44 %) harbor a duplication of 12q13-q22 due to a complete or partial 
trisomy 12. Thus, partial trisomy 12 can be considered as the second most frequent aberration in the 
mnBLL. The tumorigenic impact of the trisomy 12 is not clear. Overexpression of the oncogenic genes 
CDK4 and MDM2 located within the minimal region of gain on chromosome 12 has been described 
for CLL harboring a partial or complete trisomy 12 an [433],[434]. Hence, it is conceivable that these 
genes may also play a role in mnBLL. The oncogenic properties of those two genes for BL in interplay 
with CCND3 activating mutations and CDKN2A inactivation have already been discussed in 4.1.3. 
Chromosome 6q was identified to be deleted in six mnBLL cases and in the Su-DHL-5 cell line. The 
minimal deleted region was defined as 6q14.3-q21. Chromosomal deletions affecting 6q have been 
described to occur in 25 to 70 % of mature B-cell lymphoma [229],[435],[436],[437]. The 6q deletion 
has been associated with a progression from low to high grade FL [438]. Moreover, Offit et al. [436] 
have identified a minimal region of molecular deletion in 6q21 which was mainly seen in high-grade 
NHL. Two known tumor suppressor genes are located within the minimal region defined for the 
mnBLL: EPHA7 and PRDM1. The ephrin receptor A7 (EPHA7) gene belongs to the family of receptor 
tyrosine kinases which control several physiological processes as adhesion or migration [439]. The 
tumor suppressive property of a truncated, soluble form of EPHA7 (EPHA7TR) has been recently 
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shown for FL [229],[440]. The knock down of EPHA7TR accelerated the development of lymphoma in a 
murine model of FL [229]. Upon binding of EPHA7TR to the EPHA2 receptor it acts as a dominant, 
soluble inhibitor of its oncogenic signaling in lymphoma cells [229],[441]. PRDM1 on the other hand, 
plays an important role in terminal B-cell differentiation as a transcriptional repressor of genes 
including AID and ID3 required for B-cell proliferation and affinity maturation [442]. Frequent 
inactivation of PRDM1 has been described in about 25 % of activated B-cell like DLBCL [443]. 
Pasqualucci et al. [443] suggested that the loss of PRDM1 contributes to the lymphomagenesis by 
blocking the terminal B-cell differentiation towards plasma cells. 
In 20 % of the mnBLL cases and in the Su-DHL-5 cell line a 0.2 Mb sized minimal region of gain was 
identified in 13q31.31 which encompassed the miR-17-92 locus. This locus is frequently amplified in 
BL [132],[231],[444] and associated with a higher expression of this oncomir [231],[445],[446]. The 
miR-17-92, encoding six individual miRNAs [447], has been described to have oncogenic functions in 
survival, proliferation and differentiation [448],[449],[450]. In a murine model overexpression of miR-
17-92 together with MYC led to an increased tumor development [451] supporting its role in BL 
lymphomagenesis. Furthermore, Olive et al. [452] have shown that overexpression of miR-17-92 
reduced the expression of PTEN which in turn increased PI3K/Akt signaling. As already discussed in 
4.1.3.1, the PI3K signaling pathway is one of the main oncogenic pathways deregulated in BL. 
Furthermore, the mnBLL have been shown to have a comparable PI3K activity index as BL [166] and 
based on the experiments conducted herein, the survival of the mnBLL cell lines seems also to 
depend on the PI3K signaling (4.2.4.5). Hence, it is conceivable, that the gain of miR-17-92 in mnBLL 
might contribute to the activation of the PI3K signaling. 
Finally, a chromosomal gain on 18q21.1 including the TCF4 gene was identified in 20 % of mnBLL and 
in the MLMA cell line. TCF4 is part of the Wnt/β-catenin signaling [453],[454] which has been 
described to play a role in various solid tumors as breast cancer or colorectal carcinoma 
[232],[455],[456]. TCF4 has been described to play a minor role in B-cell development in comparison 
to the other bHLH family member TCF3 [352]. Nevertheless, it has been shown that they share 
targets including pro-B-cell genes [365]. As already mentioned in 4.1.3.1, BL without ID3 mutation 
carried 18q gains, including the TCF4 locus, which was associated with a higher TCF4 expression 
[170]. Therefore, it is reasonable to speculate that TCF4 overexpression due to the 18q gains could 
constitute an alternative mechanism to activate for example PI3K signaling in mnBLL [72],[170] and, 
thus, contribute to its lymphomagenesis. 
To sum up, together with the hallmark alteration on 11q, several recurrent CNA have been identified 
in mnBLL with known tumor suppressor genes, as EPHA7 and PRDM1, as well as oncogenes, as CDK4, 
MDM2 and miR-17-92, mapping to these regions. Some of those CNA also occur in BL, hence, the 
deregulation of those genes might contribute to the pathogenesis of mnBLL by activating 
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tumorigenic mechanisms similar to those in BL. This might explain to some extent the BL-like 
phenotype.  
 
4.2.2 The mutational landscape of MYC-negative Burkitt-like lymphomas 
 
The analyses of the mutational landscape were dedicated to: (i) identification of recurrently mutated 
genes within the altered 11q region probably indicating roles as oncogenes or tumor suppressor 
genes and (ii) identification of recurrently mutated genes throughout the exome potentially 
cooperating with the 11q changes in the lymphomagenesis of mnBLL. The results of these analyses 
are discussed in the following. 
Screening of the 54 genes of the altered 11q region by next generation sequencing did not lead to 
the identification of recurrently mutated genes. Overall, only nine genes of this region were found 
sporadically mutated including ETS1 which maps to the focal homozygous deletion. Screening of the 
mnBLL cohort for ETS1 mutations by Sanger sequencing led to the identification of mutations in 25 % 
(4/16) of cases [166]. Moreover, some of the ETS1 mutations might be inactivating, although a 
modeling of the functional consequences yielded no conclusive results [166]. Case 8 harboring an 
ETS1 mutation has been also analyzed by targeted-resequencing. The MAF of this mutation is 0.56. 
As this case has only one remaining ETS1 allele due to the heterozygous deletion of the other, this 
MAF indicates a subclonal mutational event occurring during tumor progression. Furthermore, a 
germline mutation cannot be excluded. Thus, besides the mnBLL cases with homozygous deletion in 
11q, the cases with heterozygous deletion in 11q do not seem, at least on mutational level, an 
inactivation of the remaining allele. 
As FLI1 maps also to the focal homozygous deletion of the mnBLL, the remaining allele has been 
screened for inactivating mutations using Sanger sequencing [166]. But none of the mnBLL harbored 
a mutation within this gene which does not lend support to a tumor-suppressive function though 
haploinsufficiency cannot be excluded. 
The analyses of the complete exome revealed no recurrently mutated genes. This might be due to 
the fact that only whole-genome sequencing data were available for one case whereas the other 
cases were analyzed by targeted resequencing of solely a fraction of the genes of the complete 
exome. Thus, genes with recurrent mutations might be simply not yet identified in this analysis, 
leaving ETS1 as the sole recurrently mutated gene identified in the mnBLL up to now. 
 
4.2.3 The transcriptional landscape of MYC-negative Burkitt-like lymphomas 
 
To determine an expression signature specific for mnBLL, the gene expression data provided by the 
MMML project were compared to those of BL and DLBCL separately, focusing on the 54 genes of the 
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aberrant 11q region. By this approach, combining the data of both comparisons, eight genes were 
identified to be either higher or lower expressed in mnBLL. Furthermore, two genes (IL10RA, PRDM1) 
showed a particular higher differential expression in mnBLL than in BL. Thus, overall ten genes were 
differentially expressed in mnBLL relative to BL and DLBCL, however, only three (PAFAH1B2, IL10RA, 
FLI1) were described in the literature to be associated with lymphoma (3.2.3.1.3). The role of these 
three candidate genes for the pathogenesis of mnBLL will be discussed in 4.2.4. 
In the publication of the initial cohort of mnBLL, a global gene expression analysis has been 
performed and the differentially expressed genes between mnBLL and BL, as well as DLBCL were 
determined [166]. The six candidate genes (EPHA7, PRDM1, MDM2, CDK4, TCF4, mir-17-92) mapping 
to the regions of secondary alterations (4.2.1) were analyzed for differential expression between 
mnBLL and BL was well as mnBLL and DLBCL. Of note is that the mir-17-92 gene cluster is not covered 
by the U133A gene expression array, hence, its expression was not analyzable. The analysis of the 
remaining five genes revealed MDM2, located on chromosome 12q15, to be lower expressed in 
mnBLL than in BL (adj. p-value 0.045, t-test p-value corrected according to Benjamini and Hochberg). 
This finding seems contradictory as 24 % of mnBLL harbor a complete trisomy 12 and, thus, a higher 
expression of MDM2 in mnBLL in comparison to BL might be expected. But of note is that the gene 
expression analysis has been performed for six mnBLL (case 1, MPI-078, MPI-086, MPI-148, MPI-315, 
MPI-382). These six mnBLL cases do not harbor a trisomy 12 or other alterations affecting the MDM2 
locus. Hence, the detected lower MDM2 expression in mnBLL might simply reflect the fact that those 
cases do not harbor a chromosomal gain of the MDM2 locus. This might also hold true for the other 
four candidate genes (EPHA7, PRDM1, CDK4, TCF4) as not all mnBLL harbor all secondary CNA. Thus, 
for a proper conclusion, the gene expression of the candidate genes needs to be analyzed in those 
cases which harbor the respective secondary alteration. Furthermore, these secondary alterations 
detected in mnBLL have been described to be also frequently altered in BL as well as DLBCL (4.2.1). 
Hence, this might lead to false negative or false positive results in the gene expression analysis. 
Taken together, the transcriptome data are a further criterion to narrow down the list of potent 
candidate genes identified in the genomic and genetic analysis. But as the analyses are based on data 
from six mnBLL (6/25, 24 %), the possibility of false negative and false positive results needs to be 
considered.  
 
4.2.4 Possible candidate genes in MYC-negative Burkitt-like lymphomas 
 
In the following the role of the five possible candidate genes (KMT2A, PAFAH1B2, ETS1, FLI1 and 
IL10RA) for the pathogenesis of mnBLL are discussed. These genes were identified based on four 
different criteria: (1) localization within the minimal aberrant region in 11q, (2) differential 
expression, (3) recurrent mutations and (4) published association with lymphomagenesis. 
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4.2.4.1 Oncogenic role of KMT2A in MYC-negative Burkitt-like lymphomas 
 
The KMT2A gene maps to the minimal region of amplification in the mnBLL. In line with this, 
recurrent amplification of 11q23 including the KMT2A gene have been described in B-cell lymphomas 
like DLBCL [239],[245]. Moreover, up to 10 % of AML [457] or up to 13 % of ALL [458] carry a KMT2A 
rearrangement. As gene amplification is one of the mechanisms activating proto-oncogenes, it is 
conceivable that KMT2A has oncogenic properties in the mnBLL. 
KMT2A, former known as MLL, is a methyltransferase which is part of a multiprotein complex 
[459],[460]. It mediates chromatin remodeling and transcriptional activation via chromatin 
modifications like trimethylation of histone 3 lysine 4 (H3K4me3) [461]. Other functions for KMT2A 
have been described in the regulation of transcriptional initiation and elongation via the RNA 
polymerase II [462] or regulation of the S-phase checkpoint in the cell cycle [463]. KMT2A has been 
shown to be critical for proper hematopoiesis, as severe defects like reduced numbers of 
hematopoietic stem cells were observed in homozygous knockout mice, as well as in KMT2A-
depleted zebrafish [464],[465],[466].  
KMT2A is slightly higher expressed in mnBLL in comparison to BL and DLBCL, but this difference is not 
significant (adj. p-value >0.1) [166]. In line with this, the KMT2A expression analysis in the respective 
cell line subtypes showed a higher KMT2A expression in the mnBLL cell lines. However, this might be 
biased by the particular high expression in MLMA cells, which was four times higher than in the other 
two mnBLL cell lines.  
A higher KMT2A expression has been shown to be associated with an increased expression of 
downstream target genes [467],[468] indicating an aberrant transcription regulation [469]. To clarify 
if this might be also the case in mnBLL, the gene expression data need to be analyzed with regard to 
the expression of the KMT2A target genes in comparison to for example BL or DLBCL. 
In conclusion, the amplification of KMT2A is not strongly associated with a stark overexpression in 
mnBLL, which does not support the likeliness of this gene to be an essential oncogene in the mnBLL.  
 
4.2.4.2 Oncogenic role of PAFAH1B2 in MYC-negative Burkitt-like lymphomas 
 
PAFAH1B2 maps to the minimal region of gain of mnBLL. A disruption of this gene due to a 
translocation t(11;14)(q23;q32) has been described in a case with B-cell lymphoma, placing the 
coding sequence of PAFAH1B2 under the influence of IGH regulatory elements [236],[470]. This 
translocation exhibits similarities to the t(8;14)(q24;q32) in BL leading to a deregulation of the MYC 
gene, which is the hallmark and the driving force of this lymphoma. As the amplification of 
PAFAH1B2 in mnBLL led to an increased expression on mRNA and protein level, it is conceivable that 
PAFAH1B2 might be a driving force of mnBLL.  
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PAFAH1B2 is a catalytic subunit of the platelet activating factor acetylhydrolase (PAF-AH) [471] which 
hydrolyses the phospholipid mediator PAF [472]. The synthesis of PAF is induced upon inflammatory 
stimuli [473] and it mediates upon binding to the extracellular PAF receptor (PAFR) or by PAFR-
independent mechanisms a wide range of cellular functions including proliferation, differentiation 
and transformation [474],[475],[476]. Furthermore, regulatory activities for PAF in B-lymphocytes 
[477] have been described as treatment of B-cells or an BL cell line with PAF leads to a decreased 
proliferation [478]. In line with this, patients with lymphoid or non-lymphoid malignancies have been 
shown to harbor decreased levels of PAF [479]. Due to the higher PAFAH1B2 expression in the mnBLL 
it might be possible, that the processing and, hence, the level of PAF is decreased. Thus, this might 
contribute to the proliferative properties of the cells. In line with this, an anti-apoptotic function has 
been described for PAFAH1B2 due to the hydrolysis of PAF which has been described to induce by a 
PAFR-independent mechanism caspase-3-dependent apoptosis [250].  
Another oncogenic pathway of PAFAH1B2 might be via its interaction with ZFP36L1 which is 
frequently deregulated in other B-cell malignancies [325],[480],[481]. ZFP36L1 belongs to the family 
of tristetraprolins [482] which play a role in mRNA degradation and have been associated with tumor 
suppressive mechanisms [483]. ZFP36L has been described to locate next to the IGH locus due to a 
interstitial deletion in e.g. chronic lymphatic leukemia [480],[481] and to be hypermutated in DLBCL 
[325]. Thus, the interaction of PAFAH1B2 might lead to a negative regulation of ZFP36L1.  
Despite these published evidences, using knock down experiments in the mnBLL cell line Su-DHL-5 an 
essential role for this gene could not be confirmed. The loss of PAFAH1B2 did not reduce the cell 
viability under the tested experimental conditions. But as its function might be to protect from the 
negative influence of PAF, which was not part of the experimental setting, its true role in vivo might 
be missed under the applied experimental conditions. 
Taken together, a role for PAFAH1B2 as a driving force in the lymphomagenesis of mnBLL could not 
be confirmed. Nevertheless, it is conceivable that PAFAH1B2 contributes to the progression of the 
tumor by degradation of PAF and, hence, might maintain the proliferation and survival of the cells.  
 
4.2.4.3 Tumor suppressive role of ETS1 in MYC-negative Burkitt-like lymphomas 
 
ETS1 belongs to the family of ETS transcription factors [484]. The hallmark of these transcription 
factors is a conserved DNA-binding domain, called ETS domain, which interacts with a specific 
nucleotide sequence in the target genes containing a GGAA/T core sequence [485],[486].  
Functions for ETS1 in B-cell maturation and survival have been described as regulation of class-switch 
recombination [487] and BCR-signaling dependent S-phase entry [488]. Furthermore, ETS1 has been 
described to regulate the expression of PRDM1 [246] which inhibits PAX5. As PRDM1 is important for 
the plasmacytic differentiation [247], its inhibition mediated by ETS1 might contribute to the 
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regulation of B-cell maturation. Furthermore, ETS1 has been shown to be important for the 
transcriptional regulation of diverse cytokines like IL2 and IL10 in various lymphoid cells 
[489],[490],[491]. 
As already mentioned in 4.2.1, ETS1 is one of the few genes localized in the focal homozygous 
deletion, indicating a role as tumor suppressor gene in mnBLL. A tumor suppressive function for ETS1 
has been already proposed in Hodgkin lymphoma which were shown to harbor recurrent deletions of 
the ETS1 locus as well as frequent ETS1 mutations [248],[426]. According to Knudson´s two hit theory 
as described in 1.3.2 both alleles of a tumor suppressor need to be inactivated. Only two of the 25 
analyzed mnBLL harbored a homozygous loss of the ETS1 locus, whereas the majority showed a 
heterozygous loss. In addition, although mutations of ETS1 were detected in 25 % of mnBLL, those 
mutations were subclonal and modeling of a tumorigenic impact of the mutations was not conclusive 
[166]. Analyses of the mRNA and protein expression indicated that the second allele might be still 
active, as the ETS1 expression was comparable between mnBLL and BL as well as DLBCL, and in the 
respective cell line models. Hence, in contrast to the two mnBLL cases with the homozygous loss in 
11q, the other mnBLL cases as well as the mnBLL cell lines do not seem to have lost the ETS1 
expression and, thus, function. Consequently, an essential tumor suppressive role for ETS1 in mnBLL 
is unlikely. But it might be that co-deregulated genes of the 11q region might influence directly or 
indirectly the regulation of ETS1 function and contribute in this manner to the tumorigenicity of ETS1 
in mnBLL.  
 
4.2.4.4 Tumor suppressive role of FLI1 in MYC-negative Burkitt-like lymphomas 
 
FLI1 belonging to the family of ETS transcription factors [492] maps also to the focal homozygous 
deletion in 11q24.3. The FLI1 gene is localized 106 kb telomeric from ETS1 and it is thought that both 
genes arose from a common ancestor by gene duplication [492]. In line with this, both genes have 
been shown to target the same core consensus sequence within the target genes [493]. FLI1 is mainly 
expressed in the hematopoietic lineages including lymphocytes but also in a variety of other tissues 
[494]. It has been shown in a mouse model that loss of FLI1 expression leads to impaired B-cell 
development likely due to downregulation of PAX5 and TCF3, and overexpression of ID1 and ID2 
[495]. In line with this, FLI1 has been shown to build a complex with PAX5 and ETS1 in a murine B-cell 
line and, hence, regulate the transcription of CD79 by binding to its promoter [496]. Furthermore, 
different studies in erythroid cells have shown that FLI1 is a transcriptional activator of BCL2 [497], 
MDM2 [498] and miR-17-92 [499] expression, hence contributing to the survival and proliferation of 
these cells. In monocytes, FLI1 is a positive regulator of the expression of the IL10 cytokine [500]. 
Taken together, the expression of FLI1 in B-cells as well as in erythroid cells is important for the 
maturation and survival of the respective cells. 
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Since FLI1 maps to the focal homozygous deletion it might have tumor suppressive properties in 
mnBLL. On transcriptional level, mnBLL showed a significant lower FLI1 expression than BL and 
DLBCL. This holds also true for the respective cell lines on mRNA as well as on protein level. 
Interestingly, the DLBCL cell line Karpas422 which was dismissed as mnBLL cell line model based on 
the presence of the BCL2-translocation showed a reduced FLI1 expression. Analysis of the protein 
expression revealed, that the two FLI1 isoforms were differentially expressed between the 
lymphoma subtypes, indicating different mechanism of FLI1 translational control. In the mnBLL cell 
lines no FLI1 expression (HT and Su-DHL-5) or solely expression of the small isoforms (MLMA) was 
detectable. The BL cell lines on the other hand expressed both isoforms and the DLBCL cell lines 
expressed rather the smaller isoforms. Up to now it is still discussed if both isoforms have diverse 
functions [249],[501]. Thus, whether the different expression pattern of the FLI1 isoforms reflects 
different functions of FLI1 in the lymphoma subtypes is not clear.  
Remarkably, the mRNA expression of FLI1 was reduced in the mnBLL cell lines, whereas on protein 
level the expression was lost. Whether the primary mnBLL express FLI1 protein or not is not known. 
Nevertheless, it is conceivable that the FLI1 protein expression is lost in the primary mnBLL as in the 
mnBLL cell lines. The reason for the lack of FLI1 expression is yet unclear As the mnBLL cell lines as 
well as 23/25 mnBLL solely harbor a heterozygous loss of the FLI1 locus and the coding sequence of 
FLI1 is not frequently mutated,. A possible explanation might be an epigenetic regulation of the FLI1 
expression. A differential methylation of FLI1 in mnBLL in comparison to BL as well as DLBCL could 
not be detected (data not shown). The chromatin state of Su-DHL-5 cells and six other lymphoma cell 
lines including BL and DLBCL cell lines have been analyzed by Dr. med. Anke Bergmann, Institute of 
Human Genetics, Kiel within the European BLUEPRINT consortium and were kindly provided. Figure 
45 gives an overview on the chromatin states of the FLI1 locus in the cell lines. In general, the 
chromatin states were similar besides a block of repressed heterochromatin within the first intron in 
those cell lines with lack FLI1 expression (Su-DHL-5, Karpas422). This finding might indicate an 
epigenetic regulation of the remaining FLI1 allele in the mnBLL cell line.  
So far, FLI1 has been shown to harbor oncogenic functions in different malignancies, as in Ewing 
sarcoma which harbor a recurrent FLI1-EWS fusion [502] or in DLBCL which harbor recurrent FLI1 
amplification leading to an increased cell viability [239]. The mnBLL represent the first so far 
described malignancy in which FLI1 might have a tumor-suppressive function. This is in contrast to 
the functions of FLI1 in B-cell maturation and proliferation which point towards an oncogenic role in 
those cells. But as ETS1 and FLI1 share the consensus sequence of the target genes [493] and as they 
share some functions in the B-cell maturation and proliferation, it is conceivable that ETS1 might 
substitute for some of the FLI1 functions which are essential for the cell survival whereas those 
functions which are essential to be lost for the pathogenesis of the mnBLL are not substituted. 
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Figure 45: Chromatin states of the FLI1 locus in mnBLL (Su-DHL-5), BL (BL-2 and DG-75), DLBCL (Karpas422) cell lines and cell 
lines from three other B-cell malignancies (JCM-2, U-266, Z-138). Depicted are from the top to the bottom: scale bar in kb, 
genome base position in bp, the UCSC gene track showing all transcripts of the FLI1 gene (reading direction exon 1 on the 
left to last exon on the right) as well as the chromatin states of the respective cell lines. The chromatin states are 
represented by the following color code: black, repressed heterochromatin; grey, repressed promoter; blue, active 
promoter; red, regulatory element and green, transcribed region. Highlighted in blue is a block of repressed chromatin in 
the mnBLL cell line Su-DHL-5 and the DLBCL cell line Karpas422 in the first intron of FLI1 which might be associated with the 
loss of FLI1 expression. 
 
Taken together, FLI1 maps to a focal deletion and its expression is reduced in the mnBLL indicating a 
tumor suppressive role in the mnBLL. It is conceivable that due to the loss of FLI1 the transcription of 
some of its target genes becomes deregulated and, thus, contribute to an increased proliferation and 
survival of mnBLL cells. 
 
4.2.4.5 Contribution of IL10RA and IL10 signaling to pathogenesis of MYC-negative Burkitt-like 
lymphomas 
 
IL10RA was considered as a possible candidate gene, as it maps to the minimal region of 
amplification and is significantly higher expressed on mRNA level in mnBLL than in BL. 
IL10RA encodes the α-subunit of the IL10 receptor (IL10R). The receptor is formed upon binding of 
the cytokine IL10 to IL10RA which leads to a recruitment of IL10RB and, thus, establishment of the 
active receptor [503]. IL10R belongs to the class II cytokine receptor family consisting of 6 different 
receptor chains forming heterodimers [504]. IL10RA has been described to be constitutively 
expressed in most hematopoietic cells [505],[506], but also in non-hematopoietic cells. In the latter, 
its expression needs to be usually induced [507],[508]. IL10RB on the other hand is constitutively 
expressed in most cells and tissues [509]. So far, there has been no indication for an activation-
induced expression of IL10RB in immune cells [510].  
IL10 signaling has been described to have immunstimulatory and anti-inflammatory functions in 
immune cells. It regulates the immunomodulation by downregulation of pro-inflammatory cytokines 
[511],[512] and upregulation of cytokine antagonists like the interleukin 1 receptor antagonist 
[513],[514]. Moreover, it inhibits MHC II expression in antigen presenting cells [515]. Among the 
immunstimulatory functions is the induction of proliferation in B-cells [516] as well as the induction 
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of maturation and isotype switching [517]. A role for IL10 signaling by stimulation of growth and 
progression in B-cell lymphoma has been suggested in various studies [237],[518],[519]. 
Furthermore, studies of in vivo murine lymphoma models with inducible MYC expression have shown 
that high MYC expression down-regulates IL10RA. But when MYC is turned off again, IL10RA 
expression recovers and induces cell proliferation [520]. In other experiments it was demonstrated 
that lymphomas expressing high IL10RA levels have selective growth advantage over lymphomas 
expressing low IL10RA levels likely due to upregulation of the anti-apoptotic MCL1 protein [237]. 
Thus, IL10 signaling might represent an oncogenic stimulus in the mnBLL due to autocrine signaling 
as has been proposed for other B-cell lymphoma [521],[522]. 
To get a better overview on the components of the IL10 signaling, this pathway, depicted in Figure 
46, is shortly introduced in the following.  
 
 
Figure 46: Schematic overview on IL10 signaling. Upon binding of IL10 to its receptor, the tyrosine kinases JAK1 and TYK2 
become phosphorylated and activate STAT3, which translocates into the nucleus where it induces the expression of several 
genes including the anti-apoptotic genes BCL2 and BCL2L1 as well as SOCS3 which is a negative regulator of the IL10 
signaling. IL10 signaling inhibits NFκB leading subsequently to downregulation of pro-inflammatory cytokines. Furthermore, 
the PI3K-Akt pathway becomes activated inducing the growth and survival of the cells. 
 
Initially, IL10 binds to IL10RA which subsequent interacts with IL10RB to form the active IL10R [503]. 
This leads to the phosphorylation of the tyrosine kinases TYK2 and JAK1 which are bound to IL10RB 
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and IL10RA, respectively. Different pathways have been described to be induced afterwards. Of note 
is that most of the published analyses of IL10 downstream signaling pathways have been performed 
in monocytes and T-cells, but only rudimentarily in B-cells. Thus, it is not clear if all pathways are 
active in B-cells. Upon activation of JAK1 and TYk2, the transcription factor STAT3 becomes activated 
[523] and translocates into the nucleus where it regulates the expression of several genes including 
the anti-apoptotic genes BCL2 [524] and BCL2L1 [525]. Moreover, it regulates SOCS3 expression 
which is important for the negative feedback regulation of IL10 signaling [526]. Furthermore, IL10 
signaling has been described to inhibit NFκB activation [527] by either blocking of the nuclear 
translocation or inhibition of the DNA binding activity [528], hence regulating the expression of 
inflammatory cytokines [529]. A third pathway activated by IL10 signaling via activation of the Insulin 
receptor substrate 2 [530] is the PI3K-Akt pathway which is important for the proliferative but not for 
the inflammatory effects [251]. 
An initial step to determine an oncogenic role of the IL10 pathway in mnBLL in this thesis was the 
expression analyses of IL10RA and IL10 in the respective cell line models. On mRNA level, the IL10RA 
expression was highest in the mnBLL cell lines, whereas on protein level also four of the BL as well as 
two of the DLBCL cell lines showed expression levels comparable to the mnBLL cell lines. This 
suggests a post-transcriptional regulation of the IL10RA levels. Whether this acts via mRNA 
degradation or enhanced translation is not clear. Screening of the cell lines for IL10RA cell surface 
expression revealed a higher surface expression in BL cell lines than in mnBLL cell lines. Corinti et al. 
[531] have shown that mature dendritic cells selectively upregulated IL10RA mRNA but did not 
exhibit a higher surface expression. They attributed this effect to possible posttranslational 
modifications as negative feedback regulation to prevent abnormal IL10RA expression levels [531]. 
Although these studies have been performed in dendritic cells, it might be that in the mnBLL a similar 
mechanism is active. Alternatively, due to a higher IL10 abundance and consequently signaling, a 
higher rate of IL10R internalization might occur [532]. Another possibility is that due to receptor 
shedding IL10RA becomes soluble. So far, a soluble form of IL10RA in vitro has been not described. 
Nevertheless, the IL22 receptor, which also belongs to the class II cytokine receptor family of IL10, 
exists as a soluble form (IL22BP) [533]. Furthermore, it cannot be definitely excluded that the results 
of the protein expression analyses are prone to technical artifacts. The antibody used for the FACS 
analysis was raised against a recombinant soluble form of IL10RA whereas the antibody for the 
Western blot was raised against a central epitope within IL10RA. Thus, the efficiency and specificity 
of the antibodies might differ. In line with this, the analysis of the IL10RA expression in the BL-70 cell 
line lacked detectable expression in the Western blot whereas in the FACS analysis the cells exhibited 
the highest relative surface expression. This cell line had no mutations or structural alteration within 
the epitope recognized by the antibody used for Western blot analysis. Thus, the marked difference 
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in both experiments might be a result of an unspecific binding of the FACS antibody. Despite of these 
technical issues it can be stated that the expression of IL10RA was detectable in the mnBLL which is 
the crucial prerequisite for the IL10 signaling [534]. 
An elevated expression of IL10 was detectable on mRNA and protein level in two of the three mnBLL 
cell lines but not in the BL and DLBCL cell lines as well as in the mnBLL cell line HT. The lack of IL10 
expression in latter cell line might be due to intercellular viability. To analyze the IL10 levels in mnBLL 
serum was only available for case 10. Within the serum of mnBLL case 10 an average IL10 level of 
14 pg/ml was detected. Comparable levels of IL10 were detected in the serum of two patients with 
BL. In line with this, similar IL10 levels have been detected in various studies analyzing serum from 
patients with NHL and HL [535],[536],[537]. These studies showed an average IL10 level of 15-
21 pg/ml. These levels were elevated in comparison to those of healthy donors which showed 
average IL10 level of 10 pg/ml in serum [535],[537]. Although the applied IL10 ELISA assays in those 
studies differed from the one used in this thesis, the IL10 level of 10 pg/ml in healthy donors might 
be a good reference value for the mnBLL case. Hence, the mnBLL case showed also a slightly higher 
IL10 level. Interestingly, the increased IL10 levels in the NHL and HL patients were associated with 
shorter failure-free survival [537],[538].  
The high IL10 expression in mnBLL cannot be explained by genomic, genetic or epigenetic alterations. 
Nevertheless, its expression is also regulated by a variety of transcription factors [539],[540]. 
Moreover, in different cell types the regulating network possibly varies [541]. As already mentioned, 
the transcription factors ETS1 and FLI1 have been shown in various studies to regulate IL10 
expression [500],[542],[543]. In those studies IL10 was negatively regulated by ETS1 in T cells but 
positively in monocytes. FLI1 was described as a positive regulator of IL10 expression in monocytes. A 
further indication for an ETS family regulated IL10 expression in B-cells comes from a study by 
Bonetti et al. [239]. They have shown that knock down of FLI1 led to increased expression of IL10 in a 
DLBCL cell line. Thus, the combination of gain and loss in 11q might contribute directly in cis to the 
upregulation of the IL10R subunit IL10RA and indirectly in trans to the upregulation of IL10  
To further stratify a possible role for IL10 signaling in mnBLL, single components of the pathway were 
inhibited herein. Figure 47 gives an overview on the possibility of therapeutic interaction and 
possible oncogenic mechanism conferred by IL10 signaling in mnBLL as outlined in the following. 
Blocking of IL10RA using two neutralizing antibodies resulted in opposing effects. One antibody 
reduced the cell viability not only of the mnBLL cell line (Su-DHL-5) but also of the BL cell line (BL-2). 
This might reflect either that the antibody has unspecific side effects or that both cell lines need the 
IL10 signaling for survival. Nevertheless, the latter is contradicted by the finding that the BL-2 cells do 
not show reduced cell viability upon treatment with the neutralizing IL10 antibody. Thus, the 
observed effects of the IL10RA blocking in BL-2 cells are more likely side effects. 
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Figure 47: Overview on the possibility of therapeutic interaction and possible oncogenic mechanism conferred by IL10 
signaling. The alpha subunit of the IL10 receptor (IL10RA) is overexpressed in the mnBLL which might lead to an 
overrepresentation on the cell surface. The expression of the IL10R ligand IL10 might be negatively regulated by ETS1 or 
FLI1 which map to the minimal region of homozygous loss. In mnBLL the expression of FLI1 is lost, indicating a loss of 
transcriptional regulation of IL10. A higher expression of IL10 might lead to an autocrine activation of the IL10 receptor. 
Activation of the receptor leads to the phosphorylation of the kinases JAK1 and TYK2 which subsequently activate survival 
and growth pathways via the STAT3 and PI3K signaling. Different components of the pathway were inhibited to analyze the 
dependency of mnBLL cell lines on IL10 signaling which are indicated by blue boxes. 
 
Treatment of the BL, DLBCL and mnBLL cell lines with IL10 neutralizing antibody points towards a 
dependency of the mnBLL cell line Su-DHL-5 on IL10 signaling. The viability of Su-DHL-5 cells was 
reduced to 10 % after treatment with high doses whereas BL and DLBCL cell lines showed no or only 
slight reduction. Oddly, treatment of the other two mnBLL cell lines HT and MLMA with the 
neutralizing IL10 antibody did not reduce their cell viability, although MLMA cells expressed IL10 at 
high levels. Again this might point towards intercellular variability and hence, the survival of the 
MLMA cells might not solely depend on IL10 signaling as the Su-DHL-5 cells. Furthermore, this 
indicates that IL10 signaling might not be the sole unifying mechanism in the mnBLL. 
IL10 signaling can activate the PI3K pathway [251]. Indeed, in mnBLL the PI3K signaling activity index 
was shown to be similar to that in MYC-positive BL [166]. As already described the activation of this 
pathway is important for the survival of BL [72],[133]. Therefore in this thesis, the PI3K pathway was 
inhibited in vitro using the PI3K class IA specific inhibitor called BKM120. This inhibitor has already 
been used in several clinical trials [252],[416]. As already mentioned in 4.1.3.1 the BL cell lines 
showed reduced cell viability which was in line with the findings reported by Schmitz et al. [72]. From 
the technical side of view this indicates appropriate experimental conditions upon treatment with 
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BKM120. All three mnBLL cell lines also showed reduced cell viability after treatment with BKM120 
suggesting that the PI3K pathway plays also an important role in mnBLL. Nevertheless, as the PI3K 
pathway is activated by various stimuli including BCR signaling as summarized in 1.3.4, these results 
are not a clear indicator for an IL10 dependent activation of PI3K in mnBLL. In spite of this, the 
finding that the mnBLL seem to dependent as the BL on PI3K activity might be a further cause for the 
Burkitt-like phenotype of mnBLL. Moreover, independent of the underlying mechanisms of activation 
of PI3K signaling, the responsiveness of the mnBLL cell lines to BKM120 suggests that this compound 
might be valuable in an anti-tumoral therapy approached in patients with mnBLL. 
During the writing of this thesis Béguelin et al. [544] described a deregulated IL10 signaling in DLBCL 
due to frequent genomic amplifications and overexpression of the IL10R subunits as well as of IL10. 
They suggested that, due to the deregulation of IL10R and IL10, an IL10-dependent auto-stimulatory 
loop is activated and, thus, by IL10 induced STAT3 signaling the proliferation and survival of the 
DLBCL cell is induced [544]. As described above, phosphorylated STAT3 regulates, after translocation 
into the nucleus, the expression of several target genes. Moreover, recent studies have shown that 
also unphosphorylated STAT3 can translocate into the nucleus and activate transcription of its target 
genes [545],[546]. Remarkably, STAT3 can induce its own expression upon binding to its own 
promoter [547]. Investigation of the available U133A gene expression data revealed that the STAT3 
mRNA levels were significant higher in mnBLL than in comparison to BL (adjusted p-value 7.02x106, t-
test p-value corrected according to Benjamini and Hochberg) whereas STAT3 was significant lower 
expressed in mnBLL than in DLBCL (adjusted p-value 0.03, t-test p-value corrected according to 
Benjamini and Hochberg). The latter might reflect the finding that activated B-cell like DLBCL have 
been reported to harbor elevated levels of STAT3 contributing to the pathogenesis of this lymphoma 
[548],[549]. Nevertheless, the mnBLL showed in comparison to BL elevated STAT3 levels which might 
reflect an IL10 signaling induced STAT3 activation and, thus, STAT3 expression. Whether STAT3 
signaling is activated in mnBLL and, hence, confers oncogenic signals to the mnBLL cells needs to be 
further investigated. 
Taken together, based on the functional analyses performed in the mnBLL an oncogenic role for IL10 
signaling is conceivable as (i) IL10RA is higher expressed in mnBLL than in BL, (ii) IL10 is highly 
expressed in mnBLL indicating a possible autocrine signaling, (iii) the PI3K pathway activity index is in 
mnBLL similar to BL which highly dependent on its signaling for survival, (iv) inhibition of PI3K 
signaling in vitro led to a complete loss of cell viability in mnBLL cell lines. Further experiments need 
to be performed to investigate the mechanisms and its potential to targeted intervention. 
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4.2.5 Summary of the analyses of MYC-negative BL-like lymphomas 
 
By a combination of genomic, genetic, expression and functional studies a set of candidate genes 
possibly harboring a tumorigenic role in mnBLL pathogenesis was identified. The complex alteration 
on 11q is the hallmark of mnBLL. Several of the genes mapping to this region are deregulated and 
might contribute to the pathogenesis of mnBLL by cooperating with other oncogenes and/or tumor 
suppressor genes of the same region or of the other recurrently altered region. Figure 48 gives a 
schematic overview on the candidate genes and their potential tumorigenic functions in mnBLL. 
 
 
Figure 48: Schematic overview on potential candidate genes and their potential roles in mnBLL. Based on recurrent 
genomic alteration (white outer circle) various candidate genes have been identified (dark grey circle). Some of this 
candidate genes show a differential expression in the gene expression analysis which was also confirmed in the mnBLL cell 
line panels (middle grey circle). Based on the function of the gene, published association with B-cell lymphomas or even 
functional experiments performed within this thesis, a possible tumorigenic function of the candidate genes was suggested 
(light grey circle). Based on the study of the literature some of the candidate genes might interact or regulate each other as 
indicated by dashed lines.   
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4.3 Comparison of MYC-positive Burkitt lymphoma and MYC-negative Burkitt-like 
lymphoma 
 
Based on the pathological and molecular features mnBLL resemble BL rather than DLBCL This led to 
their naming as “High grade B-cell lymphoma with features of BL, MYC-, with 11q-gain/loss pattern” 
[166]. In line with these findings, initial analyses of the methylation landscape confirmed that the 
mnBLL are more similar to BL than to DLBCL (Wagener and Ammerpohl, unpublished data). Different 
hypotheses exist to explain this similarity: (i) the altered 11q region harbors a gene with MYC-like 
properties, (ii) similar (signaling) pathways are deregulated or (iii) both lymphoma subtypes derive 
from the same cell of origin. In the following, based on all available data the three hypotheses will be 
discussed. 
None of the genes mapping to the altered 11q region have been described to be such a potent, 
general amplifier of the active transcriptional program of a cell like MYC. The finding that the mnBLL 
do not harbor such a potent deregulated MYC-like gene is further supported by the higher genomic 
complexity in contrast to BL. Thus, mnBLL harbor up to 24 CNA in addition to the 11q alteration. This 
indicates the necessity of mnBLL to acquire more alterations to induce malignant transformation in 
contrast to primary BL. In BL the deregulation of MYC is already such a crucial alteration that only 1-2 
additional CNA [170],[427] are required for full blown lymphomagenesis. Of note is that 64 % of the 
mnBLL harbored at least one of the four recurrent alterations as defined in 3.2.1.2. Remarkably, the 
spectrum of CNA identified in mnBLL is similar to that found in BL [131],[132] suggesting for similar 
tumorigenic mechanisms. In line with the chromosomal alterations, analysis of the mutational 
landscape does also suggest for more complex transformation mechanism in mnBLL than in BL. BL 
harbor frequent mutations within a core set genes like ID3, CCND3, TP53 and SMARCA4 leading 
subsequent to a deregulation of pathways already described in 4.1.3.4. In contrast, none of the 
analyzed mnBLL harbored a mutation within those core genes. Thus, the lack of a deregulated MYC-
like gene in mnBLL might be reflected by the necessity to acquire more alterations for full blown 
lymphomagenesis. 
It is highly probable that the Burkitt-like phenotype of mnBLL is due to the shared deregulation of the 
PI3K signaling which has been shown to be essential for BL (4.1.3.1). In the publication of the initial 
cohort, a PI3K activity index in mnBLL comparable to that in BL has been described [166]. This could 
be linked in subsequent analyses performed in this thesis to a deregulated IL10 signaling in mnBLL. 
Further experiments need to be performed to confirm the association of increased IL10 signaling 
with a higher PI3K signaling and, hence, as the essential oncogenic pathway in mnBLL. 
MnBLL harbor a germinal center B-cell like gene expression signature [166]. The germinal center can 
be divided into the dark and light zone. Based on gene expression signatures derived from cells of 
these zones, BL and DLBCL were shown to harbor similarities with the cells of the dark and light zone, 
respectively [68]. To unravel from which zone the mnBLL might derive, we applied the same 
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approach as published by Victora et al. [68]. The analyses performed by Dr. Maciej Rosolowski, 
Institute for Medical Informatics, Statistics and Epidemiology, Leipzig, indicate that the mnBLL might 
also derive from dark zone B-cells. This further supports an association between the Burkitt-like 
phenotype in mnBLL and the shared cell of origin with BL.  
Taken together, on genomic and genetic level the mnBLL show marked differences which are likely 
attributed to a more complex pathogenic mechanism. The findings that the mnBLL do also depend on 
PI3K signaling for survival and that they probably have a common cell of origin might cause the 
Burkitt-like phenotype of mnBLL. 
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4.4 Conclusions 
 
The analyses of this thesis focused on two mature aggressive B-cell lymphoma subtypes: MYC-
positive Burkitt lymphoma and MYC-negative Burkitt-like lymphoma. In the following the major 
observations of this thesis are summarized for each lymphoma subtype. 
Conclusion from the analyses of MYC-positive Burkitt lymphoma: 
• The PluriTest algorithm showed a higher similarity of BL to hPSC than of non-BL. Nevertheless, an 
origin of BL from or resemblance to cells with PSC features could not be established.  
• The transcription of the newly identified exon of the TERT gene could either be a mechanism to 
negatively regulate the TERT expression or function, or the truncated proteins might contribute to 
the wildtype TERT function. 
• Analyses of the mutational landscape of the BL cell lines demonstrated the resemblance of the BL 
cell line models with the primary BL. Thus, the cell lines seem to be appropriate in vitro models for 
functional analyses 
• Analyses of the mutational landscape in primary BL and BL cell lines led to the identification of 
recurrently mutated candidate genes potentially contributing to the lymphomagenesis: 
- Inactivation of the ID3 tumor suppressor contributes to subsequent deregulation of the TCF3-
BCR-PI3K pathway. This deregulation in combination with IG-MYC translocation is crucial for 
the pathogenesis of BL. 
- The frequent mutations in the catalytic domain of SMARCA4 likely have a dominant negative 
effect. Hence, SMARCA4 might also be a potential tumor suppressor in BL. 
- PCBP1 harbors frequent mutations affecting the KH III domain and/or NLS likely leading to a 
reduction or even loss of function. 
Conclusion from the analyses of MYC-negative Burkitt-like lymphoma: 
• Characterization of the altered 11q region of all 25 mnBLL led to a redefinition of the minimal 
region of loss and the included minimal region of homozygous loss. Moreover, recurrent 
secondary alterations affecting 6q, 13q and 18q as well as a complete trisomy 12 were identified. 
Each region harbored potential tumorigenic candidate genes. 
• Integrative analysis of the chromosomal, mutational and transcriptional landscape of the altered 
11q region as well as a comprehensive literature search led to the identification of three potential 
oncogenes (IL10RA, KMT2A and PAFAH1B2) and two potential tumor suppressor genes. 
• By interplay of IL10RA and possibly FLI1/ETS1 induced IL10 deregulation, an autocrine IL10 
signaling loop might be activated which subsequently induces the oncogenic PI3K pathway. Thus, 
the deregulation of IL10 signaling might be a key oncogenic pathway in mnBLL.  
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4.5 Perspectives 
 
After identification of several potential candidate genes in MYC-positive Burkitt lymphoma and MYC-
negative Burkitt-like lymphoma within this thesis, the next step should be the extensive investigation 
of their mechanisms of action using functional analyses in the here identified cell line models. 
For instance, to elucidate if the mutations within the ATPase domain of SMARCA4 have indeed a 
dominant negative effect on the transcription of its target genes, a CRISPR-Cas system [550] could be 
used to induce side-directed mutations within SMARCA4. By subsequent chromatin 
immunoprecipitation (ChIP) the binding of the protein encoded by either wildtype or mutated 
SMARCA4 to its target genes could be determined. 
The PCBP1 mutations likely lead to a loss of the KH III domain and/or NLS domain which might impair 
its function through cytoplasmatic retention. To investigate this in more detail the cellular expression 
of PCBP1 in PCBP1 mutated and wildtype cell lines as well as the primary BL could be analyzed using 
immunefluorescence. 
The transcription of the new exon of TERT might have different impacts on the protein function 
either leading to translation of an altered protein or NMD. To elucidate if a truncated protein is 
indeed translated from the alternative transcript, the translation of this transcript could be analyzed 
using in vitro translation assays. Furthermore, to elucidate if the transcript is expressed in vivo a 
specific antibody needs to be engineered to detect particularly the alternative protein e.g. in 
Western blot. In a next step the function of this alternative transcript could be analyzed using e.g. 
RNA interference assays. To study whether the alternative transcript is subjected to NMD, inhibition 
of the NMD machinery using specific compounds like caffeine or emetine [551],[552] in cell lines 
expressing this transcript could be performed. Afterwards, the abundance of the transcript could be 
quantified using qPCR. 
The description of the features of the new lymphoma subtype mnBLL is based on overall 25 cases. 
Thus, the aim of future studies needs to be the recruitment of further cases to get an even better 
overview on the chromosomal and mutation landscape as has already been started within this thesis. 
Furthermore, analyses of the methylation landscape might help to identify potential 
pathomechanisms contributing to its lymphomagenesis as has been published for other B-cell 
lymphomas [553]. The deregulated IL10 signaling pathway has been identified as a potential 
oncogenic pathway in mnBLL. To further investigate its role in mnBLL, the activation by 
phosphorylation of downstream components like the IL10 receptor associated tyrosine kinases JAK1 
and TYK2 using specific phospho-antibodies could be analyzed. Furthermore, in addition to the PI3K 
inhibition, further components of the pathway upstream of PI3K like e.g. JAK1 and TYK2 need to be 
specifically inhibited. The basis for the autocrine signaling is the expression of the ligand, IL10, which 
might be regulated by FLI1 and/or ETS1. Thus, the physical interaction of those transcription factors 
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with the IL10 gene locus could be analyzed using ChIP. Depending on the results, two different 
functional strategies might be applied to analyze if the IL10 expression is indeed regulated by those 
two transcription factors: (i) re-expression of the FLI1/ETS1 in the mnBLL cell lines and/or (ii) 
downregulation of FLI1/ETS1 in a cell line by RNA interference or usage of specific compounds as 
have been described for FLI1 [554], followed by quantification of the IL10 levels using IL10 ELISA. 
Taken together, after identification and description of potential functional relevant candidate genes 
in this thesis, the subsequent elucidation of their tumorigenic role in the lymphomagenesis of BL and 
mnBLL might help to understand their relevance for these lymphomas and, thus, their future 
suitability as potential specific therapeutic targets for the respective lymphoma subtypes. 
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5 Summary 
 
Burkitt lymphomas (BL) account for about 25 % of the mature B-cell lymphomas in childhood. The 
hallmark of BL is the chromosomal translocation t(8;14)(q24;q32), juxtaposing the MYC gene to the 
immunoglobulin (IG) heavy chain locus, or one of its light chain variants. These translocations result 
in overexpression of the oncogenic transcription factor MYC. However, the IG-MYC translocation 
alone is not sufficient to drive lymphomagenesis. Additional alterations are necessary for malignant 
transformation like mutations within CCND3 or TP53. In addition to MYC-positive BL, the existence of 
a subset of MYC-negative B-cell lymphoma resembling BL has been recently described. This 
lymphoma subset has been termed MYC-negative Burkitt-like lymphoma (mnBLL) and is 
characterized by a recurrent pattern of centromeric gain and telomeric loss on chromosome 11. 
The aims of this thesis were the identification and characterization of secondary genetic alterations 
in BL contributing to its lymphomagenesis. Moreover, BL should be investigated for traces of 
pluripotency as MYC is one of four reprogramming factors able to induce pluripotency in somatic 
cells. With regard to mnBLL, the aim of this thesis was the thorough description of the chromosomal, 
mutational and transcriptional landscape of these lymphomas in order to identify potential candidate 
genes contributing to its lymphomagenesis, which further should be functionally characterized. 
The analyses of BL were performed using 51 primary BL of the MMML cohort, which contains more 
than 800 molecularly characterized B-cell lymphomas, and of the ICGC MMML-Seq cohort. From the 
latter cohort, data from whole-genome and RNA-sequencing were available. Moreover, 25 mnBLL 
were analyzed of which 8 were newly recruited within this thesis. In addition, a panel of 23 B-cell 
lymphoma cell lines (16 BL, 3 mnBLL and 6 diffuse large B-cell lymphoma cell lines) was used for 
mutational screening and functional analyses. A variety of techniques was used to study the 
chromosomal (OncoScan DNA array, SNP 6.0 array), mutational (whole-genome, whole-exome and 
targeted re-sequencing, Sanger sequencing) and transcriptional (qPCR, Western blot, flow cytometry, 
IL10 ELISA, PluriTest) landscapes of BL and mnBLL as well as of the respective cell line models. 
Furthermore, the cell lines were used for various functional analyses including cell cycle and viability 
assays, gene knock down using lentiviral shRNA vectors or inhibition of IL10 signaling components 
using neutralizing IL10RA and IL10 antibodies as well as the PI3K inhibitor BKM120. 
Application of the PluriTest algorithm on gene expression data of 221 mature aggressive B-cell 
lymphomas demonstrated that BL showed a higher similarity to pluripotent stem cells (PSC) than 
non-BL. Nevertheless, an origin from or resemblance to cells with PSC features could not be 
established for BL. Analyses of the transcriptome of the BL led to the identification of a new, so far 
not described exon within the TERT gene. The expression of this new exon was verified in 11/11 BL 
cell lines and in 7/8 primary BL. Modeling of the impact of the new exon on the TERT reading frame 
revealed that either (i) N- or C-terminal truncated proteins might be translated or (ii) the transcript 
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might be subjected to nonsense-mediated decay due to the introduction of a premature stop codon. 
Analyses of whole-genome sequencing data of BL and mutational screening of BL cell lines by Sanger 
sequencing led to the identification of frequently mutated genes so far not described in association 
with Burkitt lymphomagenesis. Hence, ID3 mutations were identified in 35/53 (68 %) BL and 8/12 
(67 %) BL cell lines. Re-expression or overexpression of ID3 in BL cell lines induced the amount of cells 
in the pre-G1-phase as analyzed by cell cycle analysis, hence, further supporting the tumor 
suppressive function of ID3 in BL. Furthermore, 9/21 (43 %) BL and 2/16 (13 %) BL cell lines were 
shown to carry SMARCA4 mutations. 62 % of these mutations affected the catalytic domain. Lastly, in 
6/45 (13 %) BL and 6/16 (38 %) BL cell lines PCBP1 mutations were identified which might lead to a 
cytoplasmatic retention and, hence, reduced function. 
Analysis of the copy number data determined in all 25 mnBLL led to a redefinition of the minimal 
region of loss in 11q which includes a minimal region of focal homozygous loss of 1.5 Mb. Moreover, 
recurrent, secondary alterations in mnBLL affected 6q, 13q, 18q and 12p-q. Each of these altered 
regions harbored potential pathogenically relevant candidate genes. Furthermore, mutations of ETS1 
mapping to the region of loss in 11q were identified in 4/16 (25 %) mnBLL. Combining the results of 
the analyses of the chromosomal and mutational landscape with transcriptome data of 6 mnBLL 
provided by the MMML network project, and literature search led to the identification of 3 potential 
oncogenes (IL10RA, PAFAH1B2, KMT2A) and two potential tumor suppressor genes (ETS1, FLI1) in the 
altered 11q region. The expression profiles of these candidate genes were also analyzed in the mnBLL 
cell line models and were in agreement with those in the primary cases. Knock down analysis of 
PAFAH1B2 in a mnBLL cell line did not indicate an essential role of the PAFAH1B2 protein for the 
viability of the cells under the applied conditions. However, expression analysis of IL10 and IL10RA as 
well as inhibition of the IL10 signaling pathway components IL10, IL10RA and PI3K in B-cell lymphoma 
cell lines led to the identification of the IL10 signaling as a potential oncogenic signaling pathway in 
mnBLL. Hence, due to the interplay of IL10RA and FLI1/ETS1-induced IL10 deregulation, an autocrine 
IL10 signaling loop might be activated inducing PI3K signaling. The latter has been described as an 
oncogenic signaling pathway in BL. 
Taken together, the analyses performed in this thesis led to the identification of secondary 
alterations likely contributing to the lymphomagenesis of BL. Moreover, the investigations led to a 
detailed characterization of MYC-negative mnBLL on chromosomal, mutational and transcriptional 
level resulting in the identification of potential candidate genes. Thus, the results of this thesis 
provide novel insights into the pathogenetic mechanisms contributing to lymphomagenesis and, 
hence, may help to improve diagnostics and therapy of these mature aggressive B-cell lymphomas of 
childhood. 
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6 Zusammenfassung 
 
Ungefähr 25 % der reifzelligen B-Zelllymphome bei Kindern sind Burkitt Lymphome (BL). 
Charakteristisch für BL ist die chromosomale Translokation t(8;14)(q24;q32) oder eine ihrer 
Varianten. Durch diese gelangt das MYC Onkogen unter die Kontrolle der regulatorischen Einheiten 
des Immunglobulin Schwereketten oder eines der Leichtketten Gene, was zur Deregulation des 
Transkriptionsfaktors MYC führt. Die MYC Translokation reicht jedoch für die maligne Transformation 
nicht aus. Vielmehr sind sekundäre Veränderungen für die Entstehung eines BL notwendig, wie 
Mutationen in den Genen CCND3 oder TP53. Kürzlich konnten auch BL-ähnliche MYC-negative B-
Zelllymphome (mnBLL) identifiziert werden. Charakterisiert sind diese mnBLL durch einen Zugewinn 
des zentromeren und einen Verlust des telomeren Bereichs des langen Arms von Chromosom 11. 
Ziele dieser Arbeit waren die Identifizierung und Charakterisierung von sekundären genetischen 
Veränderungen, die zu der Entstehung des BL beitragen. Außerdem sollten BL auf Anzeichen von 
Pluripotenz untersucht werden, da MYC einer von vier Faktoren ist, die Pluripotenz in somatischen 
Zellen induzieren können. Zudem sollten mnBLL umfassend im Bezug auf chromosomale, genetische 
und transkriptionelle Veränderungen charakterisiert werden, um potentielle Kandidatengene zu 
identifizieren, die zur Entstehung dieser Lymphome beitragen. Diese Kandidatengene sollten 
funktionell charakterisiert werden. 
Für die Analyse der BL standen insgesamt 51 primäre BL aus den ICGC MMML-Seq und MMML 
Kohorten zur Verfügung, wobei letztere insgesamt mehr als 800 molekular charakterisierte B-Zell-
Lymphome umfasst. Für einige Fälle der ICGC MMML-Seq Kohorte waren zudem Gesamtgenom- und 
RNA-Sequenzierungsdaten verfügbar. Für die Charakterisierung der mnBLL wurden 25 Fälle 
untersucht, von denen 8 im Rahmen dieser Arbeit identifiziert wurden. Mutations- und funktionelle 
Analysen zu Kandidatengenen wurden an bis zu 23 B-Zell-Lymphom Zelllinien (ZL) (ZL: 16 BL, 3 mnBLL 
und 6 diffus-großzellige B-Zell-Lymphome) durchgeführt. Mit Hilfe verschiedener Methoden wurden 
chromosomale (DNA-Array: OncoScan, SNP 6.0), genetische (Gesamtgenom-, Gesamtexom-, Re- und 
Sanger Sequenzierung) und transkriptionelle (qPCR, Western Blot, IL10 ELISA, PluriTest, Durchfluss-
zytometrie) Veränderungen in BL, mnBLL und den entsprechenden ZL untersucht. Zudem wurden 
funktionelle Analysen an ZL durchgeführt, wie z.B. Zellzyklus- und Zellviabilitätsuntersuchungen, 
knock down mittels lentiviraler shRNA Vektoren sowie Inhibition von Komponenten des IL10-
Signalwegs mit neutralisierenden IL10- und IL10RA- Antikörpern und dem PI3K-Inhibitor BKM120. 
Für die Pluripotenz-Analyse der BL wurden Genexpressionsdaten von 221 reifzelligen, aggressiven B-
Zelllymphomen mittels PluriTest ausgewertet. Dabei wurde gezeigt, dass BL den pluripotenten 
Stammzellen (PSZ) ähnlicher sind als Nicht-BL. Eine Abstammung bzw. Ähnlichkeit der BL mit PSZ-
ähnlichen Zellen konnte jedoch nicht nachgewiesen werden. Im Rahmen der Analyse der 
Transkriptomdaten der BL konnte ein neues, bisher nicht beschriebenes Exon des TERT Gens 
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identifiziert werden. Dessen Expression wurde in 11/11 BL ZL und in 7/8 primären BL validiert. 
Vorhersagen über den Einfluss des neuen Exons auf das Leseraster des TERT Gens ergaben, dass 
entweder (i) C- oder N-terminal trunkierte Proteine translatiert oder (ii) aufgrund eines vorzeitigen 
Stopcodons Transkripte durch nonsense-mediated decay degradiert werden. Durch die Auswertung 
der Gesamtgenomsequenzierung der BL sowie durch gezielte Sanger Sequenzierung konnten häufig 
mutierter Gene identifiziert werden, die bisher nicht in Zusammenhang mit BL beschrieben wurden. 
So konnten ID3 Mutationen in 35/53 (68 %) BL sowie in 8/12 (67 %) BL ZL nachgewiesen werden. In 
Übereinstimmung mit einer tumorsuppressiven Rolle von ID3 wurden in Zellzyklusanalysen in BL ZL 
nach ID3 Re- bzw. Über-Expression vermehrt Zellen in der pre-G1 Phase nachgewiesen. Mutationen 
im SMARCA4 Gen wurden in 9/21 (43 %) BL und in 2/16 (13 %) BL ZL identifiziert. Bei 62 % der 
Mutationen ist die katalytische Domäne des Proteins betroffen. Mutationen in PCBP1 konnten in 
6/45 (13 %) BL und 6/16 (38 %) BL ZL identifiziert werden. Diese könnte zu einer zytoplasmatische 
Retention führen und somit zu einer eingeschränkten Funktion. 
Nach Analyse der chromosomalen Veränderungen aller 25 mnBLL wurde die Größe der minimalen 
Verlustregion in 11q und einer darin enthaltenen 1,5 Mb großen fokalen homozygoten Deletion 
eingegrenzt. Außerdem wurden wiederkehrende, sekundäre Imbalancen in den Regionen 6q, 13q, 
18q und 12p-q und die darin enthaltenen potentiell pathogen relevanten Kandidatengene 
identifiziert. In 4/16 (25 %) mnBLL wurden Mutationen des ETS1 Gens in der Verlustregion in 11q 
detektiert. Durch eine kombinierte Auswertung der Expressionsdaten von sechs mnBLL, der 
chromosomalen und genetischen Veränderungen der 11q Region sowie eine Literaturrecherche 
konnten drei potentielle Onkogene (IL10RA, PAFAH1B2, KMT2A) und zwei potentielle 
Tumorsuppressorgene (ETS1, FLI1) identifiziert werden. Deren Expressionsprofile in mnBLL ZL waren 
vergleichbar mit denen der primären mnBLL. Für PAFAH1B2 konnte durch knock down Experimente 
keine essentielle Rolle für die Viabilität von mnBLL Zellen nachgewiesen werden. Jedoch zeigen 
Expressionsanalysen von IL10 und IL10RA, sowie die Inhibition von IL10RA, IL10 und PI3K, dass durch 
das Zusammenspiel von IL10RA- und FLI1/ETS1-induzierter IL10-Überexpression ein autokriner IL10 
Signalweg aktiviert werden könnte, der den bereits bei BL als onkogen bekannten PI3K Signalweg 
aktiviert. 
Zusammengefasst haben die hier durchgeführten Analysen zur Identifizierung von sekundären 
Veränderungen geführt, die möglicherweise zur Entstehung der BL beitragen. Außerdem wurden 
mnBLL umfassend auf chromosomaler, genetischer und transkriptioneller Ebene charakterisiert, 
wodurch potentielle Kandidatengene für deren Pathogenese identifiziert wurden. Somit tragen die 
Ergebnisse dieser Arbeit zu einem breiteren Verständnis der pathogenen Mechanismen bei, die zur 
Entstehung dieser B-Zelllymphome führen. Diese Ergebnisse können in Zukunft zur Verbesserung der 
Diagnostik und Therapie dieser Lymphome beitragen. 
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8 Appendices 
8.1 Characteristics of B-cell lymphomas cases of the ICGC MMML-Seq cohort  
 
Table S 1 gives on overview on characteristics of the patients with BL, Burkitt leukemia or DLBCL of 
the ICGC MMML-Seq cohort as well as on the respective analyses they were subjected to. 
S 1: Overview on BL and DLBCL cases of the ICGC MMML-Seq cohort used in this thesis for different analysis. 
Case 
Age 
(yrs) 
Sex Diagnosis 
MYC-
break 
SMARCA4 
mutation
1
 
PCBP1 
mutation
2
 
TERT 
expression 
450k 
4177434 16 f BL positive x x x  
4193278 17 m BL positive x x  x 
4127766 8 m BL positive x x   
4190495 15 m BL positive x x x x 
4182393 10 m BL positive x x x x 
4119027 12 m BL positive x x x x 
4125240 4 m BL positive x x x x 
4112512 18 f BL positive x x x x 
4130003 6 m BL positive x x x  
4146289 14 m BL positive x x x  
4108627 5 f Burkitt leukemia positive x    
4133511 5 m BL positive x x  x 
4142267 5 m Burkitt leukemia positive x x   
4161696 5 m Burkitt leukemia positive x    
4177856 10 m BL positive x x  x 
4178310 10 m Burkitt leukemia positive x    
4178345 10 m Burkitt leukemia positive x x   
4189998 13 m BL positive x x  x 
4190784 4 m Burkitt leukemia negative x    
4194218 4 m BL positive x x  x 
4194891 4 m BL positive x x  x 
4116738 15 m DLBCL negative    x 
4163639 75 f DLBCL negative    x 
4135099 49 m DLBCL negative    x 
4108101 66 m DLBCL negative    x 
4101316 74 f DLBCL negative    x 
4104893 16 m DLBCL negative    x 
Age denotes patient age in years (yrs) at diagnosis; sex is denoted m for male and f for female; BL is denoted for Burkitt 
lymphoma, DLBCL for diffuse-large B-cell lymphoma; 
1
 results of the SMARCA4 mutation analysis are under revision in the 
journal Nature Genetics; 450k, analysis of the global DNA methylation using HumanMethylation 450k Bead Chip; 
2
 results of 
the PCBP1 mutations analysis are accepted for publication in the journal Genes, Chromosomes and Cancer. 
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8.2 Characteristics of B-cell lymphoma cases of the MMML cohort  
 
Table S 2 gives on overview on characteristics of the patients with BL and DLBCL of the MMML cohort 
as well as on the respective analyses they were subjected to. 
S 2: Overview on BL and DLBCL cases of the MMML cohort used in this thesis for different analyses. 
Case Age (yrs) Sex Diagnosis MYC-break PCBP1 mutation
1
 450k 
MPI-005 5 m Atypical BL positive x x 
MPI-016 44 f Atypical BL positive x  
MPI-017 40 m BL positive x x 
MPI-027 63 f Atypical BL positive x  
MPI-033 4 m BL positive x  
MPI-043 5 m Atypical BL positive x  
MPI-044 13 m Atypical BL positive x  
MPI-048 13 f BL positive x x 
MPI-055 12 m Atypical BL positive x  
MPI-071 54 m Atypical BL positive x x 
MPI-079 2 f BL positive x  
MPI-080 2 m BL positive x  
MPI-082 4 m Atypical BL positive x  
MPI-084 57 m BL positive x x 
MPI-085 26 f BL positive x x 
MPI-089 7 m BL positive x  
MPI-101 76 m Atypical BL positive x x 
MPI-114 8 m BL positive x  
MPI-123 24 m Atypical BL positive x  
MPI-139 46 m BL positive x  
MPI-144 33 m BL positive x x 
MPI-171 24 f DLBCL positive  x 
MPI-323 40 m Atypical BL positive x x 
MPI-527 8 f BL positive x  
MPI-529 10 f BL positive x  
MPI-532 5 m Atypical BL positive x  
MPI-579 5 f BL positive x  
MPI-580 9 m BL positive x  
MPI-590 17 m Atypical BL positive x  
MPI-625 12 m BL positive x  
MPI-680 43 m Atypical BL positive  x 
Age denotes patient age in years (yrs) at diagnosis; sex is denoted m for male and f for female; BL is denoted for Burkitt 
lymphoma, DLBCL for diffuse-large B-cell lymphoma; 450k, analysis of the global DNA methylation using HumanMethylation 
450k Bead Chip; 
1
 results of the PCBP1 mutations analysis are accepted for publication in the journal Genes, Chromosomes 
and Cancer. 
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8.3 Karyotypes of cell lines studied 
 
All but two cell line karyotypes were available and downloaded at the homepage of the DSMZ 
(http://www.dsmz.de/home.html, 05/10/2014). The exceptions were the karyotypes of U-698-M and 
MLMA cells which were obtained in-house.  
S 3: Karyotypes of cell line studied. 
 Cell line  Diagnosis  Karyotype 
BL-2 BL 44-47<2n>XY, der(1)t(1;7)(q32;q11.2),der(6)t(1;6)(q21;q25),t(8;22)(q24;q11.2) 
BL-41 BL 
48(42-49)<2n>XY, +7, -13, 2mar, add(8)(q24), t(8;14)(q24;q32), der(15)t(13;15)(q13;p11), 
add(17)(p12), subclonal rearrangements at 1q23, 7p22, 11q13 
BL-70 BL 47(42-49)<2n>XY, +7, inv(1)(p21q21), del(2)(q33), t(8;14)(q24;q32), t(12;22)(q21.1;q13.2) 
BLUE-1 BL 
53(49-53)<2n>XY, +6, +13, +16, +20, +20, +20, +21, t(6;20)(q15;q11.2), 
der(6)t(6;20)(q15;q11.2), t(8;14)(q24;q32), 
der(20)del(20)(p12.2p13.2)t(6;20)(q15;q11.2)t(6;11)(q16;p13)x2 
Ca46 BL 46(45-48)<2n>X/XY, dup(1)(q21q32), dup(7)(q12q22), t(8;14)(q24;q32) 
U-698-M BL 
49(44-50)<2n>XY, +3, +7, -14, +mar, dup(1)(q43q21.2), der(2)t(2;3)(p16;p11), add(3)(p11), 
del(6)(q15q22), del(9)(p22), dup(11)(q23q13), add(13)(p12), add(16)(q24) 
+t(8;14)(q24;q23), In-house data 
HT mnBLL
1
 
46(42-46)<2n>XY, +2, der(2;4)(p10;q10), der(2)(del)(2)(p11?q21), dup(10)(q11q22-23), 
dup(11)(?q23qter) 
MLMA mnBLL
1
 
44~46,X,del(X)(q13q21),-2,-3,der(3;15)(q10;p10),-4,add(4)(p16),del(5)(q23q35),der(7)(?), 
-8,der(11)dup(11)(q22q25)hsr(11)(q22~23),-12,der(15)t(?8;15)(q23;q15),add(17)(p11), 
+18,add(18)(q21),der(19)t(12;19)(q14;q13.3)+3~5mar[cp8], In-house data 
Su-DHL-5 mnBLL
1
 47(41-48)<2n>XX, +12, del(6)(q13), del(12)(q13) - sideline with del(6)x2 
Su-DHL-6 GCB-DLBCL 
47(42-48)<2n>X, -Y, +6, +7, del(4)(q23), del(6)(p21.3p22.2), i(6p), del(7)(q?22q?32), 
der(8)t(8;9)(q24;p13), der(9)t(8;19;9)(q24;q13;p13), dup(11)(q24q25), t(14;18)(q32;q21), 
der(22)t(?7;22)(?q32;p11) 
Su-DHL-10 GCB-DLBCL 
47(43-48)<2n>XY, +7, der(8)t(X;8)(q25;p23)t(8;X)(q24;q26)t(X;14)(q28;q32), 
del(10)(q22q24),der(11)t(Y;11)(q11;q25),der(14)t(8;14)(q24;q32),der(18)t(14;18)(q32;q21) 
Karpas422 GCB-DLBCL 
hyperdiploid, 10% polyploidy; 47(44-48)<2n>XX, +14, t(2;10)(p23;q22), 
t(4;11)(q21;q24), t(4;16)(q21;p13), der(14)t(14;18)(q32;q21)x2 
FISH: 4,7 t(4;16;10)(q21;p13;q23), no t(4;11)(q21;q23), t(14;18)(q32;q21), 
+der(14)t(14;18)(q32;q21) 
RIVA ABC-DLBCL 
48-51<2n>XX, +7, +18, +19, +mar, t(1;22;16)(p35;p12;q12.2), del(3)(q11-12), trp(3)(q11-
12q28-29), t(4;8)(q22;q24), del(6)(q13), der(15)t(13;15) (q11;p1?1), der(18)amp(18)(q21) 
dup(18)(q21q23), der(19)t(6;19) (p21;p13)add(19(q13.3) 
Diagnosis: mnBLL, MYC-negative Burkitt-like lymphoma; BL, Burkitt lymphoma, GCB DLBCL, germinal center B-cell like 
diffuse large B-cell lymphoma; ABC DLBCL, activated B-cell like diffuse large B-cell lymphoma. 
1 
Diagnosis as defined in this 
thesis (3.2.2). 
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8.4 Abbreviations and codons for amino acids and translation stop 
 
 
S 4: Overview on abbreviations and codons for amino acids and translational stop (•/*) 
(from http://www.operon.com/products/custom_oligos/images/geneticcode.gif, 14/04/2015). 
 
  
Appendices 
212 
8.5 Vector maps of plasmids used in this study 
 
  
 
S 5: Vector map of pCMV6-AC-GFP which was obtained 
from OriGene Technologies (http://www.origene.com/ 
destination_vector/PS100010.aspx, 25/03/2015). 
 
 
 
 
 
 
 
S 6: Vector map of pMD.G which was provided by Dr.rer. 
nat. E. Murga Penas, Institute of Human Genetics, Kiel 
(http://web.mit.edu/jacks-lab/protocols/pMDGmap.pdf, 
25/03/2015). 
 
 
 
 
 
 
S 7: Vector map of pCMV-dR8.91 which was provided by 
Dr. rer. nat. E. Murga Penas, Institute of Human 
Genetics, Kiel (http://www.addgene.org/vector-
database/2221/, 25/03/2015). 
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S 8: Vector map of pLKO_IPTG_3xLacO which was 
obtained from Sigma Aldrich 
(http://www.sigmaaldrich.com/life-science/functional-
genomics-and-rnai/shrna/library-information/vector-
map.html#inducible, 25/03/2015). 
 
 
 
 
 
 
 
S 9: Vector map of pmax which was obtained from 
Amaxa/Lonza (http://bio.lonza.com/fileadmin/ groups/ 
FAQs /public/Technology_Flyer.pdf, 25/03/2015). 
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8.6 Sequences of the new exon variants of the TERT gene 
 
Sequence of new exon variant 1, chr5:1,286,280-1,287,201 bp (hg19): 
 
5’
AGACCCGCCTGGTGCACTCTGATTCTCCACTTGCCTGTTGCATGTCCTCGTTCCCTTGTTTCTCACCACCTCTTGGGTTGCCATGTGCGT
TTCCTGCCGAGTGTGTGTTGATCCTCTCGTTGCCTCCTGGTCACTGGGCATTTGCTTTTATTTCTCTTTGCTTAGTGTTACCCCCTGATCTT
TTTATTGTCGTTGTTTGCTTTTGTTTATTGAGACAGTCTCACTCTGTCACCCAGGCTGGAGTGTAATGGCACAATCTCGGCTCACTGCAAC
CTCTGCCTCCTCGGTTCAAGCAGTTCTCATTCCTCAACCTCATGAGTAGCTGGGATTACAGGCGCCCACCACCACGCCTGGCTAATTTTT
GTATTTTTAGTAGAGATAGGCTTTCACCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAAGTGATCTGCCCGCCTTGGCCTCCCAC
AGTGCTGGGATTACAGGTGCAAGCCACCGTGCCCGGCATACCTTGATCTTTTAAAATGAAGTCTGAAACATTGCTACCCTTGTCCTGAG
CAATAAGACCCTTAGTGTATTTTAGCTCTGGCCACCCCCCAGCCTGTGTGCTGTTTTCCCTGCTGACTTAGTTCTATCTCAGGCATCTTGA
CACCCCCACAAGCTAAGCATTATTAATATTGTTTTCCGTGTTGAGTGTTTCTGTAGCTTTGCCCCCGCCCTGCTTTTCCTCCTTTGTTCCCC
GTCTGTCTTCTGTCTCAGGCCCGCCGTCTGGGGTCCCCTTCCTTGTCCTTTGCGTGGTTCTTCTGTCTTGTTATTGCTGGTAAACCCCAGC
TTTACCTGTGCTGGCCTCCATGGCATCTAGCGACGTCCGGGGACCTCTGCTTATGATGCACAGATGAAGATGTGGAGACTCACGAGGA
GGGCGGTCATCTTGGCCC
3’ 
 
 
Sequence of new exon variant 2, chr5:1,286,239-1,287,201 bp (hg19): 
 
5’
AGACCCGCCTGGTGCACTCTGATTCTCCACTTGCCTGTTGCATGTCCTCGTTCCCTTGTTTCTCACCACCTCTTGGGTTGCCATGTGCGT
TTCCTGCCGAGTGTGTGTTGATCCTCTCGTTGCCTCCTGGTCACTGGGCATTTGCTTTTATTTCTCTTTGCTTAGTGTTACCCCCTGATCTT
TTTATTGTCGTTGTTTGCTTTTGTTTATTGAGACAGTCTCACTCTGTCACCCAGGCTGGAGTGTAATGGCACAATCTCGGCTCACTGCAAC
CTCTGCCTCCTCGGTTCAAGCAGTTCTCATTCCTCAACCTCATGAGTAGCTGGGATTACAGGCGCCCACCACCACGCCTGGCTAATTTTT
GTATTTTTAGTAGAGATAGGCTTTCACCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAAGTGATCTGCCCGCCTTGGCCTCCCAC
AGTGCTGGGATTACAGGTGCAAGCCACCGTGCCCGGCATACCTTGATCTTTTAAAATGAAGTCTGAAACATTGCTACCCTTGTCCTGAG
CAATAAGACCCTTAGTGTATTTTAGCTCTGGCCACCCCCCAGCCTGTGTGCTGTTTTCCCTGCTGACTTAGTTCTATCTCAGGCATCTTGA
CACCCCCACAAGCTAAGCATTATTAATATTGTTTTCCGTGTTGAGTGTTTCTGTAGCTTTGCCCCCGCCCTGCTTTTCCTCCTTTGTTCCCC
GTCTGTCTTCTGTCTCAGGCCCGCCGTCTGGGGTCCCCTTCCTTGTCCTTTGCGTGGTTCTTCTGTCTTGTTATTGCTGGTAAACCCCAGC
TTTACCTGTGCTGGCCTCCATGGCATCTAGCGACGTCCGGGGACCTCTGCTTATGATGCACAGATGAAGATGTGGAGACTCACGAGGA
GGGCGGTCATCTTGGCCCGTGAGTGTCTGGAGCACCACGTGGCCAGCGTTCCTTAGCCA
3’ 
 
 
Sequence of new exon variant 3, chr5:1,286,014-1,287,201 bp (hg19): 
 
5’
AGACCCGCCTGGTGCACTCTGATTCTCCACTTGCCTGTTGCATGTCCTCGTTCCCTTGTTTCTCACCACCTCTTGGGTTGCCATGTGCGT
TTCCTGCCGAGTGTGTGTTGATCCTCTCGTTGCCTCCTGGTCACTGGGCATTTGCTTTTATTTCTCTTTGCTTAGTGTTACCCCCTGATCTT
TTTATTGTCGTTGTTTGCTTTTGTTTATTGAGACAGTCTCACTCTGTCACCCAGGCTGGAGTGTAATGGCACAATCTCGGCTCACTGCAAC
CTCTGCCTCCTCGGTTCAAGCAGTTCTCATTCCTCAACCTCATGAGTAGCTGGGATTACAGGCGCCCACCACCACGCCTGGCTAATTTTT
GTATTTTTAGTAGAGATAGGCTTTCACCATGTTGGCCAGGCTGGTCTCAAACTCCTGACCTCAAGTGATCTGCCCGCCTTGGCCTCCCAC
AGTGCTGGGATTACAGGTGCAAGCCACCGTGCCCGGCATACCTTGATCTTTTAAAATGAAGTCTGAAACATTGCTACCCTTGTCCTGAG
CAATAAGACCCTTAGTGTATTTTAGCTCTGGCCACCCCCCAGCCTGTGTGCTGTTTTCCCTGCTGACTTAGTTCTATCTCAGGCATCTTGA
CACCCCCACAAGCTAAGCATTATTAATATTGTTTTCCGTGTTGAGTGTTTCTGTAGCTTTGCCCCCGCCCTGCTTTTCCTCCTTTGTTCCCC
GTCTGTCTTCTGTCTCAGGCCCGCCGTCTGGGGTCCCCTTCCTTGTCCTTTGCGTGGTTCTTCTGTCTTGTTATTGCTGGTAAACCCCAGC
TTTACCTGTGCTGGCCTCCATGGCATCTAGCGACGTCCGGGGACCTCTGCTTATGATGCACAGATGAAGATGTGGAGACTCACGAGGA
GGGCGGTCATCTTGGCCCGTGAGTGTCTGGAGCACCACGTGGCCAGCGTTCCTTAGCCAGTGAGTGACAGCAACGTCCGCTCGGCCTG
GGTTCAGCCTGGAAAACCCCAGGCATGTCGGGGTCTGGTGGCTCCGCGGTGTCGAGTTTGAAATCGCGCAAACCTGCGGTGTGGCGC
CAGCTCTGACGGTGCTGCCTGGCGGGGGAGTGTCTGCTTCCTCCCTTCTGCTTGGGAACCAGGACAAAGGATGAGGCTCCGAGCCGTT
GTCGCCCAACAGGAGCATGAC
3’ 
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8.7 Sequence of the splice variant of exon 2 of the TERT gene 
 
Sequence of splice variant of exon 2, chr5:1,293,079-1,294,781 bp (hg19): 
 
5’
GTGTCCTGCCTGAAGGAGCTGGTGGCCCGAGTGCTGCAGAGGCTGTGCGAGCGCGGCGCGAAGAACGTGCTGGCCTTCGGCTTCGC
GCTGCTGGACGGGGCCCGCGGGGGCCCCCCCGAGGCCTTCACCACCAGCGTGCGCAGCTACCTGCCCAACACGGTGACCGACGCACT
GCGGGGGAGCGGGGCGTGGGGGCTGCTGCTGCGCCGCGTGGGCGACGACGTGCTGGTTCACCTGCTGGCACGCTGCGCGCTCTTTGT
GCTGGTGGCTCCCAGCTGCGCCTACCAGGTGTGCGGGCCGCCGCTGTACCAGCTCGGCGCTGCCACTCAGGCCCGGCCCCCGCCACAC
GCTAGTGGACCCCGAAGGCGTCTGGGATGCGAACGGGCCTGGAACCATAGCGTCAGGGAGGCCGGGGTCCCCCTGGGCCTGCCAGC
CCCGGGTGCGAGGAGGCGCGGGGGCAGTGCCAGCCGAAGTCTGCCGTTGCCCAAGAGGCCCAGGCGTGGCGCTGCCCCTGAGCCGG
AGCGGACGCCCGTTGGGCAGGGGTCCTGGGCCCACCCGGGCAGGACGCGTGGACCGAGTGACCGTGGTTTCTGTGTGGTGTCACCTG
CCAGACCCGCCGAAGAAGCCACCTCTTTGGAGGGTGCGCTCTCTGGCACGCGCCACTCCCACCCATCCGTGGGCCGCCAGCACCACGC
GGGCCCCCCATCCACATCGCGGCCACCACGTCCCTGGGACACGCCTTGTCCCCCGGTGTACGCCGAGACCAAGCACTTCCTCTACTCCTC
AGGCGACAAGGAGCAGCTGCGGCCCTCCTTCCTACTCAGCTCTCTGAGGCCCAGCCTGACTGGCGCTCGGAGGCTCGTGGAGACCATC
TTTCTGGGTTCCAGGCCCTGGATGCCAGGGACTCCCCGCAGGTTGCCCCGCCTGCCCCAGCGCTACTGGCAAATGCGGCCCCTGTTTCT
GGAGCTGCTTGGGAACCACGCGCAGTGCCCCTACGGGGTGCTCCTCAAGACGCACTGCCCGCTGCGAGCTGCGGTCACCCCAGCAGCC
GGTGTCTGTGCCCGGGAGAAGCCCCAGGGCTCTGTGGCGGCCCCCGAGGAGGAGGACACAGACCCCCGTCGCCTGGTGCAGCTGCTC
CGCCAGCACAGCAGCCCCTGGCAGGTGTACGGCTTCGTGCGGGCCTGCCTGCGCCGGCTGGTGCCCCCAGGCCTCTGGGGCTCCAGG
CACAACGAACGCCGCTTCCTCAGGAACACCAAGAAGTTCATCTCCCTGGGGAAGCATGCCAAGCTCTCGCTGCAGGAGCTGACGTGGA
AGATGAGCGTGCGGGACTGCGCTTGGCTGCGCAGGAGCCCAGGTGAGGAGGTGGTGGCCGTCGAGGGCCCAGGCCCCAGAGCTGAA
TGCAGTAGGGGCTCAGAAAAGGGGGCAGGCAGAGCCCTGGTCCTCCTGTCTCCATCGTCACGTGGGCACACGTGGCTTTTCGCTCAGG
ACGTCGAGTGGACACGGTGATCTCTGCCTCTGCTCTCCCTCCTGTCCAGTTTGCATAAACTTACGAGGTTCACCTTCACGTTTTGATGGA
CACGCGGTTTCCAGGCGCCGAGGCCAGAGCAGTGAACAGAGGAGGCTGGGCGCGGCAGTGGAGCCGGGTTGCCGGCAATGGGGAG
AAGTGTCTGGAAGCACAGACGCTCTGGCGAGGGTGCCTGCAG
3’ 
 
 
The underlined sequence is the sequence which is in addition to the sequence of the wildtype exon 2 
and, hence, defines the 3’ borders of the here newly identified splice variant. 
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8.8 Read coverage of CDKN2A locus in BL-2 cell line 
 
A homozygous loss was detected in the CDKN2A locus on chromosome 9p21.3 by whole-exome 
sequencing of the BL-2 cell line. This homozygous loss encompassed the adjacent genes CDKN2B and 
DMRTA1. The MTAP gene upstream and the ELAVL2 downstream to the CDKN2A locus were not 
affected by the deletion. 
 
S 10: Read coverage of the chromosomal region chr9:21,795,637-23,842,777 bp (hg19) including the CDKN2A locus in BL-2 
cell lines as analyzed by whole-exome sequencing. A: Depicted are from the top to the bottom: ideogram of chromosome 9, 
scale bar in kb, genome base position in bp, the UCSC gene track showing the genes of the region. Highlighted in blue is the 
region of homozygous loss. B-F: Plots of read coverage of MTAP (B), CDKN2A (C), CDKN2B (C), DMRTA1 (D) ELAVL2 (F). The 
red bars of the Refseq track depict all exons of transcripts with a consensus coding sequence or Refseq ID.  
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8.9 Immunohistochemical variables in PCBP1 mutated and wildtype Burkitt lymphomas 
 
In the following table S 11 the immunohistochemical variables of PCBP1 mutated and wildtype 
patients are summarized. The data are part of a manuscript which is accepted for publication in the 
journal Genes, Chromosomes and Cancer. The data were provided within the ICGC MMML-Seq as 
well as MMML project and the differences in categorical variables between groups were analyzed by 
Dr. Markus Kreuz, Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig 
using Fisher’s exact test. Of note is that immunohistochemistry data were not available of all BL 
cases. 
 
S 11: Immunohistochemical variables in PCBP1 mutated and wildtype BL. 
 ICGC MMML-Seq cohort MMML cohort Combined cohorts P-value
1
 
 mut (%) wt (%) mut (%) wt (%) mut (%) wt (%)  
Sex              
F 1 33 1 7 0 0 9 36 1 17 10 26 
1 
M 2 67 13 93 3 100 16 64 5 83 29 74 
Immunohistochemistry    
CD10              
neg 0 0 0 0 0 0 1 4 0 0 1 3 
1 
pos 2 100 12 100 3 100 24 96 5 100 36 97 
CD5              
neg 0 0 3 100 3 100 20 83 3 100 23 85 
1 
pos 0 0 0 0 0 0 4 17 0 0 4 15 
BCL2              
neg 2 67 11 92 3 100 19 83 5 83 30 86 1 
pos 1 33 1 8 0 0 4 17 1 17 5 14 
BCL6              
neg 0 0 0 0 1 33 0 0 1 17 0 0 0.15 
pos 3 100 10 100 2 67 24 100 5 83 34 100 
IRF4/MUM1             
neg 0 0 7 70 0 0 12 57 0 0 19 61 0.008 
pos 3 100 3 30 3 100 9 43 6 100 12 39 
Ki67
2
              
neg 0 0 0 0 0 0 1 4 0 0 1 3 1 
pos 3 100 11 100 3 100 24 96 6 100 35 97 
Percentages refer to analyzed cases. Of note is that immunohistochemistry data were not available of all BL cases. M, 
male; F, female; neg, negative; pos, positive; mut, PCBP1 mutated; wt, PCBP1 wildtype 
1 
P-value (Fisher’s exact test) refers to comparison of mutated vs. wildtype in combined cohorts, p-value < 0.05 was 
defined as significant. 
2 
cut-off ≥90% 
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8.10 Overview on chromosome 11 aberrations in MYC-negative Burkitt-like lymphomas  
 
S 12: Overview on the chromosome 11 aberrations identified in mnBLL cases 18-25. 
Case Aberration Cytoband Genomic position (hg19) in bp Size (kb) 
Case 18 
High level gain 11q22.3 106,233,094-107,651,609 1,418.5 
CN Gain 11q22.3 - q23.3 107,670,228-117,119,552 9,449.3 
High level gain 11q23.3 117,127,159-118,966,521 1,839.4 
CN Loss 11q23.3 - q25 118,971,251-134,938,847 15,967.6 
CN Gain whole chr. 12p13.33 - q24.33 0-133,851,895 13,385.2 
CN Gain 13q31.3 91,359,736-92,328,701 969.0 
CN Gain whole chr. 19p13.3 - q13.43 0-59,128,983 59,129.0 
Case 19 
CN Gain 11p15.5 - q24.2 192,764-127,778,007 27,585.2 
CN Loss 11q24.2 - q25 127,799,447-133,280,976 5,481.5 
CN Gain 11q25 133,305,660-134,938,847 1,633.2 
CN Loss 14q31.3 86,454,666-88,383,985 1,929.3 
Case 20 
CN Gain 8q21.12 - q23.1 80,082,078-107,358,145 27,276.1 
CN Gain 8q23.3 - q24.23 112,501,602-136,517,735 24,016.1 
CN Gain 8q24.3 140,127,523-146,292,734 6,165.2 
High level gain 11q13.2 - q23.3 67,767,160-119,460,505 51,693.4 
CN Loss 11q23.3 - q25 119,488,812-134,938,847 15,450.0 
CN Gain 13q31.1 - q31.2 85,287,625-89,609,906 4,322.3 
High level gain 13q31.2 - q31.3 89,614,856-92,150,929 2,536.1 
CN Loss 13q31.3 - q34 92,165,452-115,103,150 22,937.7 
CN Gain 14q21.3 - q32.33 48,465,864-106,325,013 57,859.2 
High level gain 18q21.2 - q21.32 51,129,489-56,719,436 5,589.9 
CN Gain 18q22.1 - q23 62,979,859-74,637,067 11,657.2 
CN Loss 18q23 74,643,905-78,007,784 3,363.9 
CN Gain whole chr. 20p13 - p11.22 0-21,420,492 21,420.5 
Case 21 
CN Gain 11q22.1 - q22.3 97,346,172-104,405,081 7,058.9 
CN Gain 11q22.3 104,423,008-105,983,140 1,560.1 
CN Gain 11q22.3 - q23.3 106,005,901-120,907,482 14,901.6 
CN Loss 11q23.3 - q25 120,931,054-134,938,847 14,007.8 
CN Gain whole chr. 12p13.33 - q24.33 0-133,851,895 133,851.9 
Case 22 
CN Loss 6q12 - q21 67,759,432-110,118,776 42,359.4 
CN Loss 11q24.2 - q25 124,440,617-132,877,670 8,437.1 
Case 23 
CN Gain 8q22.3 - q24.3 104,078,514-146,292,734 42,214.2 
CN Gain 11q12.1 - q13.3 58,169,996-69,439,860 11,269.9 
CN Gain 11q13.3 - q24.1 69,502,677-122,984,689 53,482.0 
CN Loss 11q24.1 - q25 122,996,050-134,938,847 11,942.8 
CN Gain whole chr. 12p13.33 - q24.33 0-133,851,895 133,851.9 
Case 24 
CN Gain 1p36.33 – p36 754,192-20,740,016 19,985.8 
CN Loss 3p14.2 60,206,501-60,508,340 301.8 
CN Loss 4q13.2 – q35.2 67,042,255-190,915,650 123,873.4 
CN Gain 7q36.2 – q36.6 154,812,950-155,777,228 964.3 
CN Gain whole chr. 8p23.3 - q24.3 0-146,364,022 146,364.0 
CN Gain 11p15.5 - q23.3 192,764-119,754,895 119,562.1 
CN Loss 11q23.3 - q25 119,771,843-134,938,847 15,167.1 
CN Gain whole chr. 12p13.33 - q24.33 0-133,818,115 133,818.1 
CN Gain 18q11.1 - q21.31 18,554,307-53,950,927 35,396.6 
CN Loss 18q21.31 – q23 53,962,817-78,007,784 24,044.9 
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Table S 12 continued 
Case Aberration Cytoband Genomic position (hg19) in bp Size (kb) 
Case 25 
CN Loss 2q14.3 124,730,172-125,054,416 324.3 
CN Loss 4q21.21 - q22.1 80,280,705-91,015,463 10,734.8 
CN Gain 7q21.3 - q36.3 90,789,353-159,118,443 68,329.1 
CN Loss 7q31.1 110,934,682-111,195,204 260.5 
CN Gain 11q14.1 - q23.3 80,282,364-120,687,234 40,404.9 
CN Loss 11q23.3 - q25 120,702,378-134,938,847 14,236.5 
Homozygous Loss 11q24.2 - q24.3 127,621,020-129,572,876 1,951.9 
High level gain 16p13.3 83,887-536,686 452.8 
CN, copy number 
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8.11 Overview on the chromosomal imbalances in the MLMA cell line 
 
S 13: Overview on chromosomal imbalances identified in the MLMA cell line. 
 Chromosome  CNA  Cytoband  Start in bp (hg19)  End in bp (hg19)  Size (Mb) 
2 
Loss p25.3-p25.1 12,772 12,003,659 11.99 
Loss p22.3-p22.1 35,769,789 38,723,973 2.95 
Gain p22.1-p16.3 38,727,427 50,813,047 12.09 
High level gain p16.3 49,631,385 50,813,047 1.18 
High level gain p16.1-p15 60,828,527 62,003,895 1.18 
Loss p14-p13.3 68,224,520 69,089,184 0.87 
Loss q22.3-q24.1 146,877,806 157,412,458 10.54 
3 
Gain p26.3-p26.1 60,333 6,778,609 6.72 
Loss p26.1-p25.3 6,785,721 10,270,528 3.48 
Loss p25.3-p25.1 10,587,649 14,161,890 3.11 
Loss p24.3 18,648,481 20,421,820 1.77 
Gain p24.2-p22.3 26,223,735 33,753,419 7.53 
Loss p22.3-p22.2 33,763,296 37,652,985 3.89 
Gain p22.1 39,873,605 41,929,725 2.06 
Gain p22.1 42,757,852 42,896,787 0.14 
Loss p22.1-p21.31 42,968,294 44,316,466 1.35 
Loss p21.31-p12.3 49,358,503 86,823,544 37.47 
Homoz. Loss p14.3 54,692,206 57,604,882 2.91 
Loss p14.2-p12.1 59,906,110 86,823,544 26.92 
Gain p12.1 86,917,763 87,124,205 0.21 
Gain p11.2 87,805,170 94,262,650 6.46 
High level gain p11.2 94,262,653 94,660,166 0.4 
Gain q11.2 97,068,564 98,801,390 1.73 
High level gain q12.1 98,801,400 99,799,699 0.99 
Loss q12.2-q13.32 99,799,700 118,260,457 18.46 
Gain q25.32-q25.32 158,136,848 158,646,181 0.51 
4 
Loss p16.3-p11 12,269 49,089,362 49.08 
Gain p11-q13.1 52,344,170 60,132,170 7.79 
Gain q24-q33 102,831,285 170,778,068 67.95 
Gain q34.1-q35.2 172,956,807 19,1020,138 18.06 
5 
Loss q12.1-q12.1 59,668,386 59,899,235 0.23 
Loss q21.3-q23.2 105,071,875 126,622,890 21.55 
Gain q23.2-q31.1 126,627,875 133,753,600 0.71 
High level gain q31.1 133,753,689 135,164,389 1.41 
7 
High level gain q21.11-q22.1 82,851,692 102,102,164 19.25 
Gain q22.1-q31.1 102,340,594 110,224,593 7.88 
Loss q31.1 110,225,748 110,445,011 0.22 
Gain q31.1-q31.33 110,448,308 124,881,515 14.43 
Gain q31.33 125,876,948 126,485,276 0.61 
Loss q31.33 126,493,232 126,799,388 0.31 
Gain q31.33-q33 126,801,929 137,101,515 10.30 
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Table S13 continued 
 Chromosome  CNA  Cytoband  Start in bp (hg19)  End in bp (hg19)  Size (Mb) 
7 
Loss q33 137,106,596 137,336,572 0.23 
Gain q33-q34 137,345,877 140,060,653 2.71 
Loss q34 140,065,886 140,324,890 0.26 
Gain q34 140,330,182 140,813,472 0.48 
Loss q34-q36.3 140,815,840 159,119,708 18.30 
8 
Loss p23.3-q21.13 1 83,352,762 83.35 
Homoz. loss q21.13-q21.2 83,389,273 86,565,730 3.18 
Loss q21.2-q21.3 86,821,307 89,304,055 2.48 
Homoz. loss q21.3 89,322,596 89,430,301 0.11 
Loss q21.3 89,433,842 90,064,236 0.63 
10 Gain q26.3 132,072,271 135,506,692 3.43 
11 
Gain q21 93,756,820 96,723,470 2.97 
High level gain q21-q22.1 96,725,882 99,519,286 2.79 
Gain q22.1 99,528,055 99,791,125 0.26 
High level gain q22.1 99,799,894 100,545,859 0.75 
Gain q22.1-q23.3 100,554,028 117,513,420 16.96 
High level gain q23.3 117,530,600 118,962,816 1.43 
Loss q23.3-q25 118,970,202 134,944,770 15.98 
12 High level gain q13.13-q15 54,893,027 69,935,275 15.04 
13 Loss q14.11 41,719,828 42,878,121 1.12 
15 
Gain q11.2-q13.1 24,886,177 29,813,757 4.93 
High level gain q13.1-q14 29,813,760 34,763,616 4.95 
Gain q22.2-q22.31 59,533,114 66,252,621 6.72 
High level gain q22.31-q25.2 66,252,625 83,649,934 17.4 
Loss q26.1-q26.2 92,589,340 96,373,328 3.78 
17 Loss p13.3-p11.2 514 21,547,725 21.55 
18 
High level gain q21.2-q21.33 49878,620 61,386,375 4.72 
Loss q21.33-q23 61,388,177 78,015,057 16.63 
Homoz. Loss q22.1-q23 62,941,778 74,502,552 11.56 
19 
Loss p13.2 10,151,244 10,586,984 0.44 
Loss q13.42-q13.43 56,124,049 59,097,842 2.97 
22 Gain q13.2-q13.33 42,025,057 51,188,494 9.16 
X 
Gain p22.33-q11.2 1 63,921,440 63.92 
Loss q11.2-q21.31 63,862,549 86,991,835 23.13 
Gain q21.31-q25 87,103,000 125,431,093 38.33 
High level gain q25-q28 125,419,892 154,929,486 29.51 
Homoz. Loss: homozygous loss; start and end of copy number alteration in bp; size in mega bases (Mb). 
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8.12 Protein coding genes in the minimal regions of gain and loss on chromosome 11  
 
The following table S 14 enlists all genes which map to the minimal region of gain or amplification, as 
well as minimal region of loss or homozygous loss on chromosome 11 as identified in mnBLL. 
S 14: Complete list of genes mapping to the minimal regions of alteration on chromosome 11 in mnBLL 
 Gene  Full Name  Region Chr11 (hg19) in bp  Minimal region of 
CADM1 cell adhesion molecule 1  chr11:115,044,345-115,375,241 Gain 
BUD13 BUD13 homolog (S. cerevisiae)  chr11:116,618,886-116,643,714 Gain 
ZNF259 zinc finger protein 259  chr11:116,649,276-116,658,739 Gain 
APOA5 apolipoprotein A-V  chr11:116,660,086-116,663,136 Gain 
APOA4 apolipoprotein A-IV  chr11:116,691,418-116,694,011 Gain 
APOC3 apolipoprotein C-III  chr11:116,700,624-116,703,787 Gain 
APOA1 apolipoprotein A-I  chr11:116,706,469-116,708,338 Gain 
SIK3 SIK family kinase 3  chr11:116,714,118-116,968,993 Gain 
PAFAH1B2 
platelet-activating factor acetylhydrolase 1b, 
catalytic subunit 2 
chr11:117,015,000-117,041,761 Gain 
SIDT2 SID1 transmembrane family, member 2 chr11:117,049,939-117,068,161 Gain 
TAGLN transgelin  chr11:117,070,040-117,075,508 Gain 
PCSK7 proprotein convertase subtilisin/kexin type 7  chr11:117,075,788-117,102,811 Gain 
CEP164 centrosomal protein 164kDa  chr11:117,198,571-117,283,982 Gain 
RNF214 ring finger protein 214  chr11:117,103,404-117,156,404 Gain 
BACE1 beta-site APP-cleaving enzyme 1  chr11:117,156,402-117,186,972 Gain 
DSCAML1 Down syndrome cell adhesion molecule like 1  chr11:117,298,489-117,667,976 Amplification 
FXYD2 
Sodium/potassium-transporting ATPase 
subunit gamma   
chr11:117,690,790-117,695,459 Amplification 
FXYD6 
FXYD domain-containing ion transport 
regulator 6 precursor   
chr11:117,707,691-117,747,746 Amplification 
TMPRSS13 transmembrane protease, serine 13 chr11:117,771,356-117,800,168 Amplification 
IL10RA interleukin 10 receptor, alpha  chr11:117,857,106-117,872,199 Amplification 
TMPRSS4 Transmembrane protease serine 4   chr11:117,947,727-117,990,556 Amplification 
SCN4B Sodium channel subunit beta-4 precursor   chr11:118,004,092-118,023,630 Amplification 
SCN2B Sodium channel subunit beta-2 precursor   chr11:118,033,519-118,047,337 Amplification 
AMICA1 
adhesion molecule, interacts with CXADR 
antigen 1  
chr11:118,064,442-118,095,809 Amplification 
MPZL2 myelin protein zero-like 2  chr11:118,124,131-118,135,251 Amplification 
MPZL3 Myelin protein zero-like protein 3 precursor   chr11:118,100,336-118,123,011 Amplification 
CD3G CD3g molecule, gamma (CD3-TCR complex) chr11:118,215,059-118,224,497 Amplification 
CD3E CD3e molecule, epsilon (CD3-TCR complex)  chr11:118,175,295-118,186,890 Amplification 
CD3D CD3d molecule, delta (CD3-TCR complex)  chr11:118,209,789-118,213,459 Amplification 
ATP5L 
ATP Synthase, H+ Transporting, Mitochondrial 
Fo Complex, Subunit G 
chr11:118,272,104-118,280,562 Amplification 
UBE4A ubiquitination factor E4A chr11:118,230,296-118,269,926 Amplification 
KMT2A 
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila)  
chr11:118,307,205-118,397,539 Amplification 
TTC36 tetratricopeptide repeat domain 36 chr11:118,398,210-118,401,740 Amplification 
THEM25 Homo sapiens transmembrane protein 25 chr11:118,401,803-118,406,550 Amplification 
ETS1 
v-ets erythroblastosis virus E26 oncogene 
homolog 1 (avian)  
chr11:128,328,656-128,457,453 Homozygous loss 
FLI1 Friend leukemia virus integration 1  chr11:128,563,811-128,683,162 Homozygous loss 
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Table S 14 continued 
 Gene  Full Name  Region Chr11 (hg19) in bp  Minimal region of 
KCNJ1 
potassium inwardly-rectifying channel, 
subfamily J, member 1  
chr11:128,707,915-128,712,363 Homozygous loss 
C11orf45 chromosome 11 open reading frame 45 chr11:128,769,460-128,775,964 Homozygous loss 
KCNJ5 
potassium inwardly-rectifying channel, 
subfamily J, member 5  
chr11:128,761,313-128,787,951 Homozygous loss 
TP53AIP1 
tumor protein p53 regulated apoptosis 
inducing protein 1 
chr11:128,769,460-128,775,592 Homozygous loss 
ARHGAP32 Rho GTPase activating protein 32  chr11:128,769,460-128,775,592 Homozygous loss 
BARX2 BARX homeobox 2  chr11:129,245,881-129,322,174 Homozygous loss 
TMEM45B transmembrane protein 45B chr11:129,685,741-129,729,898 Loss 
NFRKB 
nuclear factor related to kappaB binding 
protein  
chr11:129,733,670-129,762,904 
Loss 
PRDM10 PR domain containing 10  chr11:129,769,601-129,872,730 Loss 
APLP2 amyloid beta (A4) precursor-like protein 2  chr11:129,940,463-130,014,706 Loss 
ST14 
suppression of tumorigenicity 14 (colon 
carcinoma)  
chr11:130,029,682-130,080,257 
Loss 
ZBTB44 zinc finger and BTB domain containing 44  chr11:130,029,682-130,080,257 Loss 
ADAMTS8 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 8  
chr11:130,274,818-130,298,539 
Loss 
ADAMTS15 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 15 
chr11:130,318,869-130,346,539 
Loss 
SNX19 sorting nexin 19  chr11:130,745,766-130,786,382 Loss 
NTM neurotrimin  chr11:131,780,712-132,206,716 Loss 
OPCML 
opioid binding protein/cell adhesion 
molecule-like  
chr11:132,284,875-132,813,037 
Loss 
 
8.13 Non-coding RNAs in the minimal regions of gain and loss on chromosome11 
 
Following table S 15 enlists all genes of non-coding RNAs mapping to the minimal region of gain or 
amplification, as well as minimal region of loss or homozygous loss on chromosome 11 in mnBLL. 
S 15: Complete list of non-coding RNAs mapping to the minimal regions of alteration on chromosome 11 in mnBLL. 
 Gene  Full Name  Region chr11 (hg19) in bp  Minimal region of 
LOC283143 uncharacterized LOC283143 chr11:115,626,051-115,630,918 Gain 
mir-652 
 
chr11:116,349,824-116,349,914 Gain 
mir-548 
 
chr11:116,822,173-116,822,256 Gain 
LOC100652768 uncharacterized LOC100652768 chr11:117,066,329-117,072,630 Gain 
piR-43793 
 
chr11:117,158,614-117,158,647 Gain 
LOC100526771 uncharacterized LOC100526771 chr11:117,886,487-117,957,508 Amplification 
FLI-AS1 FLI1 antisense transcript chr11:128,561,567-128,565,918 Homozygous loss 
LINC00167 
long intergenic non-protein coding 
RNA 167 
chr11:129,872,519-129,875,381 Loss 
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8.14 List of recurrently mutated genes in MYC-negative Burkitt-like lymphoma 
 
Combination of whole-genome data of mnBLL case 1 with whole-exome data of three mnBLL cell 
lines (HT, Su-DHL-5, MLMA) led to the identification of 63 recurrently mutated genes (mutated in at 
least two analyzed samples) which are enlisted in S 16. Three additional mnBLL cases (cases 2, 3 and 
8) were analyzed using the TruSightTM One sequencing panel which covers 22 of the 63 genes. None 
of those 22 genes was found to be mutated in those three mnBLL. Highlighted in bold letters are 
those genes which were mutated in mnBLL case 1. 
S 16: Overview on genes recurrently mutated in mnBLL and mnBLL cell lines. 
 Gene  Chromosome   TruSight
TM
 Panel  Case 1  HT  Su-DHL-5  MLMA 
ABP1 7 
  
x 
 
x 
ADAMTS16 5 x 
 
x x 
 
ADCY6 12 x 
 
x 
 
x 
AHNAK2 14 
  
x x x 
ALG10 12 
   
x x 
ANGPTL2 9 
  
x x 
 
ARHGEF1 19 
  
x x 
 
ARID1B 6 x 
 
x 
 
x 
ARMC3 10 
  
x 
 
x 
ATRNL1 10 x 
 
x x 
 
BIRC3 11 
  
x x 
 
CD36 7 x 
  
x x 
CERK 22 
   
x x 
CLTCL1 22 x x x 
  
COL4A1 13 x 
 
x 
 
x 
DDX3X X 
  
x x 
 
DDX41 5 
  
x x 
 
DDX60 4 
 
x 
  
x 
DLAT 11 x 
 
x x 
 
DPY19L2 12 x 
 
x x 
 
DYNC1H1 14 x 
 
x 
 
x 
EIF4A1 17 
  
x x 
 
FAM186A 12 
  
x x 
 
FAM83H 8 x 
 
x 
 
x 
FAT1 4 
  
x x 
 
FBN2 5 x 
 
x 
 
x 
FBXL13 7 
  
x 
 
x 
FBXO5 6 
  
x 
 
x 
FHL5 6 
 
x 
 
x 
 
GNA13 17 
 
x 
 
x 
 
GNAS 20 x 
 
x x 
 
ITGA2 5 x 
 
x 
 
x 
ITGAX 16 
  
x x 
 
KIAA1045 9 
  
x x 
 
KIAA1755 20 
  
x 
 
x 
KRT3 12 x 
 
x 
 
x 
LAMA3 18 x 
 
x 
 
x 
TEKT4P2 21 
  
x x 
 
MAPK4 18 
  
x x 
 
MKI67 10 
  
x 
 
x 
MYH14 19 x 
 
x 
 
x 
NLRC5 16 
  
x x 
 
NOTCH3 19 x 
 
x x 
 
NOTUM 17 
  
x 
 
x 
NUP188 9 
  
x x 
 
OR7G3 19 
  
x 
 
x 
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Table S 16 continued 
 Gene  Chromosome   TruSight
TM
 Panel  Case 1  HT  Su-DHL-5  MLMA 
PABPC1 8 
  
x x 
 
PAPLN 14 
  
x 
 
x 
PCDHB7 5 
  
x x 
 
PTX4 16 
  
x x 
 
RBFOX3 17 
  
x 
 
x 
RPL35 9 
  
x x 
 
SENP3 17 
  
x x 
 
SGCD 5 x 
 
x x 
 
SPTY2D1 11 
  
x 
 
x 
ST5 11 x 
 
x 
 
x 
SVEP1 9 
  
x 
 
x 
SYNRG 17 
  
x x 
 
SYT4 18 
  
x x 
 
TNXB 6 x 
 
x 
 
x 
TP53 17 x 
 
x 
 
x 
ULK2 17 
  
x x 
 
ZNF208 19 
  
x x 
 
 
8.15 Complete Western blot figures 
 
Following Western blot figures show the complete membrane. 
 
 
S 17: Western blot of PAFAH1B2.  
 
 
S 18: Western blot of IL10RA. 
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S 19: Western blot of FLI1. 
 
S 20: Western blot of ETS1. 
 
 
 
S 21: Control of knock down of PAFAH1Bs expression in Su-DHL-5 cell line using Western blot. 
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